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ABSTRACT
Systemic sclerosis (SSc) is a connective tissue disease characterized by skin thickening 
and autoantibodies (AAbs). Generally, only one or two of a limited number of SSc- 
specific AAbs are detected, and their identification is useful for diagnosis and prognosis 
in individual cases. Certain environmental agents have been implicated in the aetiology 
of SSc, and immunogenetic associations of some AAbs have been established.
The relative influence of genetic and environmental factors on the production of 
anti-nuclear antibodies (ANAs) and anti-nucleolar antibodies (ANoAs) was addressed 
in 62 SSc patients, and in their 215 first-degree relatives and 24 spouses. By indirect 
immunofluorescence (IF), a significantly increased incidence of ANoAs was detected in 
the blood-relatives of SSc patients, but not in their spouses, when compared with 
normals. These results suggest a heritable factor may cause the nucleolus to become a 
focus of the immune response in SSc patients and their relatives. When analyzed by 
radio-immunoprecipitation (IP) techniques, ANoAs of defined specificity were shown 
to be SSc-specific. However, some family members had strong IF-ANoAs, and also 
precipitated autoantigens of unknown identity by IP. In one family, the spouse and 
three sisters of a proband all had ANA-IF, and each was found to precipitate a strong 
band of 115-kDa. Antigen depletion and affinity purification experiments suggested 
that the spouse and one sister recognized the same protein, while the other two sisters 
recognized a different autoantigen. These results strongly suggested that, due to genetic 
differences, the same environmental insult had triggered disease in the proband, while, 
in the remaining family members, the sequelae had been limited to a non-pathological 
autoimmune response.
The expression of AAbs and their clinical associations were then examined by IP in 
a further cohort of 148 SSc patients. It was confirmed that three major subsets of SSc 
patients are each characterized by a particular form of disease expression, and by the 
presence of a particular, mutually exclusive SSc-specific autoantibody, viz. anti- 
centromere, anti-topoisomerase I (anti-topo I), and anti-RNA polymerase III (anti- 
RNAP III) AAb groups. Anti-RNAP III antibodies were often accompanied by 
antibodies recognizing RNAP I, and sometimes also RNAP II. Despite their different 
clinical associations, anti-topo I sera also often had anti-RNAP II antibodies: however, 
in many cases, only the phosphorylated form of RNAP II appeared to be recognized by 
anti-topo I sera, a finding confirmed by affinity purification studies. These data 
suggested that anti-RNAP II AAbs can be produced by two alternative immune 
response pathways, possibly involving different initiating stimuli.
Together, these results are consistent with the current model of aetiopathogenesis 
in which autoantibodies, while not being directly involved in disease pathogenesis, are, 
nonetheless, extremely reliable reporters of disease-specific pathological phenomena.
(i)
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW
1.1 CLINICAL FEATURES
Systemic sclerosis (SSc) is a connective tissue disease (CTD) characterized by 
inflammatory microvascular lesions, increased deposition of extracellular matrix, and 
the presence of a limited number of disease-specific autoantibodies in patient sera. 
While its most obvious clinical manifestation is a thickening of the skin known as 
scleroderma, the increased mortality of SSc is associated with the involvement of 
internal organ systems (for reviews see (24,84,229,265,304,362)). The pathogenesis of 
SSc is not fully understood, and its aetiology is unknown.
Disease severity varies widely across the SSc spectrum, and is reflected by the 
degree and spread of cutaneous involvement. However, two main subtypes of SSc are 
recognized (198): in the limited form skin thickening is confined to the extremities and 
any serious visceral complications are late to develop, while in patients with diffuse 
disease, tethered, fibrotic skin extends over much of the body and there is early, often 
fatal, involvement of internal organs.
The reported prevalence of SSc is 100-200 cases per million, apparently increasing 
over the last few decades (326). However, this trend may be explained by changes in 
clinical criteria, modem study methods, and the inclusion of previously misdiagnosed 
and subclinical cases. The disease affects mainly women (F:M sex ratio >3:1), with 
onset typically at age 30-50. There are no particular geographical or racial proclivities, 
although some immunogenetic associations are emerging, and there may be a tendency 
in the families of some patients towards CTDs in general. There is convincing evidence 
that certain environmental agents are involved in the development of at least some 
clinical variants of scleroderma.
At present there is no cure for the disease itself: however, by reducing damage to 
internal organs, certain drug regimes have significantly improved mortality rates. While 
treatments remain inadequate and sometimes dangerous, accuracy of diagnosis and 
prognosis in this highly variable disease is an important aspect of patient care (23). An 
early designation of disease subtype serves to define the natural history of the disease, 
which is of primary concern to both patient and physician. The patient can be informed 
of the likely course, severity and time-scale of the disease, while the physician is alert to 
possible visceral complications. The costs and benefits of each available treatment can 
then be balanced appropriately.
Diagnostic criteria, disease subtypes and related disorders
Skin changes are the mainstay of diagnosis and classification in SSc. Sclerodermatous 
skin is tight, thick and characterized by non-pitting induration (218). According to the 
established criteria of the American Rheumatism Association (ARA), a diagnosis of 
generalized scleroderma, i.e. SSc, is reached on the basis of sclerodermatous skin 
extending beyond, and usually including, the digits (218). This is termed proximal 
scleroderma. However, less obvious symptoms such as sclerodactyly (digital
scleroderma), digital pitting scars, and certain characteristic symptoms of organ 
dysfunction may also lead to a diagnosis of SSc (for detailed clinical criteria see (218)).
The majority (60%) of SSc patients have limited cutaneous SSc (lc-SSc), where 
scleroderma affects only the hands, feet, face and forearms. The minority with the more 
severe diffuse cutaneous disease (dc-SSc) tend also to have upper limb and truncal skin 
involvement. The division of SSc into subtypes based on cutaneous distribution has 
been validated by consideration of the contrasting patterns of visceral involvement and 
serological findings in limited and diffuse disease. These, and other subsets of SSc, may 
represent aetiologically distinct disease processes or, alternatively, may reflect 
differences in patient vulnerabilities (86,198). The natural histories of the limited and 
diffuse forms of SSc will be described presently.
Localized forms of scleroderma are characterized by isolated patches of inflamed, 
fibrotic skin: vasculature is normal, and there are no visceral complications. Morphea 
appears as circumscribed plaques of affected skin: these may be isolated (limited 
morphea) or widespread (generalized morphea). Linear scleroderma occurs as bands of 
fibrotic skin, and is most often found in children, for whom growth abnormalities or 
disfigurement may be the consequence (229).
A rare variant of SSc, where the characteristic vascular changes and visceral 
involvement occur in the absence of cutaneous fibrosis, is known as SSc sine 
scleroderma.
As well as satisfying criteria for SSc, some patients exhibit features of other CTDs, 
and such cases are termed overlap syndromes. These include rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE), polymyositis/dermatomyositis (Pm/Dm), and 
Sjogren's syndrome (SS) overlaps. Undifferentiated connective tissue disease (UCTD) 
describes those patients whose few early symptoms are common to more than one CTD. 
The existence of mixed connective tissue disease (MCTD) as a distinct disease entity is 
controversial (319,22): the disease is defined by the presence of high titre anti-Ul RNP 
antibodies, and was originally described as a mild disorder, rarely affecting the lungs or 
kidneys. Some clinicians believe that such patients actually have UCTD, and it has been 
shown that many so-called MCTD patients subsequently satisfy the criteria for SSc, 
SLE, myositis or RA.
A number of environmentally induced scleroderma-like syndromes have been 
reported, such as vinyl chloride disease caused by the aliphatic hydrocarbon vinyl 
chloride, toxic-oil syndrome caused by aniline-contaminated rapeseed oil, eosinophilia- 
myalgia syndrome resulting from L-tryptophan supplements, and silica-associated SSc 
(Si-SSc), which can result from occupational exposure to silica dust. The aetiology of 
SSc is discussed further in Sections 1.5 and 1.6.
Vascular abnormalities and Raynaud's phenomenon
Structural and functional abnormalities of the microvasculature are present early in the 
course of SSc, most notably in the fingers. Alterations to capillary architecture are best
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observed by widefield microscopic examination of nailfold capillary loops. Areas of 
enlargement and distortion are apparent, sometimes to the point of capillary destruction. 
Large conglomerations of dilated capillaries and venules at the skin surface, known as 
telangiectases, may be directly visible, and usually occur on the fingers and face.
At autopsy, digital arteries appear narrowed, sometimes being blocked by fibrotic 
deposits. Skin biopsy samples also show evidence of arteriolar fibrosis. Small arteries 
are affected first, with a concentric pattern of intimal proliferation (40). Such 
microvascular obliteration can ultimately affect visceral vasculature.
Further evidence of vascular abnormality in early SSc includes a high incidence of 
Raynaud's phenomenon (RP) (for review (16)), an episodic digital ischaemia provoked 
by cold or emotion. In a typical attack, vasospasm causes the fingers (and/or other 
extremities) to become numb and remarkably pallid; this is followed by pain, 
venostasis, and cyanosis due to ischaemia; finally, the attack ends with the return of 
bloodflow, marked by a hyperaemic recovery phase during which the fingers appear 
reddened. In SSc patients with severe RP, chronic ischaemia may result in digital 
ulcerations and occasionally gangrene. There is evidence that the visceral vasculature of 
SSc patients is also affected by Raynaud's-like abnormalities and vasospasms, with 
consequent ischaemia and organ damage. Isolated (primary) RP is very common in the 
general population (~5-10%): however, its almost universal presence in SSc (~98%), 
being the first symptom in over 70% of patients, highlights its importance when 
considering populations at risk of developing the disease: identifying the small 
proportion of individuals presenting with RP who will go on to develop SSc or some 
other CTD is a key aim of clinical research and practice. The pathogenesis of RP and 
SSc may indeed be related, with severe RP being a formes frustes of SSc (i.e. an 
extremely mild variant on the SSc disease spectrum, or an incompletely expressed form 
of the disease).
Cutaneous involvement
While the pace and extent of skin changes in SSc vary widely, three main phases are 
recognized: oedema, induration and atrophy. The oedematous phase is characterized by 
stiff, swollen hands and feet, and the appearance of RP. The phase of induration 
follows, during which the dermis of fingers and other affected areas becomes thick, 
shiny, taut and fibrotic; the epidermis thins, the production of sweat and sebum is 
reduced, loss of hair and skin creases is apparent, and there may be areas of 
hyperpigmentation. Tethering of skin to underlying tendons and joints often causes 
contractures and friction rubs, and may severely affect hand function and overall 
mobility. Skin biopsy reveals an abnormal accumulation of collagen fibres in the 
dermis. Facial skin is often affected, producing a characteristically expressionless face, 
with thin lips and small, tightened mouth. After some years the atrophic phase begins, 
and dermal skin may soften: however, epidermal atrophy, scarring and contractures 
remain.
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of the disease).
Cutaneous involvement
While the pace and extent of skin changes in SSc vary widely, three main phases are 
recognized: oedema, induration and atrophy. The oedematous phase is characterized by 
stiff, swollen hands and feet, and the appearance of RP. The phase of induration 
follows, during which the dermis of fingers and other affected areas becomes thick, 
shiny, taut and fibrotic; the epidermis thins, the production of sweat and sebum is 
reduced, loss of hair and skin creases is apparent, and there may be areas of 
hyperpigmentation. Tethering of skin to underlying tendons and joints often causes 
contractures and friction rubs, and may severely affect hand function and overall 
mobility. Skin biopsy reveals an abnormal accumulation of collagen fibres in the 
dermis. Facial skin is often affected, producing a characteristically expressionless face, 
with thin lips and small, tightened mouth. After some years the atrophic phase begins, 




In many respects the immune system appears to function normally in SSc, with no 
increase in the rate of opportunistic infections. However, there are a number of highly 
unusual features, concerning both cell-mediated and humoral immunity (272).
Activation of certain peripheral blood mononuclear cells (PBMCs) is found, and the 
balance between their various subpopulations is altered. Skin biopsies indicate a dense 
inflammatory infiltrate of mononuclear cells (MNCs), which gradually disappears as the 
disease progresses. The mainly perivascular location of these MNCs suggests that the 
inflammatory infiltrate and the vascular disorders of SSc may be connected in some 
way. Both activation of immune cells and vascular degeneration precede cutaneous 
fibrosis, and thus may be of fundamental importance to disease pathogenesis, as 
discussed in Section 1.3.
Systemic sclerosis is often described as an autoimmune disease, and autoantibodies 
recognizing connective-tissue antigens have been reported. In addition, the majority 
(>90%) of patient sera contain autoantibodies which recognize a limited number of 
intracellular antigens, and the identity of these appears to reflect disease subtype. Some 
aspects of autoimmunity may be directly involved in the pathogenesis of SSc, while 
others may be epiphenomena.
Other immune system alterations found in a significant proportion of patients 
include the presence of circulating immune complexes, positive tests for rheumatoid 
factor, polyclonal hyper-y-globulinaemia, and abnormal levels of certain complement 
proteins (272).
Involvement of internal organs 
Renal involvement
Histopathology reveals luminal occlusion of the smaller renal arteries in the SSc patient 
with kidney involvement. Fibrosis and necrosis are also seen in the later stages of 
advanced disease. Scleroderma renal crisis involves an alteration in the renin- 
angiotensin-aldosterone axis (84), and consists of a sudden onset of malignant arterial 
hypertension, with the consequence of polyuric renal insufficiency. It typically occurs 
in those early cases of dc-SSc which display very rapid progression of skin involvement 
(~20%), and was once the most ominous complication of diffuse disease. However, 
since the introduction of a class of drugs known as angiotensin converting enzyme 
(ACE) inhibitors, mortality has been dramatically reduced. Timely administration of 
such anti-hypertensive drugs is assisted by anticipation of impending renal crisis.
Pulmonary involvement
Lung involvement can be manifested in two different ways in SSc, namely interstitial 
fibrotic lung disease and pulmonary hypertension.
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Interstitial fibrotic lung disease is revealed by X-ray as opaque areas in the lower 
lung. It occurs in a majority of dc-SSc patients (70%), but is unusual in lc-SSc. Patients 
exhibit cough and dyspnea on exertion, and crackling rales. There is an inflammatory 
infiltrate into alveolar interstitia and peribronchiolar tissues early in the disease. This is 
followed by vascular obliteration, and interstitial fibrosis.
Although pulmonary hypertension is rare in dc-SSc, it may be secondary to 
interstitial fibrosis. However, in 25% of patients with lc-SSc, pulmonary hypertension 
occurs in the absence of fibrotic lung disease, usually 10-20 years after disease onset. 
Again, the most common symptom is dyspnea. The pulmonary arteries may become 
occluded by subintimal proliferation and hypertrophy. The affected patient typically 
shows rapid deterioration followed by death.
The two patterns of lung involvement can be difficult to distinguish, and neither is 
easy to detect. Pulmonary function tests indicate a decrease in diffusing capacity of the 
lungs in both interstitial fibrosis and hypertension; total lung volume is also lowered, 
particularly in interstitial fibrosis. There has been only limited success in treating either 
condition (315). Future treatments will probably be directed at the early asymptomatic 
stages of pulmonary involvement, before extensive fibrosis and/or vascular remodelling 
have occurred (325). Identification of patient subgroups at risk of pulmonary defects is 
therefore desirable.
Cardiac involvement
Only 10% of lc-SSc patients have serious cardiac involvement, while this figure 
increases to about 15% in patients with diffuse disease. Patchy myocardial fibrosis, 
mainly affecting the ventricles, is the most common cardiac manifestation of SSc, and is 
often accompanied by contraction band necrosis. Such patterns of scarring are 
suggestive of a cardiac RP (84), with episodic ischaemia followed by reperfusion. 
Cardiac conduction systems are adversely affected by fibrosis, resulting in dangerous 
arrhythmias.
Gastrointestinal involvement
Involvement of the gastrointestinal tract in SSc occurs due to perivascular fibrosis and 
smooth muscle atrophy. Oesophageal dysmotility with chronic acid reflux is the most 
common feature of SSc after skin involvement, and occurs with similar frequency in 
both limited and diffuse subtypes (-85%). Symptoms may be eased by the use of 
histamine-2 receptor antagonists. Hypomotility of the small and large bowel may also 
be apparent as pseudoobstructional disorder, malabsorption and bacterial overgrowth.
Although gastrointestinal disorders are seldom the direct cause of death in SSc, they 




Limited cutaneous systemic sclerosis
The lc-SSc patient typically presents with recently acquired oedema of the fingers 
together with a history of RP, which may have been their only symptom for many years. 
There then follows an extensive period of very slowly developing skin fibrosis 
beginning with the hands, feet and face, which does not proceed beyond the elbow, 
knee or neck. Telangiectases and digital tip ulcers may be seen early, while calcinosis 
(deposition of calciferous material under the skin) is common later on. Serious internal 
manifestations can occur, but often take decades to appear, the most important being a 
sudden onset of isolated pulmonary hypertension, which is usually fatal. Other visceral 
complications include oesophageal hypomotility, small bowel malabsorption and, in 
some cases, interstitial lung disease. The 6-year survival rate is ~80%, while 12-year 
survival is ~50%.
Diffuse cutaneous systemic sclerosis
The most likely symptoms of the dc-SSc patient at presentation are a sudden 
development of RP, together with swollen, puffy fingers, and in some cases arthritis. 
Tendon friction rubs and skin thickening of the extremities may already be apparent. 
Pulmonary, cardiac, gastrointestinal and/or renal abnormalities are often detectable at an 
early stage. The disease progresses rapidly over the next year or two, with very severe 
and extensive skin thickening which usually includes the trunk. The pace of these 
cutaneous changes correlates with the involvement of internal organ systems, and 
consequently increased mortality. However, about 5 years after disease onset, many 
survivors experience a gradual softening of affected skin, and, although the state of 
organ systems already affected continues to decline, new organ involvement is unusual. 
Six-year survival is ~30%; 12-year survival is ~15%.
Clinical investigation, diagnosis and prognosis
When the presenting symptoms are suggestive of SSc or a related CTD, several modes 
of investigation are currently used to aid diagnosis. Once a diagnosis of SSc has been 
made (218), assignation of disease subtype is the key factor in predicting disease 
severity for the individual patient with early disease.
Some of the investigations described below are also relevant to patients presenting 
with isolated RP, and can help to detect the minority of such patients at risk of 
developing a more serious CTD.
Clinical examination
Non-invasive clinical examination of the patient at presentation makes a valuable 
contribution to both diagnosis and prognosis, particularly in poorer countries. The 
experience of the examining physician is of the utmost importance in the detection of 
early disease, as symptoms may be subtly expressed at this stage.
Skin scoring
The presence of characteristic and unambiguous sclerodermatous skin changes at 
presentation may allow an immediate and quite confident diagnosis of SSc to be made. 
The assignation of disease subtype may also be possible, based on the extent and pattern 
of cutaneous fibrosis.
For a reliable prognosis to be made on the basis of skin examination alone, a series 
of semi-quantitative assessments should be commenced immediately following 
presentation. Several such skin-scoring systems have been devised, each providing a 
numerical index of both severity and extent of skin involvement, applicable to both 
limited and diffuse disease. One widely accepted system with high reproducibility is the 
Total Skin Score (TSS) (58), based on clinical palpations throughout the body. Ten 
zones of the body are scored from 0-3 according to the degree of skin thickening: the 
sum of these scores is the TSS. In a study by Clements et al.t an inverse relationship 
was found between survival time and the TSS measured at study onset, and this proved 
to be significantly more reliable than classification systems based merely on the 
distribution of affected skin (58).
Widefield nailfold capillaroscopv
The earliest detectable sign of microangiopathy in SSc is an alteration in nailfold 
capillary architecture, and abnormalities detected by microscopic examination of 
nailfold capillary loops can be extremely useful in helping to confirm assessments 
based on skin findings (215). This cheap and relatively simple technique may be useful 
in differentiating between limited and diffuse subtypes of SSc. Its most prognostically 
impressive application, however, is in identifying those few patients with isolated RP 
who are likely to develop SSc or another CTD (42).
Examination of the nailfold capillaries of SSc patients demonstrates a striking and 
characteristic enlargement and distortion of capillary loops. The lc-SSc patient shows 
the "slow pattern" of capillary abnormality, and many giant capillaries are seen. In 
addition to dilatation, dc-SSc patients also display capillary dropout or destruction, 
which appears as avascular areas. Serial examination of dc-SSc patients reveals this 
"active pattern" of destruction. However, the technique has its limitations: these 
abnormalities can also be seen in other CTDs such as Dm and overlap syndromes, and 
are occasionally seen in diabetes mellitus, and following trauma (16).
Some patients who appear to have severe, primary RP also exhibit abnormal
nailfold capillaroscopy, usually of the slow pattern. Such patients are thought to be at an 
early stage of evolving SSc: the presence of abnormal capillaries in a patient with
primary RP is very suggestive of impending SSc (42).
Bibasilar crackles
Simply by listening to the chest, bibasilar crackles may be detected, pointing to the 
presence of pulmonary fibrosis.
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Patient history
The patient's recollections regarding the timing of onset of RP, oedema and skin 
thickening are also relevant, as are his or her comments on any other symptoms of a 
visceral nature, which may point to the involvement of particular organs. For example, 
if blood is being passed in the urine, renal involvement is indicated.
In those patients presenting with isolated RP, the age at onset of symptoms is 
particularly important: most cases of primary RP develop before adulthood, while RP 
secondary to an underlying CTD frequently appears for the first time in the third and 
fourth decades. Particularly severe cases of isolated RP have also been linked with 
likely progression to a CTD (for review, (169)).
Physiological tests
There are a number of very useful physiological tests relating to the dysfunction of 
particular organs. Measurement of oesophageal transit time by quantitative oesophageal 
scintography helps confirm gastrointestinal involvement. The detection of cardiac 
conduction abnormalities and arrhythmia's by electrocardiography is indicative of 
cardiac involvement. An important test relating to pulmonary function is measurement 
of the carbon monoxide diffusion capacity of the lung (DLCO): an abnormal result 
indicates pulmonary involvement. Information provided by chest X-ray is also an 
important determinant of pulmonary fibrosis.
While such techniques are important for the thorough assessment of a particular 
patient, their prognostic value is limited. Ideally such tests should predict, rather than 
merely record, end-organ damage -  the simple expedient of blood pressure monitoring, 
for example, is invaluable in the prevention of scleroderma renal crisis by judicious use 
of ACE inhibitors.
Biochemical markers
Many attempts have been made to correlate the presence of SSc with a variety of 
biochemical markers, the aim being early diagnosis, determination of disease subtype 
and avoidance of organ damage.
Renal involvement is frequently detected by changes in several biochemical 
markers of kidney function, including serum measurements of creatinine, creatinine 
clearance rates, and the detection of abnormal quantities of protein in the urine.
A significant positive association has been reported between serum levels of the 
inflammatory cytokine tumour necrosis factor-a (TNFa) and the development of 
pulmonary fibrosis in SSc patients (130). Further, TNFa values of both lc- and dc-SSc 
patients were significantly higher than those found in normals (130). Serum levels of a 
variety of soluble cell adhesion molecules have been found to correlate well with 
clinical disease activity in SSc patients (122). In the case of intercellular adhesion 
molecule-1 (ICAM-1), a significant difference between lc- and dc-SSc groups has been 
demonstrated (175). Meanwhile, significant differences between normals and SSc
patients have been found when plasma levels of the complement protein fragments C3d 
and C4d were measured (307).
Some markers may have potential for the differential diagnosis of primary versus 
secondary RP. For example, high plasma levels of p-thromboglobulin, a product of 
platelet activation, were found only in those RP patients who were in suspected 
transition to SSc (305), and not in those RP patients with carefully defined primary 
disease. Von Willebrand factor antigen (an indicator of vascular endothelial damage) 
has been associated with disease severity in patients with RP, being significantly higher 
in dc-SSc when compared with normals and patients with primary RP (135).
The main drawback of such markers is that, while average measured values of a 
particular marker may be significantly different between groups of SSc patients and 
normals, or between groups of patients with diffuse versus limited SSc, there is often a 
rather wide distribution of values within each group, and/or considerable overlap 
between groups. For this reason measurement of such markers in a single individual 
may have little meaning in terms of prognosis or diagnosis for that particular patient, 
and few of these markers have been appropriate or reliable enough for routine clinical 




The detection and identification of particular SSc-specific anti-nuclear antibodies 
(ANAs) in the serum of an individual patient is one of the most useful diagnostic and 
prospective guides available: ANAs appear early in the course of SSc, and several are 
highly disease specific. Furthermore, the presence of a particular class is not only 
indicative of disease subtype, but also predictive of future patterns of visceral 
involvement, even in the absence of definitive skin findings, since the particular ANAs 
found in SSc tend to segregate with clinically homogeneous disease subsets.
The presence of ANAs in the sera of patients with isolated RP is unusual and, when 
present, they are usually of low titre. Thus, the detection of high-titre ANAs in these 
patients is highly suggestive of a developing CTD, and the specificity of such 
autoantibodies can have prognostic value (168).
The substantial contribution of autoantibody identification to diagnosis and 
prognosis in SSc is reviewed in detail in Section 1.8.
Other autoantibodies
Besides autoantibodies which recognize intracellular antigens, a number of other 
autoantibodies have been associated with aspects of disease expression in SSc. For 
example, a positive correlation has been demonstrated between the presence of RP and 
the presence of specific antimyenteric neuronal antibodies in SSc patients (147). 
Antibodies recognizing interleukin-6 (IL-6) have been detected in SSc patients at a 
frequency significantly higher than in normals, being particularly common in those
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patients with limited disease (337). The occurrence of anti-endothelial cell (EC) 
antibodies has also been found to be significantly more common in SSc patients 
(particularly those with dc-SSc) than in normals, being found to coincide significantly 
with severe digital ischaemia and pulmonary arterial hypertension (242).
Whatever the target of the autoimmune response in SSc, inappropriate activation of the 
normal adaptive immune response is implied. Adaptive immunity, tolerance to self, and 
the subversion of these processes in SSc are discussed below. Possible relationships 
between the aetiopathogenic changes of SSc, and the accompanying immunological 
findings are also considered.
1.2 ADAPTIVE IMMUNITY
An ideal immune system would have evolved to cause destruction of non-self material 
whilst avoiding damage to the self. Thus, stimulation of the adaptive immune system is 
normally caused only by foreign, non-self antigens. This is not a straightforward feat, 
however, since the immune system receptors which are required to discriminate 
between self and non-self are inherited quite independently from the self antigens they 
are required to protect.
Maintenance of a healthy condition of self-tolerance is partly a dynamic, ongoing 
process, and many regulatory mechanisms are thought to be involved. Failure of any 
one mechanism of self-tolerance can lead to the body's adaptive immune system 
becoming capable of recognizing its own cells and molecules, and this is the process of 
autoimmunity.
The adaptive immune system 
Cells o f the adaptive immune system
The adaptive immune system consists of two main types of lymphocyte: thymus- 
derived lymphocytes (T cells) and bone marrow-derived lymphocytes (B cells). The T- 
cell group is further split into two distinct subsets, T helper cells and T cytotoxic cells 
(Th and Tc respectively).
The B-cell lineage is responsible for producing and secreting antibodies 
(immunoglobulins (Igs)), a process which occurs only after a B cell divides and 
differentiates into a plasma cell. Millions of different B-cell clones are each capable of 
producing a particular antibody specificity which can recognize a particular set of 
foreign antigens. The recognition and binding of these foreign antigens by the 
antibody's specific binding site facilitates their clearance by phagocytic cells, which 
bear Ig-binding surface receptors. Phagocytic cells, such as macrophages, are
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responsible for taking in foreign particles or microbes and breaking them down 
enzymatically.
A key function of Th cells is to help B cells divide, differentiate and produce 
antibodies. Thus, both B cells and Th cells are important in promoting the removal of 
extracellular foreign material. Meanwhile, Tc cells are responsible for the elimination of 
virally infected host cells, a process which also requires help from Th cells. To enable 
specific recognition of individual antigens, both types of T cell express T-cell receptors 
(TCRs). Millions of different T-cell clones are present in the body, each expressing a 
particular TCR which recognizes a particular peptide antigen. However, for effective T- 
cell recognition, the peptide must be presented on the surface of a host cell, in 
association with a major histocompatibility complex (MHC) molecule. In the case of Th 
cells, this relies on the actions of specialized antigen presenting cells (APCs), of which 
there are several types, including dendritic cells (DCs), some types of macrophage, and, 
under certain circumstances, B cells.
Activation o f helper T lymphocytes
All APCs express the MHC human lymphocyte antigen (HLA) Class II molecule, and 
ingest material from their extracellular environment. This material is broken down 
enzymatically in the acidic lysosomes, where the resulting peptides are thought to 
associate with the MHC Class II molecules (this is known as the exogenous pathway of 
antigen processing) (239). Each peptide-MHC Class II assembly is then presented on 
the surface of the APC. Meanwhile, Th cells express the CD4 co-receptor, which is 
capable of specifically recognizing and binding to MHC Class II. For an effective APC- 
Th cell encounter, a membrane-bound MHC Class II molecule bearing a peptide antigen 
must be recognized by an appropriate antigen-specific Th cell bearing the CD4 co­
receptor. To facilitate this interaction, each TCR is physically associated with a CD4 
molecule on the Th cell surface. The TCR complex also includes a CD3 accessory 
molecule, which is vital for signal transduction. The sum total of these interactions is 
known as Signal 1. However, a further requirement for successful Th cell stimulation is 
interaction of co-stimulatory molecules i.e. Signal 2. The CD28 molecule on the Th cell 
surface must bind with either a B7.1 (CD80) or a B7.2 (CD86)molecule on the APC 
surface. Only when both Signal 1 and Signal 2 are fulfilled will Th cell activation occur. 
During activation of a Th cell, a cytokine signal (IL-1; lymphocyte activating factor) is 
passed from the APC to the Th cell. In turn, the IL-1-activated Th cell releases IL-2 (T- 
cell growth factor) and also assembles IL-2 receptors (IL-2Rs) on its surface. The 
consequence is IL-2 autocrine stimulation, and clonal proliferation into many activated 
Th cells, each having the same TCR specificity.
Activation o f cytotoxic T lymphocytes
The MHC Class I molecule is expressed on the surface of all nucleated human cells, and 
presents peptides resulting from proteolysis of internally derived proteins (the
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endogenous pathway). All Tc cells express the CD8 co-receptor which is capable of 
specifically recognizing and binding to MHC Class I. The Tc-cell TCR complex 
consists of the TCR, the CD8 co-receptor and the CD3 accessory molecule. For 
effective Tc cell activation, a membrane-bound MHC Class I molecule bearing a 
peptide antigen must be recognized by an appropriate antigen-specific TCR complex. 
Other cell adhesion molecules present on the surfaces of the Tc cell and on the target 
cell function to increase the binding affinity of this interaction, and these may include 
the costimulatory molecules mentioned above.
For full activation, however, the Tc cell also needs help from Th cells which 
recognize the particular viral peptide concerned (181). Due to the inevitable presence of 
viral particles in the extracellular environment, specific Th cells will previously have 
been activated following recognition of virus-derived peptide antigens presented by 
APCs. The activated Th cell stimulates the Tc cell via the production of IL-2. Following 
Tc-cell stimulation, clonal proliferation of Tc cells takes place. The resulting activated 
Tc cells are then capable of binding to similar virally infected cells, which is followed 
by the release of cytotoxic substances aimed at enzymatic destruction of the infected 
cells.
Activation o f B lymphocytes
A further function of Th cells is in the activation of B cells. All B cells express their 
own particular type of Ig molecule on the cell surface. The Igs frequently recognize and 
bind to intact antigens i.e. they are capable of recognizing tertiary protein structure. The 
first step in B-cell activation involves interaction of the surface Ig with specific antigen. 
Such interactions are promoted by a particular type of APC. Follicular DCs are found in 
spleen and lymph node follicles, and express receptors for immune complexes 
containing complement and antigen. They are thought to accumulate and hold 
unprocessed antigens on their extracellular surfaces, which are then available for 
specific stimulation of appropriate B cells via their membrane-bound Ig receptors (179). 
Due to the constant recirculation of lymph fluid through the spleen and the lymph 
nodes, an appropriate B cell is likely to come into contact with an APC which is binding 
an immune complex which includes a particular antigenic particle. Following specific 
B-cell recognition, the APC releases IL-1 which causes activation of the B cell (clonal 
selection).
Following activation, B cells are ready for Th-cell help. Depending on the specificity 
of the Ig on the surface of the B cell, specific antigenic particles are ingested, processed 
and presented as peptide antigens in association with MHC Class II molecules. 
Activated Th cells recognize the recently stimulated B cell via an appropriate specific 
TCR complex interaction with the MHC Class II-bound peptide on the B cell surface. 
Again, co-stimulatory molecules are also vital: the CD40 receptor on the B cell surface 
specifically binds with the CD40 ligand. This ligand is upregulated on activated Th 
cells. Once an appropriate antigen-specific Th-cell encounter takes place, the Th cell
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will produce cytokines that further stimulate the B cell (IL-2, IL-4 (B cell growth 
factor), IL-5, IL-6  (B cell differentiation factor), and interferon-y ( IFNy)). These cause 
the B cell to proliferate and differentiate into a clone of plasma cells capable of 
producing vast quantities of soluble Ig.
It is thought that B cells may also function as APCs, and present peptide antigens to 
naive Th cells. To aid this process, it is believed that follicular DCs can induce 
upregulation of MHC Class II and co-stimulatory molecules on resting B cells, thus 
promoting their effectiveness as APCs (179). However, B cells only ingest the antigenic 
particles which are specifically recognized by their surface Igs. These particles will 
have other antigenic regions which are not recognized by the particular B cell 
concerned. The peptides making up these other antigenic regions will, however, be 
processed and presented by the B cell. Consequently, the presentation of antigens to Th 
cells by B cells is believed to be an important aspect of the spreading and maturation of 
the immune response to different epitopes of a single protein antigen, and is known as 
intermolecular help (see Section 1.7).
1.3 PATHOGENESIS
A satisfactory model of SSc pathogenesis would include vascular, fibrotic and immune 
aspects of the disease. Understanding in each of these areas has increased greatly in 
recent years, but interrelating them into a coherent whole remains difficult, particularly 
while knowledge of the initiating step is lacking. Although the various hypotheses vary 
in detail, a basic model of current thinking is described below (for reviews see 
(105,196,199,265,318,320)).
The culminating feature is excessive deposition of connective-tissue matrix proteins 
by scleroderma fibroblasts (FBs). However, this appears to be preceded by vascular 
endothelial injury/activation and a perivascular infiltration of activated MNCs. 
Autoimmunity may be a cause and/or an additional consequence. A number of different 
cytokines, growth factors and cell types are doubtless involved in the pathogenesis of 
SSc, and their myriad interactions are the subject of intensive current research.
Vascular endothelial injury and activation
The vascular EC is believed to play a central role in the pathogenesis of SSc (40,165). 
Indeed swelling, dysfunction and degeneration of the microvascular endothelium may 
be the earliest manifestations of the disease. Together with platelet products and 
neuropeptides, EC products control vascular tone (164). Disruption to this delicate 
three-way balance is thought to underlie the pathogenesis of RP in SSc, and there is 
certainly evidence to support this. Plasma levels of endothelin-1, a potent local 
vasoconstrictor and a product of ECs, are raised in both primary RP and SSc (166,370), 
while release of the vasodilator endothelial-dependent relaxation factor is deficient.
A further role of the endothelium is in the control of vascular permeability (for 
review see (263)), and the presence of oedema in early SSc reflects its aberrant 
function. There are signs of mast cell activation in scleroderma (155), and high 
concentrations of mast cell-derived histamine are found in SSc sera. Histamine is a 
vasoactive amine which acts on ECs to cause increased capillary permeability.
Increased expression of cell adhesion molecules by ECs is indicative of a state of 
endothelial activation. Both ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) 
have been shown to be upregulated in the vascular lesions of SSc (321). The cause of 
this EC activation is unknown, but may be related to endothelial damage.
There is evidence that the vascular endothelium becomes physically injured in SSc, 
with a certain amount of cell death. Increased serum concentrations of (3- 
thromboglobulin and circulating platelet aggregates imply platelet activation, and this is 
thought to be a direct consequence of endothelial damage. The raised levels of Factor 
VIII (von Willebrand factor antigen) found in SSc plasma are also consistent with 
endothelial destruction, since Factor VIII is known to be sequestered in EC granules.
The exact mode of assault on the vasculature is unknown. Several different factors 
may act singly or in concert. In-vitro studies have shown that a majority of SSc sera are 
directly cytotoxic to ECs by a non-immune mechanism, and the soluble protein 
responsible may contribute to vascular damage in vivo. In severe cases, RP may itself 
lead to endothelial injury, and free-radical species resulting from repeated ischaemic 
episodes have been implicated. Involvement of the complement system has also been 
suggested. Alternatively, environmental agents may be responsible. In recent years, 
immune theories of endothelial activation and injury have become increasingly 
attractive.
Whatever the initial causes of dysregulation and damage, the result is a more 
permeable, activated endothelium with physically disrupted components. Activated ECs 
are metabolically profligate, producing increased quantities of IL-1, IL-6 , basic 
fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF). Meanwhile, 
activated platelets release PDGF and transforming growth factor 3 (TGFJ3). The 
upregulated EC adhesion molecules ICAM-1 and VCAM-1 function to attach activated 
leucocytes to the vascular endothelium in preparation for extravasation, and any 
increase in microvascular permeability improves access to the interstitium for both 
PBMCs and cytokines (268). A likely consequence of a damaged, more permeable 
endothelium is to make components of the basement membrane more exposed on the 
endothelial surface: indeed, fragments of EC-derived connective tissue may be adrift in 
this inflammatory milieu.
Taken together, these factors create an environment which may provoke an immune 
attack on the vascular endothelium itself. Several interrelated mechanisms of immune- 
mediated vascular damage have been suggested, and will be discussed presently.
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Immune system activation
While there is plenty of evidence supporting activation of the immune system in SSc, 
the initiating cause is unknown, and it remains uncertain which aspects occur before, 
after, or simultaneously with the vascular lesions. The complex relationship between 
vascular and immune events in SSc is a particularly unclear and controversial subject. 
As LeRoy has said of SSc pathogenesis, '...cause and effect have not been sorted out...', 
continuing, '...a cycle of interactions seems plausible, inviting further study of what 
comes first.' (197). On the basis of present knowledge, it would appear that a destructive 
cycle of vascular injury is set up in which immune cells probably have a key role.
Distribution of activated immune cells
In SSc, while the total population of peripheral T cells appears to be normal, analysis of 
subpopulations reveals an increase in the ratio of Th cells (CD4+) to CD8 + 
(suppressor/cytotoxic) T cells. Meanwhile, the B cell:T cell ratio is normal. Activation 
of these Th cells is implied by a higher proportion of T cells expressing the IL-2R, and 
by elevated serum levels of soluble IL-2 and IL-2R, which appear to correlate with 
disease activity, severity and mortality. Other products of T cell activation such as IL-4, 
IL-6 , TNFa and soluble CD4 antigen are also raised in SSc sera, and the expression of 
protooncogenes such as c-myc by peripheral T cells is upregulated. Further, the 
increased concentration of serum IL-1 found in SSc is consistent with Th cell activation 
by APCs. As well as a/p T-cell activation, recent results point to an important role for T 
cells carrying the less common y/8 TCR: the prevalence of V51+ T cells is significantly 
increased in patient sera, and they too appear to be in an activated state (113).
A perivascular inflammatory infiltrate of MNCs around microvessels of the 
reticular dermis and between the dermis and the subcutaneous tissue is seen early in 
SSc, and consists mainly of activated Th cells and activated monocytes (macrophages) 
(93,178), including a significant accumulation of V51+ T cells (113). Co-localization of 
cytokines and Th cells has been demonstrated in the perivascular lesions of SSc, and 
implies involvement of activated Th cells in endothelial events.
Adhesion molecules and homing o f PBMCs to the vascular endothelium 
Lymphocyte homing is mediated by cell adhesion molecules. Circulating lymphocytes 
expressing appropriate and sufficient cell adhesion molecules (homing receptors) are 
known to home to high endothelial venules where they bind to complementary 
addressins. These addressins are the EC adhesion molecules ICAM-1 and VCAM-1, 
upregulated by EC activation in order to provide enhanced adhesion to passing 
activated lymphocytes (321). The natural ligands of ICAM-1 and VCAM-1 are 
lymphocyte function-associated antigen-1 (LFA-1) and very late antigen (VLA), 
respectively. The LFA-1 ligand is found on lymphocytes, monocytes and natural killer 
(NK) cells, while VLA is widely expressed on leucocytes except neutrophils (for 
reviews see (191,221,323)).
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In-vitro studies have shown that a subfraction of activated PBMCs from SSc sera 
display abnormally enhanced binding to ECs. Furthermore, the perivascular infiltrate of 
MNCs in SSc-affected skin display increased LFA-1 and abundant VLA expression. In 
the context of increased vascular permeability, this is sufficient explanation for the 
perivascular infiltrate of activated PBMCs seen in SSc. Recent evidence specifically 
suggests homing of V51+ T cells to perivascular sites of inflammation in the early 
oedematous phase of SSc (113).
Types o f immune response in SSc
Thus, several aspects of the immune system and various types of immune cell may be 
involved in the pathogenesis of SSc: the infiltration of activated Th cells and 
macrophages to perivascular sites of inflammation has been noted; the presence of 
autoantibodies in SSc sera implies a role for B cells; in addition, there is evidence of a 
MHC-independent cytotoxic immune response, and this has been associated with y/8 T 
cells and NK cells. These responses are discussed in turn below.
Delayed type hypersensitivity
Thus far, the scenario described above resembles a delayed-type hypersensitivity 
response. As discussed earlier, this involves TCR recognition of processed antigenic 
peptides bound to MHC Class-II molecules on the surface of APCs. Consequent 
activation of the Th cells causes release of IL-2, IFNy and TNFa, followed by Th cell 
proliferation, one consequence of which is macrophage activation. A hypothesis has 
been developed for SSc which proposes an autoimmune response to components of the 
vascular endothelium, possibly made available as a direct or indirect result of vascular 
injury. A basic requirement for such a hypothesis would be a breakdown of self­
tolerance mechanisms: this aspect will be discussed separately in Sections 1.4 and 1.7.
The target of endothelial immune injury may be the EC itself or its basal lamina, 
which comprises several connective tissue components. There is evidence that 
connective tissue components can cause T cell activation in SSc -  recirculating Th cells 
recognizing laminin and type I collagen have been demonstrated in patient sera. 
Peripheral blood MNCs from patients with SSc have been shown to undergo blast 
transformation when cultured in the presence of type IV collagen and laminin (150), 
both components of the endothelial basement membrane, and it was suggested that 
lymphocytes may become activated at sites of endothelial injury (150). When PBMCs 
were taken from patients with early SSc, increased production of IL-2 by CD4+ cells 
was similarly demonstrated following incubation with type I collagen (132).
It was mentioned previously that a soluble cytotoxic factor was present in many SSc 
sera, and this has been identified as the protease granzyme-1. This enzyme is a product 
of the granules of activated Tc cells and is capable of disrupting basal lamina due to its 
type IV collagenase activity, leading to production of type IV collagen and laminin 
fragments. Granzyme-1 activity may thus be an important factor leading to the
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production of an MHC-dependent autoimmune response to components of basal lamina 
in SSc (197). Evidence for the MHC-independent activation of Tc cells in SSc will be 
described later.
The identity of the particular population of APCs involved in the purported 
presentation of EC antigens in vivo is unknown. Possible mechanisms involved in Th- 
cell activation are described presently: each may be important at a different stage of the 
immune response.
Consequences o f Th cell activation
The activation of Th cells by APCs would lead to release of IL-1 by the APC and 
consequent proliferation of specific T-cell subpopulations with further cytokine 
production, and inflammation. The initial product of Th cell activation in delayed-type 
hypersensitivity is IL-2, which has paracrine and autocrine effects on antigen-activated 
T cells causing clonal proliferation. Other cytokines released by Th cells following IL-2 
stimulation include IFNy and TNFa.
Endothelial cells become activated in the presence of TNFa, causing an increase in 
the endothelial expression of ICAM-1 and VCAM-1. In addition, TNFa causes the 
release of vasodilatory substances by ECs. Together, TNFa and IFNy increase 
micro vascular permeability. This leads to EC recruitment of monocytes and 
lymphocytes from the blood.
Class-II MHC expression on ECs and monocytes is upregulated by IFNy, causing 
more efficient antigen presentation at the local site. In addition, macrophages in the 
immediate vicinity of IFNy become activated. Activated macrophages in turn produce a 
variety of cytokines and growth factors, including IFNy, TNFa, TGFp, IL-13 and 
PDGF. If endothelium-derived antigens were being presented in SSc, a self- 
perpetuating cycle of endothelial destruction could be set up. Again, it should be 
pointed out that the inciting event has not yet been identified.
Antigen presentation by dermal macrophages
Connective-tissue fragments from EC damage could be processed and presented by 
dermal macrophages and presented to T cells which coincidentally entered the tissues 
from the bloodstream. An appropriate antigen-specific encounter, with consequent T 
cell activation and TNFa release, would result in, or contribute to, EC activation. As a 
consequence of local changes to the vascular endothelium, other antigen-specific T cells 
would then be more likely to reach the site and join the reaction. This amplification 
mechanism via EC activation may be an important component of the normal delayed 
type hypersensitivity response (1).
Antigen presentation by endothelial cells
Infiltrating MNCs' production of IFNy causes enhanced Class II MHC expression on 
ECs, and renders them capable of antigen presentation. Connective tissue fragments
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produced by EC damage could thus be presented to T cells by ECs. In this way ECs 
could modulate T cell responses, giving help for IL-2 generation by T cells with 
consequent T cell proliferation.
Antigen presentation in lymph nodes
Transport of fragmented connective tissue molecules to lymph nodes is also plausible. 
Here, antigens are processed and presented by the resident APCs and there is an 
increased likelihood of a chance encounter with an appropriate T cell. Following 
antigen-specific Th-cell activation, clonal proliferation with increased expression of Th- 
cell adhesion molecules would follow. In turn, these factors lead to an increased chance 
of an appropriate encounter at the peripheral site.
Co-stimulation by connective tissue fragments
The VLA receptor is known to be capable of direct binding to a variety of connective 
tissue components (191). Exposure of basement membrane antigens such as laminin, 
fibronectin and type IV collagen may result in direct binding of these extracellular 
connective tissue matrix proteins to T cells via T-cell VLA. Together with a different 
MHC Class II-bound antigenic stimulus engaging via the T-cell antigen receptor, 
connective tissue proteins could perform a costimulatory role in T cell activation (for 
review (196,318)).
Humoral immune system
Pathogenic anti-endothelial cell antibodies
The presence of autoantibodies recognizing connective tissue components laminin, and 
collagen types I, III, IV and VI has been demonstrated in some SSc sera (285), and anti- 
EC antibodies are also found in ~30% of SSc patients (141). This suggests that 
activated autoreactive Th cells which recognize connective tissue fragments may give 
help to corresponding autoreactive B cells, promoting differentiation into plasma cells 
and subsequent autoantibody production.
Anti-EC autoantibodies, as already mentioned, occur in ~30% SSc sera. Recent 
evidence suggests that these particular antibodies could actually be involved in SSc 
pathogenesis (29,266). Anti-EC antibodies were shown to induce monocyte adhesion to 
vascular ECs in vitro coincident with increased expression of ICAM-1, VCAM-1 and 
E-selectin on ECs (45). The antibodies are of the IgG family, and bind to an unknown 
site on the EC via their antibody-binding domain (Fab) fragment. This induces 
activation of the EC, and upregulation of cell adhesion molecules, possibly by an 
autocrine IL-1 effect (45). Some believe that anti-EC autoantibodies recognize a 
particular EC surface antigen (45). Others consider that the anti-EC autoantibodies of 
SSc sera recognize a particularly heterogeneous range of EC surface antigens, and it has 
been speculated that these may include intracellular antigens abnormally expressed at 
the cell surface (141).
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Autoantibodies recognizing intracellular antigens
Autoantibodies which recognize intracellular antigens have been found in up to 97% of 
the scleroderma population. This is a rather more puzzling aspect of the SSc disease 
process, and some have dismissed it as a mere epiphenomenon, with no significance to 
disease pathogenesis (333). There is evidence that the production of these 
autoantibodies is also mediated by autoreactive T-cell help, implying that a breakdown 
in both T- and B-cell self-tolerance to certain intracellular antigens is involved in SSc. 
The expression of intracellular antigens on the surface of ECs mentioned above is one 
possible explanation of how normally sequestered self-antigens are made available to 
the immune system in SSc: others are discussed in Section 1.7.
Cell-mediated cytotoxicity
What is described as cell-mediated cytotoxicity encompasses the functions of at least 
three different cell types. Each type of cell-mediated cytotoxic response has its own 
system of receptor/ligand interactions for binding the cytotoxic cell to its target. First 
there is Tc cell killing, which is important in the removal of virally infected cells, and, 
as discussed earlier, this involves TCR recognition of processed antigens bound to the 
MHC Class I molecules of the target cell. There is no evidence of this kind of activity in 
SSc. Secondly, there is killing by activated NK cells. A third type of cell-mediated 
cytotoxicity is carried out by killer (K) cells.
It has been mentioned that the V5i+ T cell population is increased in SSc. The y/5 T- 
cell is not fully understood: while it is thought that both cytotoxic and helper 
subpopulations exist, the cytotoxic subset may predominate. This would seem to imply 
a role for typical Tc cell functions in SSc: however, only NK and K cell functions are 
thought to be important in SSc pathogenesis.
Natural killer cells
Natural killer cells are lymphocytes which express neither T cell or B cell-specific 
receptors. They bind to the target cells in inflammatory sites via the cell adhesion 
molecules discussed earlier and kill by direct cell-mediated injury. The NK cell is 
thought to be activated by Th cell-derived IL-2 in the inflammatory site, after which it 
becomes the functional lymphokine-activated killer cell (LAK), poised for non-specific 
local attack. It is believed that some Tc cells are capable of LAK-type killing -  in other 
words a cytotoxic response not involving specific antigen recognition by their TCR.
In SSc there is a low level of NK cells in the circulation while there is an 
accumulation of these cells in the perivascular inflammatory lesions. Recently a much 
higher than normal proportion (50%) of the V51+ subset of T cells in SSc patients was 
shown to co-express CD8 , the marker of the cytotoxic T cell. The SSc V51+ T cells 
were also shown to display enhanced expression of VLA. This and other evidence 
suggests that V51+. Tc cells may play an important effector role in SSc, involving MHC-
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independent, LAK-like cytotoxicity mediated via cell adhesion molecules and possibly 
directed against ECs (113).
Antibody-dependent cell-mediated cytotoxicity by K cells
Lymphocyte-like K cells have no T-cell antigen receptors. However, they do have 
receptors responsible for specifically binding the crystalline fragment domain (Fc) of 
IgG (F cy). Normally they are important in the anti-tumour response, killing antibody- 
coated cells by extracellular mechanisms. The Fcy fragment of IgG antibodies binding to 
their target cell antigen is recognized and bound by K cells. Consequent killing of the 
target cell by K cells is termed antibody-dependent cell cytotoxicity (ADCC). Rather 
than being a specific cell type, the K cell may represent a function. Evidence suggests 
that some Tc and NK cells have Fc receptors, and can kill specifically by the K-type 
method.
It has been found that normal PBMCs can kill ECs when co-cultivated in the 
presence of serum from ~20% of SSc patients, and the Ig fraction of SSc sera was 
shown to be necessary for this effect (146,216). The process is mediated by IgG 
antibodies recognizing EC surface antigens, apparently by a K-type ADCC response 
(141,146).
Fibrotic lesions
The fibrotic lesions of scleroderma result from the excess deposition of normal 
components of connective tissue by a subset of activated FBs, namely collagen types I, 
III, V, VI and VII, proteoglycans, fibronectin and tenascin (84,162). Concentrations of 
the corresponding mRNA species are also increased ((176); for review see (70)). A 
basic FB defect is not responsible since FBs taken from the unaffected skin of SSc 
patients display normal levels of matrix production (199). Nor is altered catabolism of 
collagen thought to be a factor: collagenase synthesis of SSc-FBs is normal (24). The 
SSc-FB goes on overproducing matrix proteins for several passages in vitro, and 
expression of c-myc protooncogene is also increased. Cultured SSc-FBs do not respond 
normally to growth factors (176), and resist the quiescence normally induced by serum 
deprivation. Thus, there also appears to be a defect of FB growth regulation which is 
not directly related to matrix secretion (195,196).
Since the activated phenotype of in-vitro SSc-FBs is eventually lost, in-vivo factors 
are thought to be responsible for their original activation. Histological studies reveal 
that activated FBs are colocalized with the perivascular MNC infiltrates of SSc. 
Although the initiating stimuli are not known for certain, soluble mediators from the 
inflammatory cells present in these lesions do seem to be involved. An alternative 
source of mediators is the activated EC (75) and, to some extent, the FB itself.
With regard to chemical mediators, TGFp is a particularly likely candidate: TGFp 
is the primary fibrogenic cytokine, activating and stimulating normal FBs to produce 
connective tissue components. Overproduction of TGFp by SSc MNCs during the
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autologous mixed lymphocyte reaction has been demonstrated in vitro (257), while 
increased quantities of TGF(3 mRNA in bronchoalveolar MNCs have been detected in 
SSc (and SLE) patients with lung involvement (73). A key observation was the in-situ 
identification of TGFp and type I collagen mRNA colocalized in the perivascular 
lesions of SSc skin. Type I and type VII collagen fibrils have also been demonstrated to 
occur in the same topographical distribution as TGFp in SSc skin (140,291). A likely 
initial source of TGFp in SSc is the infiltrate of activated macrophages, and the 
platelets, which pass freely through the permeable endothelium to the dermal and 
subcutaneous fibrotic site. Once stimulated by TGFp, however, FBs can produce then- 
own TGFp in an autocrine fashion.
Platelet-derived growth factor may also be important in SSc pathogenesis: it is 
thought to be a key mediator of TGF-p-directed effects, and has been found colocalized 
with ECs and macrophages in early lesions. Besides ECs and macrophages, the 
activated platelets of SSc are a further source of PDGF. Autocrine release of PDGF by 
normal FBs is also known to be induced by TGFp. It appears that TGFp upregulates the 
PDGF-AA ligand - PDGFaa receptor activity of SSc-FBs, which then respond readily 
to PDGF by proliferating and upregulating FB matrix production.
Thus, the chronically upregulated autocrine release of TGFp and PDGF by SSc-FBs 
explains the altered response to extraneous sources of growth factors displayed by 
cultured SSc-FBs in vitro: the SSc-FB fails to regulate cell growth and matrix 
production, being directed by unregulated autocrine stimulation (199).
In addition to the damage-related release of endothelin-1 from ECs mentioned 
earlier, SSc-FBs have been shown to overproduce endothelin-1 in vitro (174). This 
effect may be mediated locally by IL-ip from activated MNCs in perivascular lesions 
(174). Endothelin-1 appears to be mitogenic to fibroblasts (166), and thus may be a 
further factor in the fibrosis of SSc. Other postulated promoters of the fibrotic 
phenotype in SSc include certain products of activated mast cells (39) and the 
topoisomerase I (topo I) enzyme (77).
Models of systemic sclerosis
The main human model of SSc is chronic graft versus host disease (GVHD), which 
sometimes follows bone marrow transplantation. This phenomenon can be produced by 
injection of immunocompetent T cells into an immunocompromized host. A disease 
syndrome develops which mimics many of the features of idiopathic SSc. The disease 
results from damage caused to endothelium and epithelium by T cells via cytokine 
mediators (24), and features include MNC infiltration and tissue fibrosis.
The ideal animal model of SSc would replicate all features of the idiopathic disease 
i.e. endothelial damage and activation, cutaneous fibrosis, perivascular MNC infiltration 
of skin, and autoantibodies recognizing the characteristic SSc autoantigens. This would 
enable in-vivo experimentation to be conducted, possibly leading to greater 
understanding of disease pathogenesis and an effective treatment for the human disease.
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The animal models currently available do not fulfil these exacting criteria, and results 
obtained from them must be guardedly analyzed. The main animal models are the tight- 
skin mouse (Tsk) models Tskl (reviewed in (27)) and Tsk2 (55), and the University of 
California Line 206 chicken (27).
1.4 TOLERANCE
Mechanisms of self-tolerance and immune regulation
T cell tolerance
Central tolerance
In man, autoimmunity is primarily avoided by clonal deletion (i.e. death) of immature 
autoreactive T cells in the foetal thymus during the perinatal period (for review 
(247,352)). This process is known as central tolerance, and depends on self-antigens 
being present in, or passing through, the thymus. However, some autoantigens do not 
reach the thymus, and for these alternative methods of tolerance induction are available. 
Such autoantigens may include certain tissue-specific proteins.
The pre-T cell population is formed in the bone marrow, and, although committed to 
the T cell lineage, these cells do not yet express TCRs, the co-receptors CD4 and CD8 , 
or the accessory molecule CD3. The pre-T cells migrate to the thymus, which is the 
main site of maturation for all T cells.
Some time after entering the thymic cortex the immature T cells (thymocytes) begin 
to express both CD4 and CD8 . Processes occurring during the passage of these double 
positive cells from the thymic cortex to the thymic medulla are largely responsible for 
the mature T cell repertoire of an individual. The thymocytes divide rapidly, and the 
initial range of TCR specificities is determined by random TCR-gene segment 
rearrangements.
Each TCR contains one a  and one p chain, and each of these consists of constant (C; 
i.e. the same on many lymphocytes) and variable (V; i.e. specific to each lymphocyte 
clone) domains. There are separate a  and (3 gene loci, and these are located on separate 
chromosomes. Two allelic versions of a and p gene loci are available, each containing a 
small variety of alternative C-gene coding domains, a wide variety of V-gene coding 
domains, and several joining (J)-gene coding domains. Ultimately only one a  and one p 
locus are utilized to form the mRNA coding for the TCR of a single lymphocyte. 
Furthermore, special somatic rearrangement processes take place, involving excision of 
both DNA and RNA to form a-chain and p-chain mRNAs with random combinations of 
C, J and V genes. When all possible combinations of all possible rearranged a- and p- 
chains are considered, an individual could generate up to 1010 different TCRs (268). 
From this extremely large and variable range of TCRs, each thymocyte expresses only 
one, with individual antigen-binding properties. Division of one such T cell results in
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many clones sharing the same TCR. Once the TCRs are expressed on the cell surface, 
the CD3 molecule may join the TCR complex.
Selection events then take place, which are thought to involve MHC-expressing 
cortical epithelial cells, and bone marrow-derived non-lymphoid cells such as DCs and 
macrophages, which may act as APCs. Positive selection ensures that only cells 
expressing TCRs which can recognize a self MHC molecule (Class I or Class II) are 
stimulated and allowed to survive, and is known as MHC restriction. Thymocytes with 
no affinity for self MHC are allowed to die (benign neglect), probably by programmed 
cell death (apoptosis). This is followed by a process of negative selection, during which 
self-reactive thymocytes (i.e. thymocytes whose TCRs can bind tightly to presented 
(self) antigen in association with MHC) are killed by apoptosis, leading to a state of 
self-tolerance. During these selection processes, the double positive (CD4+CD8+) cells 
begin to express only one co-receptor molecule, either CD4 or CD8 , forming the helper 
subset and the suppressor/cytotoxic subset respectively. This is dependent upon which 
particular MHC molecule is recognized by the thymocyte: thus, CD4+ cells will 
recognize MHC Class II molecules, while CD8 + cells will recognize MHC Class I. 
Thus, in theory, only those T cells with TCRs which can recognize a foreign antigen 
associated with a self MHC molecule (Class I or II) will mature. Following maturation, 
the cells are released into the bloodstream and peripheral tissues.
Peripheral tolerance
Peripheral tolerance occurs after the mature T cells have migrated from the thymus. The 
process involves the inactivation (anergy) of autoreactive T cells, rendering them 
incapable of responding to antigenic stimulation.
As mentioned above, for effective stimulation, the mature Th cell must 
simultaneously receive two different signals. The first of these depends on specific TCR 
recognition of a peptide antigen associated with a Class II MHC on an APC. Secondly, 
the APC must provide co-stimulatory signals in the form of cell surface molecules. 
When a Class II-associated antigen is presented in the absence of such co-stimulation 
the T cell becomes unresponsive (anergic). Even when subsequently stimulated by a 
competent APC expressing the same Class II-associated peptide, the cell will not 
respond.
Meanwhile, peripheral tolerance of Tc cells could involve a process known as cross- 
presentation. Cross-presentation involves the induction of CD8 + T-cell responses by 
bone marrow-derived APCs capable of MHC Class I-restricted presentation. This 
process requires help from appropriate Th cells. Organ-specific self-antigens may be 
transported to draining lymph nodes for Class I-restricted presentation (41). In the 
absence of appropriate Th cell help, this leads to Tc cell deletion (181), a mechanism 
known as cross-tolerance (134).
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Suppressor T cells
Some immunologists believe that a subpopulation of antigen-specific CD8+ T cells is 
capable of recognizing and inhibiting self-reactive lymphocytes. These suppressor T 
cells (Ts) may be important in controlling the immune response to antigens which do 
not reach the thymus. They may function by being capable of activation by antigens in 
the absence of APCs or MHC molecules.
B cell tolerance
Comparable mechanisms are also thought to affect self-reactive B-cell populations. 
Deletion of immature self-reactive IgM-expressing B cells may take place in the bone 
marrow following exposure to self-antigens. However, clonal deletion of B cells 
appears to be a much less thorough aspect of self-tolerance than the deletion of 
autoreactive T cells, and evidence suggests a rather large population of self-reactive B 
cells reaches the circulation in the normal individual. Such cells appear to have been 
rendered unresponsive to antigenic stimulation by mechanisms of clonal anergy. This 
form of tolerance is induced by the interaction of self-antigen with the B-cell Ig 
receptor. If it occurs at an early developmental stage, the Ig receptor expression of the 
mature B cell may be chronically down-regulated. There is, however, a further source of 
autoreactive B cells. During the course of an ordinary immune response against foreign 
antigen, Th cell stimulation of the appropriate B cell results in its migration to a primary 
follicle to from a germinal centre where proliferation of the particular B cell takes place. 
One aspect of this Th cell-induced proliferation of B cells is somatic hypermutation of 
the hypervariable regions of the Ig genes. This results in a population of B cells with 
slightly different antigen binding regions. In the germinal centre, B cells with high- 
affinity Ig receptors are selected over low-affinity receptor-bearing B cells by 
programmed cell death. Nevertheless, some of these selected clones may be 
autoreactive. However, B cells require multiple signals to enable differentiation into 
plasma cells. The antigen recognized by the B cell must be bound to the B cell's surface 
Ig, and T-cell help must be available via binding of the TCR to MHC Class II-bound 
antigenic peptide on the B cell surface. Interactions of cell-surface adhesion molecules 
on the T and B cells are also important. The T cell can then release lymphokines to the 
B cell. In the absence of T-cell help, binding of antigen to surface Ig of the B cell may 
result in anergy. Thus, the activation of autoreactive B cells is normally inhibited and 
kept in check by a lack of T-cell help.
Anti-idiotype networks
The Ig or TCR binding site (idiotype) may itself be seen as foreign by the immune 
system. This may result in the production of an anti-idiotypic immune response, and 
anti-idiotype autoantibodies (and so on, virtually ad infinitum). Anti-idiotype 
autoantibodies may have a regulatory role in the immune system, perhaps by inhibiting
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the activation of the idiotype-expressing lymphocytes, as suggested by Jeme's Network 
Theory.
1.5 AETIOLOGY: GENETICALLY RELATED FACTORS
Discussed below are a range of factors which have been reported to be responsible for 
eliciting or promoting the autoimmune features of SSc and/or aspects of the SSc disease 
process itself. In some cases information relating to SLE has also been included: the 
two diseases are often found in overlap, and appear to have much in common. Both 
diseases involve autoreactivity with a restricted group of intracellular autoantigens, and 
there are further similarities regarding aetiological risk factors and suspected 
environmental triggers. Furthermore, the literature regarding the aetiology of SLE is 
considerably larger than that concerning SSc, indeed, it has been described as the model 
autoimmune disease (63). Nonetheless, the two diseases are usually distinct, and only 
through studying the nature of SSc itself can a complete aetiopathogenetic model of SSc 
eventually emerge.
Gender
Many CTDs have a predominantly female bias, including SSc, and a number of theories 
have been put forward to explain this. These usually offer a hormonally related 
interpretation, since the discrepancy between females and males (relative incidences of 
new cases) is greatest prior to the menopause. As reported by Simeon et al. (316), the 
expression of the disease is, nonetheless, similar in both sexes.
Hormonal influences
Possible hormonal contributions to the aetiology of the CTDs have been reviewed by 
Masi et al. (69,217). A variety of types of immune cell have been shown to express 
oestrogen receptors on their surfaces, and both male and female sex hormones may 
affect immunoreactivity, including autoreactivity. Recently, for example, it was shown 
that testosterone suppresses in-vitro anti-DNA antibody production by PBMCs derived 
from SLE patients (172). High concentrations of oestrogens, as found during 
pregnancy, may inhibit Ts cells, and increase B cell differentiation (217). Oestrogens 
are also believed to affect cytokine production levels and vascular cell adhesion 
molecule expression (69). It has also been suggested that hormonal imbalances during 
growth and development could predispose to CTDs by causing changes to the 
immunological and/or vascular systems (217).
Microchimerism
Male foetal progenitor cells have been detected in maternal blood for up to 27 years 
postpartum, and it was surmized by Lee Nelson et al. that pregnancy confers a long­
term, low-grade chimeric status (21). Further work by the same group showed that SSc
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patients with male offspring had a significantly higher concentration of male (i.e. Y- 
chromosome-specific) DNA in their blood than did similar women without SSc (244). 
Furthermore, HLA Class-II compatibility between mother and son was more common 
in the SSc patients, and this finding was used to support the argument that such 
microchimerism may be involved in SSc pathogenesis, and that SSc represents a form 
of chronic GVHD (243,244). The syndrome of GVHD occurs in a minority of bone 
marrow transplant recipients, and has been likened by some to scleroderma (157). The 
conclusions of Lee Nelson et al. (359) were not supported by others, however, who 
questioned the methods used in their study, and also pointed out that HLA-compatible 
organ-transplant and blood-transfusion patients do not actually develop SSc as such. On 
the other hand, scleroderma-like skin changes are observed in some GVHD patients 
(18), and at least one study has demonstrated that this particular subset of GVHD 
patients do sometimes test positive for autoantibodies recognizing topo I or Pm-Scl 
autoantigens, which are characteristic of idiopathic SSc. Therefore, microchimerism as 
one possible explanation for at least some cases of SSc in women does warrant further 
examination.
X-chromosomal inactivation
It has been suggested by Stewart (332) that SLE (and presumably SSc) may actually 
result from the phenomenon of X-chromosomal inactivation, which occurs in all female 
mammals. The number of dendritic APCs which a developing thymocyte encounters 
during its passage through the thymus may be very small. Therefore, in theory, a T cell 
with TCR-specificity for an antigen encoded by the active paternal X-chromosome (for 
example) could, by chance, interact only with APCs which had an active maternal X- 
chromosome (i.e. presented only maternally encoded proteins), thus escaping negative 
selection. In the periphery, this same T cell could later encounter paternal antigens 
presented by APCs with an active paternal X-chromosome, which it would recognize as 
foreign. The T cell could then go on to activate appropriate B cells with the 
consequence of autoimmunity. In the case of a multisubunit/macromolecular particle, 
the immune response could spread to other antigens with which the original antigen was 
physically associated, i.e. intermolecular diversification (88,210) (see Section 1.7); 
however, only X-chromosome-encoded proteins would be capable of actually inciting 
such a response. Also, this theory does not explain the occurrence of CTDs in males; 
nonetheless it is an interesting and novel hypothesis, and may account for some cases of 
autoimmunity, especially paediatric cases.
Immunological factors
Complement deficiency
Complement deficiency has been postulated as an important predisposing factor to 
autoimmune syndromes, particularly SLE (10). Complement particles are vitally
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important for the efficient clearance of immune complexes (i.e. antigen/antibody 
aggregates). Following sequential activation and selective fragmentation of the various 
types of complement particle (C1-C9), the immune complex is solubilized and 
opsonized with a coating of fragments C3b and C4b. This promotes attachment by 
phagocytes and subsequent engulfment (10).
There are two similar but distinct C4 loci, known as C4A and C4B, and the C4A 
and C4B particles have slightly different functions on account of different binding 
affinities. It has been estimated that 10-15% of SLE patients are C4A null homozygotes, 
while a further 50-80% have a heterozygous C4A or C4B deficiency (10). Furthermore, 
it has been reported that 64% of a cohort of 25 SSc patients had one or two C4A null 
alleles (33).
Interestingly, the C4A and C4B genes are located in-between those coding for the 
MHC Class I molecules and the MHC Class II molecules. It is thought that some 
apparent associations between autoimmune diseases and HLA alleles may actually be 
due to complement deficiency genes which are in linkage disequilibrium with the HLA 
gene concerned. Specifically, it has been deduced that the association of SSc with the 
extended phenotype HLA-A1/B8/DR3 is, in fact, due to linkage disequilibrium with the 
C4A null allele (33).
It has been suggested that a deficiency of C4 particles could result in an inadequate 
host immune response to particular infectious agents (11,33,154). Chronic infection, 
and/or excessive inflammation and damage to the infected tissues, could lead to 
spreading of the immune response to the hosts own antigens i.e. autoimmunity (11).
It has also been established that complement components are also involved with 
clearing potential self antigens released by dying or apoptotic cells (for review, (43)). 
Apoptotic cells generate surface blebs which contain a range of antigens normally found 
in the intracellular environment, and these are known to include the Ro particle, 
recognized by many SLE sera. Therefore, complement deficiencies may result in an 
abnormal accumulation of normally intracellular self-antigens, with the result of an 
autoimmune response (see Section 1.7).
It has further been suggested that complement may be involved in the initial process 
of B-cell tolerance induction by negative selection in the bone marrow (43). While most 
of this work has been carried out with regard to the aetiopathogenesis of SLE, the 
deficiency of complement components in SSc suggests that analogous processes may be 
found to occur in SSc.
Subset skewing ofTh cells
Two different Th cell subtypes have been recognized (Thl and Th2), and each has 
different functions and releases different sets of cytokines when activated. Cells having 
the Thl phenotype release IL-2, IFNy and TNFa, and are characteristic of cell-mediated 
immunity. Meanwhile, Th2 cells characteristically produce IL-4, IL-5, IL-6  and IL-10,
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and are involved in B-cell proliferation and differentiation. The two cell types also both 
have other functions related to Ig isotype switching.
Either the Thl or the Th2 subset may predominate in different autoimmune 
diseases, and alterations in the balance of the two populations and their cytokine 
products may be important in disease generation (54,106) and potential treatment 
strategies. The mechanism of immune deviation, which causes a deviation away from a 
Thl- towards a Th2-like response, has been proposed to result in an enhancement of 
antibody responses, which, in susceptible individuals, may contribute to autoimmune 
diseases where the Th2 response predominates (317). However, the issue is complicated 
and unresolved (224). Moreover, both types of response appear to be important in SSc, 
and cytokines from both types of Th cell are elevated in patient sera, as discussed in 
Section 1.3.
Restricted T-cell receptor usage
There is patchy evidence, mainly from mouse models, that TCRs with particular V- 
regions are overexpressed in certain diseases. Some indirect evidence of oligoclonality 
of TCRs has also been shown for human autoimmune diseases. For example, certain V a 
and VP alleles have been associated with multiple sclerosis (MS) (for review, (365)).
Race and MHC-related effects
The human MHC locus contains both the HLA Class I genes (A, B and C) and the HLA 
Class II genes (DP, DQ and DR). Each of the three Class II molecules consists of an a- 
and a P- chain, while each Class I molecule comprizes only one main chain, also 
denoted a , which is associated with the smaller P-microglobulin polypeptide. The HLA 
genes are extremely diverse in the general population, although each individual carries 
only two allelic versions of each component polypeptide chain. With regard to the 
HLA-DR molecule, only the P-chain shows significant diversity between individuals, 
while in the case of HLA-DQ, both the a -  and the P-chains are highly polymorphic 
(190). It has been found that differences between alternative alleles of the same HLA 
gene often relate to those amino acids which will be situated in the peptide binding 
groove of the functional HLA molecule (365). The binding grooves of the different 
allelic forms of a particular HLA molecule vary in their ability to bind a given peptide, 
depending on its net charge, size and hydrophilicity (330). As such, HLA molecules 
with different functional properties affect the individual's immune responsiveness to 
particular antigens, including autoantigens. It therefore follows that certain HLA genes 
may confer susceptibility to certain kinds of autoimmunity (267,301).
In SSc, a number of HLA alleles have been associated with an increased frequency 
of the disease (for a review of HLA nomenclature, see (245)). These include the MHC 
Class I alleles A l, B8  and B35 (25), and the Class II alleles DR1, DR3, DR5, DRw8 
and DRw52 (25,111,115,202). Importantly, associations sometimes differ when 
different populations are examined, particularly when racial origins are noted (188,202).
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The HLA associations are especially strong when clinical subsets and/or 
autoantibody-defined subgroups of SSc are considered. Thus, anti-topo I antibodies 
have been associated with HLA-DR2, DR5 (D Rw ll subgroups DRB 1*1101-* 1104), 
DR8 and DRw52 (86,112,202,236,281,327), while the anticentromere antibody (ACA) 
subset displays a high incidence of DR1, DR4 (Dwl3 subtypes, DRB1*0403, *0407), 
DR5 (DRwll), and DRw8 (25,86,112,282,327). In terms of antinucleolar antibodies 
(ANoAs), anti-Pm-Scl-positive patients are characterized by the presence of DR3 
(DRB 1*0301) (112,251) and DQw2 (251), anti-Th RNP have a high prevalence of 
HLA-DR11 (85), anti-RNA polymerase (anti-RNAP) antibodies have been associated 
with DQB 1*0201 (8 6 ), and anti-U3 RNP antibodies have been associated with 
DRB 1*1302, DQA 1*0501, and DQB1*0602 or *0604 subtypes (7,279).
Recently, several HLA-DQ alleles have been closely associated with certain SSc 
autoantibody subsets (86,184,226,281,282,361). This work has prompted some authors 
to conclude that the previously reported HLA-DR associations of some SSc antibodies 
are actually due to linkage disequilibrium of certain DR alleles with particular DQ 
alleles. These HLA-DQ associations have, in some cases, been shown to be so close 
that they depend on a particular amino acid residue. For example, an uncharged polar 
amino acid residue (tyrosine) at position 30 of the second hypervariable region of the 
first domain of the DQB 1 molecule has been shown to be present in most anti-topo I- 
positive SSc patients (281,338,361). An association of ACAs with the presence of a 
polar amino acid (specifically not hydrophobic leucine) at position 26 of the HLA- 
DQB1 first domain has also been demonstrated (86,226,282). In the latter study, 100% 
of ACA-positive Caucasian patients had a polar amino acid at position 26 of DQB 1. 
Therefore, the DR associations of ACAs may be due to linkage disequilibrium of DR5 
(D Rw ll) and some DR4 (Dwl3) haplotypes with DQw7, of DR1 with DQw5, and of 
DRw8 with DQw4. Similarly, the anti-topo I studies were taken to imply that there was 
linkage disequilibrium of DR2 with DQB 1*0602 (DQw6 ), and of DR5 with 
DQB 1*0301 (DQw7) (281). However, it has recently been suggested that the DR and 
DQ alleles together control the autoimmune response to topo I in SSc (184).
The different prevalences of HLA genes found in different racial groups are thought 
to underlie the finding that each racial group contains a different proportion of patients 
with each particular SSc-specific antibody (189). For example, a much higher incidence 
(76%) of anti-topo I antibodies has been detected in a Thai population of SSc patients 
than in an equivalent population of Caucasian Australians (26%) (228). It has also been 
shown that, in Japanese SSc patients, different DR alleles from those reported in 
Caucasians confer disease susceptibility i.e. the DR4 and DR8 alleles are very common 
amongst Japanese SSc patients (188,338). A study by Sato et al. (189) demonstrated 
marked and significant differences in autoantibody responses produced by 275 
Japanese, 416 North American Caucasian and 24 North American Black SSc patients, 
with the predominant autoantibodies detected in each group being anti-Ul RNP, anti-
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RNAPs and anti-U3 RNP, respectively. The authors also noted a higher frequency of 
anti-Ku antibodies in Japanese SSc patients, while anti-Pm-Scl antibodies were absent 
from this population. To some degree these differences were consistent with the 
different proportions of dc- and lc-SSc patients in the three racial groups (see Section 
1.8). Perhaps the most interesting finding was that, when the patients were subgrouped 
according to disease subtype, significant differences were still apparent. Thus, when dc- 
SSc patients were considered, the Caucasian group showed a much higher incidence of 
anti-RNAP I antibodies (43%) than the other two groups, while for Black dc-SSc 
patients the main association was with the anti-U3 RNP antibody (50%), and Japanese 
dc-SSc patients had predominantly anti-topo I antibodies (65%). It was concluded that, 
to some degree, the expression of particular autoantibody specificities is dependent on 
race independently of disease expression. Again, the immunogenetic background was 
convincingly argued as a possible explanation for these findings: e.g. the anti-Pm-Scl 
antibody response has been associated with the HLA-DR3/DQ2 haplotype, which is 
common in Caucasians, but rare in the Japanese, and this may explain the lack of any 
anti-Pm-Scl-positive sera in the Japanese patient group. Meanwhile, in a study by 
Reveille et al. (280), the frequency of anti-topo I antibodies was found to be higher 
(37%) in a population of 27 North American Black SSc patients than in their 118 North 
American Caucasian patients (17%).
Such results may have important implications for a proposed aetiology of SSc. 
However, it is also clear that further genetic or environmental factors are important in 
SSc aetiology, besides the presence of certain predisposing HLA haplotypes (6 ). A 
particular group of Choctaw (Native American) Indians has been reported in whom SSc 
is especially common (prevalence ~ 1/213 in full-blooded Choktaws) (6 ). The patients 
displayed a remarkable degree of homogeneity in their disease, with mostly dc-SSc and 
anti-topo I antibodies. While a number of HLA allele associations were found in this 
study, namely B35, DR2 (DRB1*1602), DQA1*0501, and DQ7 (DQB1*0301), a 
population of Choktaws in a different location had a negligible incidence of SSc, whilst 
having a similarly high frequency of these same HLA haplotypes.
The closeness of the HLA associations in SSc have recently been tested according 
to the following model (8 6 ). It was hypothesized that each different case of SSc may 
emerge as a similar pathological aberration, which is channelled by the individual's 
HLA molecules into one of several distinct subtypes characterized by certain symptoms 
and particular autoantibodies, or, alternatively, that SSc may encompass two or three 
separate diseases, each having distinct pathogenetic origins which determine disease 
expression (8 6 ). The results of the study of Fanning et al., suggested, but did not prove, 
that the latter hypothesis was the correct one (8 6 ). Clearly, however, acceptance of this 
second hypothesis does not in any way preclude the possibility that these purportedly 




It has been suggested that patients with SLE have a defect in apoptosis. In one pathway 
of apoptosis, the Fas ligand (Fas-L) binds to membrane-bound Fas (mFas; CD95), 
which leads to a sequence of events culminating in apoptosis. (for review, (238)). A 
number of defects relating to Fas and/or Fas-L may be involved in SLE, specifically 
concerning the apoptosis of self-reactive T cells during thymic selection, and the 
removal of activated mature T cells following an effective immune response (163).
For example, it has been found that there is a higher than normal level of soluble 
Fas (sFas) in SLE patients, and that this may be capable of competitively inhibiting the 
binding of Fas-L to mFas, with the consequence of inhibiting apoptosis (163). If this 
resulted in an altered threshold for T cell deletion, autoreactive cells with a whole range 
of different specificities may be allowed to persist (238). It has also been suggested that 
apoptotic events occurring in the thymus are an important source of apoptosis-related 
antigens, and, if insufficient apoptosis occurs in the thymus during early ontogeny, an 
abnormally large population of T cells which are capable of recognizing these particular 
antigens will escape deletion (47). Studies using animal models of SLE (e.g. the 
MRL/Mp-/pr/7pr mouse) imply that defects in apoptosis and/or upregulation of factors 
which promote lymphocyte survival can indeed result in a lupus-like disease, 
characterized by massive lymphadenopathy due to a reduction in activation-induced T 
cell apoptosis (83,203,237).
In terms of SSc, the possibility that subpopulations of FBs acquire a reduced 
propensity for apoptosis has been suggested (238), and is currently being investigated in 
our laboratory (Mr J.Dixey, pers.comm.). Exciting recent developments include the 
demonstration that anti-EC antibodies from SSc patients can induce EC apoptosis (29). 
This finding provides further evidence that anti-EC antibodies may be involved in the 
pathogenesis of SSc.
Cancer
A significantly higher incidence of malignancies, especially lung cancer, has been 
reported to occur in SSc patients, and some have suggested a causal link (51,290). An 
elevated and epitope-rich anti-topo I antibody response has also been found following 
the development of lung cancer in two anti-topo I-positive SSc patients (182). This may 
be related to the increased production and activity of topo I in cancer (182). An 
important finding was that SSc-free lung cancer patients did not have anti-topo I 
antibodies, and it was surmized that topo I overexpression per se is an inadequate 
stimulus for the breakdown of tolerance to this molecule (182). However, in another 
study, a high proportion (31%) of patients with hepatocellular carcinoma in the absence 
of a CTD did have ANAs, including those recognizing NOR-90, RNAPI and U3 RNP 
i.e. antigens which are specifically recognized by some SSc sera (153).
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Other genetic factors
Innumerable genes are involved in the adaptive immune response. Each gene will have 
a number of polymorphisms in the general population, and some alleles may confer a 
genetic susceptibility to autoimmune disease. Candidate genes are currently being 
assessed in a number of different centres using modem microsatellite techniques. Genes 
of particular interest include those coding for TNFa and PDGF.
1.6 AETIOLOGY: ENVIRONMENTAL RISK FACTORS 
Pathogens
Pathogens may be involved in the induction of an autoimmune response and/or in 
triggering a CTD by at least four different mechanisms (260,284).
Molecular mimicry
Molecular mimicry occurs when there is a structural homology between a self antigen 
and an antigen present in an infecting pathogen (44,256). This stimulus is thought to 
induce an immune response that cross-reacts with the self antigen (15). A very short 
sequence of amino acids may be sufficient to cause such cross-reactivity. A number of 
viruses have been shown to contain peptides with a high degree of homology with 
certain autoantigens characteristic of particular rheumatic diseases (374). In terms of 
SSc, it has been reported that a highly antigenic region of the topo I molecule comprizes 
six sequential amino acid residues that are identical to a sequence found in p30gag - a 
group-specific antigen contained in several mammalian retroviruses (222). This report 
was made all the more interesting by the earlier finding that an adjacent sequence of the 
retroviral p30gag antigen displayed cross-reactivity with autoantibodies against the 70- 
kDa polypeptide of U1 RNP, which are found in MCTD and SLE (273).
However, it is important to distinguish between an autoimmune response and a 
disease syndrome: in some cases, the presence of autoantibodies which recognize a 
particular self antigen is sufficient to cause symptoms of the disease itself, e.g. 
antibodies recognizing the nicotinic acetyl choline receptor in myasthenia gravis, while 
in other diseases, including SSc, the presence of a disease-specific ANA alone is not 
thought to be directly pathogenic (256). The induction of an autoimmune response by 
mechanisms of molecular mimicry is discussed further in Section 1.7.
Microbial superantigens
Certain bacteria and mycoplasma have been shown to cause clinical relapses in some 
autoimmune diseases by inducing polyclonal activation of particular lymphocyte 
subpopulations via soluble products called superantigens. Superantigens can 
simultaneously bind to non-polymorphic determinants of Class II MHCs on APCs and 
to the p chain of certain TCRs without involvement of the antigen-specific binding site.
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Each kind of superantigen binds to certain amino-acid sequences expressed by all 
members of a particular V-gene family. This results in the activation of various T-cell 
clones having different antigen specificities but sharing a high degree of amino acid 
homology (67).
Cell lysis and death
It has been suggested that, in some circumstances, autoantibodies are produced as a 
result of large amounts of cell lysis and death. This could involve destruction of 
anatomical barriers, an increase in vascular permeability, or the release of normally 
sequestered, intracellular antigens, with the subsequent engulfment and presentation of 
autoantigens by macrophages. Such overwhelming quantities of self-antigens could, in 
turn, make the development of an autoimmune syndrome more likely (15,284).
Subversion o f the immune system
It has recently been hypothesized by Pandey & LeRoy (260) that human 
cytomegalovirus may be involved in the aetiopathogenesis of SSc by mechanisms not 
directly related to the induction of autoimmunity. The ubiquity of the latent virus 
amongst the general population was noted, as was its ability to infect ECs and 
macrophages, to increase the expression of fibrogenic cytokines such as TGFP, and to 
induce type IV collagenase expression. It was proposed that, by several different 
mechanisms, including the down-regulation of MHC Class I molecules, the virus 
subverts the immune system for its own purposes, establishes a chronic infection of 
vascular ECs, and induces collagenase and TGFP activity. The consequence may well 
be the vascular obliteration and fibrosis characteristic of SSc (260).
Drugs and environment toxins
A very diverse range of chemical substances has been suspected of causing SSc or a 
CTD resembling it. Occupational exposure to chemicals such as formaldehyde, 
biogenic amines, epoxy resins, aliphatic and aromatic hydrocarbons has been reported 
to cause SSc (109), and administration of certain pharmaceutical drugs has also been 
implicated. A large number of individuals were affected by an SSc-like syndrome 
termed toxic-oil syndrome following a one-off incident of rapeseed cooking oil 
contaminated with an aniline derivative. A similar SSc-like syndrome known as 
eosinophilia myalgia was caused by L-tryptophan supplements which contained the 
synthetic by-product 3-(phenylamino)alanine (137,173).
Silicosis and silica-induced systemic sclerosis
One fairly well studied example of environmentally induced SSc is the induction of SSc 
in coal miners and stonemasons, which is thought to be due to silica inhalation. One 
early report found that Si-SSc could not be distinguished from the idiopathic disease 
(293). The mine workers studied had all been exposed to silica dust, and 17 had 
developed Si-SSc. Meanwhile 30 mineworkers who had developed silicosis alone were
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also studied, along with a further 22 who had developed neither disease. The miners 
with Si-SSc had clinical, immunological and serological features which were typical of 
the idiopathic disease. These features included cutaneous sclerosis in all cases, and a 
high prevalence of anti-topo I antibodies, oesophageal involvement and bibasilar 
pulmonary fibrosis. Interestingly, a subset of each of the three groups of miners had 
evidence of EC damage. Furthermore, ANoAs were surprizingly frequent in the 
silicosis group (27%), although no SSc-specific antibodies were detected in individuals 
with silicosis. In a subsequent report by the same group, and involving our own 
laboratory, anti-Ro/La antibodies were detected in two of the silicosis patients who had 
no signs of a CTD (227). While the existence of a Si-SSc syndrome has been supported 
by others (97,295), some studies have found no evidence of SSc amongst persons 
exposed to silica in the workplace (313).
Silica particles can be ingested by alveolar macrophages, and it is thought that their 
subsequent IL-1 release causes the FB proliferation and collagen accumulation 
characteristic of pulmonary involvement (214). Also, in the context of Si-SSc, 
macrophage-derived TNFa could contribute to lymphocyte proliferation, Ig synthesis 
and upregulation of MHC and cell adhesion molecules (97). It was also hypothesized 
that the silica particles may be transported by the lymphatic system, and ultimately may 
reach the general circulation and be phagocytozed by vascular ECs (293).
It was subsequently shown that the effect of silica on macrophages was specific, 
since TiC>2 dust did not have a similar effect (98). Clearly, genetic factors are also 
involved, since only a proportion of silica dust-exposed individuals develop Si-SSc, and 
this may be on account of particular MHC Class II alleles (227). This effect has recently 
been demonstrated by Frank et al. (97), who showed an association between anti-topo I- 
positive Si-SSc and the HLA-DR3 allele. This finding was particularly exciting since 
the anti-topo I-positive idiopathic SSc cases in their study were associated with DR2 
and DR5, as has previously been reported (97). The authors concluded that different 
pathogenic mechanisms lead to the production of anti-topo I antibodies in the two 
groups, and that a different topo I-derived peptide was presented by MHC Class II 
molecules in Si-SSc. It was suggested that the presentation of different peptides in the 
two groups could have been due to (i) the involvement of a different kind of APC (these 
have been shown to contain different proteases), or (ii) altered antigen processing 
caused by macrophage-derived cytokines following silica exposure (it is known that 
TNFa can modulate the pattern of antigen processing by APCs) (97).
An interesting recent finding is that the relative level of sFas:mFas is raised in 
silicosis patients, but not in SSc patients (345). These findings are reminiscent of those 
described in SLE earlier. The authors, who had previously found evidence that silica 
acts as a superantigen, suggested that there may be an accumulation of self-reactive 
clones in such patients, which, ultimately lead to an autoimmune syndrome (258).
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Controversy surrounds purported cases of CTDs (including SSc) resulting from 
leakage of silicone gel from breast implants. Several studies have demonstrated a high 
frequency of ANAs in silicone-implanted women, and these included ANoAs, anti-topo 
I, anti-Pm-Scl, anti-Ro/La and ACAs (6 8 ). Others report no increase of SSc in women 
with silicone implants (37,145,363).
Metal-induced autoimmunity
It has been observed that, in susceptible mouse strains (e.g. the H-2S strain), chronic 
exposure to mercuric chloride via injection leads to the development of anti-U3 RNP 
antibodies by a process requiring Th-cell help (249), and this has become an established 
experimental model of autoimmunity (120). Possible mechanisms are discussed in 
Section 1.7. In the context of human autoimmune syndromes, exposure to mercury 
could occur via dental amalgams or environmental contamination (1 2 0 ).
Physical trauma
Vibration white finger is a condition resembling RP, and appears to arise through 
damage caused to vascular endothelium by the use of pneumatically powered drills and 
surgical instruments. An individual with this disorder was reported subsequently to 
have developed SSc, along with ACAs (60). It is a possibility that such vibrational 
effects cause tissue destruction and EC disintegration. In susceptible individuals, this 
could be the trigger for an immune-mediated attack on the vascular endothelium, as was 
described in Section 1.3.
It is clear that the above-mentioned genetic and environmental risk factors may interact 
in myriad ways, ultimately leading to the final common pathway of SSc, together with 
autoantibody production. It seems highly unlikely that all cases of SSc (even all cases of 
'idiopathic' SSc) originate from the same combination of propounded genetic and/or 
environmental risk factors. This is not to say that certain combinations are not more 
common than others: indeed, the particular manifestations of SSc expressed by an 
individual patient may reflect the unique aetiopathogenetic mechanisms involved in his 
or her case (288).
As has been mentioned, in certain organ-specific autoimmune diseases the 
production of autoantibodies has severe and obvious consequences, which are clearly 
involved in disease pathogenesis, a good example being the destruction of pancreatic 
islet cells in insulin-dependent diabetes mellitus. In such cases clinical symptoms can be 
produced in normal individuals by transfer of the relevant autoantibodies, or by 
immunization with an appropriate autoantigen. However, the development of 
autoimmunity is not always so closely associated with clinical disease (54,259). This is 
particularly true when one considers systemic autoimmune diseases such as SLE and 
SSc: passive transfer of the anti-DNA autoantibodies of an SLE patient, for instance, 
does not cause disease symptoms in a healthy person (4). However, there is a
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remarkably close association between the presence of particular SSc-specific 
autoantibodies and disease expression. Research into these connections must surely 
contribute to a future elucidation of important aetiopathogenic pathways in SSc.
Proposed mechanisms involved in the breakdown of tolerance to autoantigens are 
discussed below. The nature of autoantigens is then discussed, together with the 
phenomenon of epitope spreading. The clinical associations of the autoantibodies found 
in SSc are then reviewed in detail.
1.7 BREAKDOWN OF TOLERANCE AND AUTOIMMUNITY
As Mamula has pointed out, APCs have no inherent prejudice regarding which peptides 
they will or will not present (2 1 0 ), and both central and peripheral tolerance 
mechanisms are imperfect. Thus, the normal immune system of a healthy person does 
contain some autoreactive T and B cells (28), and these remaining autoreactive 
lymphocytes may escape control mechanisms and become activated. In these 
circumstances, autoimmunity ensues.
The nature of autoimmunity
Just as in normal immune responses, both T and B cells are required for the production 
of autoantibodies (186,312). Specifically, it was recently shown that T and B cell 
collaboration is required for the autoantibody response to topo I in SSc (187). In many 
CTDs, only a limited number of autoantibodies are produced (125), and these often 
occur as linked sets, characteristically appearing in the same order in different patients
(125,340). Such observations imply that these responses are not polyclonal: 
autoimmunity in both SLE and SSc is believed to be antigen-driven (87,125). 
Furthermore, processes which are characteristic of an ongoing immune response, such 
as Ig isotype switching, somatic mutation, and affinity maturation, are also found to 
occur as part of an evolving autoimmune response (47).
General features o f autoantigens in connective tissues diseases 
For unknown reasons it has been observed that many autoantigens share a number of 
characteristics (for review, (340,341)). First, autoantigens tend to be ubiquitous, and are 
usually found to occur amongst extremely diverse species, e.g. homologues of the La 
autoantigen, which is recognized by autoantibodies present in many SLE sera, have 
been found in amphibians, flies and yeast; the three classes of eukaryotic RNAP (which 
are precipitated by some SSc sera), have the same basic structure as bacterial RNAP. 
Secondly, many autoantigens play fundamental roles in cellular biochemistry or 
architecture, being involved in such functions as pre-mRNA splicing, mitotic spindle 
formation, DNA binding, and charging of amino-acyl-tRNAs in preparation for 
translation. Thirdly, there is a very high degree of conservation of the amino acid
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sequence of autoantigens. Fourthly, autoantibodies appear to specifically recognize the 
catalytic centres or functionally important domains of such molecules, which have been 
highly conserved during evolution.
Consequently, many autoantibodies have been found to be capable of inhibiting 
biochemical processes and functions. In SLE there is evidence for the direct 
involvement of some autoantibodies in disease. For example, the deposition of insoluble 
immune complexes in the kidneys is thought to cause lupus nephritis. However, a 
directly pathogenic role for SSc-specific antibodies seems unlikely (340): the 
expression of autoantibodies is not the cause of SSc symptoms, but it is thought to be 
intimately associated with the disease process, and thus may be an important indicator 
of aetiology, pathogenesis, and disease expression (340).
The nucleolus as a focus of the immune response in SSc
While autoantigens recognized by SLE sera are mostly located in the nucleus, many 
SSc autoantigens, including topo I and the centromere proteins (CENPs), have been 
found to co-localize to the nucleolus during some stage of the cell cycle (94,250). This 
raises the possibility that the nucleolus is the target of the autoimmune response in SSc
(288,340), just as the nucleosome appears to be the immunogen in SLE (125).
Escape from tolerance induction
Several mechanisms have been proposed to explain how an autoreactive T cell could 
escape tolerance induction.
Failure to present antigen
If a particular self-peptide is not presented by thymic APCs, deletion or anergy of T 
cells which are capable of recognizing that peptide will not occur. Such a scenario may 
prevent an autoantigen from being ’seen' by the developing immune system. One 
example concerns certain organ-specific antigens, which may not be made available to 
APCs. A further example is the process of X-chromosome inactivation described 
earlier, which may lead to some antigens not being encountered by APCs in the thymus.
Somatic mutation and forbidden clones
The structure of TCRs was discussed earlier. The rate of random somatic mutations is 
approximately 104 times greater for V-gene base pairs than it is for the base pairs of the 
remaining spontaneously mutating genes. This amounts to the accumulation of about 
one base pair mutation per cell division, although some of these will be in flanking 
sequences and others will not actually alter the amino acid sequence.
These high mutation rates serve to supply additional T and B cell clones to the 
immune repertoire. For example, the binding of a pathogenic antigen to a TCR complex 
causes clonal proliferation of that T cell. Some of these multiplying clones may acquire 
mutations, expressing a TCR differing in a single amino acid. A slightly altered binding 
site on one such clone may provide even tighter binding for the inciting antigen than the
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clone from which the mutation arose (2). At the same time, however, there is the risk of 
self-reactive clone production, as envisaged by Burnet's forbidden clone theory.
Major and minor determinants
When self-reactive T cells were first shown to be present in healthy animals, it was not 
understood how they had escaped tolerance, and, further, why such cells were not 
subsequently activated by self antigens (107). Work by Sercarz and colleagues 
suggested that not all epitopes of an antigen are equally antigenic. Following 
immunization with native antigen, some peptides were subsequently found to induce a 
much stronger T-cell recall response than others. These are known as major and minor 
determinants, respectively (107). The reason for this discrepancy is that the minor 
epitopes of a particular antigen are much less likely to be efficiently processed and 
presented by APCs. Thus, during intrathymic negative selection, the minor determinants 
are prone to being 'overlooked' by the immune system. Subsequently, the inefficiently 
presented epitopes of the self-antigen also fail to adequately stimulate the resultant, 
undeleted, autoreactive T cells. In contrast, major epitopes are characterized by the 
efficiency of their production by APC processing pathways, and any T cells which 
recognize them are effectively deleted in the thymus.
Thus, a pool of autoreactive T cells recognizing the minor determinants of self 
antigens is believed to remain unactivated in vivo. They are kept in check by a paucity 
of the appropriate minor epitopes being presented on APCs. However, stimulation of 
these cells can occur under particular circumstances: using synthetic peptides, it has 
been shown that minor determinants which are not efficiently processed and presented 
by APCs in vivo, when introduced from an extraneous source, are capable of 
stimulating T cells (209).
Activation of T cells recognizing minor determinants by cryptic epitopes
It is believed that the activation of a T cell recognizing a minor determinant is a key 
moment in the initiation of an autoimmune response, and several scenarios have been 
proposed which may lead to such an event occurring in vivo. The term 'cryptic' epitope 
is applied to any peptide which is capable of activating autoreactive T cells which 
recognize minor autoantigenic determinants. Another way of viewing a cryptic epitope 
is as "an epitope which is not normally generated by APCs at levels sufficient to 
activate T cells" (15). In its widest sense, cryptic epitopes closely resemble, but need 
not necessarily be derived from, minor determinants of an endogenous autoantigen. A 
wide variety of events can lead to the immune system encountering a cryptic epitope, 




It has been demonstrated that proteolytic events occurring outside the APC, prior to 
antigen internalization, may affect the peptides produced and presented by the APC 
(200). Antigens pre-cleaved in an unusual fashion may lead to the production of unique 
peptide fragments (47), which could act as cryptic epitopes, and such events may 
therefore be involved in overcoming T cell tolerance.
A subset of autoantigens has been shown to be specifically cleaved during apoptosis 
(48). These include the 70-kDa subunit of the U1 RNP particle, poly-(ADP-ribose) 
polymerase (PADPRP) and DNA-dependent protein kinase (DNA-PK) (48-50). 
Significantly, all these autoantigens are known to be recognized by certain SLE sera. It 
was proposed by Casciola-Rosen et al. that such selective cleavage reactions produce 
'immunocryptic' fragments, and, in susceptible individuals, an autoimmune response 
(48).
More recently, unusual cleavages of certain SSc autoantigens have also been shown 
to occur, specifically under conditions of oxidative stress (46). The autoantigens 
involved include topo I and RNAP II. These specific fragmentations, which are only 
thought to occur in the setting of SSc, require metal ion-catalysis and the generation of 
reactive oxygen species (ROS). It is believed that such reactions occur during the 
ischaemic reperfusion events which are a characteristic component of SSc pathology. 
The specific site is thought to be the nucleolus, since metal ions are known to become 
localized there. Indeed, an abnormal accumulation of metal ions could be a predisposing 
factor to SSc in the context of pre-existing RP, with its recurring episodes of ischaemia 
(288).
It is also possible that high levels of Tc cell activity occurring in SSc lead to a 
concentrated source of granzyme-1-cleaved autoantigens, which, as mentioned earlier, 
may involve the generation of connective tissue fragments. There is evidence that 
granzyme-B causes the production of cryptic epitopes during Tc cell-induced apoptosis 
(5). Such unusually cleaved protein fragments could be internalized by APCs, resulting 
in the presentation of novel peptide epitopes. As discussed earlier, in the setting of SSc, 
there is evidence that, due to EC destruction, fragments of connective tissue-derived 
proteins are readily available in the inflammatory perivascular micro-environment. 
Together, these facts could explain the origin of the proposed autoimmune attack on 
components of the vascular endothelium in SSc.
Oxidative damage to self-antigens
In 1984 LeFeber et a l made the intriguing observation that u.v. light-treated cultures of 
normal human keratinocytes bind autoantibodies derived from SLE sera. The binding of 
these antibodies was consistent with the extemalization of Ro, U1 RNP and Sm 
antigens onto the cell surface of damaged, but not dead, cells (193). These results were 
later confirmed by others, who also demonstrated that SLE-derived keratinocytes were
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especially prone to u.v. light-induced cell-surface expression of these antigens (116). 
Subsequent work by Casciola-Rosen et al. indicated that sub-lethal doses of u.v. light 
cause apoptosis of cultured human keratinocytes, and that these apoptotic cells are 
characterized by surface blebs of ectopically expressed intracellular antigens (47,341). 
Smaller surface blebs were found to contain endoplasmic reticulum fragments, 
ribosomes and the Ro antigen, while larger blebs contained Ro, La, nucleosomal DNA 
and RNPs. It was further suggested that, by reason of their topology, these particular 
autoantigens were particularly prone to oxidative damage by free radicals during the 
process of apoptosis (47). Such unusual oxidation reactions may result in structural 
alterations to these antigens (47).
The exact pathway leading to the development of autoantibodies recognizing Ro, La 
and U1 RNP antibodies in SLE remains to be clarified. The frequent occurrence of 
complement deficiency in SLE has been mentioned, as has defective apoptosis, with the 
likely accumulation of autoreactive T cells, particularly those recognizing apoptotic 
antigens. Thus, the potential for cryptic determinants of these particular self-antigens to 
induce an autoimmune response in SLE is clear.
Phosphorylation of self-antigens
The particular range of proteins phosphorylated during stress-induced apoptosis have 
also been shown to be recognized by a subset of SLE sera (347). This was taken to 
indicate that phosphorylation occurring during apoptosis lead to the production of 
neoepitopes (i.e. cryptic epitopes) of self antigens.
Viral proteins in novel packages of self-antigen
The ideas of Rosen et al. were subsequently elaborated in a paper describing apoptosis 
induction by Sindbis virus. It was reported that the viral antigens and the autoantigens 
co-cluster in the small surface blebs of the apoptotic cells (287). It was suggested that 
these complexes represent autoantigens occurring in a 'novel immune context' which 
may lead to the activation of autoreactive T cells in infected individuals (287). 
Xenobiotics
The chemical modification of a self antigen by a pharmacological agent or an 
environmental toxin is thought to be a further possible source of neoepitopes (for 
review, (121)). Both mercury and gold are known to be capable of forming stable metal - 
protein complexes by binding to the side groups of certain amino acid residues, thus 
altering the tertiary structure. Consequently, intralysosomal processing of such proteins 
by APCs may be altered, leading to the presentation of cryptic epitopes on the APC 
surface which could circumvent self-tolerance mechanisms. For example, it has been 
proposed that fibrillarin (the protein component of U3 RNP), is especially prone to 
mercury-induced modification (270). In the report of Pollard et al. (270), mercury was 
shown to interact with two cyteine residues of fibrillarin, producing a disulphide- 
bonded form, probably incorporating a mercury molecule as part of the disulphide 
bridge. Furthermore, evidence was presented which suggested that, while the T-cell
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response to fibrillarin was mounted against the mercury-modified form of fibrillarin, the 
anti-fibrillarin antibodies of these mice recognized the unmodified fibrillarin. This 
implied that, once T cell tolerance was broken by a cryptic epitope of an autoantigen, an 
autoreactive B cell response was invoked, which was capable of causing intramolecular 
epitope spread to other epitopes of the cryptic antigen, and in so doing, propagated a T- 
cell immune response against the native antigen.
Unusual exposure o f normally sequestered self-antigens
Physical damage to the retina of the eye may result in the availability of autoantigens 
previously not encountered by the immune system. Another such instance may be 
vibration white finger: it is possible that, in severe cases, vibrational stimuli cause 
mechanical damage to ECs which results in an accumulation of EC fragments normally 
only available in small quantities.
Molecular mimics
The role of microbial pathogens in the induction of autoimmune diseases has been 
reviewed by Behar & Porcelli (15). Microbial antigens which have structural 
similarities to self-antigens are thought to be capable of inducing immune reactions 
which cross-react with self-antigens, and this is known as molecular mimicry. The 
presence of a molecular mimic can lead to the activation of T cells recognizing minor 
determinants of the analogous self antigen, as described presently.
Altered antigen processing
Exogenous provision of endogenous antigens
One interesting paper has demonstrated that the proteolytic processing of a particular 
self-antigen differs depending on whether it is endocytosed by, or endogenously 
synthesized in, the APC. Significantly, it was shown that the process of tolerance 
induction involves the presentation of endogenously synthesized self-antigens (12). 
Heterogeneity in antigen processing bv antigen-presenting cell subsets 
Several cell types constitutively express Class II MHC, including macrophages and 
DCs, and are collectively known as professional APCs. As previously mentioned, the 
B-cell lineage represents a further important APC population.
It has been demonstrated by Vidard et al. that not all types of APC contain the same 
complement of proteolytic enzymes (351). Thus, for a given native antigen internalized 
by an APC, the array of peptides produced following intralysosomal enzymatic 
cleavage may differ depending on the lineage of the APC concerned. For example, the 
processing of ovalbumin appears to differ when carried out by B cells as opposed to 
splenic APCs, resulting in an alternative profile of presented peptides (351). 
Furthermore, it was also shown that, under different physiological states, the relative 
activities of the different enzymes expressed by a particular APC may alter. During 
tolerance induction in the thymus, a particular population of DCs is thought to be
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involved in the process of negative selection of autoreactive T cells (123). Thus, it is 
possible that antigens processed by non-professional APCs, such as ECs, may lead to 
the production of cryptic epitopes of a self-antigen. In the context of the wide 
availability of connective tissue fragments in SSc, together with the apparent 
upregulation of MHC Class-II molecules on the surface of ECs in the proinflammatory 
perivascular environment, this provides an additional explanation for the origin of an 
autoimmune attack on components of the vascular endothelium in SSc.
Other mechanisms leading to autoimmunity
Breakdown of suppressor mechanisms
Any factor affecting the purported populations of Ts cells may result in a rising 
incidence of autoreactivity.
Superantigens
The potential for polyclonal activation of autoreactive T cells by bacterial superantigens 
was mentioned earlier (for review, (15)).
Epitope spreading
Thus, autoreactive T cells recognizing cryptic epitopes may be activated by APCs, 
resulting in their clonal proliferation. Once stimulated, these Th cells will be capable of 
providing help to appropriate B cells. These will include any B cell which has, via its Ig 
receptors, recognized, internalized, and processed the whole native antigen, and 
successfully presented the particular cryptic epitope on one of its MHC Class II 
molecules. As mentioned earlier, the pool of autoreactive B cells is considerable, but 
they are normally kept in check by the lack of appropriate Th cell help. Once such help 
becomes available, a B cell which recognizes an epitope of the native, unmodified 
autoantigen may be specifically activated. Furthermore, it is believed that the primed Th 
cells are capable of upregulating co-stimulatory molecules in the B cells -  a vital pre­
requisite of an effective APC (212). Clearly, a source of native self antigen must also be 
available. It is significant that B cells only process antigens recognized by their surface 
Ig, since, when a B cell acts as an APC there is likely to be a rather high concentration 
of minor epitopes successfully presented on its cell surface. In other words, B cells 
upregulate the generation of minor self epitopes (15).
Indeed, recent results suggest that, on account of their different antigen processing 
patterns, B cells may present a much more heterogeneous array of peptides than DCs 
(108,212). It has been concluded that DCs focus the T-cell response onto certain 
immunodominant (major) epitopes of an antigen, while B cells subsequently diversify 
T-cell responses onto subdominant epitopes of the antigen (88,108). It is believed that 
these B cells can effectively stimulate naive T cells (213), and, under conditions of 
chronic antigen exposure, effectively spread and diversify the immune response to 
different epitopes of the same antigen (212).
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Furthermore, once initiated, re-stimulation of memory T cells by processing of 
whole native antigen may occur since less peptide is needed to be presented on the 
surface of an APC for effective stimulation of a secondary response by memory T cells. 
Thus, as the immune response develops, minor epitopes of an antigen can become 
i major epitopes.
However it begins, autoimmunity to one epitope of an antigen appears to spread to 
other epitopes on the same antigen and, ultimately, to other antigens with which the first 
antigen may physically associate (194,210). This association need not be covalent, and 
may pass through multisubunit complexes such as the uridene-rich small nuclear RNPs 
(UsnRNPs). There is evidence that both intra- and intermolecular epitope spreading 
occur in SLE, and similar mechanisms are believed to operate in SSc. The mechanisms 
involved are thought to be essentially analogous to epitope spreading involving 
exogenous pathogens.
Evidence for intramolecular spreading
Experimental results show evidence of epitope spreading in animal models of SLE. 
Upon immunizing rabbits with an eight-residue peptide from the B, B' antigen (which 
forms part of UsnRNP complexes), autoantibodies were produced, not only to the 
immunizing peptide, but to other peptides of the snRNP complex (158). In this study 
the rabbits even developed a lupus-like illness.
Evidence for intermolecular spreading to non-covalently associated proteins 
Other work has shown that immunization of mice with ~ 100-residue fragments of La 
autoantigen results in autoantibodies to other areas of the La peptide and, further, to the 
expression of anti-Ro autoantibodies (283). The Ro-heterogenous nuclear RNP 
(hnRNP) complexes are known to physically associate with the La protein during 
certain functional processes.
Conversely, rabbits immunized with short Ro peptides produce autoantibodies to 
other epitopes of native Ro and, in some animals, an anti-La and anti-DNA response 
was also found to occur (303). Thus, immunization with short peptides of certain self 
antigens is capable of breaking down tolerance to entire multiprotein complexes in 
which that particular amino acid sequence naturally occurs.
Epitope spread in molecular mimicry
Such responses have been studied using foreign versions of self proteins. For example, 
it has been found that co-immunization of mice with foreign and self cytochrome c 
results in tolerance to the self molecule being broken (213). Meanwhile, immunization 
with self cytochrome c alone did not result in autoimmunity. The two forms of the 
protein have a high degree of homology, with some shared, and some unique, epitopes. 
It appears that activation of Th cells recognizing an epitope specific to the foreign 
molecule occurred first, as would be expected. The stimulation of such Th cells would
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have made them available to help appropriate B cells. These would have included B 
cells which had, via their Ig receptors, recognized a cross-reactive epitope of the foreign 
cytochrome c, and subsequently internalized and presented the various epitopes of the 
foreign molecule (211). One of these presented epitopes could have been the foreign 
antigen-specific peptide recognized by the Th cell described above. Thus, this T cell, 
which recognized a foreign epitope was now able to help a B-cell clone which 
recognized a cross-reactive epitope. The activated B cell then appeared to have 
activated naive T cells recognizing common cytochrome c epitopes, which were also 
present on its surface. This resulted in the breakdown of tolerance to self-cytochrome c 
(213). This, and other, experiments by the same group, helped establish the currently 
accepted model of molecular mimicry (211), which may be responsible for the 
triggering of some autoimmune syndromes.
1.8 AUTOANTIBODIES AND THEIR CLINICAL ASSOCIATIONS
Many CTDs are characterized by the presence in patient sera of particular 
autoantibodies, some of which are disease-specific (for review, see (205,339,353)). 
These autoantibodies are sometimes detected before the complete disease syndrome is 
clinically apparent, for example in primary RP patients destined to develop SSc, or in 
patients with UCTD who do not yet display sufficient symptoms to identify the 
particular CTD concerned. Where the physician suspects the presence of a particular 
disease, this can often be confirmed by routine serological testing in a hospital 
laboratory. Thus, identification of autoantibody specificities can be important in the 
diagnosis of individual cases.
A patient's autoantibody profile also aids prognosis in SSc, since some autoantibody 
specificities are associated with a particular disease subtype, and some are strongly 
suggestive of certain types of organ involvement. This information allows the clinician 
to anticipate the most likely complications, and to plan treatments and investigations in 
a rational manner, with regard to such factors as life expectancy, quality of life, the cost 
and unpleasantness of certain investigatory procedures, the side-effects of particular 
drug regimes, and the possible dangers of non-intervention. By advising the patient of 
the likely progress of their disease, the patient's own views can also be taken into 
account on these matters.
Autoantibody specificities which are typical of a particular disease but which are 
not wholly disease-specific do not have the same diagnostic significance, though they 
may still point to a symptomatic pattern and can alert the physician to possible 
complications beyond the presenting symptom. In some cases the non-disease-specific 
autoantibody is in fact characteristic of an overlap syndrome between two types of CTD 
e.g. anti-Ul RNP antibodies are often found in patients who show some symptoms of 
SSc, SLE and RA.
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It is unusual for a single CTD patient to express more than two or three different 
autoantibody specificities. Further, where more than one is found, there is a tendency 
for some autoantibodies to occur together, as discussed below.
Autoantibodies in Sjogren's syndrome and their clinical associations
The Ro and La autoantigens were originally designated SS-A and SS-B, respectively, 
on account of the very high prevalence of anti-Ro and anti-La antibodies in SS patients 
(~90% and ~80%, respectively) (3). However, these antibodies are also common in 
SLE, and are detected in a minority of SSc patients (17,104,143), particularly those who 
also fulfil a diagnosis of SS (104).
Interestingly, while anti-Ro antibodies sometimes occur in isolation in SS, anti-La 
antibodies almost always occur in association with anti-Ro antibodies. Despite the fact 
that anti-Ro antibodies are not disease specific, their presence is closely associated with 
the same particular symptoms in a variety of CTDs (30) i.e. photosensitive rashes, SS 
and neonatal lupus.
Autoantibodies in SLE and MCTD and their clinical associations
Four main autoantibodies are characteristic of SLE sera. The anti-Sm specificity is 
found in ~ 15% of SLE patients (342), and is virtually disease-specific, while anti-Ul 
RNP antibodies (~35% of SLE sera) are also closely associated with the so-called 
MCTD syndrome. The Sm antigens (termed B, B' and D) are core proteins of most U 
snRNP complexes of which U1 RNP is one example. Anti-Ul RNP antibodies react 
with U1 RNP-specific proteins of the U1 RNP particle (A, C and the "70-kDa" antigen). 
In SLE patients, anti-Sm antibodies are rarely seen in the absence of anti-Ul RNP 
antibodies, though anti-Ul RNP antibodies frequently occur in the absence of anti-Sm 
antibodies. Anti-Sm antibodies in the context of SLE have been associated with kidney 
disease and lung fibrosis, while anti-Ul RNP antibodies in the absence of anti-Sm 
antibodies are indicative of less severe disease. Anti-Ul RNP antibodies have been 
detected in up to 12% of SSc patients (143). The U2 RNP antibody specificity has also 
been detected in SLE/SSc/Pm overlap syndromes (66,233), and anti-U4 RNP/U6 RNP 
antibodies have been reported in a patient with SSc (253).
Anti-Ro antibodies and anti-La antibodies are also very frequently found in SLE sera 
(-40% and 20% of sera respectively), although it would be considered fairly unusual for 
a single serum to contain all four antibodies. Just as in SS, anti-La antibodies rarely 
occur in the absence of anti-Ro antibodies, but anti-Ro antibodies are frequently found 
alone in SLE sera. The clinical associations of anti-Ro and anti-La antibodies are as 
described above for SS, although the presence of anti-La antibodies is also negatively 
associated with lupus nephritis.
Other SLE antibodies include anti-PADPRP antibodies (240,368,369), anti-Ku 
antibodies, and antibodies recognizing DNA-PK (335). The latter two antibodies have
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been found to occur together in some SLE patients. Some SSc and Pm sera also contain 
anti-Ku (232,234,371), and anti-DNA-PK antibodies (335).
In general, the autoantibody response is less restricted in SLE than in other CTDs, 
with single sera frequently containing two, three or more autoantibody specificities 
(339).
Autoantibodies in Pm and Dm and their clinical associations
Many different antibodies have been associated with the occurrence of Pm and Dm 
(110,275), the most common being anti-Jo 1 antibodies, found in ~20% of myositis 
sera. Anti-Jo-1 and anti-PL-7 autoantibodies are restricted to those CTD patients with 
myositis who also fulfil diagnostic criteria for Pm or Dm (231,350) and in whom they 
are indicative of interstitial lung disease, arthritis, RP, and poor overall prognosis. 
Meanwhile, the clinical association of antibodies recognizing the Pm-Scl antigen is with 
the Pm-SSc overlap syndrome. Anti-Ku antibodies have also been associated with Pm- 
SSc overlap, particularly in Japanese patients.
Autoantibodies in systemic sclerosis
Systemic sclerosis is also characterized by the presence in serum of disease-specific 
autoantibodies which have been found to be associated with clinical subgroups of 
disease (for review, see (133,271)). Precipitating antibodies in the sera of SSc patients 
were first reported in 1963 (14). One of the nuclear antigens uniquely recognized by 
SSc sera was subsequently identified as a 70-kDa nuclear protein and termed Scl-70 
(78), though this was later shown to be a degradation product of a larger antigen found 
in vivo (349). The Scl-70 antigen was eventually identified as being the 100-kDa 
enzyme topo I (124,311). These early studies established the link between anti-topo I 
antibodies and the presence of clinical features of SSc as such.
Soon after, the ACA system was detected (20,343), which was also shown to be SSc- 
specific (52). The component antigens of the centromere which were recognized by 
ACAs were subsequently identified by Eamshaw et al. (82). It was quickly realized 
that, within the SSc group as a whole, these two SSc-specific antibodies were associated 
with particular disease subgroups (53,343,349). It is now well established that patients 
with anti-topo I antibodies tend to have different clinical features from those with ACA 
specificities. Each of these specificities is found in roughly 25% of SSc sera, and they 
are generally considered to be disease-specific and mutually exclusive.
The third major class of autoantibodies present in SSc are directed against proteins 
found predominantly in the nucleolus (177,276,344). The presence of ANoAs in some 
SSc sera was first reported some time ago using IF methods (14,20,343), and three 
different nucleolar staining patterns were observed (speckled, homogeneous, clumpy) 
(20,160). It was appreciated that these probably represented several different nucleolar 
autoantibody systems (20,343). However, more sensitive techniques were required for 
the isolation and identification of the autoantigens recognized by these sera (177).
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Using IP techniques, antinucleolar antibodies in SSc have been found to precipitate 
RNAP I (10-15%), fibrillarin (the protein component of U3snRNP) (8%), Pm-Scl (4- 
17%), ThRNP (4-13%) and, less commonly, nucleolus organizer region protein-90 
(NOR-90) (177,251,252,278,286). Rather less data is available concerning their clinical 
associations, but recent studies are beginning to show that ANoAs are also each 
associated with particular subsets in the disease spectrum.
While RNAP I is located in the nucleolus, the other two RNAPs (II and III) are 
found in the nucleoplasm. Although both anti-RNAP I and anti-RNAP III reactivities 
are SSc-specific, occurring in 10-15% of sera (144,183,277), anti-RNAP II antibodies 
also occur in SLE and in MCTD/overlap syndromes (297). As mentioned above, a 
number of other antibodies have been detected in SSc sera, many of which are not 
disease-specific: these include anti-Ul RNP antibodies (-5%), anti-Ro antibodies 
(~5%), and anti-Ku antibodies (1-15%).
With the exception of anti-RNAP I and anti-RNAP III antibodies, coexistence of 
more than one SSc-specific autoantibody in the same serum is generally considered to 
be very uncommon (327), although isolated cases have occasionally been reported 
(139,161,185,296).
Clinical associations of autoantibodies in systemic sclerosis 
Anti-topoisomerase antibodies
The anti-topo I antibody identifies a subgroup with diffuse disease together with an 
increased risk of pulmonary interstitial fibrosis (52,102,327,349,357), digital pitting 
scars (327), malignancies and cardiac abnormalities (357).
Anti-centromere antibodies
Meanwhile, ACAs are associated with a subgroup with limited skin involvement and 
prominent vascular features (20,53,225,327,343). While ACA-positive patients often 
have less severe systemic disease (357) and a more protracted disease course (52), a 
close association between ACAs and severe digital ischaemia has been noted. 
Furthermore, lc-SSc patients with ACAs are more likely to have telangiectasiae of the 
digits, and calcinosis than are those lc-SSc patients who are ACA-negative (328).
Anti-RNA polymerase antibodies
Antibodies recognizing RNAPs have been associated with diffuse cutaneous disease, 
renal involvement, and a very high degree of skin thickening (255,277,278). Other 
clinical associations reported for anti-RNAP antibodies include decreased survival, joint 
involvement, and cardiac involvement (185,278). Interestingly, anti-RNAP I-positive 
patients have been reported to have a low rate of RP early in their disease (278).
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Antibodies recognizing the Pm-Scl autoantigen
Anti-Pm-Scl antibodies occur almost exclusively in the Pm/SSc overlap form of 
disease, which often includes myositis, calcinosis, pulmonary involvement and arthritis 
(26,208,251,278). This is generally characterized by limited skin involvement and few 
serious visceral complications, although one report found a high incidence of renal 
involvement (278).
Antibodies recognizing the Th RNP autoantigen
Anti-Th RNP antibodies (also called anti-To (274)) have been linked with lc-SSc, puffy 
fingers, poor long-term prognosis (due to pulmonary hypertension), and hypothyroidism 
(252). The reported association with small bowel involvement (252) has not been 
confirmed (85). In other respects, the clinical features of anti-Th RNP-positive patients 
resemble those found in the ACA group, with a low incidence of renal and cardiac 
involvements (85). Anti-Th RNP antibodies are SSc-specific.
Anti-fibrillarin antibodies
The anti-U3 RNP antibody specificity has been found to recognize the protein 
component of U3 RNP (201). Anti-U3 RNP antibodies are also SSc-specific, and have 
been associated with skeletal muscle involvement, primary pulmonary arterial 
hypertension, and small bowel disease (7,35,254,294). One group has found an 
association with renal disease and cardiac involvement (7). A particularly high 
proportion of Black patients have been found to express this autoantibody.
Antibodies recognizing the nucleolus organizer region
The anti-nucleolus organizer region (anti-NOR-90) specificity was reported to occur in 
Spanish cases of SSc (286). The antibody was also reported in two children with RP 
(101). However, others have estimated that less than 1% of SSc patients have anti- 
NOR-90 antibodies, and have reported that the antibody is not at all disease-specific, 
being found in a small proportion of SS, RA and SLE patients (76,103).
Other anti-nucleolar antibody specificities
Antibodies recognizing the nucleolar phosphoprotein B23 have been found to occur in 
more than 50% of GVHD, and in some SLE patients (360,366).
Predictive value of autoantibodies in Raynaud's phenomenon
Several different groups have detected autoantibodies of defined specificity in sera from 
primary RP patients who did not have a definite CTD diagnosis (171,357). These have 
included anti-topo I, anti-centromere, anti-Ro and anti-Ul RNP antibodies.
The significance of ANAs detected in 53% of 138 patients referred on the basis of 
severe RP was studied by Kallenberg et al. (170), by following the patients up over a 
six-year period (171). The patients were divided into primary RP (28%), secondary RP 
(55%), and suspected secondary RP (17%), on the basis of other CTD symptoms.
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Initially, it had been found that ANAs (detected by IF methods) were more frequently 
found in patients with suspected secondary RP (71%), and in those with a defined CTD 
(66%), than in patients with apparently primary RP (who had no signs of a CTD) (16%) 
(170). Anti-topo I antibodies and ACAs were subsequently detected in the initial study 
sera by immunoblotting (IB). While 14/50 sera from SSc patients had ACAs, these were 
also detected in sera from 7/62 patients without a specific CTD diagnosis. At follow-up, 
three of these primary RP patients had since received a diagnosis of SSc. Further, two 
primary RP patients who had had topo I-positive sera had also developed symptoms 
fulfilling a diagnosis of SSc, and anti-Ro/La antibodies were detected in two sera from 
RP patients who went on to a diagnosis of SLE (171).
A prospective study of 77 primary RP patients without signs of CTD, carried out by 
Weiner et al. (358), showed essentially analogous results: a 63-fold risk of going on to 
develop signs of a CTD was calculated for those patients who tested positive for either 
anti-topo I or ACAs at the start of the study. Also, the presence of one of these 
autoantibodies was shown to be a more sensitive indicator of impending CTD 
symptoms than were results from widefield nailfold capillaroscopy. In the same study, 
ELISA methods were used to detect sera containing anti-topo I antibodies and ACAs. 
Two anti-topo I-positive, and two ACA-positive sera came from four patients who went 
on to develop tight skin at follow-up, three of whom subsequently attained a full 
diagnosis of SSc.
Together, these results illustrate the usefulness of autoantibody screening tests for 
patients with primary RP, in helping to identify those patients at risk of developing a 
defined CTD, and in predicting the particular CTD concerned. It is possible that ANoAs 
will also be shown to be useful prognostic markers in a minority of RP patients. Most 
interesting is the concept that antibodies may precede the full development of the 
symptoms with which they have found to be associated, thus placing autoantibodies at 
an early stage of aetiopathogenesis.
Significance of the autoantigens recognized by SSc sera
The cellular location and function of many autoantigens have now been determined. 
Consequently, associations between the biochemical roles of different autoantigens 
have emerged. Stefano (329) suggested that La autoantigen is a termination factor for 
RNAP III by demonstrating preferential binding of La to the RNAP III transcription 
termination signal. All rRNAs are transcribed by RNAP III, and the 60-kDa Ro particle 
may be involved in a discard pathway for defective 5s rRNA precursors (248). Nascent 
RNAP II transcripts have been found to occur in association with small nuclear 
ribonucleoproteins, including the U1 RNP particle (220). The Ku autoantigen was 
shown to be the regulatory component of the kinase complex responsible for 
phosphorylating RNAP IIA to form RNAP IIO (80). Finally, there is the recent 
identification of topo I as a transcription factor for RNAP II-transcribed genes (180).
49
Thus, various combinations of autoantigen which come together at certain stages of 
the cell cycle are recognized by sera of patients with autoimmune CTDs (125). It is 
thought that reactivity with one epitope on a complex may spread to other epitopes on 
the same particle(89). Antibodies to certain proteins such as centromere proteins, U3 
RNP, Th RNP and Pm-Scl seem to be mutually exclusive in SSc, and there is no 
evidence for their direct interaction in vivo. However, it does appear that autoantigens 
which colocalize to the nucleolus are preferred targets for autoantibodies in SSc.
1.9 FAMILY STUDIES
As reviewed earlier, many genetic and environmental factors have been reported to 
cause or promote the development of SSc. Current thinking regarding aetiology, 
suggests a combination of genetic and environmental influences may be the best 
explanation of the available data, with an environmental trigger leading to disease in 
genetically susceptible individuals (138,331). However, the many possible ways in 
which individual factors may interact are complex and little understood. Indeed, one 
leading epidemiologist has described SSc as an epidemiological and genetic enigma 
(314). Moreover, even in the presence of the appropriate genetic and/or environmental 
stimuli, still other genetic polymorphisms may influence the particular subtype or 
severity of disease expression -  as mentioned earlier, for instance, RP may represent a 
formes frustes of SSc (117). In order to track down the most significant genetic and/or 
environmental influences in SSc, to understand the interplay of such factors as the 
disease progresses, and to construct a general aetiological model (or models), further 
demographic research is vital, and this should include family studies.
The value of family studies
A familial background of immunological abnormalities is thought to be a contributory 
factor to the expression of SSc, and certain clinical features of CTDs have also been 
reported in the relatives of SSc patients. Such characteristics of SSc, occurring in an 
incompletely expressed form, can be assessed in family members of SSc patients by 
detailed and careful clinical examination, history-taking and laboratory investigations. 
Thus, in family studies, the characteristics of affected and unaffected individuals are 
inventoried in a setting where genetic and environmental influences have converged, in 
one or more individuals, to promote disease development and/or a set of features typical 
of the disease.
Shared genetic background
The first-degree relatives of large kinships provide a pool of individuals sharing many 
of the same genetic characteristics. Identical twins, where either one or both individuals 
are affected by the disease, would be of particular interest.
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Shared environmental factors
Shared environmental influences are a further common feature of family members, 
particularly in the case of siblings who have lived together since early childhood. 
Another important group to consider is the spouses of SSc patients, who may have been 
exposed to similar environmental conditions in adulthood, whilst having very different 
genetic influences.
Genetic and environmental interactions
Multicase families are of particular value for the study of genetic and environmental 
interactions: certain differences between the genetic and/or environmental factors to 
which various members of the same family have been exposed may be found to 
coincide with affected versus unaffected individuals. Furthermore, by detecting more 
subtle clinical and immunological abnormalities, such information may also be obtained 
from the family members of isolated SSc cases.
Timing o f disease onset
Genetic and environmental factors may be distinguishable according to patterns of 
disease onset in genetically related individuals (56,331). A strong genetic component 
might tend towards a non-contemporaneous onset of disease for individuals of different 
generations, while environmental influences may be reflected by simultaneous disease 
onset in individuals of different ages. Study of multicase families, where individuals 
from different generations are found to be affected by SSc, would be of particular 
significance in this regard.
Multicase family studies
Systemic sclerosis is a very rare disease: multicase SSc families are extremely unusual. 
However, some clinical and immunological features of the disease have been reported 
in first-degree relatives of patients. Most of this information has come from case studies 
of individual affected kindreds, and the genetic and environmental background of such 
families is sometimes difficult to assess. A variety of relationships have existed between 
the family members in these reports, e.g. mother/daughter (61,99,241), mother/son
(117), sister/sister (61,138), sister/brother (138,310), brother/brother (310), and 
aunt/nephew (334).
Multicase systemic sclerosis
One early report by Frayha et al. described a mother-daughter pair, each having lc-SSc 
together with SS. Both patients had the same autoantibody specificity, and developed 
their first symptom, RP, within one year of each other (99). Other multicase families 
have since been reported (61,71,117,138,223,235,241,295,310,334), with the following 
general findings: (i) in several such instances, there have been considerable similarities 
in disease expression between the related SSc patients (241,334); (ii) as recorded in a 
review by Christy & Rodnan (56), it was found that, of eleven cases surveyed, eight
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recorded the interval between the onset of the disease in the two affected individuals as 
being three years or less; (iii) the same HLA alleles have often been detected in the 
involved family members (61,138,223,235,241,310); (iv) where an environmental agent 
was suspected in a particular case, both affected family members had been exposed to it 
(56,295). Some of these findings are exemplified below.
One particularly interesting paper described five siblings: two of the brothers and a 
sister had SSc, and a brother and a sister had RP (310). Two other close relatives had 
features of a CTD. The two brothers with SSc and their sister with RP had an identical 
HLA haplotype (A2, B21, DRw4/A2, B12, DRw4).
Of especial note was a report of conjugal SSc (56). This husband and wife, who had 
lived together for 31 years before onset, both developed the disease within three years 
of each other, and, in fact, both had HLA-A1, -B8 and -DR3 alleles. The husband was a 
stonemason/cement mixer, with considerable silica exposure. Following detailed 
history-taking it emerged that the wife had hand-washed all her husband's overalls, 
which were likely to be contaminated by silica dust.
A study by Hietarinta (138) included a very important finding: in a family with three 
cases of SSc (two sisters and a brother), it was found that all three had the HLA alleles 
A2, B8, DR3, as did another sibling with immunological abnormalities. However, a 
further four healthy family members also had these alleles. Furthermore, three of them 
(all siblings of the SSc patients) were reported to be HLA identical with two of the 
patients (HLA-A, -B, -C and -DR alleles were assessed in this study). It was concluded 
that the A2, B8, DR3 haplotype is a predisposing factor for SSc, but that other genetic 
and/or environmental influences are required for disease expression.
The interplay of genetic and environmental factors was apparent in the paper of 
Sanchez-Roman et al. (295). In their prospective study of workers exposed to silica dust 
at a scouring powder factory, they found that several sets of siblings had worked there 
together, and that, in two families, more than one had developed SSc.
Multicase connective tissue disease
Reports of multicase SLE families are also to be found (57,295). In some cases, both 
SSc and SLE have been found in different members of the same kindred: Flores et al. 
recorded a high degree of serological and HLA concordance in eight such cases studied 
(95). Such findings suggest some commonality in the aetiology of these two disorders, 
and it was suggested by the authors that these factors were genetic rather than 
environmental, since three of the pairs had never lived together.
Meanwhile Molta et al. reported on the families of two unrelated SSc patients in 
which multiple cases of CTDs occurred, including discoid lupus, SS, RP, RA and 
psoriasis and ulcerative colitis (235). A similar family was described by Sels et al., with 
cases of RA, SLE, psoriasis and inflammatory bowel disease were found (306). Familial 
aggregation of RP has also been reported (100).
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Immunologically based family studies
Autoantibodies in systemic sclerosis family members
Immunological abnormalities in the relatives of SSc patients were first noted in 1961 by 
Corcos et al. (64). This group reported that 37% of 78 blood-relatives of SSc patients 
had abnormal IgG levels. A number of other papers have been published since then, and 
the following points have been made with a fair degree of consistency: (i) an increased 
incidence of anti-nuclear reactivity has been reported in sera from the consanguineous 
relatives of SSc patients; (ii) a less pronounced increase in anti-nuclear reactivity in sera 
from spouses of SSc patients has also been reported; (iii) SSc-specific antibodies are 
only present in patients with the disease, or in certain cases, in individuals who are in 
suspected transition to SSc; (iv) in multicase SSc families, the affected individuals have 
tended to express the same autoantibody specificity. A variety of examples is presented 
below.
An early study of 90 relatives of SSc patients by indirect immunofluorescence (IF) 
observed that, although CTDs were not common in the relatives, ANAs were detected 
in some 58%, compared with only 2% of normal controls (90). Some time later this 
finding was confirmed by Rothfield et al. (289), who detected ANAs in 12% of 83 first- 
degree relatives of SSc patients, in one of 17 spouses (6%), and in only 4% of 50 
healthy controls (289). In this study, it was also noted that, while 10% of ANA-positive 
patients had high-titre ANAs, all ANA-positive blood-relatives had low-titre antibodies.
A particularly thorough serological study of 21 SSc patients and their 35 first-degree 
relatives was carried out by Takehara et al., using IF and immunodiffusion techniques 
(336). None of the family members had a defined CTD. The use of the new HEp-2 cell- 
line in this study showed that 100% of patients had positive IF-ANAs (1:40 serum 
dilution), while the rate in relatives was 26%, and, of twenty control normals, only one 
was positive (5%). Of the relatives, several were found to have high-titre IF-ANA (one 
1:2560, one 1:1280, three 1:640), while the normal control was positive at 1:160 
dilution. It was also noted that positive ANAs were more common in daughters of 
patients than in sons (54% versus 7%, respectively). Patterns detected included fine 
nuclear speckles and granular patterns. Of note was the detection of ACAs (by IF) in the 
mother of an anti-topo I-positive SSc patient. Interestingly, the titre of this serum was 
1:320, which would be considered unusually low in SSc. Interesting findings by 
immunodiffusion included anti-Ul RNP antibodies in the brother and in the daughter of 
one SSc patient who herself had anti-topo I/Ul RNP antibodies. The overall rate of 
positivity by immunodiffusion was thus 6% of SSc relatives (2/35), as compared with 
76% of patients and 0% of normal controls.
A subsequent study by Ruffatti et al. specifically concerned the incidence of ACAs 
and ANAs in the 116 blood-relatives of 22 ACA-positive SSc patients (292). A total of 
82 healthy normal controls were included. Scleroderma was absent from relatives, 
though some features of RP were present in eight of them. A low-titre ACA pattern
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(1:40) was found by IF in four relatives (3%) and in none of the controls. Of the four 
ACA-positive relatives, one had hypoparathyroidism, one had myasthenia gravis, and 
one had cold-sensitivity. When ANA-IF was examined, 17 (15%) of relatives were 
found to be positive (one had a titre of 1:320), and all of these were first-degree 
relatives. Of the normal controls, only four (5%) were positive (all titres were 1:40 or 
1:160), a result which was significantly different from the relatives. Positive 
immunodiffusion results were obtained for one proband (topo I), no relatives and no 
controls.
Importantly, not all investigators have supported these findings. The study of Barnett 
& McNeilage in 1993 produced no evidence that environmental or genetic factors 
influence the development of ANA positivity in SSc. Their paper describes a study of 
58 SSc patients, their 30 spouses and 74 of their first-degree relatives, together with 66 
age-matched controls (13). They found positive ANA (titre 1:40 or above) in 95% of 
patients, 7% relatives, 3% spouses and 18% of controls. No defined ANAs were 
detected in family members or normals.
Autoantibodies in connective tissue disease family members
A higher than normal incidence of ANAs has also been noted in family members of 
SLE patients (74,289). In the latter study, a key finding was that close household 
contact with the proband was associated with ANA positivity. Furthermore, a study of 
multicase SLE families by Cleland et a l detected ANAs in 53% of consanguineous and 
57% of non-consanguineous relatives, as compared with 5% of controls (57).
Southwood et al. conducted a study of ANAs in juvenile chronic arthritis patients 
and their families, and found that 70% of patients and 17% of relatives had IF-ANA. 
Furthermore, in five families, IB studies showed common banding patterns between the 
probands and other family members. It was suggested that there is an inherited 
component to the autoimmune response in some of these families (322).
Other abnormalities in the family members of systemic sclerosis patients
Chromosome instability
An increased level of chromosome instability compared with controls has been reported 
in SSc patients and in their family members (8). This was implied by a significant 
increase in the number of alterations occurring to the variable number tandem repeat 
sequences (minisatellites). A further report by the same group found that telomeres 
were also significantly shorter in SSc patients, as well as in their spouses and blood- 
relatives. It was suggested that chromosome instability may be due to an 
environmentally related cause (8,9). However, a report by another group found no 
evidence of actual chromosome damage in SSc patients or their relatives (31).
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Complement deficiency
It was reported that 67% of SSc patients, 49% of SSc blood relatives, 33% of spouses 
and only 17% of normal controls had a C4 null allele (264). A significant association 
between the presence of a C4 null allele and/or a DR5 allele and the presence of an 
ANA was observed for both patients and relatives.
Endothelial-related abnormalities
Compared with controls, significantly raised levels of a Factor Vlll-related antigen have 
been detected in 20% of the first-degree relatives of SSc patients and in 15% of their 
spouses (159). This compared with raised levels in 62% of SSc patients and 17% of 
primary RP patients. Furthermore, one of two spouses with a positive result had RP and 
was ANA-positive. In the case of the SSc patients, those with either ACAs or anti-U 1 
RNP antibodies had a significantly higher rate of positivity than the remaining patients. 
These results are indicative of an abnormal degree of EC damage occurring in these 
individuals. Furthermore, the data suggested that EC damage and the propensity for 
autoantibody production in the relatives are related in some way (159). These results 
were especially significant in light of earlier findings by Sheldon et al. (310). In their 
report, five siblings were described, three of whom had SSc, with a further two having 
RP. Endothelial cell cytotoxicity assays revealed positive results in 2/3 of the SSc 
patients, both RP patients and in a further 3/13 healthy relatives.
Twin studies
Information concerning monozygotic twins, one or both of whom are affected by SSc, 
is clearly of paramount significance. However, it should be remembered that twins are 
not necessarily identical. Such differences have been highlighted by Gregersen et al.
(118), and include X-chromosome inactivation, placental separation, somatic develop­
ment and stochastic events.
A pair of concordant identical twins with SSc was reported by Cook et al. (61). A 
review of their genetic and environmental background suggested that genetic factors 
were of greatest importance in this particular case, particularly as their mother also had 
SSc (61).
Abnormal lymphocyte function in a pair of discordant monozygotic twins was 
investigated by Dustoor et al. (79). Abnormalities were detected in the SSc-affected 
twin (e.g. low absolute T cell count; high CD8+-T cell count; decreased mitogen 
responsiveness; increased Th-cell help for Ig synthesis) but not in the healthy twin, and 
the authors concluded that the immunological defects in scleroderma are not completely 
genetically determined.
An interesting study of discordant and concordant monozygotic twins with regard to 
MS were studied by Utz et al. (348). The myelin basic protein (i.e. the self-antigen 
implicated in MS) and the tetanus toxoid antigen were separately incubated with 
peripheral blood lymphocyte cultures. It was found that TCR usage by control twins
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and by concordant twins involved the selection of similar V a  chains by the related 
twins, and this was true in the case of either stimulating antigen. However, related 
discordant twins selected different V a chains in the case of both stimulating antigens. 
The preference for certain V a chains was antigen-specific. It was postulated that 
environmental factors or somatic events were responsible for skewing the TCR 
repertoire in MS. The authors suggested that either superantigens, or a chronic T-cell 
mediated disease may be responsible.
1.10 AIMS OF THIS STUDY
In order to explore in more detail the relative importance of genetic and environmental 
factors in the expression of SSc autoantibodies, the clinical, serological and 
immunogenetic features of sixty-five SSc patients, together with their relatives and 
spouses, were studied by the U.K. Systemic Sclerosis Study Group (206), with a follow- 
up study being carried out seven years later (207,226,331,361).
One report by members of the group specifically considered four multicase SSc 
families (331). Disease subtype assignation was the same for each pair of related 
patients, and three of the four pairs had common HLA-DR alleles. The clinical features 
of the related SSc patients were reported to be similar in the mother/daughter pair, in the 
father/daughter pair, in the sister/sister pair, as well as in the identical twin pair. The 
onset of disease for each pair was considered with regard to both absolute dates as well 
as with respect to each individual's age. Based on these results, it was concluded that 
environmental factors were involved in the appearance of SSc in these multicase 
families (331).
Other interesting information was provided by the SSc family study. For example, 
relatives with other CTDs occurred, and included RP, RA, SLE, Pm, morphea and 
pernicious anaemia (PA). Probands had a significantly higher incidence of HLA-DR3, 
-DR5 and C4A null alleles compared with controls. Anti-topo I and ACAs were found 
exclusively in probands or family members with SSc and not in unaffected relatives, 
and were closely associated with certain HLA-DQB1 alleles (226,361). Furthermore, 
ANAs characteristic of other CTDs, such as SLE, were also found to be limited to 
individuals with a defined CTD (206,207). In the present study, the frequency and type 
of ANoAs have been investigated in the same families.
While the distribution and disease subtype associations of the SSc-specific ANAs,
anti-topo I and ACAs, have been well studied, much less data is available concerning
ANoAs, which are also very common in SSc. As already mentioned, all antigens known
to be recognized by SSc-specific antibodies have been found to co-localize to the
nucleolus at some stage of the cell cycle. Given that the nucleolus appears to be the
focal point of autoimmune responses in SSc, the importance of detecting anti-nucleolar
reactivity in family members of SSc patients can be appreciated. Such work may lead to
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a greater understanding of aetiology and pathogenesis. Therefore, using the highly 
sensitive technique of radio-immunoprecipitation (IP), the present study aimed to 
identify the antinucleolar reactivities occurring in serum samples taken from these 
family members. Since the method of IP is extremely sensitive, the detection of 
additional antinuclear specificities not found in the original study was also anticipated. 
The technique involves the radiolabelling of proteins including RNPs expressed by 
human cell lines, followed by incubation of the radiolabelled cell extracts with Protein- 
A Sepharose CL-4B beads precoated with patient antibodies. The proteins and RNPs 
bound to the beads are then extracted, separated on polyacrylamide gels, and detected 
by autoradiography (proteins) and silver staining (RNAs). Other techniques, such as IF, 
IB and Ouchterlony double immunodiffusion were also used, with the aim of complete 
autoantibody profiling of each serum.
Summary of initial aims and objectives
The initial aims and objectives of the present study were as follows:
(i) To determine the prevalence of IF-ANAs and IF-ANoAs in the sera of SSc 
patients and their family members
(ii) To assess the prevalence of previously characterized ANAs and ANoAs in the 
sera of SSc patients and their relatives by IP, and to further define their clinical 
associations
(iii) To report and identify any novel antinuclear or antinucleolar antigens recognized 
by the study sera
(iv) To further investigate any unusual autoimmune features in the family members of 
SSc patients
Expected value of results
The study as a whole was intended to provide further information about genetic and 
environmental factors operating in the expression of disease-specific autoantibodies, 
which may contribute to an understanding of the pathogenesis and aetiology of the 
disease. It was also hoped that a more detailed examination of the relationships between 
ANoAs and clinical expression of the disease would provide clinicians with additional 




2.1 PATIENTS AND SERA
2.1.1 Selection of patients, relatives and controls
For the SSc family study (Chapter 3), 62 SSc patients were selected, and 239 of their 
relatives agreed to participate. One hundred-and-twenty normal control samples were 
also obtained, taken from a bank of sera from healthy donors.
For the subsequent study of anti-RNAP antibodies and their clinical associations 
(Chapter 4), the 62 SSc patients from the family study were included, together with 
nine patients from a Si-SSc study (227), and 144 additional consecutive SSc patients 
recruited from the Royal National Hospital for Rheumatic Diseases, Bath, U.K. 
(RNHRD).
2.1.2 Diagnostic criteria and scoring systems 
Clinical examination
For the SSc family study, clinical assessments of probands and their relatives were 
carried out by clinicians at the various participating centres (Dr NJ.McHugh and 
Professor PJ.Maddison, RNHRD; Professor C.M.Black, Royal Free Hospital, London; 
Dr R.Bemstein, Royal Infirmary, University of Manchester; Dr P.Bacon, Rheumatism 
Research Wing, University of Birmingham; Dr M.I.V.Jayson, Hope Hospital, Saltford; 
Dr N.G.Gusseva, Russian Academy of Medical Sciences, Moscow, U.S.S.R.; Dr 
NJ.Olsen, Vanderbilt University, Nashville, TN, U.S.A.). Clinical field work (U.S.S.R. 
and U.S.A.) was also undertaken by Dr C.Stephens (Royal Free Hospital).
For the study of anti-RNAP antibodies, additional SSc patients were examined by Dr 
N.J. McHugh and Dr Y. Patel at the RNHRD, while Si-SSc patients were assessed by 
Dr U.F.Haustein, University of Leipzig, Germany.
Diagnostic criteria and disease subtype classification
In 1980 the ARA published preliminary criteria for the diagnosis of SSc (218). This 
document has since become the accepted world-wide standard for research purposes. 
The major criterion is scleroderma proximal to the metacarpophalangeal joints, while 
minor criteria are (i) sclerodactyly, (ii) digital pitting scars of the fingertips, or loss of 
substance of the distal finger pad, and (iii) bibasilar pulmonary interstitial fibrosis. 
Either the main criterion or at least two minor criteria must be met for a diagnosis of 
SSc (97% sensitivity and 98% specificity (218)).
Raynaud's phenomenon
In the SSc family study, the presence of RP in the family members of SSc patients was 
recorded, being defined as a biphasic or triphasic response to cold (16,218).
Disease subtype assignation
In both the SSc family study and the anti-RNAP antibody study, disease subtype was
classified as either lc-SSc or dc-SSc (198). Limited cutaneous SSc was defined as
cutaneous sclerosis not extending proximal to the elbows or knees, with or without
58
facial involvement, while dc-SSc was defined as cutaneous sclerosis extending 
proximal to the elbows or knees.
Scoring systems
Clinical data were recorded in greater detail for the anti-RNAP antibody study:
Disease subtype classification
Where possible, a modified version of Barnett's classification system (13,225) was used 
to assign each patient to one of three categories based on the extent of cutaneous 
involvement: (1) sclerodactyly only, (2) skin involvement limited to the hands, 
forearms, face and neck, or (3) diffuse skin involvement. In practise, this meant a 
further subdivision of the lc-SSc patients (as defined above) into either category 1 or 2, 
while patients with dc-SSc (as defined above) were recorded as being in category 3. 
Pulmonary involvement
Pulmonary involvement was assessed by chest X-ray and standard DLCO tests. If the 
DLCO value was <80% of that predicted, and/or significant shadowing of the lungs 
characteristic of bibasilar pulmonary fibrosis was apparent by X-ray examination, 
pulmonary involvement was recorded (225). Further classification into mild, moderate 
or severe involvement (where possible) was according to the definitions described in 
Appendix I.
Renal involvement
One or more of the following features (unless attributable to unrelated disease) was 
taken to imply renal involvement: (i) creatinine clearance rate <60 ml/min (or serum 
creatinine >1.3 mg/dl), (ii) active urinary sediment, (iii) proteinuria (>0.5 g/day), and
(iv) accelerated hypertension (diastolic B.P. >105 mmHg) (225). Again, severity 
classifications were recorded where possible, as described in Appendix I.
2.1.3 Preparation and storage of sera
Samples for the family study, and all Si-SSc patient samples, were supplied as frozen 
sera for immediate storage at -20°C. Samples from the RNHRD were supplied as 
freshly collected whole blood in unheparinized 10-ml collection tubes, from which 
serum was prepared by the following method.
Method 2.1,3: Extraction of serum from human blood
Following collection, the blood-sample tubes were gently mixed, and left at room 
temperature for at least 30 min. After clotting had occurred, the tubes were centrifuged 
at room temperature in a Hereaus Labofuge 6000 Centrifuge (Hereaus Instruments) for 
10 min at 3000 r.p.m. (Centrifugation Protocol 1: see Appendix II). Serum 
supernatants were removed, with several aliquots (0.5-2.0 ml) of each sample being 
stored at -20°C. Excessive freeze-thawing of sera was avoided during subsequent 
investigations.
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2.2 TISSUE CULTURE TECHNIQUES
Tissue culture (TC) procedures were performed in standard Class II TC cabinets with 
lamina flow of high-pressure filtered air. Ethanol-sprayed gloves were worn, and all 
reasonable care was taken to avoid extraneous infection of cultures. All solutions and 
growth media were prepared using double-distilled water, which was passed through a 
Milli-Q water purification system (Millipore, Watford, U.K.), and autoclaved in-house 
prior to use. Pasteur pipettes, microfuge tubes, TC bottles and pipette tips were also 
autoclaved.
Unless stated otherwise, sterile TC-media concentrates and media-supplementing 
solutions were obtained from Life Technologies Ltd, Paisley, U.K.; sterile TC-grade 
plastics (Falcon brand) were from Becton Dickinson Labware, New Jersey, U.S.A., and 
general laboratory reagents were obtained from Sigma Chemical Co. Ltd, Poole, U.K.
2.2.1 Preparation of tissue-culture media
Method 2.2.1a: Preparation o f RPMI media
Rosewell Park Memorial Institute 1640 medium (RPMI) was obtained as a lOx 
concentrate without sodium bicarbonate or glutamine. A 50-ml volume was diluted in 
375 ml water, and supplemented with 15 ml sodium bicarbonate solution (7.5% w/v), 5 
ml penicillin/streptomycin solution (10000 I.U./ml and 10000 pg/ml respectively), and 
5 ml L-Glutamine solution (200 mM). The volume was made up to 500 ml with water 
('Serum-free RPMI'), or with 50 ml heat-inactivated foetal calf serum (FCS) 
('RPMI+10% FCS'). The pH of the medium was adjusted to pH7.0-7.5 by adding drops 
of saturated sodium hydroxide solution (25 ml water were equilibrated with 10 g 
sodium hydroxide pellets and sterilized by passing through a small bottle-top filter 
(pore size 0.22 pm; Millipore) from a solution-filled syringe).
Method 2.2.1b: Preparation of methionine-deficient RPMI media 
A powdered RPMI base, deficient in sodium bicarbonate, glutamine, methionine, 
leucine and lysine, was obtained from Sigma Chemical Co. Ltd. One container of the 
non-sterile powder supplied was dissolved in 775 ml water, as instructed by the 
manufacturer. To sterilize, the solution was passed through a large bottle-top filter 
(cellulose acetate membrane, 0.22 pm pore size; Becton Dickinson Labware) attached 
to a vacuum pump. The medium was then supplemented with 30 ml sodium bicarbonate 
solution (7.5% w/v), 10 ml penicillin/streptomycin solution (10000 I.U./ml and 10000 
pg/ml respectively), 10 ml L-Glutamine solution (200 mM), 5 ml L-Leucine (200x 
solution for TC; Sigma Chemical Co. Ltd) and 5 ml L-lysine (200x; Sigma Chemical 
Co. Ltd). The volume was made up to 1 1 with water ('Serum-free Met-deficient 
RPMI'), or with 50 ml dialysed FCS (d-FCS; prepared according to Method 2.2.1c)
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('Met-deficient RPMI+5% d-FCS'). The pH of the medium was adjusted to 7.0-7.5, if 
necessary, as described above.
Method 2.2.1c: Preparation o f dialysed foetal calf serum
Beginning in the morning, an 800-mm length of dialysis tubing (20-mm in diameter; 
Sigma Chemical Co. Ltd) was washed according to the manufacturer's instructions and 
used immediately. After two tight knots had been made in one end of the tube, FCS was 
poured into the other end until the tubing was about 3/4 full. The open end was 
similarly secured, and the tubing was briefly rinsed in phosphate-buffered saline (PBS, 
prepared from PBS tablets according to manufacturer's instructions (Oxoid Unipath 
Ltd, Basingstoke, U.K.)) to remove any spillages. It was then put into a large beaker 
containing 3 1 of ice-cold PBS, which was placed on a magnetic stirrer at 4°C for about 
8 h. The tubing was placed in fresh PBS overnight, and again the following morning. 
After a total of -30 h cold dialysis, the tubing was rinsed in PBS, cut open and carefully 
emptied.
Before adding to medium, it was necessary to filter-sterilize the d-FCS: a 10-ml 
syringe was filled, and attached to a small bottle-top filter (pore size 0.22 pm; 
Millipore), through which the serum was forced in a dropwise fashion.
2.2.2 Maintenance of cell lines
The following cell lines was maintained in standard TC incubators programmed to a 
temperature of 37°C, with 5%-carbon dioxide-enriched air.
Maintenance o f the HEp-2 cell-line
The adherent HEp-2 cell-line is derived from a human orolaryngeal carcinoma. Cells 
were maintained in 100-mm-diameter petri dishes in -10 ml RPMI+10% FCS. Fresh 
medium was applied 1-2 times per week, until plates were confluent (-2 million cells 
per plate): the cells were then washed and resuspended (Method 2.2.2a) for passaging 
(see below), storage (Method 2.2.2b) or preparation of HEp-2 slides (Method 2.2.3).
To passage cells, 50 pi of washed, resuspended cells were added to each new plate 
along with 10 ml fresh medium. The plates were gently swirled, and placed in the TC 
incubator: cells were then allowed to recover and adhere overnight.
Maintenance o f the K562 cell-line
Derived from a human chronic myelogenous leukaemia (ECACC No. 89121407), these 
fast-growing, non-adherent cells were maintained in 75-cm2 TC flasks in -30 ml 
RPMI+10% FCS. Cells were checked every two or three days until flasks were 
confluent (-7-35 million cells/flask): the cells could then be split (see below), stored 
(Method 2.2.2b), or used immediately to prepare cell extracts (Section 2.2.4).
To split cells, 5 ml of confluent cell suspension was added to 25 ml fresh medium in 
a new flask. Alternatively, cells were rapidly expanded by splitting the confluent 
suspension between two new flasks, and topping up to 30 ml with fresh medium. When
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particularly large quantities of cells were required, 175-cm2 flasks were used, 
containing 100 ml of culture (20-100 million K562 cells per flask when confluent).
Method 2.2.2a: Resuspension of HEp-2 cells
At least ten plates of confluent HEp-2 cells were processed at one time. Aliquots of 
trypsin-EDTA (lx  solution in modified Puck’s Saline A; Life Technologies Ltd) were 
first thawed at room temperature. Medium was carefully removed from the plates by 
aspiration. Each plate was immediately washed with 10 ml PBS, after which 2.5 ml 
trypsin-EDTA was added. The plates were gently swirled, and incubated at room 
temperature for 2-5 min: during this time frequent progress checks were made under the 
microscope, and the plates were swirled occasionally. When the majority of cells had 
floated into suspension, trypsinization was halted by adding about 10 ml RPMI+10% 
FCS to each plate with gentle swirling, and the cell suspensions were pooled into an 
appropriate number of 50-ml centrifuge tubes. The suspensions were centrifuged in a 
Beckman GPR/GS-15R centrifuge set at 1°C for 5 min at 1500 r.p.m. (Centrifuge 
Protocol 2). After carefully pouring off supernatants, the cells were resuspended in 
fresh Serum-free RPMI medium (~2 ml per tube) by gently mixing up and down with a 
1-ml pipette. Cells from different tubes were pooled into one centrifuge tube, and the 
volume was made up to 50 ml with Serum-free RPMI medium to wash. After 
recentrifuging according to Protocol 2, the supernatant was poured off, and the cell 
pellet was very slowly resuspended in a total of 2 ml Serum-free RPMI medium using a 
0.5-mm bore needle (Becton Dickinson Labware) and syringe. The cells were then 
counted using a haemocytometer, after which an appropriate amount of Serum-free 
RPMI medium was mixed in to give a final concentration of 10 million cells/ml.
Method 2.2.2b: Freezing tissue-culture cells
Tissue-culture cells were frozen down in liquid nitrogen for long-term storage. A 
concentration of around 4-5 million cells/ml is usually recommended.
HEp-2 cells
About 25 confluent plates of HEp-2 cells were required for the preparation of one batch 
of ten 1-ml aliquots of HEp-2 cells (50 million cells in total). The appropriate volume 
of resuspended HEp-2 cells was first prepared, as described in Method 2.2.2a. An equal 
volume of freezing solution (20% dimethylsulphoxide : 50% FCS : 30% Serum-free 
RPMI) was gently mixed in (final concentration 5 million cells/ml), and 1-ml aliquots 
were placed in 2-ml screw-top freezing vials. The vials were securely tightened, 
wrapped in cotton wool, and placed in a polystyrene box, which was stored at -80°C 
overnight. Next morning the vials were transferred into a liquid nitrogen bank for long­
term storage.
K562 cells
About 150-200 ml confluent K562-suspension was required for the preparation of 
twenty 1-ml aliquots of K562 cells (100 million cells in total). After counting the
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pooled contents of several flasks, the appropriate volume of confluent culture was 
decanted into 50-ml centrifuge tubes, and centrifuged according to Protocol 2. After 
carefully pouring off supernatants, the cells were resuspended in Serum-free RPMI (~2 
ml per tube) by gently mixing up and down with a 1-ml pipette. Cells from different 
tubes were pooled into one centrifuge tube, and the volume was made up to 50 ml with 
Serum-free RPMI to wash. After recentrifuging according to Protocol 2, the supernatant 
was poured off, and the cell pellet was very slowly resuspended in a total of 5 ml 
Serum-free RPMI using a 0.5-mm bore needle (Becton Dickinson Labware) and 
syringe. The cells were re-counted, after which an appropriate amount of Serum-free 
RPMI was mixed in to give a concentration of 10 million cells/ml. An equal volume of 
freezing solution was gently mixed in (final concentration 5 million cells/ml), and cells 
were prepared for freezing as described above for HEp-2 cells.
Method 2,2.2c: Thawing tissue-culture cells
A single vial of stored cells was removed from the liquid nitrogen store and 
immediately rinsed, with gentle shaking, under very hot, running tap-water. Once 
thawed, the outside of the vial was dried with tissue paper, and swabbed with ethanol. 
The contents of the vial were then added to a 25-ml centrifuge tube containing 10 ml 
RPMI + 10% FCS, and gently mixed in. The cells were centrifuged according to 
Protocol 2 after which the supernatant was poured off, and the pellet resuspended in 2 
ml RPMI + 10% FCS using a 1-ml pipette. The volume was made up to 10 ml and the 
resuspended cells were added to a 10-mm petri dish (HEp-2 cells) or to a 25-cm2 flask 
(K562 cells), and allowed to recover overnight.
2.2.3 Preparation of HEp-2-cell slides
Method 2.2.3: Preparation ofHEp-2-cell slides for immunofluorescence 
Forty 10-well, glass, multispot microscope slides (C.A.Hendley (Essex) Ltd, Loughton, 
U.K.) were cleaned with ethanol and a soft cloth. After air-drying, slides were double­
bagged, autoclaved, and stored, ready for use.
To prepare each batch of forty HEp-2 slides, ten plates of HEp-2 cells were grown to 
confluence (Section 2.2.2). Cells were trypsinized, washed, counted, and resuspended 
in a total of 20 ml RPMI + 10% FCS (1 million cells/ml), according to Method 2.2.2a.
Slides were laid out inside 100 x 100-mm square petri dishes (four slides per plate) 
to maintain sterility. A 50-pl drop of the diluted cell suspension was then placed on 
each well of the microscope slides, taking care that the medium covered the whole 
surface of each well (a pipette tip was used to guide the medium where necessary). The 
petri dishes were placed in TC incubators overnight.
Next morning slides were individually rinsed twice by pouring PBS over them. The 
slides were placed in a slide rack and immediately dunked in an ice-cold (-20°C) 
acetone bath for a few seconds. Next they were placed in another ice-cold acetone bath
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for 5 min to fix the cells. Fixed slides were laid out to dry for 5 min, after which they 
were wrapped in aluminium foil, and stored at -20°C, ready for use.
2.2.4 Preparation of K562-cell extracts
Method 2.2.4a: Preparation o f35S-methionine-radiolabelled K562-cell extract
Radiolabelling
Radiolabelling was based on the method of Craft, Mimori & Olsen (1988) (66). About 
400 ml of semi-confluent, actively proliferating, K562-cell culture suspension were 
used for the preparation of one batch of radiolabelled K562-cell extract (-80 million 
cells prior to labelling). After counting, the appropriate volume of cell suspension was 
decanted into 50-ml centrifuge tubes, and centrifuged according to Protocol 2. Each 
pellet was resuspended in about 2 ml Serum-free Met-deficient RPMI using a 1-ml 
pipette, and cells were pooled into two 50-ml centrifuge tubes. Each of the two tubes 
was made up to 50 ml with Serum-free Met-deficient RPMI, and gently inverted to 
wash the cells. After further centrifugation as before, each washed pellet was 
resuspended in 2 ml Met-deficient RPMI + 5% dFCS, and cells were pooled; the total 
volume was made up to 50 ml with Met-deficient RPMI + 5% dFCS, and cells were re­
counted using a haemocytometer.
An appropriate volume of the cell suspension was added to each of four 175-cm2 TC 
flasks (20 million cells/flask), and the volume of each flask was made up to 80 ml 
(density 0.20-0.25 x 106 cells/ml was acceptable (66)). The suspension was gently 
swirled to mix, and the flasks were put in the TC incubator for about 20 min, in order to 
deplete the intracellular pool of unlabelled methionine. The addition of 160 pi 35S- 
labelled L-methionine solution (6.7 pM; 10 mCi/ml; NEN Biologicals, NEN Dupont, 
Stevenage, U.K.) to each of the four flasks gave a final activity of 20 pCi/ml. The flasks 
were gently swirled, and returned to the incubator for overnight labelling (16-18 h: half 
the doubling time of the cell line (66)).
Preparation o f cell extract
The following morning the condition of the cells was checked under the microscope: if 
a large proportion of cells was judged to be dead the procedure was abandoned. The 
suspension was transferred into 50-ml centrifuge tubes, and the cells were centrifuged 
according to Protocol 2. From this point on, all work was done on ice. After pouring off 
the supernatants, each pellet was resuspended in 5 ml ice-cold tris-buffered saline 
(TBS: 10 mM Tris.Cl pH7.4, 150 mM NaCl), and all cells were pooled into a 50-ml 
centrifuge tube. The volume was made up to 50 ml with TBS, and gently inverted to 
wash the cells. After further centrifugation as before, the cell pellet was resuspended in 
a total of about 8 ml protein IP buffer (IPP: 10 mM Tris.Cl pH8.0, 500 mM NaCl, 0.1% 
(v/v) Nonidet P-40 (NP-40)), which caused cell lysis. Lysed cells were sonicated in the 
50-ml centrifuge tube using a sonicator (Soniprep 150 MSE) at setting 3 (three periods 
of 60 sec separated by 20-sec rests).
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Immediately following sonication the cell extract was transferred to a number of 1.7- 
ml microcentrifuge tubes, which were centrifuged in a Beckman GS-15R/F2402 at a 
speed of 12 000 r.p.m. for 20 min at 1°C (Centrifuge Protocol 3). Following 
centrifugation, the supernatants of cell extract were removed from the tiny pellets of 
insoluble cell debris, transferred into clean microfuge tubes in 1.25-ml aliquots (total 
volume approximately 7.5 ml), and stored at -80°C for later use. Each aliquot of final 
K562-cell extract corresponded to -12.5 million cells before labelling (cells were not 
counted after overnight labelling for safety reasons).
Method 2.2.4b: Preparation o f unlabelled K562-cell extract for IP
With the exception of the overnight labelling step, an adapted Method 2.2.4a was used 
to prepare unlabelled K562-cell extracts suitable for affinity purification of 
autoantigens by IP (see Method 2.33d).
About 200-300 ml of confluent K562-cell culture suspension was used for the 
immediate preparation of one batch of unlabelled K562-cell extract (150 million cells: 
total yield of cell extract -7.5 ml, stored in 1.25-ml aliquots at -80°C).
Method 2.2.4c: Preparation of unlabelled K562-cell extract for RNA-IP
For the preparation of K562-cell extracts suitable for RNA-IP experiments (Method 
2.33b), RNAse-free conditions were maintained using standard precautions (see 
Appendix 2). Otherwise, the same basic method as described above (Method 2.2.4a) 
was used: modifications are detailed below. The method was an adaptation of that 
described by Forman, Nakamura, Mimori et al. (1985) (96).
About 200-300 ml of confluent K562-cell culture suspension were used for the 
preparation of one batch of extract (150 million cells). After washing the cells in TBS 
as described in Method 2.2.4a, the cell pellet was resuspended in a total of about 8 ml 
of an adapted (high Tris, low salt) IP buffer (NET-2: 50 mM Tris.Cl pH7.4, 150 mM 
NaCl, 0.05% (v/v) Nonidet P-40). Lysed cells were then sonicated and centrifuged, as 
described in Method 2.2.4a (total yield of cell extract -7.5 ml, stored in 1.25-ml 
aliquots at -80°C, or used immediately).
Method 2.2.4d: Preparation o f unlabelled K562-cell extract fo r  immunoafpnity 
column chromatography
The same basic method as described above (Method 2.2.4a) was used to prepare 
unlabelled K562-cell extracts suitable for purification of autoantigens by 
immunoaffinity column chromatography (Section 2.3.4). Modifications are detailed 
below (adapted from a combination of the methods of Craft et al. (1988) (66), Plunkett 
& Springer (1986) (269), and Springer (1993) (324)).
About 900-1100 ml of confluent K562-cell culture suspension were used for the 
preparation of one batch of extract (500 million cells). After washing the cells in 100 ml 
TBS, as described in Method 2.2.4a, the cell pellets were pooled and resuspended in a
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total of 5.5 ml modified (low salt) IP buffer (MIP: 10 mM Tris.Cl; 140 mM NaCl; 0.1% 
(v/v) NP-40). Lysed cells were then sonicated and centrifuged as described in Method 
2.2.4a (total yield of cell extract -5.0 ml, stored at -80°C or used immediately).
2.3 SEROLOGICAL AND BIOCHEMICAL TECHNIQUES
2.3.1 Ouchterlony double immunodiffusion 
Technical basis
An antigen-rich saline-extracted tissue suspension and a test serum are put into 
separate, adjacent wells of a horizontal agarose gel. The porous gel allows diffusion of 
both antibodies and soluble antigens: should the serum sample contain antibodies which 
recognize components of the extract, a visible precipitin line will form between the two 
wells, consisting of an insoluble immune complex ('zone of equivalence'; Fig. 2.1a). It 
is important that sufficient quantities of antigen and antibody are present, and that the 
respective wells are at an appropriate distance apart, otherwise a false negative reading 
may result.
Once reactivity of a serum with a component of a particular extract has been 
demonstrated, the serum is re-tested, this time placing a prototype serum of known 
antibody specificity in an equivalent well close by (Fig. 2.1 b and c). Examination of the 
physical interaction between two adjacent precipitin lines indicates whether the two 
sera contain antibodies which recognize the same, different, or related antigenic 
particles (Fig. 2.1 d).
Important advantages of the Ouchterlony technique in terms of the present study are 
(i) its ability to discriminate between anti-Ul RNP sera (i.e. sera recognizing only U1 
RNP-specific subunits) and sera recognizing both U 1 RNP-specific and Sm subunits 
(the Sm subunits being found on other UsnRNPs as well as on U1 RNP); (ii) its ability 
to discriminate between anti-Jo-1 and anti-La antibody specificities: the Jo-1 and La 
antigens have very similar molecular weights, and there is a risk of misreading results 
produced by IP or IB. However, the technique is rather less sensitive than IP, and 
results can be difficult to visualize and therefore interpret.
Method 2.3.1: Ouchterlony double immunodiffusion
An adaptation of the method described by Isenberg & Maddison (1987) (156) was used. 
A solution of 1% (w/v) agarose (type I) in PBS was slowly heated to boiling point. 
After cooling to -35°C, 5 |xg/ml penicillin/streptomycin solution (10 000 IU/ml and 10 
000 jig/ml respectively) was stirred in, and gels were poured immediately onto glass 
plates (80 mm x 80 mm), previously arranged on a levelling table. Each plate was 
evenly coated with 12.0 ml of molten agarose which was allowed to solidify at room
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FIGURE 2.1 Detection and identification of autoantibodies by Ouchterlony double 
immunodiffusion. The technique is based on the formation of an insoluble immune complex in a 
horizontal agarose gel when an antigen (Ag) diffusing from one well is recognized by antibodies (Ab) 
diffusing from an apposing well (a). Wells are arranged in rosettes, consisting of a central tissue- 
extract well surrounded by six or seven serum wells (b and c). Sample and prototype sera (S1-S7) are 
applied as shown (d), and the central well is filled with tissue extract as a source of Ag. This results in 
a visible precipitin line where the serum contains Abs which recognize a component of the extract 
(SI), or a clear area if no such Abs are present (S2). A line of identity formed by precipitin lines of 
adjacent wells indicates that both sera contain Abs which recognize exactly the same antigenic particle 
(S3 and S4), while crossed lines of non-identity show that the two sera contain Abs which recognize 
quite different specificities (S5 and S6). A line of partial identity (between S4 and S5) means that a 
particular Ag is recognized by Abs present in both sera, while a separate Ag is recognized by Abs 
occurring in only one serum (S5). Sera with more than one specificity often show multiple precipitin 
lines (S6), each of which interacts independently with adjacent precipitins. Sera with very low titres of 
Ab produce precipitin lines as shown for S7: identification of such specificities is sometimes possible 
by repeating the experiment, this time making the serum well as large as the Ag well, and increasing 
sample volume.
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temperature for 1 h. Gels were then stored in heat-sealed polythene bags at 4°C for up 
to 3 weeks.
Immediately before use, circular wells were punched into the gel using standard size 
1 and 3 cork borers: seven small wells (diameter 4 mm) surrounded one large well 
(diameter 7 mm) at a distance of 1.5 mm to form a single rosette (Fig. 2.1 b). Six such 
rosettes could be accommodated on each plate. When testing sera against topo I extract 
(TIE), a central 4-mm well was surrounded by only six outer wells (Fig. 2.1c). After 
removal of agarose plugs by suction, each outer well was loaded with 20 pi of an 
undiluted test or standard serum before loading the central well with 60-80 pi of the 
relevant tissue extract (20 pi in the case of TIE).
Once sera and extracts had soaked into the gel, loaded plates were placed inside 
square petri dishes and left at room temperature for up to 5 days, during which they 
were examined on a daily basis for the presence of precipitin lines. Gels were viewed 
against a matt black background with overhead illumination from a strong desk lamp. 
The positions of lines of identity, partial identity and non-identity (Fig. 2.1 d) were 
recorded and interpreted before discarding the gel.
Each serum sample was tested against the following complementary extracts: rabbit 
thymus extract (RTE; Pel Freez Ltd, Arkansas, U.S.A./Bradshaw Biologicals, Market 
Harborough, U.K.), containing U1 RNP, Sm, La and Pm-Scl antigens; an in-house 
preparation of calf thymus extract (CTE; prepared by Mrs. J.James according to a 
previously described method (156)), which contained Jo-1 antigen; Ro/La Extract 
(RLE; Biodiagnostics Ltd, Worcester, U.K.), rich in Ro and La antigens, and TIE ('Scl- 
70 Extract'; Biodiagnostics Ltd) containing topo I.
A number of reference sera of known autoantibody specificity were available from 
amongst our own patients, including sera containing antibodies to U1 RNP, Sm, Ro, La, 
topo I, Jo-1 and Pm-Scl. Depending on the tissue extracts used, positive control sera of 
the relevant specificities were included on each plate to confirm the presence of 
antigens. Identification of each resulting precipitin line was achieved by sequential 
testing of the serum sample alongside appropriate prototype sera, with subsequent 
analysis of precipitin-line interactions (Fig. 2.1 d).
2.3.2 Indirect immunofluorescence
Technical basis
Adherent human TC cells (HEp-2 cells) are suspended in fresh medium. Drops of 
suspension are deposited onto glass multiwell microscope slides, and incubated 
overnight. During this time most cells will adhere to the slide, and will continue to be 
engaged in cell division. After washing, the process of fixing the cells renders them 
penetrable by antibodies. A diluted sample of test or standard serum is applied to each 
well, and autoantibodies against cellular components remain bound after rinsing away 
the serum solution. Next the cells are incubated with a fluorescein isothiocyanate
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(FITC)-conjugated anti-human-immunoglobulin antibody, and re-washed. This allows 
visualization of any previously bound autoantibody: upon viewing the cells under a 
fluorescence microscope, characteristic patterns of bright fluorescence indicate the 
presence of autoantibodies in the original serum sample and the intracellular location of 
the autoantigens recognized. Most normal human sera give a negative result, where the 
level of fluorescence observed is minimal.
Method 2.3.2: Indirect immunofluorescent localization
For most of the work reported here, 18-well HEp-2 slides for indirect IF were obtained 
commercially (Biodiagnostics Ltd; Quadratech Ltd, Epsom, U.K.). Alternatively, 10- 
well slides were prepared in-house (Method 2.2.3), and the HEp-2 cell-line was 
maintained as described in Section 2.2.2.
As has been previously described (361), for initial screening purposes, sample and 
standard sera were first diluted 1:40 in PBS. Slides were put inside square petri dishes 
on two leaves of water-dampened tissue-paper: this minimized evaporation from 
antibody solutions. Each well was loaded with 20 pi of a diluted test or standard serum, 
taking care to cover the whole area of the well. The slides were incubated at room 
temperature for 30-60 min, after which samples were rinsed away by gently pouring 
PBS over each slide. Washing was continued by soaking slides in a PBS bath for 5 min, 
followed by a second rinse and another 5-min soak in fresh PBS.
Meanwhile, a 1:1000 dilution of conjugate (anti-human polyvalent immunoglobulins 
(IgA, IgG, IgM) FITC-conjugate developed in goat, IgG fraction of antisera; Sigma 
Chemical Co. Ltd) was prepared in PBS. After shaking excess liquid from each slide, a 
tissue-paper-wrapped orange stick was used to dry all areas lying between the wells. 
The cells were not allowed to dry out -  12-pl of diluted conjugate were immediately 
loaded onto each well, followed by incubation and washing as before, plus a final rinse 
in distilled water.
Following removal of excess water from around the wells, two drops of mounting 
medium (2.5% (w/v) l,4-diazobicyclo-[2,2,2]-octane(triethylene-diamine) (DABCO) in 
5% (v/v) PBS in glycerol) were placed on each slide, avoiding air-bubbles, and a 
suitable cover-slip applied. This was pressed gently until all wells were covered with a 
very thin layer of mounting medium, and the cover-slip was aligned and stable. The 
slides were air-dried for 5 min, then clear cosmetic nail varnish was used to secure the 
edges of cover-slips where necessary. After leaving to harden for about 30 min, slides 
were read under a fluorescence microscope, or stored at -20°C for up to two weeks.
2.3.3 Immunoprecipitation
Technical basis
The method is based on the specific binding of the Fc fragment of human IgG 
antibodies to Protein-A, derived from the cell wall of certain strains of S. aureus.
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Protein-A is isolated, purified and immobilized by covalent binding, via a spacer arm, 
to highly cross-linked, spherical agarose beads (Protein-A Sepharose). These beads are 
easily sedimented by standard centrifugation protocols, to allow thorough washing 
procedures to be carried out. Such products are available commercially, with a variety 
of spacer-arm lengths (CL-4B, CL-6B etc.).
The Sepharose beads are first incubated with a diluted sample of human serum. Any 
IgG antibodies present in the serum may then bind to the immobilized Protein-A. The 
remaining components of the serum, including excess unbound antibodies, are washed 
away, and the beads are re-incubated with a radiolabelled extract of human TC-cells. 
After further washing to remove unbound components of the extract, the bound 
antigens are removed, reduced and denatured, by boiling in standard Laemmli sample 
buffer. Constituent polypeptides are then separated according to molecular weight in 
sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) gels, followed by 
autoradiographic detection of polypeptide bands. Each precipitated antigen produces a 
characteristic banding pattern according to the molecular weights of its component 
subunits. Banding patterns produced by a particular serum are interpreted by 
comparison with the patterns produced by internal standard sera, included on the same 
gel.
Method 2.3.3a: Immunoprecipitation o f  radiolabelled proteins 
A modified version of the method of Craft et al. (1988) (66) was used to 
immunoprecipitate 35S-labelled proteins from K562-cell extracts (prepared according to 
Method 2.2.4a), using human antibodies linked to Protein-A Sepharose. Wherever 
possible, samples were kept on ice or refrigerated during preparation, and all solutions 
were ice-cold.
Protein-A Sepharose CL-4B (Sigma Chemical Co. Ltd) was weighed into a 5-ml 
glass vial: 2 mg Sepharose beads were required for each serum sample to be tested. 
According to the manufacturer's instructions, the product was first washed as follows. 
Normally, 50 mg of Sepharose beads were weighed, and transferred into a 15-ml 
centrifuge tube using 5 x 3-ml volumes of IPP. To wash, hydrate and swell the beads, 
the suspension was incubated at 4°C for 30 min with end-over rotation. The beads were 
then sedimented in a refrigerated (1°C) centrifuge (Beckman GPR/GH-3.7) for 3 min at 
4000 r.p.m. (Centrifuge Protocol 4; approximately 1 lOOg), and most of the supernatant 
was removed using a pipette, taking care not to disturb the Sepharose pellet. Following 
a second brief wash in 15 ml IPP, the beads were sedimented according to Protocol 4, 
and resuspended in 12.5 ml IPP. A 500-pl quantity of the suspension was aliquotted 
into each of 24 1.7-ml microcentrifuge tubes, keeping the beads evenly suspended by 
capping and inverting the 15-ml tube every minute or so. A 10-pl serum sample was 
then added to each sample tube, samples were gently mixed by inversion, and incubated 
with end-over rotation for 2 h (or overnight) at 4°C.
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Following incubation, unbound components of the sample serum were removed by 
repeated washing in IPP: the beads were sedimented by centrifugation in a microfuge 
(MSE Microcentaur: 10-sec pulse-spin at 13000 r.p.m. at room temperature (Centrifuge 
Protocol 5)), and each supernatant was carefully removed; the beads were then 
resuspended in 500 pi IPP by brief vortexing. The spin-wash cycle was repeated until 
each sample had been spun down four times. Quick-thawed radiolabelled cell extract 
(100 pi per sample, corresponding to ~1 million cells prior to labelling) was then added, 
together with 400 pi IPP, and the tubes were re-incubated for 1-2 h as before.
After similar IPP washing cycles, each sample of beads was resuspended in 50 pi 
Laemmli sample buffer (SDS reducing buffer: 62.5 mM Tris.Cl pH6.8, 10% (v/v) 
glycerol, 2% (w/v) SDS, 5% (v/v) p-mercaptoethanol) by brief vortexing, and stored at 
-80°C for subsequent analysis of precipitated proteins.
Samples were prepared for SDS-PAGE according to Method 2.3.5a. A 15- to 30-pl 
volume of each denatured sample was loaded into a separate well of a 15-well maxi-gel 
(8-12.5% acrylamide), as described in Method 2.3.5c, or a 10-well mini-gel (Method
2.3.5b), and run as usual (5-20 pi of a solution of broadrange kaleidoscope molecular 
weight markers (BioRad Laboratories) was loaded into one well of each gel). Once run, 
gels were enhanced (Method 2.3.9a), dried onto blotting paper (Method 2.3.9c), and 
autoradiographed (Method 2.3.8d).
Method 2.3.3b: Immunoprecipitation of ribonucleoproteins
A similar method to that described above (Method 2.3.3a)  was used to 
immunoprecipitate RNPs from unlabelled K562-cell extracts (prepared according to 
Method 2.2.4c). Standard precautions were taken to prevent RNAse contamination. 
Other modifications, as described by Forman, Nakamura, Mimori et al. (96), were as 
follows.
For each sample, 4 mg Sepharose beads and 20 pi serum were added to the 500 pi 
IPP buffer. Following incubation with serum, the beads were washed in IPP, as usual, 
three times. After a further spin (Centrifuge Protocol 5), the beads were resuspended in 
300 pi NET-2 buffer, and 200 pi quick-thawed K562-cell extract was added 
(corresponding to ~8 million cells); the samples were then reincubated as usual. 
Following incubation with cell extract, the beads were washed four times in NET-2 
buffer, using standard spin-wash cycles.
Finally, RNA extraction was performed: keeping everything on ice, the beads were 
resuspended in 300 pi NET-2 buffer to which was added 30 pi sodium acetate (3 M, 
pH5.2 (acetic acid was used to adjust the pH)), 15 pi SDS (20%, w/v), 2 pi oyster 
glycogen (Type XI, Sigma Chemical Co. Ltd; 10 mg/ml) and 300 pi phenol:chloro- 
form:isoamyl alcohol (50:50:1, v/v/v; PCA). The tubes were vortexed briefly and 
centrifuged in an MSE Microcentaur for 2 min at 13 000 r.p.m. (Centrifuge Protocol 6). 
If two distinct layers had not formed in the sample tube, further, shorter spins were 
carried out. Working in a fume cupboard, the majority of the upper, aqueous layer of
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each sample was carefully removed with a gel-loading tip into 900 pi ice-cold ethanol: 
the buffy surface between the two liquid layers consisted of precipitated proteins, and 
was not disturbed. The samples were then gently mixed with the ethanol and left 
overnight at -20°C to allow precipitation of RNAs.
The following day, samples were centrifuged in a refrigerated microfuge (Heraeus 
Biofuge Fresco set at 1°C for 10 min at 9000 r.p.m. (Centrifuge Protocol 7)), and the 
supernatants were removed, taking care not to disturb the tiny white pellet of RNA. The 
pellets were then washed by adding 300 pi ice-cold 70% (v/v) ethanol, and the tubes 
were recentrifuged using Protocol 7. The supernatants were again removed from the 
tiny white pellets, and the tubes were then loaded into a vacuum centrifuge (GyroVap 
and Refrigerated Solvent Trap, Howe Ltd, attached to a strong vacuum pump) for a 
period of 20 min. Once dry, the pellets were dissolved in 20 pi RNA sample buffer (10 
M urea, 90 mM Trizma base, 90 mM boric acid, 2 mM sodium EDTA, 0.025 (w/v) 
bromophenol blue, 0.025% (w/v) xylene cyanol) by brief vortex, and stored at -80°C for 
subsequent analysis of precipitated RNAs.
Samples were prepared for urea-PAGE according to Method 2.3.5a. A 10- to 20-pl 
sample was loaded into a separate well of a 15-well maxi-gel (7.5 or 10% acrylamide), 
as described in Method 2.3.5e, or a 10-well mini-gel (Method 2.3.5d) and run as usual. 
Once run, RNA gels were silver-stained (see Method 2.3.8e), fixed (2.3.9b), and dried 
between cellulose sheets (Method 2.3.9c).
Method 2.3.3c: Antigen depletion o f radiolabelled K562~cell extracts 
This method was adapted from a protocol described by Hirakata, Okano, Pati et al.. 
(1993) (144). A batch of 35S-methionine-radiolabelled K562-cell extract was prepared 
as usual (Method 2.2.4a). The cell extract was then specifically depleted of one or more 
autoantigens using human antibodies linked to Protein-A Sepharose CL-4B.
First, six separate aliquots of 30 mg Sepharose beads were prepared for use as 
previously described (Method 2.3.3a). For two cycles of depletion, three sets of beads 
were incubated for 1-2 h with the relevant prototype serum (30 mg beads, 75 pi serum 
and 7.5 ml IPP in each of three 15-ml centrifuge tubes); the other three was similarly 
incubated with normal human serum, to serve as a control.
Following incubation, unbound components of serum were removed by repeated 
washing in IPP: the beads were sedimented according to Centrifuge Protocol 4, and 
each supernatant was carefully removed; the beads were then resuspended in 7.5 ml IPP 
by gentle inversion. The spin-wash cycle was repeated until each set of beads had been 
spun down four times. One set of beads incubated with prototype serum ('prototype- 
coated beads'), and one set of beads incubated with normal human serum ('normal 
serum-coated beads') were put aside on ice. The remaining four sets of beads were 
incubated with 3.0 ml of K562-cell extract plus 4.5 ml IPP for 1 h, after which these 
beads were immediately spun down according to Centrifuge Protocol 4, and the 
supernatants put on ice. One supernatant (semi-depleted extract) was then re-incubated
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for 1 h with the third tube of fresh autoantibody-coated beads. After incubation and 
centrifugation, the supernatant (depleted extract) and the remaining sample of semi­
depleted extract were each incubated with 5 mg fresh preswollen beads in order to 
remove any excess antibodies. All three extracts (depleted, semi-depleted and original 
whole-cell extract) prepared from the same batch were then tested for the presence of 
the autoantigen by the usual IP method. For comparison, similar "depleted" and "semi­
depleted" extracts were prepared using a normal human serum. In some cases four 
cycles of depletion were carried out in an analogous fashion.
Method 2.3.3d: Affinity purification o f autoantigens by immunoprecipitation
This method was basically a scaled-up version of Method 2.33a. A  20-mg quantity of 
Protein-A Sepharose was pre-swollen in 5 ml IPP buffer in a 15-ml tube. Following 
incubation at 4°C (50 pi serum in 5 ml IPP), the beads were repeatedly washed and 
spun down according to Centrifuge Protocol 4. Re-incubation of the beads for 1 h with 
1 ml of the unlabelled or radiolabelled K562-cell extract and 4 ml IPP was followed by 
similar washing cycles. Washed beads were resuspended in 500 pi Laemmli sample 
buffer, or stored at -80°C for later use.
Samples were prepared for SDS-PAGE according to Method 23.5a. The 500-pl 
denatured sample was loaded into a 45-mm-wide well of a 10-12.5% maxi-gel, as 
described in Method 2.3.5c, or a 10-well mini-gel (Method 2.3.5fc), and run as usual (a 
solution of 20-30 pi kaleidoscope molecular weight markers (BioRad Laboratories) was 
loaded into a standard-sized well of the same gel). Once run, gels were processed for 
transfer to nitrocellulose membranes (Method 2.3.6a) for subsequent blotting studies 
(Method 2.3.7) and, where appropriate, autoradiography (Method 233d).
2.3.4 Antigen purification by immunoaffinity column chromatography
Technical basis
Affinity chromatography refers to chromatographic separation procedures relying on 
specific interactions of biomolecules (for review see (367)). Where a protein is purified 
by a specific antibody, the technique is known as immunoaffinity chromatography. This 
is a three-stage process involving (i) covalent binding of ligand (i.e. antibody) to 
particles of an insoluble support matrix, which is then packed into a column; (ii) 
application of an antigen source to the column followed by extensive washing: the 
desired protein will remain inside the column, having been recognized by the matrix- 
bound antibody; (iii) the use of extreme elution conditions, which disrupt the bond 
between antibody and antigen, while leaving the intact matrix-antibody particles 
behind.
Due to the myriad proteins present in whole human serum, the solid support matrix 
must be capable of specifically binding antibodies. A suitable matrix for this purpose is 
Protein A-coated Sepharose CL-4B beads. The serum is first incubated with a slurry of
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the beads to allow specific, non-covalent binding of serum antibodies to Protein-A. 
After the remaining serum components have been washed away, the antibody-Protein A 
binding is stabilized by direct covalent coupling. This is achieved with a bifunctional 
coupling reagent such as dimethylpimelidate (DMP). There are two binding groups on 
the DMP molecule, each of which is capable of binding to free amino groups of 
proteins. In the majority of cases, a free amino group will be available on both the 
Protein A molecule and the Fc portion of the Ig molecule to which it is bound. 
However, any free amino groups on either of the two proteins will react with DMP, and 
if such groups are in or near the antigen binding site, antigenicity will be lost. Other 
binding techniques are available however, should the need arise.
Under optimal conditions immunoaffinity chromatography is an extremely effective 
technique: a 10000-fold purification of starting material is not uncommon, and at least 
1000-fold purification is normally achieved. Elution conditions are, however, critical to 
the success of the procedure, and must be empirically determined for each individual 
protein-antibody system in advance of large-scale purifications. Antibody affinity and 
antigen concentration are also key to efficient separation.
Problems can arise when using polyclonal antibody sources, since a single antigen 
may be bound simultaneously by several different antibodies resulting in very high 
avidity and consequent difficulties in effective elution. Moreover, each different 
antigen-antibody bond has its own elution conditions. Multiple binding of single protein 
molecules can be minimized by ensuring saturation of antibody with antigen.
Method 2.3.4a: Purification o f autoantigens by immunoaffinity column chromato­
graphy
The coupling of antibodies to Protein A Sepharose CL-4B beads was carried out using 
an adaptation of a previously described method (367).
Non-covalent binding o f serum antibodies to Protein-A Sepharose 
A suspension containing 1.3 g Sepharose beads in ice-cold IPP was prepared, as 
previously described (Method 2.3.3a); total volume 50 ml). The beads were 
resuspended by gentle vortexing, and 650 pi of the relevant serum sample was added. 
Following a 2-h (or overnight) incubation at 4°C with end-over rotation, the Sepharose 
beads were spun and washed four times in 40 ml IPP, being centrifuged according to 
Protocol 4.
Covalent binding o f serum antibodies to Protein-A Sepharose matrix 
For covalent coupling of bound antibodies to Protein-A Sepharose, the beads were spun 
and washed twice in 40 ml sodium borate solution (saturated, pH9.0), being centrifuged 
according to Protocol 4, but at room temperature. After resuspending in 30 ml sodium 
borate solution, a 260-mg quantity of solid DMP was added to the borate-Sepharose 
suspension (final concentration 20 mM), and the mixture was incubated for 90 min at 
room temperature with end-over rotation. The pH was checked before and after
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coupling (usually found to be ~pH9.0): a minimum pH of 8.3 is required for the DMP 
coupling reaction.
The reaction was stopped by washing the beads once (as above) in 40 ml 
ethanolamine (0.2 mM, pH8.0; room temperature). The beads were then resuspended in 
10 ml ethanolamine solution in a 15-ml tube, and the mixture was incubated at room 
temperature for 2 h with end-over rotation. Finally the beads were centrifuged 
according to Protocol 4 (at room temperature), resuspended in 10 ml PBS containing 
0.01% merthiolate as preservative, and stored at 4°C until use.
Packing the immunoaffinitv column
Empty, reusable 10-ml columns (Model CIO) were obtained from Pharmacia Biotech 
AB, Sweden. The columns were fitted with a volume-adjusting device (AC-10 Adaptor, 
Pharmacia Biotech AB) to give an available bed volume of 1-10 ml (Fig. 2.2). The 
manufacturer's instructions were followed when filling the column with the antibody- 
coupled Sepharose beads. A length of the flexible 1-mm-bore tubing supplied was 
attached to the bottom end of the column via a special sealing ring and screw piece 
('column outlet tube', Fig. 2.2). A separate piece of tubing ('column inlet tube') was 
passed through the adaptor plunger, and attached inside the end of the plunger using a 
special sealing device: this allowed delivery of solutions to the main column via the 
column inlet tube (Fig. 2.2).
The Sepharose beads were centrifuged according to Protocol 4, and resuspended in 
10 ml PBS. The column outlet tube was opened, by removing the stopper, and the 
suspension was loaded into the column using a pipette. As the column drained, PBS 
washings from the 15-ml centrifuge tube were added. When all the beads had been 
transferred, the column outlet tube was closed. Keeping the column in a vertical 
position, the beads were allowed to settle. The column was then filled right to the top 
with PBS, taking care not to disturb the Sepharose bed. The column inlet tube (attached 
to the adaptor; Fig. 2.2) was opened before slowly pushing the adapter plunger into the 
column, avoiding the introduction of air bubbles. Displaced liquid from the column was 
automatically expelled via the column inlet tube. The plunger was pushed down the 
column until it was about 5 mm above the Sepharose bed, and secured with its screw- 
pin attachment. The top-piece of the column was attached, and the column inlet tube 
was closed: the column was then ready for operation. All subsequent steps were carried 
out in a cold cabinet set at 4°C, and using ice-cold solutions.
Pre-washing the immunoaffinitv column
The actual process of immunoaffinity column chromatography was carried out by an 
adaptation of the method of Plunkett & Springer (1986) ((269): see also Springer 
(1993)(324)). The free end of the column inlet tube was attached (using the special 
sealing ring and screw-piece) to a 30-ml reservoir positioned several cm above the 
affinity column (Fig. 2.2) The following solutions were then used to wash the column, 
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FIGURE 2 .2 . S c h e m a tic  re p re s e n ta tio n  o f im m m u n o a f f in ity  c o lu m n  
chrom atography
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(i) 50 ml Wash Buffer
(10 mM Tris.Cl, pH8.0; 14 mM NaCl; 0.5% (v/v) Triton X-100)
(ii) 25 ml Tris Buffer, pH8.0
(50 mM Tris.Cl, pH8.0; 500 mM NaCl; 0.1% (v/v) Triton X-100)
(iii) 25 ml Tris Buffer, pH9.0
(50 mM Tris.Cl, pH9.0; 500 mM NaCl; 0.1% (v/v) Triton X-100)
(iv) 25 ml Triethanolamine Solution
(50 mM triethanolamine, ~pH11.5; 150 mM NaCl; 0.1% (v/v) Triton X-100)
(v) 25 ml Wash Buffer
When passing each solution through the column, the following procedure was followed: 
a 5-ml excess of the relevant solution was poured into the empty reservoir, and the 
column outlet tube was opened whilst holding it level with the bottom of the column. 
The end of the outlet tube was positioned above an effluent collection vessel, and its 
height was adjusted to obtain a satisfactory flow-rate: for washing purposes, this was 
about 1 drop per second. When the level of the reservoir had dropped to about 5 ml, the 
column outlet tube was closed, and the reservoir was emptied by inversion, ready for 
application of the next solution.
Application o f cell extract to immunoaffinity columns
In a similar manner to that described above, the cell extract preparation was passed 
through the two pre-washed columns in series. First, the extract was applied to the 
preclearing column: the end of the column outlet tube was held above the reservoir 
before being opened, placed in a clean collection tube, and slowly lowered, to allow a 
flow rate of approximately 5 ml/h. A series of 15-ml tubes was used to collect 5-ml 
quantities of the precleared extract. Once the reservoir had virtually emptied, the 
column outlet tube was closed, and the reservoir was rinsed with Wash Buffer to clean. 
A 25-ml volume of MIP was then put through the column, in order to flush through the 
remainder of the cell extract for collection (this was continued until the column contents 
appeared white, after which the column was closed).
Secondly, the precleared extract was applied to the immunoaffinity column: flow- 
rate was adjusted to 3 ml/h, as recommended for optimal binding of antigen (324). The 
5-ml quantities were applied to the column in the same order as they had been 
collected, being careful not to allow the reservoir to be completely empty at any time. 
Washing the immunoaffinitv column
The following solutions were used to wash unbound components of the extract from the 
column, prior to elution of antigen:
(i) 25 ml Wash Buffer
(ii) 25 ml Tris Buffer, pH8.0
(iii) 25 ml Sodium Phosphate Buffer
(50 mM sodium phosphate, pH6.3; 150 mM NaCl; 0.1% (v/v) Triton X-100)
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Low pH elution o f bound antigen
The first attempt at eluting bound antigen from the immunoaffinity column was made 
using a low-pH glycine buffer (50 mM glycine.HCl, pH 2.5; 150 mM NaCl; 0.1% 
Triton X-100), as recommended (324). A 25-ml quantity of this elution buffer was 
passed through the column as usual, with a flow rate of approximately two drops per 
second. A 1.2-ml volume of eluate was collected by hand into each of twenty tubes 
containing 300 pi of 1 M Tris.Cl, pH9.0.
After use, the immunoaffinity column was washed with 25 ml Wash Buffer, and 
then filled with PBS containing 0.01% merthiolate for long-term storage at 4°C. A 1-pl 
quantity of preservative solution (2% sodium azide) was added to each fraction of 
eluate, and tubes were stored at 4°C until analysis.
Analysis o f fractions for eluted antigen
A quick assessment of the relative protein content of each eluted fraction was made 
using SDS-PAGE followed by silver-salt staining: a 20-pl sample of each fraction was 
added to 20 pi SDS-reducing buffer and prepared as usual (Method 2.3.5a). Twenty-pl 
samples were run on 10%-acrylamide SDS-PAGE mini-gels (Method 2.3.5b), which 
were then silver stained (Method 2.3.8c), fixed (Method 2.3.9b) and dried between 
cellulose membranes (Method 2.3.9c). Each well was visually assessed for the presence 
of a prominent band of the appropriate molecular weight: the fractions judged to have 
the highest yield were selected for further purification (usually four or five fractions).
Method 2.3.4b: Concentration and desalting o f antigen-rich immunoaffinity fractions 
Microfuge filtration units (Ultrafree-MC NMWL:30K PLTK: 400-pl volume, 0.2-cm2 
low protein-binding membrane; Sigma Chemical Co. Ltd) were used to de-salt and 
concentrate antigen-rich immunoaffinity fractions. Each concentrator had a nominal 
exclusion value of 30 kDa. A 400-pl fraction of eluate was loaded into the concentrator, 
and the tube was spun in a refrigerated (1°C) microcentrifuge (Biofuge Fresco; Hereaus 
Instruments) at 9000 r.p.m. for 10 min (Centrifuge Protocol 7; approximately 4000g, as 
recommended by the manufacturers). Following centrifugation, the antigens of interest, 
having a molecular weight above 30 kDa, were contained in the remaining supernatant 
of the upper chamber, while salts and water were contained in the lower chamber. The 
upper chamber was topped up with eluate, while the lower chamber was emptied, its 
contents being discarded. This process was repeated until all the eluate had been loaded 
into the filtration unit, and similar 5- or 10-min centrifugation cycles were repeated 
until the upper chamber contained 25-50 pi of supernatant. This was removed into a 
0.5-ml microfuge tube, to which an equal volume of Laemmli sample buffer was added: 
the sample was immediately prepared (Method 2.3.5a) for running on a 10%- 
acrylamide SDS-PAGE mini-gel in a 30-mm-wide well (Method 2.3.5b), after which it 
was transferred to a PVDF membrane (Method 2.3.6b). The PVDF membrane was then 
stained with Coomassie blue (Method 2.3.8b), the band of interest was excised with a
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scalpel blade, and sent to a commercial sequence analysis service (Alta Bioscience, 
University of Birmingham, U.K.) for protein sequencing.
Method 2.3.4c: Protein sequencing
Protein sequencing was carried out at Alta Bioscience by the classic Edman degradation 
method. This involves labelling of the NH2-terminal residue of the protein with phenyl 
isothiocyanate, thus forming a phenylthiocarbamoyl derivative. This is followed by 
mildly acidic cleavage of the modified NH2-terminal residue to form a cyclic 
pheiiylthiohydantoin amino acid, plus the original polypeptide chain shortened by one 
residue. This whole procedure is repeated for a number of cycles, and the 
phenylthiohydantoin amino acids produced are detected sequentially using an in-line 
high-performance liquid chromatographic analysis system.
Once the NH2-terminal sequence is known, a variety of protein sequence databases 
is available, and these can be accessed via servers on the World-wide Web (e.g. the 
Blitz server: Blitz@ebi.ac.uk). By providing details of sequenced residues, and the 
position of the sequence (if known, e.g. NH2-terminal), programmes are available to 
search these databases for any protein which matches the stipulated sequencing criteria. 
If enough residues have been sequenced, the identity of the unknown protein may be 
matched with a small number of candidate proteins, ideally a single protein.
While many proteins can be directly sequenced following purification, over 50% of 
naturally occurring proteins are found to be blocked at the NH2-terminal due to post- 
translational modifications such as acetylation, phosphorylation, formylation, 
cyclization or poly(ADP-ribos)ylation (62), and such proteins are incompatible with 
standard sequencing protocols. This situation is immediately apparent to the operator 
during a sequencing run, due to the production of a characteristic output signal.
Method 2.3.4d: Cyanogen bromide-digestion o f Nfy-terminally blocked proteins 
Where proteins were reported to be NH2-terminally blocked, it was necessary to repeat 
the immunoaffinity purification procedure, break down the resulting protein into a 
number of polypeptide fragments, and attempt to sequence these instead. A number of 
protocols have been described to achieve this aim, one of which is "digestion" with 
cyanogen bromide (CNBr), which cleaves proteins at the COOH-terminal of each 
methionine residue, and forming a modified COOH-terminal of homoserine lactone in 
its place: most proteins contain a small number of methionine residues.
In such cases, following identification of antigen-rich fractions eluted from the 
immunoaffinity column, a more thorough desalting/concentration stage was carried out. 
To this end, a different type of filtration unit was used (Centriplus-100), obtained from 
Amicon Ltd (Stonehouse, Gloucestershire, U.K.). All proteins purified by the immuno­
affinity method in the present study had a molecular weight of at least 110 kDa. The 
filtration units had a 15-ml capacity, and a nominal exclusion value of 100 kDa via a 
2.34-cm2 YM hydrophilic cellulose membrane (i.e. all contaminating proteins of below
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100-kDa would be removed with these filters, and the inadvertent detection and 
sequencing of such contaminants would thus be avoided).
The pooled antigen-rich eluate fractions (~7.2 ml in total) were loaded into the 
concentrator, and the tube was spun in a refrigerated (1°C) centrifuge (Jouan, BR4i; S40 
rotor) at 4100 r.p.m. for repeated periods of 5-20 min (Centrifuge Protocol 8; ~3000g, 
as recommended by the manufacturers). Following centrifugation, the antigen of 
interest was contained in the remaining supernatant of the upper chamber, while salts 
and water were contained in the lower chamber. Centrifugation was continued until 
about 30 pi of supernatant was remaining: this process took about 2 h, and frequent 
progress checks were made to avoid the total elimination of the aqueous phase. The 
remaining solution was recovered, as advised by the manufacturers, by a 4-min inverted 
spin at 3400 r.p.m. (~2000g) in the same centrifuge (1°C; Centrifuge Protocol 9), the 
sample collected in the receptacle provided, and transferred to a 0.5-ml microfuge tube.
The previously described CNBr cleavage method of Cook was used (62), with 
modifications as advised by Dr J.Fox of Alta Bioscience (pers.comm.). All procedures 
were carried out in a high-performance fume cupboard, and nitrile gloves, and goggles 
were worn (CNBr is extremely toxic and volatile). A 70-pi quantity of formic acid was 
added to the sample tube, followed by two small crystals of CNBr. The tube was 
vortexed, and left in the dark in the fume cupboard for 16-20 h (room temperature).
The next day the tube was again vortexed. The same precautions were taken, and all 
equipment was enclosed in the fume cupboard. The more volatile components (i.e. 
water, CNBr, formic acid) were evaporated using a vacuum centrifuge (GyroVap and 
Refrigerated Solvent Trap, Howe Ltd, attached to a strong vacuum pump) until about 
10-20 pi of solution remained. A 200-pl volume of water was then added, and further 
evaporation was carried out as before. This was repeated using two further 200-pl 
quantities of water, after which the sample was dried to completion, and 30 pi SDS- 
PAGE sample buffer was added to the dried residue, theoretically containing the CBr- 
fragmented polypeptide products of the purified protein.
The sample was immediately prepared (Method 2.3.5a) for running on a 10%-SDS- 
PAGE mini-gel in a 15-mm-wide well (Method 23.5b ), after which it was transferred 
to a PVDF membrane (Method 23.6b). The PVDF membrane was then stained with 
Coomassie blue (Method 233b)\ any clearly visible bands were to be excised with a 
scalpel blade, and sent to Alta Bioscience for protein sequencing.
All equipment was thoroughly decontaminated using hypochlorite-type bleach 
followed by a good rinsing in water (this process oxidizes cyanides to much less toxic 
cyanates).
80
2.3.5 Polyacrylamide gel electrophoresis 
Technical basis
Proteins are denatured using Laemmli sample buffer, resulting in loss of primary, 
secondary, tertiary and quaternary structure. The SDS component of the sample buffer 
coats the unravelled polypeptides with a negative charge. After loading into a 
polyacrylamide gel (which acts as a molecular sieve), the polypeptides are attracted by 
the application of a positive charge potential, applied via a Tris-glycine buffer system, 
and the extent of their migration is negatively correlated with their molecular weights. 
This results in bands of protein, which may be detected by a variety of methods.
A similar principle is used to separate RNAs on the basis of their length using a 
urea-acrylamide gel, and a TBE buffer system.
Method 2.3.5a: Sample preparation for polyacrylamide gel electrophoresis 
The sample, prepared by IP or immunoaffinity column chromatography, had been 
placed in a tube capable of withstanding boiling temperatures, which had an air-tight, 
secure closing mechanism (screw-top poly-propylene tubes and polypropylene 
microfiige tubes fitted with lid-locks are suitable for this purpose).
After adding an appropriate quantity of sample buffer to each sample (refer to 
individual protocols), lids were securely fitted, tubes were placed into floating racks, 
and the racks were floated on boiling tap water for 3 min (water at 65 °C in the case of 
RNA samples), such that the samples were under the surface of the water, while the lids 
were protected from submersion. The samples were allowed to cool for 5 min at room 
temperature. Where Protein-A Sepharose beads were present in the sample, tubes were 
centrifuged according to Protocol 5.
Method 2.3.5b: SDS-PAGE of proteins on a mini-gel
Standard mini-gel electrophoresis equipment (Modular Mini-Protean II Electrophoresis 
System (Bio-Rad); Mighty Small II/SE250 (Hoeffer Scientific Instruments, San 
Francisco, CA, U.S.A.)) was used to separate denatured polypeptides according to their 
molecular weight.
Assembly o f  gel-casting unit
The equipment was assembled according to the manufacturer's instructions: for each 
gel, two clean, ethanol-polished glass plates (-80 x 100 mm) were placed one on top of 
the other, the shorter edges being separated by two 1.0-mm-thick Teflon spacers (-10 x 
80 mm) such that a space of -1.0 x 70 x 80 mm was left in the middle. The plates and 
spacers were carefully aligned to avoid leaks, and the sandwich was gripped in place by 
casting clamps. The lower open end of this assembly was locked tightly onto the 
casting stand on top of a casting gasket, such that a water-tight space was formed 
between the two plates for casting the gel.
81
Gel composition and pouring
The gel components were assembled as follows: 10% (w/v) ammonium persulphate 
(AMPS; Bio-Rad Laboratories) solution which was prepared freshly each day; 
N,N,N',N'-tetramethylethylenediamine (TEMED) was also obtained from Bio-Rad 
Laboratories; solutions of 1.5 M Tris.Cl, pH8.8; 0.4% (w/v) SDS (Lower Gel Buffer) 
and 0.5 M Tris.Cl, pH6.8; 0.4% (w/v) SDS (Upper Gel Buffer) were prepared well in 
advance, and stored at 4°C; 30% (w/v) acrylamide : bisacrylamide (37.5:1) was 
obtained from nbl Gene Sciences Ltd, Cramlington, U.K, also being stored at 4°C.
The recipes used to prepare two SDS-PAGE mini-gels of the appropriate percentage 
are shown in Table 2.1a. First, the lower gel components were added to a 50-ml 
polypropylene tube in the order shown, with the AMPS and TEMED being added just 
before the gel was ready to be poured. The tube was closed and gently inverted three 
times to mix, after which -3-4 ml of the mixture was poured carefully between the 
glass plates to a height of -50 mm, avoiding air bubbles. Immediately after being 
poured, a 100-jLil volume of water-saturated butan-2-ol (30 ml butan-2-ol and 20 ml 
water were shaken and allowed to equilibrate and separate for 24 h: the top layer was 
then ready for use) was carefully introduced via a gel-loading tip, which was whisked 
along the gap between the plates, taking care not to touch the gel directly.
The gel was left to polymerize for at least 45 min, after which the butan-2-ol and any 
surplus water was washed away with several pourings of water and shaking. The 
apparatus was then shaken well to clear its surface, ready to pour the upper gel: this was 
prepared in much the same way as the lower gel (see Table 2.1a). The upper gel was 
poured between the glass plates on top of the lower gel, avoiding air bubbles, until the 
gap between the plates was full. Immediately, an appropriate Teflon comb was inserted 
between the glass plates, displacing some of the upper gel mixture, and such that the 
teeth of the comb were -5  mm above the surface of the lower gel. It was checked that 
the comb was parallel with the top of the lower gel, and any small air bubbles could 
usually be removed by gentle tapping of the glass plates.
The gel was left to set for at least 30 min, after which the comb was carefully 
removed in a vertical direction, and the wells were immediately washed out with water, 
as before.
Running conditions
The gel clamps were immediately removed from the casting stand, and clipped into the 
electrophoresis apparatus assembly. The upper and lower buffer chambers thus formed 
(between two separate gels) were then filled with freshly made running buffer (25 mM 
Trizma base, 190 mM glycine, 0.1% (w/v) SDS), prepared by diluting a 5x concentrate 
(125 mM Trizma base, 950 mM glycine, 0.5% (w/v) SDS) stored at 5°C .
Appropriate sample volumes (see individual protocols) were then carefully loaded 
into separate wells using a gel-loading pipette tip: great care was taken not to overfill
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TABLE 2.1. Recipes used for preparing polyacrylamide gels for polyacrylamide gel 
electrophoresis (PAGE): (a) sodium dodecyl sulphate- (SDS-) PAGE mini-gel 
recipes; (b) SDS-PAGE maxi-gel recipes; (c) urea-PAGE mini-gel recipes; (d) urea- 
PAGE maxi-gel recipes
(a) Proportion of acrylamide in gel mixture (%)
5.0* 8.0 10.0 12.5 15.0
Component volume (ml) 
Milli-Q water 3.9 4.8 4.2 3.3 2.5
Lower gel buffer** - 2.5 2.5 2.5 2.5
Upper gel buffer*** 1.7 - - - -
Acrylamide mixturet 1.1 2.7 3.3 4.2 5.0
AMPS§ 0.04 0.07 0.05 0.04 0.03
TEMED! 0.01 0.02 0.01 0.01 0.01
Total volume (ml) -6.7 -10.0 -10.0 -10.0 -10.0
(c) Proportion of acrylamide in gel mixture (%)
7.5 10.0
Component volume (ml)
Milli-Q water 3.4 2.6
TBEx5* 2.2 2.2
Urea (mass in g) 4.6 4.6
Acrylamide mixturet 2.8 3.6
AMPS§ 0.08 0.06
TEMED! 0.02 0.02
Total volume (ml) -13.0 -13.0
*Upper gels were always 5% for SDS-PAGE
**1.5M Tris.Cl pH8.8; 0.4% (w/v) SDS
***0.5M Tris.Cl pH6.8; 0.4% (w/v) SDS 
t30% (w/v) acrylamide : bisacrylamide (37.5:1)
5 10% ammonium persulphate (w/v)
1 N,N,N’,N’-tetramethylethylenediamine 
#Tris-borate-EDTA x5 (450 mM Trizma base, 
450 mM boric acid, 10 mM disodium EDTA)
Proportion of acrylamide in gel mixture (%)
5.0* 8.0 10.0 12.5 15.0
Component volume (ml) 
Water 11.8 14.5 12.5 10.0 7.5
Lower gel buffer* - 7.5 7.5 7.5 7.5
Upper gel buffer** 5.0 - - - -
Acrylamide mixturet 3.2 8.0 10.0 12.5 15.0
AMPS§ 0.10 0.21 0.15 0.11 0.09
TEMED! 0.03 0.06 0.03 0.02 0.02
Total volume (ml) -20.0 -30.0 -30.0 -30.0 -30.0





Urea (mass in g) 9.2 9.2
Acrylamide mixturet 5.5 7.3
AMPS§ 0.15 0.12
TEMED! 0.04 0.04
Total volume (ml) -26.0 -26.0
wells, and cross-contamination of wells was avoided. Molecular weight markers (5-30 
ini, as appropriate) were similarly added to a separate well (see individual protocols).
The lid assembly was put into place, and electrodes were attached to a suitable 
power pack: two mini-gels were typically run at a constant voltage of 75 mV. When the 
blue dye front was observed to be fully below the upper gel, the voltage was increased 
to 125 mV. When the dye front had virtually reached the bottom of the lower gel (~60- 
90 min) the power was switched off, the whole unit was carefully dissembled, and the 
glass plates were prised apart, the gel then being ready for further processing, as 
described in individual protocols.
Method 2.3.5c SDS-PAGE of proteins on a maxi-gel
Standard maxi-gel electrophoresis equipment (Protean II xi Vertical Electrophoresis 
Cell (Bio-Rad Laboratories); SE600 Gel Electrophoresis System (Hoeffer Scientific 
Instruments)) was used to separate denatured polypeptides according to molecular 
weight.
Assembly o f the gel-casting unit
The plate sizes were ~200 x 200 mm (Bio-Rad Laboratories) and ~160 x 140 mm 
(Hoeffer Scientific Instruments), and spacers were also larger.
Gel composition and pouring o f  gels
The process was essentially the same as described for mini-gels, with the following 
modifications. The recipes used to make the maxi-gels are shown in Table 2.1 b. A 
larger (200 pi) volume of butan-2-ol was overlaid on the lower gel.
Running conditions
The same basic method was used, except the two maxi-gels were run at constant current 
-  48 mA to start with, being increased to 72 mA when the dye front had completely 
passed through to the lower gel. In addition, both types of equipment included cooling 
coils through which cold running tap-water was allowed to flow. Total running time 
was ~3-5 h depending on how far the dye front was allowed to travel down the lower 
gel: this was determined largely according to convenience.
Method 2.3.5d: Urea-polyacrylamide gel electrophoresis ofRNAs on a mini-gel
The electrophoretic separation of RNAs was carried out using the same equipment as 
for protein electrophoresis (Method 2.3.5&), and a similar basic technique was used. 
Standard precautions were taken to avoid contamination by RNAse. All modifications 
are detailed below.
Gel composition and pouring o f gels
The gel components were as follows: 10% (w/v) AMPS (freshly prepared each day); 
TEMED; a 5x solution of Tris-borate-EDTA (TBE: 450 mM Trizma base, 450 mM 
boric acid, 10 mM disodium EDTA) was prepared well in advance, and stored at 4°C; 
30% (w/v) acrylamide : bisacrylamide (30:1) was obtained from Sigma Chemical Co. 
Ltd, also being stored at 4°C.
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The recipes used to prepare two 7M-urea-polyacrylamide mini-gels of the 
appropriate acrylamide percentage are shown in Table 2.1c. The gel components were 
added to a 50-ml polypropylene tube in the order shown, with the AMPS and TEMED 
being added just before the gel was ready to be poured. The tube was closed and gently 
inverted three times to mix, after which the gel was poured between the glass plates, 
avoiding air bubbles, until the gap between the plates was full. Immediately, an 
appropriate Teflon comb was inserted between the glass plates, displacing some of the 
upper gel mixture, and such that the teeth of the comb were fully immersed in the 
unpolymerized gel solution. It was checked that the comb was parallel with the top of 
the lower gel, and any small air bubbles could usually be removed by gentle tapping of 
the glass plates.
Each gel was left to set for at least 60 min, after which the comb was carefully 
removed in a vertical direction, and the wells were immediately washed out with water, 
as usual.
Running conditions
The upper and lower buffer chambers were filled with freshly made running buffer 
(TBExl).
Markers were not used: relative mobilities were compared by the use of internal 
standards i.e. RNA samples prepared using prototype sera.
Two mini-gels were typically run at a constant current of 12 mA for 1 h: this meant 
the gels were heated to a temperature of ~50-60°C during the run. When the first dye- 
front had virtually reached the bottom of the lower gels (-60-90 min) the power was 
switched off, the whole unit was carefully dissembled, and the glass plates were prised 
apart, the gels then being ready for further processing, as described in individual 
protocols.
Method 2.3.5e: Urea-poly acrylamide gel electrophoresis o f RNAs on a maxi-gel
Gel composition and pouring o f  gels
The process was essentially the same as described for mini-gels. The Hoeffer system 
was used. The recipes used to make the maxi-gels are shown in Table 2.1d .
Running conditions
The same basic method was used, except two gels were run at a constant current of 40 
mA, until the samples had entered the gel, when the current was raised to 60 mA (in the 
absence of cooling coils, this permitted a running temperature of ~50-60°C). Total 
running time was -1-2 h.
2.3.6 Electrophoretic transfer
Technical basis
Polypeptides are separated according to molecular weight by SDS-PAGE. The SDS- 
polyacrylamide gel is then laid onto a sheet of nitro-cellulose (or other suitable
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membrane). The gel and membrane are sandwiched between sheets of blotting paper 
and Scotchbrite pads and put inside a special cassette. All components of the gel 
sandwich are kept wet with a special electrophoretic transfer buffer throughout the 
process of sandwich assembly.
The cassettes are loaded into a transfer buffer-filled electrophoretic transfer tank in 
such a way that, during application of an electric current, the negatively charged SDS- 
coated polypeptides are attracted to the positive anode. The sandwich is constructed so 
the polypeptides will consequently move across from the gel to the membrane. The 
composition of the membrane is highly attractive to polypeptides, which will bind and 
remain adhered to the membrane surface, even after membrane washing. Because the 
proteins pass straight across, the banding pattern is essentially analogous to that of the 
original gel. Coloured molecular weight markers on the surface of the membrane from 
the original gel allow visual confirmation of a successfully transferred gel.
Choice of membrane type depends on application. Nitro-cellulose membranes are 
cheap, and are useful for routine blotting procedures. However, they are also fragile, 
difficult to stain with Coomassie blue, and unsuitable for protein sequencing 
applications. Polyvinylidene fluoride (PVDF) membranes (Immobilon-PsQ; Millipore) 
are more expensive, but are also more robust, than nitro-cellulose membranes, and are 
suitable for use in protein sequencing applications and when Coomassie blue staining is 
required. A further disadvantage of PVDF is that it must be pre-wetted before use in 
aqueous solutions, and must not be allowed to dry out during a subsequent procedure 
(to do this the membrane is soaked in methanol for a few seconds, until grey in colour, 
then washed in water for two minutes to elute the methanol, making sure the membrane 
is fully submerged at all times).
Method 2.3.6a: Electrophoretic transfer onto nitro-cellulose membranes 
Standard equipment was used, obtained from BioRad Laboratories (Mini Trans-Blot 
Electrophoretic Transfer Cell; Trans-Blot Electrophoretic Transfer Cell). Maxi-gel and 
mini-gel transfers were essentially the same.
First, transfer buffer (20 mM Trizma base, 150 mM glycine, 20% (v/v) methanol, 
0.1% SDS) was freshly prepared using a lOx concentrate of Transfer Buffer Mixing 
Solution (200 mM Trizma base, 1.5 M glycine). Eight pieces of blotting paper, a little 
larger than the gel itself, were soaked in transfer buffer, together with four similarly 
sized pieces of Scotch-Brite pad, and two pieces of pre-wetted nitro-cellulose 
membrane (BioRad Laboratories), each a little larger than a gel.
Following removal of the gels from the glass plates after SDS-PAGE, each gel was 
equilibrated in Transfer Buffer for 10 min. The two gel sandwiches were then 
assembled "underwater", each comprizing the following layers: Scotchbrite pad x 1, 
blotting paper sheet x 2, SDS-polyacrylamide gel x 1, transfer membrane x 1, blotting 
paper sheet x 2, Scotchbrite pad x 1. It is extremely important to avoid air bubbles, 
especially between the gel and the membrane, in order for effective transfer to take
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place. Each sandwich was placed in a transfer cassette, and immediately afterwards the 
two cassettes were fitted into the tank apparatus in an appropriate orientation, according 
to the manufacturer's instructions. The tank was filled to the brim with transfer buffer, 
the tank lid was fitted, and the current was switched on: 215 mA constant current was 
used for both mini- and maxi-gels. For mini-gels, the partly submerged ice-pack 
cooling method was used (a suitable vessel being provided by the manufacturer), while 
maxi-gels were cooled by attaching cold-water taps to the cooling coils provided.
After 2 h had elapsed, the apparatus was partly dissembled so a small corner of the 
membrane could be checked for effective transfer of coloured molecular weight 
markers: if transfer was incomplete the apparatus could be re-assembled and run again 
for a while. Following transfer, gels were discarded, and membranes were briefly rinsed 
in water, stained with Ponceau S to check for protein content (Method 2.3.8a) and 
allowed to dry, ready for use. Membranes could be stored at room temperature for 
several days, but temperatures of -20°C were used for longer periods of storage, with 
the membrane being carefully wrapped in aluminium foil.
Method 2.3.6b: Electrophoretic transfer onto PVDF membranes 
The same basic method as that described above was used, with the following 
modifications: (i) the SDS-polyacrylamide gel used was 24-36 h old to prevent amino- 
acid modification due to non-polymerized acrylamide monomer; (ii) an alternative 
transfer buffer was used, as recommended (62) (25 mM Tris, 192 mM glycine, 10% 
(v/v) methanol), (iii) after removal of the PVDF membrane from the transfer cassette, 
the membrane was repeatedly washed in water over a 10-min period to remove all 
contaminating traces of Tris and glycine.
2.3.7 Immunoblotting
Technical basis
The technique of IB relies on antibodies which recognize linear epitopes. A 
disadvantage of IB is that it can only be used to detect antigenic epitopes of primary 
structure, which are still intact on the denatured particle.
Whole-cell extracts do not contain sufficient quantities of nucleolar antigens for 
effective detection of antinucleolar antibodies by IB. However, appropriate sera may be 
used to affinity purify autoantigens from cell extracts by scaled-up IP techniques, thus 
enabling IB studies to be performed using the purified protein extracts as the antigen 
source.
The purified source of antigen is run on SDS-PAGE, followed by electrophoretic 
transfer to a nitro-cellulose membrane. The membrane is cut into strips which are 
incubated with a diluted sample of serum. Autoantibodies recognizing linear epitopes 
then bind to the denatured antigens. After washing, the strips are incubated with an 
alkaline phosphatase-conjugated anti-human immunoglobulin. After re-washing, the
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samples are incubated with appropriate alkaline phosphatase substrates, which results in 
a coloured product in the vicinity of bound conjugate. Bands are thus visualized, which 
are indicative of the molecular weights of the particular antigenic subunits recognized 
by autoantibodies in the sample serum.
Method 2.3.7: Immunoblotting o f purified autoantigens
Immunoblotting was performed by a modified version of the previously described 
method of McHugh, James & Maddison (1988) (225) using sample sera and prototype 
sera of known autoantibody specificities.
Preparation o f blotting strips
Membranes, prestained with Ponceau S, were cut into 3- to 5-mm-wide strips with a 
clean scalpel blade, perpendicular to the dye front: the orientation of the transferred 
proteins on the membrane was aided by pencil marks made on the membrane 
immediately following transfer (the transferred gel had been traced around), and the 
Ponceau S staining helped make sure the strips were cut perpendicular to the linear 
patterns of electrophoresed proteins. A couple of cm of clean membrane were left at 
either end of each strip to aid handling (membranes were handled using clean 
tweezers). A pencil was used to mark a reference number on one end of each strip. 
Incubation o f blotting strips with sample sera
A standard 20-well blotting tray was used (BioRad Laboratories) for separately 
incubating strips in 2 ml fat-free milk, freshly reconstituted from a dried domestic 
skimmed milk powder as a 5% solution in PBS (Blotto): this served to block non­
specific protein-binding sites. The blotting tray was put on a moving platform during all 
incubations. After 2 h, the blotto was removed, and immediately replaced with 2 ml 
fresh blotto. Typically, a 2-20 pi sample of each sample serum was then added to the 
relevant well (i.e. 1/1000 - 1/100 dilution), and the samples were incubated at room 
temperature for a further 60-90 min. A range of prototype sera were always included to 
act as positive and negative controls during colour development, and to act as internal 
standards for the purpose of band identification. The strips were then washed in three 
separate lots of fresh PBS over a 10-min period.
Binding of the second antibody (anti-human IgG/IgM developed in goat, conjugated 
to alkaline phosphatase; Sigma Chemical Co. Ltd) was added at a typical concentration 
of 1/1000 - 1/250 (2-8 pi in 2 ml blotto per well). After further washes as before, the 
strips were ready for developing.
Developing immunoblotting strips
A  100-ml quantity of developing buffer (100 mM Tris.Cl, 100 mM NaCl, 5 mM 
magnesium chloride; pH9.6) was placed in a clean, white, polypropylene tray. The 
substrates were then added: 200 pi 5-bromo-4-chloro-3-indolyl phosphate solution 
(BCIP; 50 mg/ml in dimethylformamide (DMF)) and 200 pi nitroblue tetrazolium 
solution (NBT; 50 mg/ml in 70% (v/v) DMF), and the substrate preparation was mixed 
by swirling. The strips were briefly rinsed in developing buffer, and then placed into the
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incubation tray. All strips were placed with transferred proteins facing upwards, and 
any overlapping strips were gently moved with tweezers. The tray was left for 5-20 min 
at room temperature, with very frequent checks being made for colour development. 
When optimal contrast between positive bands and negative background was judged to 
have been achieved, the reaction was halted by removing all strips into a large tray of 
water. After 2-3 min the strips were laid out onto blotting paper and allowed to air-dry. 
Autoradiography
Immunoblots were also subject to autoradiography where appropriate (Method 2 3 .Sd) 
to reveal the positions of transferred polypeptides.
2.3.8 Protein and RNA detection methods
A variety of methods is available for the detection of proteins in polyacrylamide gels 
and/or on membranes, and the method of choice depends on the particular application.
Ponceau S staining is the easiest method, and also has the advantage of being 
reversible. However, the method lacks sensitivity.
Coomassie blue staining is typically used for the detection of pg quantities of protein 
in SDS-polyacrylamide gels. However, an adapted technique can also be used to detect 
proteins which have been transferred from acrylamide gels onto PVDF membranes, and 
this method is considerably more sensitive than Ponceau S staining, allowing detection 
of 100-200 ng of protein (62).
Staining of proteins using silver-salt staining is a very sensitive technique capable of 
detecting proteins in acrylamide gels at the ng level (62). However, the method is long- 
winded, technically more difficult and more hazardous.
Autoradiography is probably the most sensitive technique, but it relies on 
radiolabelled proteins, and is thus technically difficult and more hazardous. If signals 
are weak, then films can be exposed for several weeks by this method. However, 
background staining will also accumulate during such long exposures, and so samples 
should be of the highest purity for optimal sensitivity: this amounts to thorough 
washing cycles during IP procedures (Method 2.3.3a).
The detection of RNAs by silver staining is a sensitive technique, and is 
considerably less hazardous than the alternative, which is autoradiography of 32P- 
labelled RNAs immunoprecipitated from previously radiolabelled TC cells.
Method 2.3.8a: Detection of proteins by Ponceau S staining
The nitro-cellulose membrane was placed in a suitable tray containing sufficient 
Ponceau S solution (0.2% Ponceau S, 1% (v/v) acetic acid) for full immersion. The tray 
was placed on a moving platform, and allowed to stain for 5 min at room temperature. 
The membrane was then destained with several washings of water over a 5-min period.
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Method 2.3.8b: Detection of proteins by Coomassie blue staining 
The PVDF membrane was pre-wetted as described in Section 23.6b , and placed in a 
suitable tray containing sufficient Coomassie blue solution (0.1% Coomassie blue 
(w/v), 50% methanol (v/v), 2% glacial acetic acid (v/v)) for full immersion. The tray 
was placed on a moving platform, and allowed to stain for no longer than 5 min at room 
temperature (longer staining times result in too much background staining). The 
membrane was then destained using several changes of 50% methanol over a 10- to 30- 
min period (destaining was halted when protein bands were clearly visible over the 
background). The membrane was then rinsed in several washings of water over a 5-min 
period, and allowed to air-dry.
Method 2.3.8c: Detection of proteins by silver staining
A "Plusone" protein silver staining kit was used, supplied by Pharmacia, and the 
manufacturer's instructions were carefully followed. Briefly, each gel was carefully 
removed from glass plates following SDS-PAGE (Section 2.3.5), and placed in fixative 
solution ( 4 : 1 : 5 ,  ethanol : glacial acetic acid : water). The container of fixative was 
placed on a moving platform for 30 min, ensuring there was sufficient quantity of 
fixative to allow total submersion of the gel throughout this period. The fixative 
solution was then removed from the container by aspiration, a similar volume of 
sensitizing solution (0.125% (w/v) glutardialdehyde, 0.2% (w/v) sodium thiosulphate, 
830 mM sodium acetate, in 30% ethanol) was added, and the gel was reincubated for a 
further 30 min. After removal of sensitizing solution, the gel was washed three times 
for 5 min each time, in water. Next, the gel was soaked in silver solution (0.25% (w/v) 
silver nitrate, 0.015% (w/v) formaldehyde) for 20 min, followed by two 1-min washes 
in water. Gels were then developed for 2-6 min in developing solution (240 mM 
sodium carbonate, 0.0075% (v/v) formaldehyde): once bands had appeared the 
developer was removed and replaced with stopping solution (39 mM EDTA), for a 
period of 10 min. Finally, the gel was washed three times for 5 min each with water. 
The gel was then ready for fixing (Method 2 3 .9b ) and drying between cellulose 
membranes (Method 2.3.9c)
Method 2.3.8d: Detection o f S35-labelledproteins by autoradiography 
Dried gels or blots containing radiolabelled proteins were taped into autoradiography 
cassettes and exposed to film (blue-sensitive X-ray film; Genetic Research 
Instrumentation Ltd, Dunmow, U.K.) for 1-4 weeks, depending on strength of signal.
Method 2.3.8e: Detection ofRNA by silver staining
A 'Silver Stain Kit' silver-staining kit was used, supplied by BioRad Laboratories, and 
the manufacturer's instructions were followed carefully.
Once urea-polyacrylamide gels were run, they were removed from the glass plates, 
placed in a glass tray containing sufficient 'Fixative Solution 1' (40% (v/v) methanol) to
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completely immerse the gel, and the tray was placed on a moving platform at room 
temperature for 30 min. In a similar fashion, gels were then incubated in 'Fixative 
Solution 2' (10% (v/v) ethanol) for 15 min, in a fresh quantity of 'Fixative Solution 2' 
for a further 15 min, and in oxidizing solution (1/10 dilution of 'Oxidizer concentrate' 
(BioRad Laboratories)) for 5 min. Several water washes were then carried out over a 
15-min period. The gels were then placed in the 'Silver Reagent' for 20 min, washed in 
water for 20-30 s, and then placed in 'Developer Solution' ('Developer' solid (BioRad 
Laboratories) was dissolved in water: 32 g/1) for -30 s or until a brown precipitate was 
visible in the solution. Fresh quantities of 'Developer' were added in this way until an 
optimal balance between background and positive bands was judged to have been 
reached. The gel was then soaked in 5% acetic acid for 15 min to stop the reaction. 
Finally, the gel was fixed (Method 23.9b) and dried between cellophane sheets 
(Method 2.3.9c).
2.3.9 Processing of gels and membranes
Method 2.3.9a: Enhancement of SDS-polyacrylamide gels for autoradiography
Gels were enhanced as described by Craft et ad. (1988) (66). After removal from glass 
plates, SDS-polyacrylamide gels containing radiolabelled samples were soaked in 0.5 
M sodium salicylate for 15 min. Gels were then fixed (Method 23.9b) for 30 min, 
before drying onto blotting paper (Method 2.3.9c).
Method 2.3.9b: Fixing polyacrylamide gels
After removal from glass plates each gel was placed in a tray containing sufficient 
fixative solution (methanol:water:glacial acetic acid, 4.5:4.5:1) to completely submerge 
it. The tray was placed on a moving platform for at least 30 min (or overnight).
Method 2.3.9c: Drying polyacrylamide gels
All gels were dried using a Rapidry gel dryer (ATTA Electrophoresis) attached to a 
Vacuum pump (Pump PV 300, Hoeffer Scientific Instruments U.K., Newcastle-under- 
Lyme, U.K.). Each gel was placed onto a clean glass plate. A larger piece of blotting 
paper was then placed over the gel, and gently pressed against it. The blotting paper 
was slowly peeled away, bringing the gel with it. Alternatively, the gel was placed 
between two sheets of cellophane (Cellophane Membrane Backing, BioRad 
Laboratories) before being placed onto filter paper. A larger piece of cling-film was 
placed over the whole gel and its coverings, before being placed onto the drying 
platform; the gel-dryer covers were closed, the vacuum applied, and gels were dried at 




All comparisons were performed by %2-analysis of 2 x 2 contingency tables. This test is 
suitable for comparing the distribution of a discrete variable in one sample with the 
distribution of the same discrete variable in another sample where there are only two 
possible values of the discrete variable. Using Table 2.2 below as a guide, the value of 
X2 (the test statistic) is calculated using the following formula:
X2 = (ad-bc)2 . N
U . t 2 .n i  .n 2
The significance level of P<0.05 was used, and X2 values were assessed according to 
the tables of Fisher & Yates (92).
It should be noted, however, that a X2-test is inappropriate in cases where N<20, or if 
20<N<40 and the smallest expected value is less than five (59) (i.e. the value expected 
if the Null hypothesis (no difference between the populations) was correct). In cases 
where the values were small, but appropriate for a X2-analysis, a correction factor for 
continuity was used, as divized by Yates (372). Yates' correction was included when 
N<100, and/or any cell contained a number less than ten. The following formula was 
used for calculating the value of X2 when Yates' correction was required:
X2 = { (|a d -b c |)-N /2 }2 .N
t l . t2 . n i . n2
TABLE 2.2 Standard 2 x 2  contingency table for %2-analysis of discrete variables
Discrete variable
Y Z Total
Population l a  b tj=a+b
Population 2 c d t2 =c+d




Characterization of anti-nucleolar antibody reactivity in systemic 
sclerosis patients and their relatives
3.0 SUMMARY
The prevalence and specificity of ANAs and ANoAs in 58 SSc probands, four first- 
degree relatives with SSc, 215 first-degree relatives without SSc, and their 24 spouses 
were studied. All sera were screened for ANAs, ACAs, and ANoAs by IF. Nuclear and 
nucleolar autoantigens were then characterized by IP of 35S-methionine-labelled K562- 
cell extracts; ANAs were also identified by Ouchterlony double immunodiffusion.
Antinuclear-IF was present in 51 patients with SSc (82.3%), in 50 SSc-free relatives 
(23.3%), and in six spouses (25.0%). Antinucleolar-IF was detected in 25 SSc patients 
(40.3%), in 33 SSc-free relatives (15.3%), and in four spouses (16.7%). Forty-three sera 
had autoantibodies to defined nuclear antigens, including eleven with anti-RNAP III, 
nine with anti-RNAP II, eight with anti-topo I, and 13 with ACAs. All but two were 
from SSc patients: anti-Ro/La antibodies were detected in two first-degree relatives, 
one with SLE, and one with PA. Twenty-four sera had autoantibodies to defined 
nucleolar antigens by IP (seven Pm-Scl, ten RNAP I, four U3 RNP and three Th RNP), 
and all were from patients with SSc (38.7%). No serum was found to contain more than 
one defined ANoA. Furthermore, ACAs, anti-topo I antibodies, and each of the defined 
ANoAs appeared to be mutually exclusive. Four sera had autoantibodies to topo I and 
RNAP II, one of which also precipitated RNAPs I and III. The disease subtype 
associations of the defined ANoAs were consistent with previous reports.
Sera from 118 randomly chosen family members without CTDs were then 
separately compared with 120 age- and sex-matched blood-donor controls to determine 
whether they had an increased frequency of ANAs or ANoAs to that expected. 
Antinucleolar-IF was significantly more common in the unaffected first-degree relatives 
of SSc patients (18.1%), but not in their spouses (7.7%), when compared with controls 
(8.3%; P<0.05). Most of the IF-ANoA-positive sera from relatives displayed only a 
weak staining pattern. During subsequent IP studies, strong bands were precipitated by 
a small number of sera from blood-relatives (12; 5.6%), spouses (one; 4.2%), and 
normals (three; 2.5%), although none was identified as an SSc-specific autoantigen.
Thus, although antinucleolar reactivity was more common in the first-degree 
relatives of SSc patients than in normal controls, SSc-associated ANoAs were only 
present in individuals with the disease, and appeared to be mutually exclusive. 
Together, these results confirm the remarkably close association between the expression 
of certain defined ANoAs and the presence of SSc, while suggesting that a heritable 
factor may cause the nucleolus to become a focus of the immune response in both SSc 
patients and their blood-relatives. The autoantibodies detected in some healthy relatives 
of SSc patients may represent alternative responses to this shared susceptibility factor: 
the lack of certain other pro-pathological factors in vivo could have protected against 
disease onset, and may also have prevented the particular nucleolar antigen processing 
pathways which are required for the generation of SSc-specific ANoAs.
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3.1 INTRODUCTION
The work described in this chapter concerns the initial detection and characterization of 
antinuclear and antinucleolar reactivities in the serum samples contributed by the U.K. 
SSc Study Group, viz. 58 SSc patients (the probands), four of their first-degree relatives 
with SSc, 215 of their first-degree relatives without SSc, and 24 spouses of the SSc 
patients. The directive was to screen all sera for anti-cytoplasmic, antinuclear and 
antinucleolar reactivities by IF. Each sample was also to be tested by immunodiffusion. 
All positive results were to be further investigated by IP using 35S-methionine-labelled 
K562-cell extracts: defined ANA and ANoA specificities would then be identified, and 
any novel autoantibody systems would be further investigated. The disease subtype 
associations of the defined ANoAs detected in the patient group would also be 
examined.
In addition, the relative prevalences of antinuclear and antinucleolar reactivities in 
probands, relatives and spouses were compared, and sera from 118 randomly chosen 
CTD-free family members were separately compared with 120 age- and sex-matched 
blood-donor controls to determine whether they had an increased frequency of ANAs 
and/or ANoAs to that expected.
3.2 MATERIALS AND METHODS
Clinical details and serology
Clinical details were supplied for the 58 probands with SSc, 219 of their first-degree 
relatives and the 24 spouses (for complete details see Appendix IV), all of which were 
Caucasian. All families were British, apart from two Russian families (Families NRM 
and NRT), and three from the United States (Families NAA, NAB and NAC). Some 
families were selected on the basis of more than one member having a CTD -  a total of 
four families had two members with a diagnosis of SSc (Families I, NAA, NRM and 
NRT). Serum samples from all probands and family members were supplied to our 
laboratory, and stored as described (Section 2.1.3).
Protocols regarding clinical examination, diagnosis and disease subtype assignation 
of patients and their family members are described in Section 2.1.2. All features 
characteristic of a CTD were recorded. All probands and four consanguineous relatives 
were confirmed as fulfilling the required criteria for SSc (218). Of the probands, 23 
(39.7%) had dc-SSc, and 35 (60.3%) had Ic-SSc. Most of the probands were female 
(91%). A further 12 consanguineous relatives were diagnosed as having a different 
CTD (two SLE, one SLE/Pm overlap, three RA, one morphea (and hyperthyroid), and 
one chronic active hepatitis); in addition, 62 relatives (26%) without SSc had symptoms 
of RP, three had PA, and two more had hyperthyroid. The 120 age- and sex-matched
control sera were obtained from a blood-bank.
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Immunofluorescence
All serum samples were screened by IF (Method 2.3.2) using (i) HEp-2 slides prepared 
in-house (Method 2.2.3), and (ii) commercially obtained HEp-2 slides (Biodiagnostics 
Ltd). Antinuclear and antinucleolar IF intensities were each scored as negative (-), very 
weak (+/-), weak (+), moderate (++), strong (+++) or very strong (++++). A score o f ' 
was assigned only to those samples displaying minimal background staining (Fig. 3.1a; 
the samples shown in Figs 3.1& and 3.1c were assigned nuclear staining scores o f '+/-' 
and V , respectively, and are shown for comparison). Only those samples with a score 
of V  and above were counted as positive. Cytoplasmic staining was also recorded, 
since such patterns are indicative of antibodies recognizing mitochondrial-E2, 
ribosomal RNP (rRNP), PL-7 and Jo-1 antigens, which are sometimes found to occur in 
SSc sera. A variety of prototype anti-cytoplasmic (Fig. 3.2a-c), antinuclear (Fig. 
3.3a,c,e,g) and antinucleolar (Fig. 3Aa,c,e,g,h) sera with previously defined specific­
ities were included as positive controls, and to aid with pattern identification.
In addition, all sera from family members who had SSc, SLE, Pm, morphea or PA 
were excluded before randomly selecting 105 sera from first-degree relatives (mean age
47.5 yr, S.D. 22.4 yr; range 7-88 yr; 49.5% male) and 13 sera from spouses (mean age
59.1 yr, S.D. 15.8 yr, range 40-87 yr; 91.7% male), which were intermingled with 120 
normal control sera (mean age 50.9 yr, S.D. 12.3 yr, range 26-85 yr; 50.0% male). A 
double-blind study was then conducted, comparing antinuclear and antinucleolar IF 
intensity scores at a 1/40 dilution using slides from Biodiagnostics Ltd.
Immunodiffusion
Sera from all probands and family members were screened by immunodiffusion 
(Method 2.3.1) using RTE (Pel Freez Ltd), TIE (Bradsure Biologicals Ltd), RLE 
(Bradsure Biologicals Ltd) and CTE (in-house preparation) as the sources of antigens.
Radioimmunoprecipitation
For the identification of defined ANoAs, all samples showing any trace of nucleolar 
staining by IF (+/- or greater) were further tested by IP. Also, all patients with a defined 
CTD, and sera with moderate or strong nuclear staining by IF (at least ++), were tested 
by IP in order to detect any ANoAs missed by the other methods: a strong anti-nuclear 
pattern can mask a weaker anti-nucleolar reactivity occurring in the same serum, and 
sera with anti-RNAP antibodies in particular may recognize both nuclear and nucleolar 
constituents (Fig. 3.5a). All samples showing a positive result by immunodiffusion 
were also tested, as were those sera with distinct cytoplasmic patterns by IF.
Immunoprecipitation of 35S-methionine-labelled K562-cell extracts was performed 
as described (Method 2.3.3a). Antinucleolar antibody specificities were identified by 
comparison with a set of reference antinucleolar sera (Pm-Scl, U3 RNP, Th RNP and 
RNAP I/II/III: kind gift from Dr Joe Craft, Yale University School of Medicine, 
U.S.A.; Fig. 3.6). Antinuclear specificities, including those detected by
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immunodiffusion, were also identified, by comparison with prototype sera of defined 
autoantibody specificities from our own laboratory (topo I, Jo-1, PL-7, Ku, 
UlRNP±Sm, Ro, and La; Fig. 3.6).
3.3 RESULTS 
Immunofluorescence
Although many ACAs, ANoAs and ANAs were detected using the in-house prepared 
HEp-2 slides, background fluorescence was a problem. It was for this reason that 
commercially available slides were sought: these were found to give a superior result, 
with less background staining and a generally cleaner appearance which was easier to 
read. Consequently, only those results obtained using commercial slides are reported 
and illustrated here.
Of the 62 sera from SSc patients (58 probands and four relatives), 61 (98.4%) had 
positive IF scores (centromere, nuclear and/or nucleolar). Thirteen sera (21.0%) showed 
the characteristic centromere staining pattern (Table 3.1; Fig. 3.3/), including four 
patients from two multicase families (samples NAA1 and 2, NRT1 and 2; (226)). Sixty- 
six (30.7%) of the 215 SSc-free relatives, and seven spouses (29.2%), had positive 
nuclear and/or nucleolar IF. None of the SSc-free family members showed any trace of 
ACAs.
Nuclear staining
Excluding sera displaying only nucleolar patterns, positive staining of the nucleus 
and/or nucleoplasm was found in 51 SSc patients (82.3%; Figs 3.2d, 3.3b,d, 3Ab,f, 
3.5a,b and 3.1b,c), 50 SSc-free relatives (23.3%; Figs 3.3i, 3.8c,g) and six spouses 
(25.0%) (Table 3.2). These results were significantly different when comparing SSc 
patients with either SSc-free relatives or spouses (Table 3.2). Of the twelve family 
members with a moderate or stronger ANA (Table 3.3), one had SLE/Pm, one had RA, 
one had morphea, five had RP, and one had PA. Examples of cytoplasmic staining 
detected in SSc patients and SSc-free relatives can be seen in Figs 3.1 b, 3.2d, 3Ab,f, 
and 3.1b,d, and in Fig. 3.8b,f,g,h respectively.
Nucleolar staining
Positive staining of the nucleolus was found when testing sera from 25 SSc patients 
(40.3%; Figs 3.2d, 3.3b, 3Ab,d,f,h, 3.5b, and 3.1a,c,d), 33 SSc-free relatives (15.3%; 
Figs 3.3* and 3.8c,f,g,h) and four spouses (16.7%) (Table 3.2), and these results were 
significantly different when comparing SSc patients with SSc-free relatives (Table 3.2). 
Moderate or stronger nucleolar staining was also significantly more frequent in sera 
from SSc patients (20 patients; 32.3%) than from SSc-free relatives (eleven; 5.1%), and
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was absent in the case of spouses (Table 3.2). Of the eleven family members with a 
moderate or stronger ANoA (Table 3.3), three had RP and one had thyroid disease.
ANA and ANoA in relatives compared to controls
Anti-nucleolar IF was significantly more frequent in sera from CTD-free first-degree 
relatives than from age- and sex-matched blood-donor controls (P = 0.029; 5C2-test) 
(Table 3.4). As indicated, most of the difference between the two groups was accounted 
for at a weak level of reactivity (+)• Nuclear IF was not significantly different between 
the three groups (Table 3.4).
Immunodiffusion
Nineteen sera from patients with SSc (30.6%) had precipitating antibodies by 
immunodiffusion (Tables 3.1 and 3.5; Fig. 3.9); sixteen of these were identified by this 
method (Fig 3.9), and the remainder were identified by subsequent IP. The antibodies 
identified in SSc patients by immunodiffusion recognized topo I (8), Pm-Scl (3), Jo-1
(2), U1 RNP (4), Sm (1), Ro (2) and La (1). No serum recognized both Pm-Scl and topo 
I, and no serum was found to contain both ACAs and anti-topo I antibodies.
None of the spouses, and only four SSc-free relatives (1.9%) had precipitating 
antibodies by immunodiffusion. Of these four relatives, one had SLE, one had RP, and 
one had PA. By immunodiffusion, both the SLE serum (BC4) and the PA serum (U8) 
had antibodies to Ro and La (Table 3.1; Fig. 3.9), results which were later confirmed by 
IP. The specificities of the other two sera (BE6 and LJ7) could not be identified (Table
3.6) by either immunodiffusion (Fig. 3.9) or subsequent IP (Fig. 3.11).
Radioimmunoprecipitation 
Defined antinuclear specificities
All specificities determined by immunodiffusion were confirmed by IP, and several 
more were detected (Table 3.1). Although IP is not a suitable method for the detection 
of ACAs, all sera positive for ACAs by IF were tested for the presence of other 
specificities (Fig. 3.10), but none was detected. Excluding ACAs, a total of 30 sera (28 
SSc, one SLE/Pm and one PA) had autoantibodies to a defined nuclear antigen (Ro (6 
sera; Fig. 3.11), La (4 sera; Fig. 3.11), U1 RNP (5 sera; Fig. 3.11), Sm (one serum; Fig. 
3.11), Ku (one serum; Fig. 3.12), Jo-1 (three sera; Fig. 3.11), PL-7 (1 serum), topo I 
(eight sera; Fig. 3.13a), RNAP II (nine sera; Figs 3.14 and 3.15), and RNAP III (eleven 
sera; Figs 3.14 and 3.15) (Table 3.1). A number of sera displayed multiple ANA 
specificities (Table 3.1), and will be discussed presently.
All sera found to contain ANAs of defined specificities had produced nuclear 
staining by IF (Table 3.1; Figs 33b,d ,i, 3.5b and 3.7c), but five had also produced 
nucleolar staining of an even stronger intensity (Table 3.1): in two cases this was 
explained by the subsequent detection of defined ANoAs in these sera, however, three
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ANA sera (all containing both anti-topo I and anti-Ro antibodies) had produced 
predominantly nucleolar staining patterns (Table 3.1; Fig. 3.56). While topo I is known 
to be located in both the nucleus and nucleolus, this was an interesting result, especially 
when compared with the staining pattern produced by a typical anti-topo I serum (Fig. 
3.3*).
Defined antinucleolar specificities
Of the 62 SSc patients, 70 SSc-free relatives and eight spouses whose sera were tested 
by IP, 24 were found to have autoantibodies to a defined nucleolar antigen (RNAP I 
(ten sera; Figs 3.14 and 3.15), Pm-Scl (seven sera; Figs 3.15 and 3.16), U3 RNP (four 
sera; Figs 3.15 and 3.17), and Th RNP (three sera; Fig. 3.15) (Table 3.5). All of these 
were from SSc patients (38.7%).
All sera with anti-U3 RNP specificities had produced a distinct clumpy nucleolar 
pattern on IF (Table 3.5; Fig. 3Ah). Anti-Th RNP and anti-Pm-Scl antibodies had also 
produced staining of the nucleolus, though this was occasionally obscured by additional 
nucleoplasmic staining (Table 3.5; Fig. 3 Ad  and/, respectively). All anti-RNAP I sera 
were also found to contain anti-RNAP III antibodies (Table 3.5), and all had produced 
positive staining of the nucleoplasm by IF (Table 3.5; Figs 3.46 and 3.5a): while RNAP 
I is a nucleolar enzyme, RNAPs II and III are located in the nucleoplasm.
Sera containing multiple defined specificities
Four sera were found to precipitate both topo I and the metabolically active, 
phosphorylated (IIO) form of RNAP II, and three of these also precipitated the inactive, 
unphosphorylated form of the enzyme (RNAP IIA) (Table 3.1; Figs 3.136 and 3.18). 
However, unlike anti-RNAP I and anti-RNAP III, anti-RNAP II antibodies are not 
specific for SSc, and have recently been reported in SLE and MCTD sera (297). Apart 
from sera with antibodies to both RNAP I and RNAP III (which are known to share 
structural homologies), only one serum was found to contain more than one SSc- 
specific antibody, viz. sample II, which precipitated RNAPs I, IIO, IIA and III, as well 
as topo I (Table 3.1; Fig. 3.136). Altogether 14 sera precipitated one or more RNAP 
complex. Antibodies to the three classes of RNAP in SSc, and their relationship to topo 
I antibodies, are investigated in detail in Chapter 4 (see also (128,299)). The three anti- 
topo I sera which also contained anti-Ro antibodies have already been mentioned 
(Table 3.1).
Undefined specificities
Twenty-nine of the immunoprecipitated samples (eight SSc patients (12.9%), 20 SSc- 
free relatives (9.3%) and one spouse (4.2%)) produced bands of unknown specificity, 
including samples from four probands that also had defined SSc-specific autoantibodies 
(Table 3.6; Figs 3.19 and 3.20). A band o f -115 kDa occurred in four SSc patients and 
seven SSc-free family members, including the spouse and three sisters of a proband
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with anti-Ul RNP antibodies (Table 3.6; Fig. 3.20). However, many of the unidentified 
IP bands were weak, and strong unidentified bands were precipitated by sera from six 
SSc patients (9.7%), twelve SSc-free relatives (5.6%) and one spouse (4.2%) (Table
3.6).
A variety of staining patterns had been produced by these sera by IF (Table 3.6) 
including cytoplasmic, nuclear and nucleolar staining (Fig. 3.8), but no consistent 
pattern was produced by the eleven samples which had been found to precipitate a band 
of ~115 kDa (Table 3.6; Figs 3.1b,c,d and 3.8b,c,f)
Of the 32 normal sera selected for IP (by the same criteria), a smaller, though 
comparable, proportion also showed the presence of unidentified bands by IP (seven 
(5.8%); Fig. 3.21), though only three were strong (2.5%; Fig. 3.21), and none was 
found to precipitate a band of ~115 kDa.
Clinical associations
Associations between autoantibody specificities in sera from probands, and disease 
subtypes, are shown in Table 3.7. That the majority of ACAs occurred in patients with 
lc-SSc was consistent with previous reports, while the 50:50 distribution of anti-topo I 
antibodies between limited and diffuse disease was less typical (349). Both RNAP-II 
and RNAP-III antibodies were found to be more common in dc-SSc.
Clinical associations with each type of ANoA were consistent with other studies: 
antibodies to Pm-Scl and to Th RNP were associated with lc-SSc (251,252), while 
antibodies to U3 RNP and to RNAP I were associated with diffuse disease (254,278). In 
contrast to previous reports (278), however, no patients with antibodies to RNAP I had 
renal disease despite a minimum period of follow-up of five years (207). The lack of 
renal disease in the total proband group may reflect a bias in selection of suitable 
families to study, however (Dr N.J.McHugh, pers.comm.). There was no apparent 
association of ANoAs with RP in SSc-free relatives (data not shown).
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TABLE 3.1 Sera from SSc patients and their relatives found to contain antinuclear 
antibodies of defined specificities. Specificities were identified by radio- 












LI F lc-SSc ACA§ ++++cent.
MB1 F dc-SSc - ACA§ ++++cent. -
MCI F dc-SSc - ACA§ ++++cent. -
NAA1 F lc-SSc - ACA§ ++++cent. -
NAA2 F lc-SSc Sister ACA§ +++cent. -
NAB1 F dc-SSc - ACA§ +++cent. -
NAC1 F dc-SSc - ACA§ -H-H-cent. -
NRT1 F lc-SSc - ACA§ ++++cent. -
NRT2 F lc-SSc Id. twin ACA§ +++cent. -
01 F lc-SSc - ACA§ +cent. -
PI F lc-SSc - ACA§ -H-cent. -
SD1 F lc-SSc - ACA§ ++++cent. -
XI F lc-SSc - ACA§ ++++cent. -
SF1 F dc-SSc - RNAP III +f.sp +sp.
BE1 F dc-SSc - RNAP I,III# +++dis.sp. +sp.
LC1 F dc-SSc - RNAP I,III ++dif.gr.sp. *
SHI F lc-SSc - RNAP I,III +f.sp. +sp.
U1 F dc-SSc - RNAP I,in +++h. ++h.
BG1 F lc-SSc - r n a p  i,no,nA ,III +f.sp. -
U 1 F dc-SSc - RNAP I,nO,IIA,III +++h./gr.sp. *
N1 F dc-SSc - RNAP I,IIO,IIA,m -j-dis.sp. -
SE1 F dc-SSc - RNAP I,IIO,IIA,III ++++h./sp. *
VI F dc-SSc - RNAP I,IIO,IIA,m ++f.sp. ++++sp.
11 M dc-SSc - RNAP I,IIO,IIA,III,topo It +++f.sp. +++sp.
13 F dc-SSc Daughter RNAP IIO,IIA,topo It +++h.sp. -
NRM2 F lc-SSc Daughter RNAP IIO,IIA,topo It,Rot,La -H-f.Sp +++sp.
LAI M lc-SSc, dLE - RNAP no,topo It ++++h./f.sp. -
LD1 F dc-SSc, Mor - topo It +cs.sp. -
MD1 F lc-SSc - topo It +++h./sp. +
MK1 M dc-SSc - topo It,Rot,Lat ++f.sp. +++sp.
NRM1 F lc-SSc - topo It,Ro ++dif.f.sp. +++h.
BB1 F dc-SSc - Jo-1# ++gr.sp. +
M il F lc-SSc - Jo-lt +++sp. -
MM1 F lc-SSc - Ku ++++sp. -
G1 F lc-SSc - PL-7, Pm-Scl -H-f.sp. +++h.
BC4 F SLE/Pm Mother Rot, Lat ++f.sp. -
LJ8 M PA Father Rot, Lat ++++sp. +
LK1 F lc-SSc - Ro +++dis.cs.sp. -
BC1 F lc-SSc - U1 RNPt,Smt, Jo-lt ++++f.sp. -
BD1 F dc-SSc - U1 RNPt ++++cs.dif.sp. -
LG1 F lc-SSc - U1 RNPt ++++cs.sp. -
MN1 F lc-SSc - U1 RNPt ++++dif.cs.sp. -
SGI F dc-SSc - U1 RNP±Sm +f.sp. -
*The staining pattern of the nucleolus was not distinct from the nucleoplasmic pattern.
^Identified by immunodiffusion
identified by indirect immunofluorescence (IF)
Ifor IF scoring system definitions, see text
#Precipitin detected but not identified by immunodiffusion
lc-SSc, limited cutaneous SSc; dc-SSc, diffuse cutaneous SSc; dLE, discoid lupus erythematosus; Mor, 
morphea; SLE, systemic lupus erythematosus; Pm, polymyositis; PA, pernicious anaemia; ACA, anti­
centromere antibody; RNAP, RNA polymerase; topo I, topoisomerase I; cent, centromere; f. fine; dif. 
diffuse; dis. discrete; cl. clumpy; gr. grainy; sp. speckled; h. homogeneous; cs. course
1 0 0
TABLE 3.2 Comparison between indirect immunofluorescence scores of sera from SSc patients and from their SSc-free family members




Negative - 9 (14.5) 111 (51.6)
± 2 (3.2) 54 (25.1)
Positive* + 12 (19.4) 39 (18.1)
++ 10 (16.1) 6 (2.8)
+++ 14 (22.6) 3 (1.4)
++++ 15 (24.2) 2 (0.9)
Total positive (+)* 51 (82.3)* 50 (23 .3)









13 (54.2) 37 (59.7) 158 (73.5) 16 (66.7)
5 (20.8) 0 (0.0) 24 (11.2) 4 (16.7)
5 (20.8) 5 (8.1) 22 (10.2) 4 (16.7)
1 (4.2) 3 (4.8) 7 (3.3) 0 (0.0)
0 (0.0) 9 (14.5) 3 (1-4) 0 (0.0)
0 (0.0) 8 (12.9) 1 (0.5) 0 (0.0)
6 (25.0) 25 (40.3)1 33 (15 .3) 4 (16 .7)
1 (4 .2) 20 (32 .3)# 11 (5 .2 ) 0 (0 .0)
Figures in parentheses are percentages 
♦Positive sera had a score of at least"+"
^Number of sera positive when using "++" as cut-off point for positivity 
*P < 0.0001 compared with either relatives or spouses (X2-test)
Ip < 0.0001 compared with relatives (X2-test); not significant compared with spouses, but note low titre in the four spouses: on using ++ as cut-off point for positivity* ANoAs are significantly more frequent 
in patients than in relatives (P < 0.0001) or spouses (P < 0.005) (X2-test)
TABLE 3.3 Clinical status of SSc-free family members whose sera produced 
















BA2 Sister ++++h. 90/92/95
BC4 SLE/Pm Mother ++f.sp. - - Ro+, Lat
BC6 Arthritis Sister ++dis.cs.sp. 47- - -
BD3 RP Sister +++f.sp. +/- 115 -
BD5 RP Sister +++g.sp. +sp. 115 -
BE6 RP Mother +/-g.sp. +++sp. 115# -
BG3 - Husband ++f.sp. - - -
F2 RP Mother +++cs.sp. +++sp. 15 (wk) -
U 8 PA Father ++++sp. + - Rot, Lat
MC2 - Daughter +/-f.sp. -H-Cl. - -
MD3 - Sister +sp. 4-4-sp./cl. - -
MD5 RP Brother -H-Sp. ++sp./cl. - -
MD9 - Son +sp. +++sp. 115 -
MI2 - Sister ++cs.sp. - - -
M 02 - Son +sp. ++sp. - -
NA3 Morphea Sister ++++dis.sp. - - -
NR2 - Sister +sp. ++sp. - -
05 - Father - 4-+Sp./cl. 49 -
SC6 - Grandfather -H-CS.Sp. +sp. 37 (wk) -
SG2 RP Mother ++sp. - - -
V8 Hyperthyroid Sister - ++h. - -
tIdentified by immunodiffusion
!for indirect immunofluorescence (IF) scoring system, see text 
# Precipitin detected but not identified by immunodiffusion
IP, immunoprecipitation; SLE, systemic lupus erythematosus; Pm, polymyositis; RP, Raynaud's 
phenomenon; PA, pernicious anaemia; f, fine; sp, speckled; dis, discrete; cs, course; g, grainy; h, 
homogeneous; cl, clumpy.
1 0 2
TABLE 3.4 Comparison between indirect immunofluorescence scores of sera from randomly selected connective tissue disease-free family members and 
normal controls
















66 (62.9) 10 (76.9) 82 (68.3) 77 (73.3) 9 (69.2) 101 (84.2)
± 21 (20.0) 3 (23.1) 23 (19.2) 9 (8.6) 3 (23.1) 9 (7.5)
Positive* + 11 (10.5) 0 (0.0) 9 (7.5) 13 (12.4) 1 (7.7) 4 (3.3)
++ 6 (5.7) 0 (0.0) 6 (5.0) 5 (4.8) 0 (0.0) 6 (5.0)
+++ 1 (1.0) 0 (0.0) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0-0)
++++ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0-0) 0 (0.0) 0 (0.0)
Total positive (+)* 18 (17 .1 ) 0 (0 .0) 15 (12 .5) 195 (18 .1 ) 1 (7 .7 ) 10 (8 .3 )
Total positive (++)t 7 (6 .7 ) 0 (0 .0) 6 (5 .0) 6 (5 .7 ) 0 (0 .0 ) 6 (5 .0 )
Figures in parentheses are percentages 
*Positive sera had a score of at least"+"
^Number of sera positive when using "++" as cut-off point for positivity 
5P < 0.05 compared with normal controls (X2-test).
TABLE 3.5 Sera from SSc patients found to contain antinucleolar antibodies of 











BA1 F dc-SSc Pm-ScP + f.sp. ++h.
El F dc-SSc Pm-Scl# Neg. +++cl./sp
G1 F lc-SSc Pm-ScP, PL-7 -H-f.sp. +++h.
LEI F lc-SSc Pm-ScP Neg. +++h.
MP1 F lc-SSc Pm-Scl Neg. +++cl.
NA1 F lc-SSc Pm-Scl# ++f.sp. ++++sp.
SCI F lc-SSc Pm-Scl +++h. *
BEI F dc-SSc RNAP I,III# +++dis.sp. +sp.
BG1 F lc-SSc RNAP i,n ,m +f.sp. ♦
11 M dc-SSc RNAP I,II,III,topo P -HH-f.sp. +++sp.
LC1 F dc-SSc RNAP I,in -H-dif.gr.sp. *
U 1 F dc-SSc RNAP i,n ,m +++h./gr.sp. *
N1 F dc-SSc RNAP i,n ,m +dis.sp. *
SE1 F dc-SSc RNAP I,n,IH ++++h./sp. *
SHI F lc-SSc RNAP I,III +f.sp. +sp.
U1 F dc-SSc RNAP I,III +++h. ++h.
VI F dc-SSc RNAP i,n ,m -f+f.sp. ++++sp.
LL1 F lc-SSc, arthritis Th RNP +++h./sp. *
MAI F lc-SSc Th RNP +/-f.sp. ++++sp.
SI1 F lc-SSc Th RNP +sp. +++cl.
B1 F lc-SSc U3RNP Neg. ++++cl./sp.
SA1 F dc-SSc U3RNP Neg. ++++cl.
T1 F dc-SSc U3RNP Neg. ++++cl.
W1 F dc-SSc U3RNP Neg. ++++cl.
*The staining pattern of the nucleolus was not distinct from the nucleoplasmic pattern. 
tAlso identified by immunodiffusion
lfor indirect immunofluorescence (IF) scoring system, see text 
#Precipitin detected but not identified by immunodiffusion
IP, immunoprecipitation; lc-SSc, limited cutaneous SSc; dc-SSc, diffuse cutaneous SSc; RNAP, RNA 
polymerase; topo I, topoisomerase I; h. homogeneous; cl. clumpy; sp. speckled; f. fine; dif. diffuse; gr. 
grainy; dis. discrete.
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TABLE 3.6 Sera from SSc patients and their family members found to precipitate 
















A1 F lc-SSc 140 ++++h.
A2 M - Father 105 (wk) - - +h.
B1 F lc-SSc - 49,57,115,190 U3RNP - ++++cl./sp.
B8 F - Sister 18 (wk) - +cs.sp. +h.
BA2 F - Sister 90,92,95 - - ++++h.
BA3 F - Twin sister 65 - +!- +/-
BB2 F - Sister 35 (wk) - +/-f.sp. +h.
BD2 M - Husband 115 - +f.sp. +sp.
BD3 F RP Sister 115 - -H-+f.Sp. +/-
BD5 F RP Sister 115 - +++gr.sp. +sp.
BD7 F - Sister 115 - - -
BE6 F RP Mother 115# - +/-gr.sp +++sp.
E6 F - Sister 130 (wk) - - + /-
F2 F RP Mother 15 (wk) - +-H-CS.Sp. -HH-Sp.
14 F - G.daughter 28,30 - +/-cs.sp. -
K1 F lc-SSc - 115 (wk) - ++cs.sp. -
LA6 M - Father 190 (wk) - +sp. +sp.
LJ7 F - Mother 115# - +f.sp. -
LK1 F lc-SSc - 115 Ro +++dis.cs.sp. -
MD9 M - Son 115 - +sp. +++sp.
MJ2 M - Son 17 (wk) - - +sp.
MOl F lc-SSc - 20 (wk) - - ++cl.
NR1 F SSc - 25 - +gr.sp. -
NRM1 F lc-SSc - 115,125 topo It,Ro -H-dif.f.sp. +++h.
NRM7 M RP Son 25 (wk) - +/-sp. +/-
05 M - Father 49 - - ++sp./cl.
SCI F lc-SSc - 240 Pm-Scl +++h. *
SC3 F - Sister 37 (wk) - +/-gr.sp. +/-
SC6 M - G.father 37 (wk) - ++cs.sp. +sp.
*The staining pattern of the nucleolus was not distinct from the nucleoplasmic pattern 
+Identified by immunodiffusion
*for indirect immunofluorescence (IF) scoring system, see text 
#Precipitin detected but not identified by immunodiffusion
IP, immunoprecipitation; lc-SSc, limited systemic sclerosis; RP, Raynaud's phenomenon; wk weak; cs. 
course, sp. speckled; f. fine; gr. grainy; dis. discreet; dif. diffuse; h. homogeneous; cl. clumpy
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TABLE 3.7 Disease subtypes of probands with defined autoantibody specificities:
(a) antinuclear antibody specificities; (b) antinucleolar antibody specificities
(a) Disease subtype
lc-SSc dc-SSc
No. of probands n=35 (60.3) n=23 (39.7)
Antinuclear
antibody
ACA 11 (19.0) 7 (63.6) 4 (36.4)
Jo-1 3 (5.2) 2 (66.7) 1 (33.3)
Ku 1 (1.7) 1 (100.0) 0 (0.0)
PL-7 1 (1.7) 1 (100.0) 0 (0.0)
RNAP IIO±IIA 7 (12.1) 2 (28.6) 5 (71.4)
RNAP III 11 (19.0) 2 (18.2) 9 (81.8)
Ro±La 3 (5.2) 2 (66.7) 1 (33.3)
Topo I 6 (10.3) 3 (50.0) 3 (50.0)














Pm-Scl 7 (12.1) 5 (71.4) 2 (28.6)
RNAP I 10 (17.2) 2 (20.0) 8 (80.0)
ThRNP 3 (5.2) 3 (100.0) 0 (0.0)
U3RNP 4 (6.9) 1 (25.0) 3 (75.0)
Total positive: 24 (41.4)
Figures in parentheses are percentages.
*ten sera had more than one of these antinuclear antibody specificities
ACA, anti-centromere antibody; RNAP, RNA polymerase; topo I, topoisomerase I; lc-SSc, limited 
cutaneous systemic sclerosis; dc-SSc, diffuse cutaneous SSc
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FIGURE 3.1 Indirect immunofluorescence scoring system. (a ) Negative (-) 
staining pattern produced by a prototype normal human serum taken from a healthy 
donor. (b ) Serum from proband SB1 had a negative nucleolar score and barely 
discernible (+/-) nuclear staining, which was counted as negative; stronger cytoplasmic 
staining was also evident, but no autoantibodies were subsequently identified, (c) 
Control serum NS27, from a healthy donor, produced weak, diffuse fine speckled 
nuclear staining (+), sparing the nucleolus. However, no autoantibodies were detected 
by other serological tests.
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FIGURE 3 .2  Indirect immunofluorescence: cytoplasmic patterns produced by 
sera with defined autoantibody specificities from patients with connective tissue 
diseases, (a) Course speckled cytoplasmic pattern produced by a prototype anti- 
mitochondrial-E2 serum from a patient with primary biliary cirrhosis. (b) Fine speckled 
cytoplasmic pattern produced by a prototype anti-ribosomal RNP (rRNP) serum from 
an SLE patient; speckled staining of the nucleus was also apparent (c) Very fine 
speckled cytoplasmic pattern produced by a prototype anti-PL-7 serum from an SSc 
patient. (d) Serum from proband BB1 produced a very fine, filamentous cytoplasmic 
pattern along with a weak grainy nuclear speckle; nucleoli can also be distinguished in 
some cells: anti-Jo-1 antibodies were subsequently identified by immunodiffusion.
FIGURE 3.3 Indirect immunofluorescence: nuclear patterns produced by sera 
with defined autoantibody specificities from  patients with connective tissue 
diseases (CTDs). {a) Homogeneous nuclear staining produced by a prototype anti-DNA 
serum from a systemic lupus erythematosus (SLE) patient. (b) Serum sample SF1 
apparently produced a weak homogeneous pattern; however, on close inspection, this 
was seen to consist of dense fine speckles, and some nucleoli were distinguishable: anti- 
RNA polym erase III antibodies were subsequently  iden tified  by 
radioimmunoprecipitation techniques (Fig. 3.13b, lane 2). (c) Diffuse, fine speckled 
nuclear staining, nucleolar sparing, produced by a prototype anti-Ro serum from an 
SLE patient. (d) Diffuse, course speckled nuclear staining, nucleolar sparing, was 
produced by sample BD1: anti-Ul RNP antibodies were subsequently identified by 
immunodiffusion (Fig. 3.11, lane 5). (e) Discrete course speckled nuclear pattern 
produced by a prototype anti-centromere serum from an SSc patient. (/) A strong, 
characteristic centromere pattern was also produced by serum sample NAC1. (g) 
Typical diffuse grainy speckled nuclear pattern with prominent nucleolar staining 
produced by a prototype anti-topoisomerase I serum from an SSc patient. (h) Diffuse, 
fine speckled/grainy nuclear pattern with nucleolar staining produced by a prototype 
anti-Ku serum from an SSc patient. (/) A diffuse, fine speckled nuclear pattern with 
occasional nucleolar staining was produced by serum LJ8 , from a family member with 
pernicious anaemia: anti-Ro and anti-La antibodies were subsequently identified by 
immunodiffusion and confirmed by radioimmunoprecipitation (Fig. 3.13, lane 9). 
(Continued overleaf...)
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FIGURE 3.3 (Continued) Indirect im m unofluorescence: nuclear patterns 
produced by sera with defined autoantibody specificities from patients with CTDs.
FIGURE 3 .4  Indirect immunofluorescence: nucleolar patterns produced by sera 
with defined autoantibody specificities from patients with SSc (a) Weak fine 
speckled nuclear staining with a speckled nucleolar pattern was produced by a prototype 
anti-RNA polymerase (RNAP) I/III serum from an SSc patient, {b) Fine speckled 
nuclear staining with a strong speckled nucleolar pattern was produced by serum VI, 
and very weak cytoplasmic staining was also seen: anti-RNAP I/II/III antibodies were 
subsequently identified by radioimmunoprecipitation (Fig. 3.14a, lane 5).(c) A speckled 
nucleolar pattern in the absence of nucleoplasmic staining was produced by a prototype 
anti-Th RNP serum, (d) A very strong speckled nucleolar pattern with feint speckled 
nuclear staining produced by serum M AI: anti-Th RNP antibodies were subsequently 
identified by radioimmunoprecipitation techniques (Fig. 3.15b, lane 7). (e ) Homo­
geneous nucleolar pattern with weaker, fine speckled nuclear staining produced by a 
prototype anti-Pm-Scl serum. (/) A homogeneous nucleolar pattern with fine speckled 
nuclear staining was produced by serum BA1, and weak grainy cytoplasmic staining 
was also visible: anti-Pm-Scl antibodies were subsequently identified by 
radioimmunoprecipitation techniques (Fig. 3.16, lane 5). (g) Characteristic clumpy 
nucleolar staining produced by a prototype anti-U3 RNP serum, (h) Strong clumpy 
nucleolar staining was produced by serum W l: anti-U3 RNP antibodies were 
subsequently identified by radioimmunoprecipitation techniques (Fig. 3.15a, lane 5). 
(Continued overleaf...)
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FIGURE 3 . 4 (Continued) Ind irect im m unofluorescence: nucleolar patterns 
produced by sera with defined autoantibody specificities from patients with SSc.
FIGURE 3.5 Indirect immunofluorescence: interpretation and significance of 
staining patterns produced by sera from patients with connective tissue diseases
(a ) A homogeneous/grainy speckled nuclear pattern was produced by serum LJ1. Anti- 
RNA polymerase (RNAP) I/II/III antibodies were subsequently identified by radio­
immunoprecipitation techniques (Fig. 3. 15a , lane 8). Although RNAP I is a nucleolar 
antigen, nucleolar staining had apparently been obscured by strong nuclear staining 
produced by anti-RNAP II and III antibodies. (b) Serum MK1 appeared to contain 
predominantly anti-nucleolar antibodies, with only weak anti-nuclear staining, but only 
antinuclear antibodies were subsequently identified (Ro, La and topoisomerase I; Fig. 
3. 13a , lane 10). While the La and topoisomerase I antigens are nuclear proteins they are 
also found in the nucleolus.
FIGURE 3.6 Radioim m unoprecipitation of prototype sera with defined 
antinuclear and antinucleolar antibody specificities. Autoradiograph of SDS-PAGE- 
separated 35S-methionine-labelled proteins immunoprecipitated from K562-cell extracts 
by serum antibodies attached to Protein-A Sepharose beads. Samples of immuno­
precipitated proteins were diluted in sample buffer xlO before loading into lanes 1-6 
(lane 1, anti-Ul RNP standard; lane 2, anti-Ro/La standard; lane 3, anti-Ku standard; 
lane 4, anti-Jo-1 standard; lane 5, anti-PL-7 standard, lane 6, normal serum). Undiluted 
radioimmunoprecipitation (IP) samples were loaded into lanes 7-12. (lane 7, normal 
serum; lane 8, anti-Pm-Scl standard; lane 9, anti-topoisomerase I standard; lane 10, anti- 
Th RNP standard; lane 11, anti-U3 RNP standard; lane 12, anti-RNA polymerase EII/III 
standard). Samples were prepared identically in all other respects, using prototype sera 
of high autoantibody titre. The technique of IP is particularly suitable for the 
identification of antibodies which recognize multimeric proteins, as a characteristic 
pattern of bands is produced (lanes 1, 3, 8, 10 and 12). However, the presence of 
antibodies which recognize monomeric proteins (lanes 2, 4, 5 and 9) can be confirmed 
by comparison with internal standards. The antigens detected in lanes 1-5 are relatively 
more abundant in K562-cell extracts than those in lanes 8-12, which are consequently 
more difficult to detect.
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FIGURE 3.7 Indirect immunofluorescence patterns produced by sera from SSc 
patients which precip ita ted  unidentified autoantigens by rad io im m uno­
precipitation. (a) A very strong homogeneous nucleolar pattern was produced by 
serum A l. Subsequent serological tests failed to identify antibodies of defined 
specificity: however, a strong, unidentified 140-kDa band was apparent by 
radioimmunoprecipitation (IP). (Fig 3.19, lane 11). (b) A discrete course speckled 
nuclear pattern was produced by serum Kl, which was distinct from the characteristic 
anti-centromere pattern, and weak cytoplasmic filaments were also visible. Although no 
antibodies of defined specificity were detected by subsequent serological tests, a weak 
115-kDa band was apparent by IP. (c) A diffuse fine speckled nuclear pattern with 
prominent nucleolar staining was produced by serum NRM1: anti-topoisomerase I 
antibodies were subsequently identified by immunodiffusion. A 100-kDa band was 
produced by IP, consistent with the presence of anti-topoisomerase I, and anti-Ro 
antibodies were also detected by IP (Fig. 3.13a, lane 5). In addition, unidentified bands 
of 115- and 125-kDa were produced on IP gels (Fig. 3.19, lane 2). (d) Clumpy/speckled 
nucleolar staining was produced by serum Bl: anti-U3 RNP antibodies were 
subsequently identified by IP techniques (Fig. 3.17, lane 5). Unusually for a serum of 
this specificity (cf  Fig. 3.4g and h), fine speckled cytoplasmic staining, and perinuclear 
staining were also produced, and additional unidentified bands were apparent by IP (Fig 
3.19, lane 13).
FIGURE 3.8 Indirect immunofluorescence: nuclear and nucleolar patterns 
produced by sera from connective tissue disease (CTD)-free relatives which 
precipitated unidentified autoantigens by radioimmunoprecipitation. (a) A very 
weak speckled nuclear and nucleolar pattern was produced by serum BA3, the healthy 
twin sister of proband BA1: no defined autoantibodies were detected by subsequent 
serological tests, but an unidentified 65-kDa band was produced by 
radioimmunoprecipitation (IP) (Fig. 3.19, lane 8 ). (b) Weak, fine speckled nuclear 
staining, nucleolar sparing, with weak speckled cytoplasmic staining was produced by 
serum from LJ7, the disease-free mother of SSc patient LJ1. Subsequent serological 
tests failed to identify antibodies of defined specificity: however, a strong, unidentified 
115-kDa band was apparent by IP (Fig. 3.20, lane 9). (c) A strong diffuse grainy 
speckled nuclear pattern with very weak speckled nucleolar staining was produced by 
serum from BD5, a disease-free sister of SSc patient BD1. Although no antibodies of 
defined specificity were detected by subsequent serological tests, a very strong, 
unidentified 115-kDa band was apparent by IP (Fig. 3.20, Lane 6 ). (d) A very weak 
nucleolar pattern was produced by serum from E6 , the disease-free sister of SSc patient 
E l. Subsequent serological tests failed to identify antibodies of defined specificity: 
however, a weak, unidentified band of 130 kDa was apparent by IP (Fig. 3.19, lane 9). 
(e) Weak nuclear and nucleolar patterns were produced by serum LA6 , the disease-free 
father of SSc patient LAI. Although no antibodies of defined specificity were detected 
by subsequent serological tests, a weak unidentified 190-kDa band was apparent by IP 
(Fig. 3.19, lane 10). if) A  strong nucleolar pattern was produced by serum BE6  with 
very weak background nuclear staining and weak cytoplasmic staining; this serum also 
produced an unidentified precipitin by immunodiffusion, and an unidentified 115-kDa 
band by IP. (g) A  strong nucleolar pattern with weak speckled nuclear staining and 
discernible cytoplasmic fluorescence was produced by serum from MD9, the disease- 
free son of SSc patient MD1. Subsequent serological tests failed to identify antibodies 
of defined specificity: however, a strong, unidentified band of 115 kDa was apparent by 
IP (Fig. 3.20, lane 5). (h) A  strong nucleolar pattern was produced by serum from BA2, 
the disease-free sister of SSc patient BA1; peri-nuclear and weak cytoplasmic staining 
is also apparent. Although no antibodies of defined specificity were detected by 
subsequent serological tests, an unidentified triplet of (90-95 kDa) was produced by IP 
(Fig. 3.18, lane 7). (Continued overleaf...)
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FIGURE 3.8 (Continued) Indirect immunofluorescence: nuclear and nucleolar 
patterns produced by sera from CTD-free relatives which precipitated 













FIGURE 3 .9  O u ch te rlo n y  double im m u n o d iffu s io n : id e n tific a tio n  o f defined  
an tin u c lear an tibody specificities in patients w ith  connective tissue diseases, (a)
Photograph and (b) schematic representation of autoantibody identification using the 
method of immunodiffusion. Central well, 50:50 mixture of rabbit thymus extract 
(RTE) and Ro/La extract (RLE); well 1, anti-Sm standard; well 3, very weak anti-La 
standard; well 5, anti-Ul RNP standard; well 7, anti-Sm standard. A line of identity is 
demonstrated between wells 1 and 7. Samples in wells 4 and 6 produced distinct 
precipitin lines and were counted as positive; an extremely weak precipitin line was also 
produced by the sample in well 2. Serum from proband BD1 (well 6) produced a line 
of identity with well 5 and a line of partial identity with well 7, and was judged to 
contain anti-UlRNP but not anti-Sm antibodies. Serum LJ8 (well 4) from the 
pernicious anaemia-affected father of proband LJ1 produced two precipitin lines of non­
identity with well 5, and a single line of identity with well 3 is just discernible: this 
serum was later shown to contain anti-Ro and anti-La antibodies by both 
immunodiffusion and radioimmunoprecipitation (IP) techniques (Fig. 3.11, lane 9). 
Sample LJ7 from the healthy mother of proband LJ1 (well 2) consistently produced a 
very weak precipitin line, and was also found to precipitate an unidentified band by IP 
(Fig. 3.11, lane 10).
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FIGURE 3.10 Radioimmunoprecipitation: sera from SSc patients which displayed 
the anti-centrom ere staining patte rn  by ind irec t im m unofluorescence.
Autoradiograph of SDS-PAGE-separated 35S-m ethionine-labelled proteins 
immunoprecipitated from K562-cell extracts by serum antibodies attached to Protein-A 
Sepharose beads. Lane 1, normal control serum; lane 2, very high titre anti-centromere 
standard. Sera from SSc patients found to contain anti-centromere antibodies by indirect 
immunofluorescence (Table 3.1) were found to produce a variety of bands by 
radioimmunoprecipitation (IP) (lanes 3-15). However, the bands were generally weak, 
and no consistent IP profile was apparent.
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FIGURE 3.11 R adio im m unoprecip itation : con firm atio n  of defined an tin u c lea r 
an tibody specificities identified by im m unodiffusion in se ra  from  SSc p ro b an d s 
an d  SSc-free re la tives. A utoradiograph o f  S D S -P A G E -sep ara ted  35S-m ethionine- 
lab elled  proteins im m unoprecipitated from K 5 6 2 -ce ll extracts by serum  antibodies  
attached to Protein-A  Sepharose beads. Lane 1, norm al serum; lane 2, a n ti-U l R N P  
standard; lane 7, anti-Ro/La standard; lane 11, anti-U3 R N P/L a standard. Sera from S S c  
probands LG 1, M N 1, BD1 and BC1 contained antibodies to U1 R N P ± Sm  (lanes 3 -6  
r e sp e c tiv e ly ) . A n t i-J o -1 an tib o d ies  w ere a lso  id e n tif ie d  in sam p le  B C 1 by  
im m unodiffusion , and w ere confirm ed by radioim m unoprecipitation (IP) (lane 6: c.f. 
Fig. 3.6 , lane 4). Serum  from  B C 4, the S L E /p o lym yositis-a ffected  m other o f  proband 
BC 1, contained anti-Ro and anti-La antibodies (lane 8). Serum  from  both the pernicious 
anaem ia-affected father (LJ8) and the healthy m other (LJ7) o f  proband LJ1 both had a 
p ositive  result by im m unodiffusion: w hile  anti-R o/L a an tib odies w ere id en tified  in 
serum  LJ8 (confirm ed  here by IP (lane 9)), the sp ec ific ity  o f  serum  LJ7 w as not 
identified  by either technique, although it was found to precipitate an unidentified band 
o f - 1 1 5  kDa (*, lane 10)
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FIGURE 3.12 Radioimmunoprecipitation: identification of anti-Ku antibodies in 
serum from an SSc proband. Autoradiograph of SDS-PAGE-separated 35S- 
methionine-labelled proteins immunoprecipitated from K562-cell extracts by serum 
antibodies attached to Protein-A Sepharose beads. Lane 1, normal serum; lanes 2, 3 and 
5, anti-Ku standard; lane 4, anti-Ku/Sm standard. Serum from SSc patient MM1 
contained anti-Ku antibodies (lane 6).
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(a)
FIGURE 3 .13  Radioimmunoprecipitation: identification of anti-topoisomerase I 
antibodies in sera from SSc patients. Autoradiograph of SDS-PAGE-separated 35S- 
methionine-labelled proteins immunoprecipitated from K562-cell extracts by serum 
antibodies attached to Protein-A Sepharose beads. (a) Lane 1, normal serum; lane 6, 
topoisomerase I (topo I) standard; lane 11, anti-Ro/La standard. Sera from SSc patients 
LD1, LAI, MD1, NRM1, II, 13, NRM2 and MK1 contained anti-topo I antibodies 
(lanes 2-5 and 7-10); NRM2 and MK1 sera also contained anti-Ro/La antibodies (lanes 
9 and 10), while NRM1 contained anti-Ro antibodies (lane 5). In addition, serum from 
NRM1 precipitated strong unidentified bands of 115 and 125 kDa (a doublet was 
observed on autorads exposed to the same gel for shorter time periods), and further 
unidentified bands were precipitated by several sera, especially at higher molecular 
weights (a, lane 3 and lanes 7-9). (b) A longer autoradiograph exposure of the same gel 
showed these high molecular weight bands more clearly (b, lane 3 and lanes 7-9). It was 
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FIGURE 3.14 Radioimmunoprecipitation: identification of anti-RNA polymerase 
antibodies in sera from SSc patients. Autoradiograph of SDS-PAGE-separated 35S- 
methionine-labelled proteins immunoprecipitated from K562-cell extracts by serum 
antibodies attached to Protein-A Sepharose beads, (a) Lane 1, normal serum; lane 2, 
anti-RNAP I/III standard; lane 4, anti-RNAP I/II/III standard; lane 7, anti-RNAP I/III 
standard. Note the bands of high molecular weight characteristic of RNAP I (subunits la 
and lb), RNAP II (subunits Ho, Ha and lie) and RNAP III (subunits Ilia and Illb). Sera 
from SSc patients BE1 and U1 contained anti-RNAP I/III antibodies (lanes 3 and 5 
respectively), while serum from patient VI contained anti-RNAP I/II/III antibodies 
(lane 6). Samples were run on a 10% polyacrylamide gel. (b) Lane 1, normal serum; 
lane 3, anti-RNAP I/III standard; lane 4, RNAP I/II/III standard. Samples were run on 
an 8% gel. Bands precipitated by serum from SSc patient SF1 are shown in lane 2: 
relative mobilities are consistent with the presence of antibodies which precipitated only 
RNAP III, while serum from SSc patient VI was again shown to precipitate subunits 
characteristic of all three RNAP enzymes.
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FIGURE 3.15 Radioimmunoprecipitation: identification of defined antinucleolar 
antibody specificities in sera from SSc patients. Autoradiograph of SDS-PAGE 
separated 35S-methionine-labelled proteins immunoprecipitated from K562-cell extracts 
by sera attached to Protein-A Sepharose beads, (a) Lanes 1 and 2, normal sera; lane 4, 
anti-Pm-Scl standard; lane 6, anti-U3 RNP standard; lane 7, anti-RNA polymerase 
(RNAP) I/III standard; lane 10, anti-Th RNP standard. Sera from probands LEI, Wl, 
LJ1 and SI1 contained antibodies which precipitated Pm-Scl (lane 3), U3RNP (lane 5), 
RNAPs I, II and III (lane 8), and Th RNP (lane 9), respectively. (b) Lanes 1 and 12, 
normal sera; lane 2, anti-U3 RNP standard; lane 4, anti-RNAP I /III standard; lane 6, 
anti-Th RNP standard; lane 8, anti-Pm-Scl standard; lane 11, anti-topoisomerase I 
standard. Sera from probands SA1, VI, MAI, LEI and LD1 contained antibodies which 
precipitated U3 RNP (lane 3), RNAP I/II/III (lane 5), Th RNP (lane 7), Pm-Scl (lane 9) 
and topo I (lane 10) respectively.
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FIGURE 3.16 Radioimmunoprecipitation: identification of anti-Pm-Scl antibodies 
in sera from SSc patients. Autoradiograph of SDS-PAGE separated 35S-methionine- 
labelled proteins immunoprecipitated from K562-cell extracts by serum antibodies 
attached to Protein-A Sepharose beads. Lanes 1 and 2, anti-Pm-Scl standards; lane 10, 
anti-PL-7 standard; lane 11, normal human serum. Sera from SSc probands LEI, SCI, 
BA1, MP1, El, NA1 and G1 contained anti-Pm-Scl antibodies (lanes 3-9, respectively). 
Note the extra band of -240 kDa precipitated by serum SCI.
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FIGURE 3.17 Radioimmunoprecipitation: identification of anti-fibrillarin (U3 
RNP) antibodies in sera from SSc patients. Autoradiograph of SDS-PAGE-separated 
35S-methionine-labelled proteins immunoprecipitated from K562-cell extracts by serum 
antibodies attached to Protein-A Sepharose beads. Lane 1, normal human serum, lane 2 
anti-U3 RNP standard. Sera from SSc probands SA1, T1 and B1 contained anti-U3 
RNP antibodies (lanes 3-5, respectively). Note the extra bands precipitated by serum 
Bl.
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FIGURE 3.18 Radioimmunoprecipitation: co-precipitation of topoisomerase I and 
RNA polymerases. Autoradiograph of SDS-PAGE-separated 35S-methionine-labelled 
proteins immunoprecipitated from K562-cell extracts by serum antibodies attached to 
Protein-A Sepharose beads. Anti-topoisomerase I (topo I) sera which precipitated bands 
of high molecular weight (see Fig. 3.12b) were included in further immunoprecipitation 
studies along with prototype anti-RNA polymerase (RNAP) and anti-topo I sera. Lane 
1, normal serum (NS); lane 3, anti-RNAP I/III serum; lane 4, anti-RNAP I/II/III serum; 
lane 7, anti-topo I serum. Bands precipitated by serum from SSc patient LAI are shown 
in lane 6, and are consistent with the presence of antibodies which precipitated both 
topo I and the phosphorylated (IIO) form of RNAP II (RNAP IIO contains subunits Ho 
and lie); bands precipitated by serum NRM2 are shown in lane 5, and are consistent 
with the presence of antibodies which precipitated topo I, RNAP IIO and RNAP IIA 
(the unphosphorylated form of RNAP II, which contains subunits Ha and lie). 
Meanwhile, serum from SF1, shown in lane 2, precipitated only RNAP III.
FIGURE 3.19 Radioimmunoprecipitation: sera from SSc patients and connective 
tissue disease-free relatives found to precipitate unidentified autoantigens.
Autoradiograph of SDS-PAGE separated 35S-m ethionine-labelled proteins 
immunoprecipitated from K562-cell extracts by sera attached to Protein-A Sepharose 
beads. Lane 1, anti-Ro/La/topoisomerase I standard; lane 4, normal serum; lane 5, anti- 
Pm-Scl standard; lane 12, anti-U3 RNP standard. Serum from proband NRM1 
precipitated unidentified bands (115 and 125 kDa) and contained anti-Ro/topoisomerase 
I antibodies (lane 2); serum from proband SCI precipitated an unidentified 240-kDa 
band and contained anti-Pm-Scl antibodies (lane 3); serum from proband BA1 
contained anti-Pm-Scl antibodies (lane 6), while serum from BA2 (healthy sister of 
BA1) precipitated an unidentified 90-95 kDa protein triplet (lane 7), and serum from 
BA3 (healthy twin sister of BA1) precipitated an unidentified 65-kDa band (lane 8); 
serum from E6 (healthy sister of proband El) precipitated a weak 130-kDa band (lane 
9); serum from LA6 (healthy father of proband LAI) precipitated a weak 190-kDa band 
(lane 10); serum from proband A1 precipitated an unidentified 140-kDa band (lane 11), 
and serum from proband B1 precipitated several unidentified bands in addition to the 
fibrillarin antigen (lane 13).
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FIGURE 3.20 Radioimmunoprecipitation: sera from SSc patients and family 
members found to precipitate unidentified 115-kDa autoantigen/s. Autoradiograph 
of SDS-PAGE separated 35S-methionine-labelled proteins immunoprecipitated from 
K562-cell extracts by sera attached to Protein-A Sepharose beads. Lane 1, normal 
serum; lane 2, anti-topoisomerase I standard (topo I); lane 3, anti-Pm-Scl standard. An 
unidentified 115-kDa band (arrowed) was precipitated by a prototype Pm-Scl serum 
from an SSc patient (lane 4). Serum from MD9 (healthy son of proband MD1), BD5 
(Raynaud's phenomenon-affected sister of proband BD1), BD2 (healthy husband of 
BD1) and LJ7 (healthy mother of proband LJ1) also precipitated an unidentified 115- 
kDa band (lanes 5-7 and 9, respectively). Serum from proband NRM1 precipitated 
unidentified 115- and 125-kDa bands and contained anti-topo I/Ro antibodies (lane 8), 
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FIGURE 3.21 Radioim m unoprecipitation of sera from  healthy controls.
Autoradiograph of SDS-PAGE-separated 35S-methionine-labelled proteins 
immunoprecipitated from K562-cell extracts by sera attached to Protein-A Sepharose 
beads. Samples NS1 and NS2 each produced a strong band, while sample NS23 
produced only background bands, detected in all lanes. The remaining samples shown 
here produced weak or very weak unidentified bands. Samples NS1 and NS2 had both 
produced a '+++' nuclear staining score by IF, while sample NS23 received a score 
for both nuclear and nucleolar staining.
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3.4 DISCUSSION
Prevalence of positive immunofluorescence patterns in family members
In the original family study, carried out in 1986 (206), increased frequencies of IF- 
ANAs were reported in the blood-relatives of patients with SSc compared with controls 
(27% and 8%, respectively). The present study is one of a number of follow-up studies 
conducted by various members of the U.K. SSc Study Group (207,226,331,361). 
Although 17% of first-degree family members demonstrated IF-ANAs in the present 
report, this was not significantly different from the figure of 12% in controls. However, 
the trend towards increased IF-ANAs in first-degree relatives of SSc patients found 
here would be in support of previous findings by others (90,289,292,336).
It may be important that these previous studies tended to classify all IF patterns 
together. By contrast, in the present study, we have specifically and separately recorded 
IF-ANAs and IF-ANoAs. Interestingly, it was observed in the original family study that 
a high proportion of the IF-ANA-positive sera from family members had nucleolar 
staining patterns (206). In the present study, whilst the incidence of IF-ANoAs was 
significantly lower in the first-degree relatives of SSc patients than in the SSc patients 
themselves, when independently compared with a large group of age- and sex-matched 
normal controls, the incidence of IF-ANoAs in blood-relatives was shown to be 
significantly increased. In the original family study, it was apparent that sera from 
family members with positive ANA-IF generally had low titre IF, a finding also 
supported here by the fact that most of the IF-positive family members had a low IF 
score.
Meanwhile, despite initial indications ((206); Table 3.2), neither IF-ANAs nor IF- 
ANoAs were increased in the spouses of patients compared with normal controls. 
Together, these results would point to genetic effects being relevant to the generation of 
an IF-ANoA response. However, the number of spouses included in this and in the 
previous family study (206) was small. Furthermore, environmental effects occurring in 
childhood cannot be excluded.
Detection and identification of autoantibodies by immunoprecipitation
The identification of many IF-ANoAs detected in the present study was possible due to 
the availability of the sensitive technique of IP, which has been developed since the 
original family study was carried out. Radioimmunoprecipitation has proven to be a 
valuable method for the detection of ANoAs not identified by other techniques. With 
the possible exception of anti-U3 RNP antibodies (35), ANoAs of defined specificity 
are difficult to predict from IF tests alone. In addition, unlike ANAs, most ANoAs are 
not detectable by immunodiffusion techniques, or by straightforward IB.
Most sera which were subsequently found to contain antibodies recognizing the 
nucleolar antigens U3 RNP, Pm-Scl or Th RNP by IP techniques did display obvious 
nucleolar staining by IF, often with weaker staining of the nucleoplasm. However, it
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seems likely that some anti-nucleolar patterns were obscured by stronger staining of the 
entire nucleus: in particular, all sera with anti-RNAP I antibodies also contained anti- 
RNAP III antibodies, and a variety of mixed nucleolar and nuclear staining patterns was 
therefore observed. Clearly, when testing SSc sera, the possible presence of an ANoA 
should be checked by IP assays wherever possible.
Disease-specific autoantibodies in SSc
The results indicated that, despite an increased incidence of IF-ANoAs in the unaffected 
first-degree relatives of SSc patients compared with controls, only individuals with an 
SSc diagnosis had a defined ANoA. Together with related studies carried out by various 
members of the U.K. SSc Study Group (128,226,361), the present study implies that 
AC As, anti-topo I, anti-RNAP I, anti-RNAP III, anti-Pm-Scl, anti-U3 RNP and anti-Th 
RNP antibodies are all SSc-specific. Considering the detection of strong IF-ANoAs in 
some of the non-SSc sera, the fact that SSc-associated ANoAs were subsequently 
detected only in SSc patients seems quite remarkable. It would appear, therefore, that 
an SSc-associated ANoA is a reliable marker indeed of some aspect of the pathological 
changes characteristic of SSc. Moreover, in those families where a relative of the 
proband also had a CTD, any defined autoantibodies detected were consistent with their 
particular diagnosis (see Table 3.1). Thus, the close association of CTDs with certain 
autoantibodies was further confirmed.
It has been suggested previously that, in multicase SSc families, both affected 
individuals tend to have the same autoantibody specificity, and, further, that there is a 
fundamental resemblance of their disease subtype (99). Reports by the U.K. SSc Study 
Group concerning the present families would support this conjecture (see Table 3.1; 
(226,331,361)). The implication is, that the same cause, or combination of causes, 
(environmental or genetic) is behind the development of the disease in both of the SSc- 
affected members of a single family.
Mutually exclusive SSc-specific autoantibodies
Anti-nucleolar antibodies of defined specificity were mutually exclusive, as previously 
reported by others. Furthermore, apart from sera with antibodies to both RNAP I and 
RNAP III (which are known to share structural homologies), each of the SSc-specific 
autoantibodies (ACA, anti-topo I, anti-U3 RNP, anti-ThRNP, anti-Pm-Scl, anti-RNAP I 
and anti-RNAP-III) were also mutually exclusive, with the exception of a single serum.
Clinical associations o f SSc-specific autoantibodies
As found by other studies, each different ANoA tended to be associated with a 
particular disease subtype, although the numbers of anti-U3 RNP, anti-Th RNP, and 
anti-Pm-Scl antibody-positive sera detected here were too small for meaningful analysis 
(Table 3.7). As previously reported by members of our group, in the present cohort of 
SSc patients, the ACA response was associated with lc-SSc (Table 3.7a; (226)).
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Although anti-topo I antibodies were equally distributed between limited and diffuse 
forms of the disease, the numbers involved were small (Table 3.7a\ (361)). The present 
data does, however, support an association between RNAP I antibodies and dc-SSc 
(Table 3.1b).
These results suggest that the anti-RNAP I antibody specificity, occurring in 17% of 
SSc patients, is the largest, and most significant, of the SSc-specific ANoAs: the 
remaining ANoAs (i.e. anti-Pm-Scl, anti-U3 RNP and anti-Th RNP) occurred here in 
only 12%, 7% and 5% of SSc patients respectively. About half of the SSc patients were 
found to have anti-RNAP I, anti-topo I, or ACAs. Given that, along with anti-topo I and 
ACAs, the anti-RNAP I response appears to define a third major subgroup of SSc 
patients, it was decided to concentrate on these three groups in future studies. Thus, the 
occurrence of anti-topo I, anti-RNAP I, and ACAs and their clinical associations were 
subsequently investigated in a larger group of SSc patients, and this is the subject of 
Chapter 4.
Co-precipitation ofRNA polymerase II and topoisomerase I
Sera from four patients were found to contain antibodies which precipitated both topo I 
and the 240-kDa phosphorylated (IIO) form of RNAP II: Satoh et al. have also 
observed co-precipitation of topo I and RNAP II in Japanese patients with SSc (299). 
Since topo I is a transcription factor for RNAP II-transcribed genes (180), it appears 
possible, based on the present results, that anti-topo I and anti-RNAP II antibodies 
recognize separate epitopes that co-localize on a key multienzyme transcriptional 
complex (Dr N.J.McHugh, pers.comm.). The co-precipitation of topo I and Ro, seen in 
three of our SSc sera, was also reported by Satoh et al. (299). It was decided that the co­
precipitation of RNAP II, topo I, and Ro also warranted further study, and this was a 
second aim of the work reported in Chapter 4.
Novel SSc autoantibodies
In sera from eight SSc patients, autoantibodies of a defined specificity were not 
demonstrated. However, the unidentified autoantigens precipitated by four of these sera 
(A l, K l, MOl and NR1: Table 3.6; Fig. 3.18) may represent novel SSc-specific 
autoantigens occurring in a minority of SSc sera: the unusual, characteristic staining 
patterns produced by two of these sera are shown in Fig. 3.1 a,b. Of the remaining four, 
only one was counted as negative by IF, and even this sample had discernible nuclear 
staining (Fig. 3.1&), receiving a score o f I d e n t i f i c a t i o n  of these antigens would 
clearly be of interest.
Novel autoantibodies in disease-free family members
Slightly higher frequencies of both precipitating antibodies by immunodiffusion and 
unidentified bands on IP gels occurred in the SSc-free relatives compared with the 
spouses. Some CTD-free family members showed evidence of ANoAs by both
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techniques. When IF and IP results were compared, three SSc-free blood-relatives 
(BA2, BE6 and MD9) had both strong unidentified bands by IP (Figs 3.19 and 3.20) 
and an antinucleolar IF score of +++ or ++++, which was greater than the nuclear IF 
score by at least two gradations of intensity (Fig. 3.8f,g,h) (Table 3.3): therefore, these 
unidentified autoantigens may represent nucleolar proteins. This provides further 
evidence that, in a minority of the first-degree relatives of SSc patients, certain genetic 
(and/or environmental factors) lead to the production of antibodies which recognize 
specific nucleolar autoantigens. Given that 40% of SSc sera produced positive nucleolar 
staining scores by IF, and that 41% of SSc sera were shown to recognize defined 
nucleolar autoantigens, it is difficult to avoid concluding that a common factor is 
behind the production of ANoAs by a proportion of both SSc patients and their SSc- 
free first-degree relatives. However, the particular nucleolar antigens recognized by 
these relatives appear to be different from the antigens recognized by the SSc patients 
themselves.
The 115-kDa bands precipitated by sera from different members of the same family 
(Fig. 3.20), were also of great interest: two of these sera had also been found to produce 
strong nuclear staining patterns by IF (Table 3.3) (Fig. 3.8c). The presence of an 
autoantibody in the spouse of an SSc patient points to environmental effects, at least in 
this particular family, and is especially significant in light of the previously mentioned 
case of apparently environmentally induced conjugal SSc (56). It was therefore decided 
that sera from this very interesting family would be studied in greater detail, and this 
was the purpose of work described in Chapter 5.
3.5 CONCLUSIONS
The nucleolus is a focal point for the immune response in SSc patients and their 
relatives
It has been suggested that the nucleolus may be a focal point of the autoimmune 
response in SSc (288,340). Such observations have been based on an analogy with SLE, 
where the nucleus appears to be the focus of an antigen-driven autoimmune response 
(125). The present results would strongly support this hypothesis, with the added point 
that the nucleolus may be a focus of immunity also in the blood-relatives of SSc 
patients. These results did not hold for SSc spouses, however. Therefore, such an effect 
may have a genetic basis.
As discussed earlier, the ANA response in SLE has been linked by some to the 
inadequate clearance of apoptotic blebs which contain nuclear antigens. In part, this 
effect is thought to be linked to a genetically determined complement deficiency in SLE 
patients. The probable presence of modified (i.e. cryptic) self-epitopes in these 
apoptotic blebs is likely to be an important factor leading to the breakdown of tolerance 
to component nuclear antigens (47). Again, by analogy, the IF-ANoA results reported
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here may imply that some genetic factor is working specifically to make the nucleolus, 
or certain components of it, more prone to an autoimmune response in SSc patients and 
their blood relatives, possibly by causing the production of cryptic epitopes of nucleolar 
antigens. The fact that complement deficiencies have also been observed in both SSc 
patients and in their relatives may be of relevance here (264). Importantly, a significant 
association between the presence of a C4 null allele and the production of autoreactive 
ANAs has also been reported both in SSc patients and in their relatives (264).
However, based on the present data, it appears that the nucleolar antigens commonly 
recognized by SSc patients are different from those recognized by the ANoA-positive 
relatives. It follows that distinct sets of cryptic self-peptides have probably been 
presented by the patients' APCs that were not presented by the APCs of the ANoA- 
positive relatives. Thus, although the presence of a genetic abnormality in some first- 
degree relatives of SSc patients is suggested by the current data, it would appear that 
additional factors are present in the proband: furthermore, the likelihood is, that these 
additional conditions are responsible both for the development of the SSc symptoms, 
and for the production of disease-specific autoantibodies, as these two aspects of the 
disease process appear to be inextricably linked.
The SSc-specific ANoAs are markers of disease-specific pathological conditions 
leading to the production of the particular cryptic peptides presented on the 
surface of APCs
One genetic factor which is known to be associated with the development of SSc, and, 
more specifically, with the production of particular SSc-specific antibodies, is the 
presence of certain HLA alleles. In theory, if an identical pool of cryptic peptides was 
produced, this factor alone could explain the proposed differential display of cryptic 
peptides on the surface of APCs in patients versus ANoA-positive relatives. However, 
it has already been pointed out that the characteristic autoantibodies found in SSc are 
not believed to be the cause of the disease itself. Therefore, in the particular context of 
ANoA production, the presence of certain types of HLA molecules on the surface of 
APCs seems an inadequate explanation for the development of disease, and the 
production of disease-specific antibodies. A more satisfactory explanation is that a 
characteristic set of modified autoantigens has been made available to the APCs of the 
proband; other possibilities include the involvement of a different population of APCs 
in the SSc patient, or the presence of physiological factors which could have led to the 
use of alternative antigen processing pathways by the same type of APC (see Section 
1.7). Any of these three possibilities would reflect the existence of distinct 
physiological or pathological conditions in the proband. This is not to say that HLA 
differences between different SSc patients (and between different ANoA-positive 
family members) do not subsequently determine the binding potential of the particular 
cryptic peptides available for presentation. Indeed, this effect would still explain the
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association of particular SSc-specific autoantibodies with the presence of certain HLA
alleles.
To summarize, the presence of one or more particular genetic or environmentally 
induced abnormalities in a minority of SSc-free blood-relatives appears to have lead to 
the production of particular sets of cryptic nucleolar epitopes, while additional 
abnormalities present in the SSc patients themselves have lead to the production of 
alternative (or additional) sets of cryptic nucleolar epitopes. These additional 
abnormalities are also necessary for the development of the complete disease syndrome.
So, what might these altered conditions be? Possibilities were recently reviewed by 
Rosen et al., and include a pre-existing vascular defect, the presence of ROS from 
ischaemic reperfusion events, and abnormal metal-ion status. In addition, the potential 
role of environmental agents in the aetiology of SSc has been stressed by several groups 
(see Section 1.6), and the pro-inflammatory perivascular environment so characteristic 
of SSc may also be of relevance.
These altered states, some or all of which have converged only in the individual 
destined to develop SSc, may be responsible for unique nucleolar antigen fragmentation 
events, which, in turn, determine the particular identity of cryptic nucleolar epitopes 
produced and presented by APCs (288). It seems likely that one or more of these factors 
occurring in the absence of the others is responsible for the production of the 
unidentified ANoAs by the family members of SSc patients. The lack of the remaining 
factors being responsible for the lack of the particular SSc-associated ANoAs in the 
ANoA-positive family members.
Further characterization of the antinucleolar antigens recognized by disease-free 
first-degree relatives of SSc patients would be of great interest, as they could identify 
early participants in the aetiopathogenesis of the disease. Equally likely, based on the 
present data, is the possibility that they represent alternative responses to the same 
shared susceptibility factor, be it genetic or environmental; the lack of certain other of 
the purported pro-pathological factors mentioned above could have protected against 
disease onset, and may also have prevented the generation of particular sets of altered 
nucleolar antigens, with the subsequent processing and presentation events which are 
responsible for the generation of SSc-specific autoantibodies. The identification of the 
autoantigens recognized by sera from the relatives of SSc patients may help clarify 
these issues, and this is one aim of our future research. Meanwhile, the present study 
helps to confirm the status of SSc-associated ANoAs as unique markers of the specific 
pathological changes characteristic of SSc, as suggested by Rosen et al. (288).
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association of particular SSc-specific autoantibodies with the presence of certain HLA
alleles.
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induced abnormalities in a minority of SSc-free blood-relatives appears to have lead to 
the production of particular sets of cryptic nucleolar epitopes, while additional 
abnormalities present in the SSc patients themselves have lead to the production of 
alternative (or additional) sets of cryptic nucleolar epitopes. These additional 
abnormalities are also necessary for the development of the complete disease syndrome.
So, what might these altered conditions be? Possibilities were recently reviewed by 
Rosen et a l , and include a pre-existing vascular defect, the presence of reactive oxygen 
species (ROS) from ischaemic reperfusion events, and abnormal metal-ion status. In 
addition, the potential role of environmental agents in the aetiology of SSc has been 
stressed by several groups (see Section 1.6), and the pro-inflammatory perivascular 
environment so characteristic of SSc may also be of relevance.
These altered states, some or all of which have converged only in the individual 
destined to develop SSc, may be responsible for unique nucleolar antigen fragmentation 
events, which, in turn, determine the particular identity of cryptic nucleolar epitopes 
produced and presented by APGs (288). It seems likely that one or more of these factors 
occurring in the absence of the others is responsible for the production of the 
unidentified ANoAs by the family members of SSc patients. The lack of the remaining 
factors being responsible for the lack of the particular SSc-associated ANoAs in the 
ANoA-positive family members.
Further characterization of the antinucleolar antigens recognized by disease-free 
first-degree relatives of SSc patients would be of great interest, as they could identify 
early participants in the aetiopathogenesis of the disease. Equally likely, based on the 
present data, is the possibility that they represent alternative responses to the same 
shared susceptibility factor, be it genetic or environmental; the lack of certain other of 
the purported pro-pathological factors mentioned above could have protected against 
disease onset, and may also have prevented the generation of particular sets of altered 
nucleolar antigens, with the subsequent processing and presentation events which are 
responsible for the generation of SSc-specific autoantibodies. The identification of the 
autoantigens recognized by sera from the relatives of SSc patients may help clarify 
these issues, and this is one aim of our future research. Meanwhile, the present study 
helps to confirm the status of SSc-associated ANoAs as unique markers of the specific 




Anti-RNA polymerase antibodies in systemic sclerosis: clinical 
significance, association with anti-topoisomerase I antibodies, and 
identification of autoreactive subunits of RNA polymerase II
4.0 SUMMARY
The occurrence of anti-topo I, anti-RNAP, and ACAs was examined in 210 SSc 
patients, and their clinical associations were determined. In addition, the observed 
occurrence of multiple ANA specificities in certain SSc sera was further investigated.
Forty-six anti-RNAP sera were detected (21.9%) and three main groups were 
identified: anti-RNAP I/III sera (10; 4.8%), anti-RNAP I/II/III sera (15; 7.1%), and sera 
precipitating the phosphorylated (IIO) form of RNAP II in the absence of RNAPs I and 
III (18; 8.6%). All sera in the third group also precipitated topo I, and eight of them also 
precipitated the unphosphorylated (IIA) form of RNAP II. A total of 44 sera were found 
to precipitate topo I (21.0%), and eleven sera (5.2%) precipitated both topo I and Ro 
(±La), five of which also precipitated RNAP IIO. A further eleven sera (5.2%) 
precipitated Ro in the absence of either topo I or RNAPs. Meanwhile, anti-Jo-1 and 
anti-Ul RNP antibody specificities (detected in eleven sera (5.2%) and 13 sera (6.2%) 
respectively) tended to occur alone, and sera containing ACAs (55; 26.2%) appeared to 
form a separate group.
Although RNAP II/topo I multienzyme complexes may occur in cell extracts, 
autoreactive epitopes were shown to be located on both enzymes by a combination of 
antigen depletion studies, and IB experiments using affinity purified antigens. 
Furthermore, it was demonstrated that all sera with anti-RNAP II antibodies recognized 
the largest RNAP II subunit in its phosphorylated form (Ho), whereas the 
unphosphorylated subunit (Ha) was only recognized by sera which also precipitated 
RNAP IIA. Therefore, at least two different sites on the largest subunit of RNAP II are 
recognized by SSc sera, and one of these sites is unique to the phosphorylated form.
Based on the above findings, together with analysis of the clinical associations of 
individual autoantibodies, and particular autoantibody profiles, it was concluded that 
there are three main groups of SSc patients, each characterized by the presence of a 
particular, mutually exclusive SSc-specific antibody (ACA, anti-topo I or anti-RNAP 
III), and distinguished by certain clinical features. The ACA group had significantly 
less diffuse disease and internal organ involvement. Anti-topo I antibodies were 
frequently accompanied by antibodies recognizing Ro (±La), and/or RNAP IIO (±11 A): 
patients in this group had an intermediate risk of dc-SSc, and a high incidence of 
pulmonary disease. Anti-RNAP III antibodies were usually accompanied by antibodies 
recognizing RNAP I, and sometimes also by anti-RNAP II antibodies: this group had 
the highest incidence of diffuse disease. The suggestion was, that the context in which 
anti-RNAP II antibodies are produced is a key aspect of their clinical significance.
Based on these data, it was further hypothesized that, in each of the three main 
groups of SSc patients, distinct pathological processes are occurring, which are respon­
sible for the characteristic symptoms, for the modification of particular autoantigens 
and, consequently for the production of particular autoantibodies.
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4.1 INTRODUCTION
The aim of the present study was to examine the occurrence of anti-topo I, anti-RNAP 
and ACAs in a larger cohort of SSc patients, and to determine more clearly their 
clinical associations. In addition, the observed co-precipitation of RNAPs, topo I, 
and/or the Ro antigen by certain SSc sera was further investigated.
In order to appreciate the significance of antibodies recognizing the different 
RNAPs, a brief description of their structure and function is required. Three different 
classes of eukaryotic DNA-dependent RNAP enzyme have been described, denoted I, II 
and III, and each is responsible for the transcription of different sets of genes (for 
review, (308,373)). Thus, pre-mRNA is synthesized by the nucleoplasmic enzyme 
RNAP II, while RNAP III, also located in the nucleoplasm, transcribes 5S rRNA and 
tRNA genes. The function of RNAP I is to synthesize rRNA precursors, and this 
enzyme is located in the nucleolus.
Eukaryotic RNAP enzymes are highly conserved (149) and have been most 
extensively studied in yeast. Each of the three classes of RNAP consists of two 
different large subunits and around ten smaller polypeptides. The large subunits of 
RNAPs I, II and III have approximate molecular weights of 190 and 125 kDa, 155 and 
138 kDa, and 220-240 and 145 kDa, respectively (142). Meanwhile, several of the 
smaller subunits are identical in two or all three of the enzyme complexes (34,149,364). 
Although each pair of large subunits is unique, there is a some homology between 
classes with regard to both sequence and conformation. Thus, a single antibody may 
recognize either a unique or a shared RNAP epitope or subunit, and immunoprecipitate 
one, two or all three enzymes.
In vivo, RNAP II occurs both in a phosphorylated and an unphosphorylated form, 
known as RNAP IIO and RNAP IIA respectively (38). Unlike RNAPs I and III, the 
largest subunit of RNAP II has a characteristic carboxy terminal repeat domain (CTRD) 
(65), which is the site of multiple phosphorylation/dephosphorylation reactions which 
control intraconversion of the two forms (262,376). The largest subunit of RNAP IIO 
(designated Ho; M r ~240 kDa) is conformationally distinct from that of RNAP IIA 
(subunit Ha; Mr ~220 kDa) (375), and the two forms of the enzyme are active at 
different stages of the transcription process, sometimes in a site-specific manner 
(192,204,262,346,356). It is therefore possible that autoantibodies could recognize 
either one or both types of RNAP II.
The occurrence of anti-RNAP antibodies in the sera of SSc patients has been studied 
by several groups (36,144,183,185,255). The consensus of these reports is that anti- 
RNAP III antibodies occur alone in a very small minority of sera (0-7%), and are 
accompanied by anti-RNAP I antibodies in a further 4-25% of patients. Meanwhile, a 
third group of sera is able to precipitate all three RNAPs (I, II and III) (1-5%). In these 
studies, other combinations of anti-RNAP antibodies were only very rarely found in 
individual sera (144).
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Until recently, anti-topo I antibodies and anti-RNAP antibodies were considered to 
be mutually exclusive, and each was thought to be disease-specific (144,183,255,277). 
However, a more recent study by Satoh et al. (298,299) reported the simultaneous 
presence of anti-topo I antibodies and antibodies to the phosphorylated (IIO) form of 
RNAP II in the sera of 19.7% of Japanese SSc patients. In contrast, only 5.3% of Black 
SSc patients were found to co-precipitate RNAP IIO and topo I, and no anti-RNAP 
IIO/topo I specificities were found when 39 Caucasian sera were tested (299). In 
contrast, sera containing antibodies which recognized the other two RNAP classes (I 
and III) were not found to co-precipitate topo I. Additionally, anti-RNAP II (i.e. IIO 
and IIA), and anti-RNAP IIO antibodies have been detected in the sera of Japanese SLE 
and MCTD/overlap syndrome patients, although none of these sera contained anti-topo
I antibodies (297).
Topoisomerase I is known to catalyze the relaxation of supercoiled DNA in vivo 
(354), and was recently identified as a cofactor for activator-dependent RNAP II 
transcription (180,230). The two enzymes may interact with each other by direct 
binding (180). Consequently, the presence of multi-enzyme complexes in cell extracts 
may account for the observed co-precipitation of topo I and RNAP II by autoantibodies 
in a single serum.
While results from the previous chapter would support the occurrence of anti-RNAP
II antibodies in some anti-topo I-positive sera (127), this finding has not been 
substantiated by others: in their study of 735 SSc patients, Bunn et a l (36) found anti- 
RNAP antibodies (III, I/III or I/II/III) in 11.7% of sera by IP, and, while anti-topo I 
antibodies were also detectable by their IP method (36), no serum was found to 
precipitate both topo I and any type of RNAP enzyme.
To further investigate our own preliminary findings on this issue (126), the present 
study was carried out, which included a further cohort of SSc patients: using the 
technique of radioimmunoprecipitation, the prevalences of antibodies to the three 
classes of RNAP enzyme, and to topo I, were measured in the sera of 213 SSc patients. 
The clinical associations of the antibodies detected in this study were then examined in 
detail.
The presence of anti-topo I antibodies in approximately 25% of SSc sera
(52.53.327.357) has been associated with diffuse cutaneous involvement
(91.114.327.349.357), and with the occurrence of pulmonary interstitial fibrosis 
(32,52,261,327). However, most studies linking anti-topo I antibodies with dc-SSc were 
carried out before the characterization of anti-RNAP antibodies. Therefore, in these 
studies, anti-topo I-positive patients could only be considered in relation to ACA- 
positive patients, or, alternatively compared with anti-topo I-negative groups: the 
presence of ACAs has been closely linked with a particular subtype of SSc found in 
about 25% of patients and characterized by very limited skin involvement, often 
confined to sclerodactyly (20,52,53,343).
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Since then, anti-RNAP I and anti-RNAP III antibodies have together been 
associated with an increased risk of developing dc-SSc (255,277), and with a higher 
incidence of renal disease (255). For the purposes of clinical comparisons, some studies 
have tended to classify all sera containing anti-RNAP antibodies into a single group, 
often due to the small numbers involved: however, similar associations with dc-SSc 
(36,144,183,185) and with renal involvement (36,185) have been observed. In addition, 
some groups have reported an association of anti-RNAP antibodies with cardiac 
involvement (183,185). Different clinical features in patients with anti-RNAP 
antibodies compared with those with anti-topo I antibodies have also been noted by 
some of these authors (36,185,255), including an increased incidence of diffuse disease 
and renal involvement in the anti-RNAP group (36,255), and a higher rate of 
pulmonary involvement in patients with anti-topo I (36,297). Clinical associations were 
also considered in the study of Satoh et al. (299), who found that patients with both 
anti-RNAP IIO and anti-topo I antibodies had a significantly higher incidence of dc- 
SSc than did patients who had anti-topo I antibodies alone. However, only a small 
number of groups have so far studied the clinical associations of ACAs, anti-topo I 
antibodies and anti-RNAP antibodies in the context of a single study (36,185). Based 
on their results, together with others' (255), one of these studies concluded that there are 
three main, mutually exclusive groups of SSc sera: those with ACAs, those with both 
anti-RNAP I and anti-RNAP III antibodies, and those with anti-topo I antibodies (36).
In the previous chapter, sera which precipitated topo I together with the Jo-1, Ro, 
and/or La antigens were detected in a minority of sera, some of which also contained 
anti-RNAP II and anti-topo I antibodies. These sera were of particular interest, since 
Satoh et al. had reported on the co-precipitation of RNAP IIO and topo I together with 
either U1 RNP, Ku or Ro autoantigens (299). Bunn et al. have also noted that these 
particular ANAs did not occur in any of their anti-RNAP III, anti-RNAP I/III or anti- 
RNAP I/II/III sera (36). Consequently, the incidence of SSc sera containing these other 
multiple specificities was also examined, along with their clinical associations.
4.2 MATERIALS AND METHODS 
Patients and sera
A total of 210 patients fulfilling criteria for SSc were studied, and disease subtype 
classifications were recorded (see Section 2.1.2). Nine patients had Si-SSc (sera and 
clinical data kindly provided by Dr U.Haustein, University of Leipzig, Germany) (227), 
while the remaining cases were ostensibly idiopathic, and included the 62 patients from 
the family study of SSc (Chapter 3; (127,207)). Blood samples were taken from the 
remaining 139 patients, from which sera were prepared (Method 2.1.3), all sera being 
stored at -20°C before serological analysis.
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For RNHRD patients, renal and lung involvements were determined according to the 
definitions in Section 2.1.2. Organ involvement definitions in the remaining patients 
have been described elsewhere (207,227).
A proportion of the RNHRD patients were available to attend Dr McHugh's CTD 
clinic for a more detailed clinical assessment. All members of this subgroup had 
idiopathic SSc. For these patients, disease subtype was also recorded according to 
Barnett's three-point classification system (Section 2.1.2), and organ involvement 
severity scores were assigned (see Appendix I).
Immunodiffusion
The 62 family study sera had already been tested by this method (Chapter 3). 
Ouchterlony double immunodiffusion (Method 2.3.1) was carried out on all remaining 
serum samples, excluding those already known to contain ACAs. Anti-centromere 
antibodies are not detected by this method, and sera containing ACAs are generally 
considered to form a mutually exclusive group (see below).
Radioimmunoprecipitation
The 62 family study sera had already been tested by IP (Chapter 3). Also, 55 (26.2%) of 
the sera included in this study had previously been found to contain ACAs by IF and/or 
IB tests (either in the family study or in previous SSc studies carried out by various 
members of the laboratory). Anti-centromere antibodies are not well detected by IP 
assays (177), and, in the family study, no ACAs had been detected in conjunction with 
anti-topo I, anti-RNAP antibodies or any other AN As. Consequently, only a proportion 
of ACA-positive sera were tested by IP in the present study, fourteen (25% of the total) 
being excluded.
The remaining 134 sera were subject to IP assays using K562-cell extracts (Method 
2 .3.3a) for the detection of antibodies precipitating RNAPs, topo I, Jo-1, U1 
RNP(±Sm), PL-7, Ku, Ro and/or La antigens. While several other autoantibody 
specificities (mainly ANoAs) were also noted, these were not the focus of this 
particular study, and were not confirmed or further investigated. Note that, in the 
minority of sera not previously tested by IF and/or IB methods, some additional ACA 
specificities would also be expected to occur, but these would not be detected by IP 
methods.
Antigen depletion of radiolabelled K562-cell extracts
Similar IP experiments were performed using aliquots of radiolabelled K562-cell 
extract which had been precleared of topo I. Two cycles of depletion were carried out 
using a prototype anti-topo I serum (Method 2.3.3c). For comparison, similar 
"depleted" and "semi-depleted" extracts were prepared using a normal human serum.
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Immunoblotting of affinity purified autoantigens
Appropriate sera were then used to purify RNAP and topo I antigens for IB studies. To 
validate this technique, a prototype anti-Ul RNP serum was first used to purify the 
constituent subunits of the U1 RNP particle (Method 2.3.3d). Following separation by 
SDS-PAGE, constituent polypeptides from affinity purified U1 RNP were transferred 
onto a nitro-cellulose sheet. Immunoblotting was performed as described previously 
(Method 2.3.7) using prototype anti-Ul RNP±Sm sera of known subunit specificity: 
these were mainly SLE sera, but two anti-Ul RNP sera from the present study were 
also included. Immunoblots were later subject to autoradiography to reveal the 
positions of transferred polypeptides.
The same basic method was then used to prepare extracts rich in (i) RNAPs I, II and 
III, (ii) RNAP IIO and topo I, and (iii) RNAP III. Similar IB experiments were then 
carried out using sample sera and prototype sera of known autoantibody specificity.
Immunofluorescence
A representative group of sera found to contain multiple antibody specificities by IP 
were subject to IF (Method 2.3.2). The patterns produced were then compared with 
those of prototype sera containing autoantibodies of a single specificity.
4.3 RESULTS
Immunodiffusion
A total of 32 sera had anti-topo I antibodies by immunodiffusion, while antibodies 
recognizing Jo-1, U1 RNP±Sm, Ro and/or La antigens were detected in eight, six, eight 
and four sera respectively. No anti-Ku antibodies were detected by this method.
Radioimmunoprecipitation
All ANA specificities identified by immunodiffusion were confirmed on IP gels, and 
many other sera containing antibodies to topo I, Jo-1, U1 RNP±Sm, Ku, Ro and/or La 
were also identified by IP techniques (Table 4.1). Many of these samples had shown a 
weak positive unidentified result by immunodiffusion. A number of sera were found to 
precipitate more than one of these antigens. One anti-PL-7 serum was detected (see 
previous Fig.3.6; specificity kindly confirmed by Dr I.Targoff, Department of 
Medicine, Oklahoma University Sciences Centre, Oklahoma, U.S.A.).
Co-precipitation ofRNA polymerases and topoisomerase I
A total of 46 anti-RNAP sera was detected by IP (Tables 4.1-4.3), representing 21.9% 
of SSc patients included in this study. Three main groups of sera with anti-RNAP 
antibodies were identified: anti-RNAP I/III sera (ten; 4.8%), sera precipitating all three 
RNAPs (sixteen; 7.6%), and sera precipitating the phosphorylated (IIO) form of RNAP 
II in the absence of RNAPs I and III (18; 8.6%) (Tables 4.2 and 4.3). All sera in the
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third group also precipitated topo I, and eight of them (3.8%) also precipitated the 
unphosphorylated (IIA) form of RNAP II (Table 4.3). Typical examples from each 
group are shown in Fig. 4.1a, lanes 3-6. In addition, two samples precipitated RNAP III 
in the absence of RNAPs I and II (1.0%; Table 4.2; Fig. 4.1a, lane 2), and one of the 
anti-RNAP I/II/III sera was also found to precipitate topo I (0.5%) (as described in 
Chapter 3; Table 4.2; Fig. 4.1 b, lane 8). The subunit molecular weights of unusual 
RNAP specificities were verified by comparison with prototype anti-RNAP and anti- 
topo I sera on an 8% SDS-polyacrylamide gel (Fig. 4.1b).
Other multiple antinuclear antibody specificities
Of the 22 sera containing anti-Ro antibodies (10.5%), eight also contained anti-La 
antibodies (3.8%) (Tables 4.1 and 4.4). Only one anti-La serum failed to precipitate the 
Ro antigen (an anti-Pm-Scl serum; Table 4.4). Of the 44 sera (21.0%) containing anti- 
topo I antibodies (Table 4.3), eleven (5.2%) also precipitated the Ro antigen (Fig. 4.2, 
lane 1), including three anti-RNAP II/topo I sera (1.4%) and two anti-RNAP IIO/topo I 
sera (1.0%) (Table 4.3; Fig. 4.2, lanes 3 and 4; Fig. 4.1a, lane 5). Notably, the Ro, La 
and Jo-1 antigens were only precipitated by those anti-RNAP sera which also contained 
anti-topo I antibodies (c.f Tables 4.2 and 4.3). Despite a fairly high prevalence of sera 
containing anti-Jo-1 and/or anti-Ul RNP antibodies (eleven sera (5.2%) and 13 sera 
(6.2%) respectively; Tables 4.1 and 4.5), most were monospecific, and only one was 
found to co-precipitate an RNAP (one anti-RNAP IIO/topo I/Jo-1 serum) (Table 4.5). 
However, a small number of sera containing other multiple ANA combinations was 
detected (Table 4.5). Despite reports on the co-precipitation of RNAP IIO and the Ku 
antigen (299), only one serum (0.5%) was found to contain anti-Ku antibodies, and this 
was monospecific (Table 4.5).
Antigen depletion studies
A radiolabelled extract was specifically depleted of topo I by successive incubations 
with anti-topo I-coated Protein-A Sepharose beads (Fig. 4.3b, lanes 12-14), while a 
normal serum did not adsorb out topo I or RNAP I, II or III (lanes 1-5). All sera that 
contained antibodies to topo I, irrespective of whether they also contained antibodies to 
RNAP, were unable to precipitate topo I from the topo I-depleted extract (lanes 6-12). 
In contrast, sera that contained antibodies to RNAP and topo I were able to precipitate 
RNAP subunits from the topo I-depleted extract with the same intensity as from the 
undepleted extract. These findings help confirm that anti-topo I antibodies and anti- 
RNAP antibodies exist separately, even when found in the same serum.
Immunoblotting of affinity purified autoantigens
The technique of using affinity purified autoantigens for IB studies was validated by the 
preliminary experiment using prototype anti-Ul RNP±Sm sera (Fig. 4.4, lanes 2-10). 
All U 1 RNP subunits were successfully immunoprecipitated, separated and transferred
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to nitro-cellulose (Fig. 4.4a). The subunit specificities of all anti-Ul RNP±Sm sera 
tested (Fig. 4.46) were consistent with results previously obtained on the same sera 
using whole-cell, or nuclear-enriched, K562-cell extracts (Dr Jean Whyte, pers.comm.). 
Results obtained with the two anti-Ul RNP sera from the present study are shown in 
Table 4.5, and on Fig. 4.46, lanes 6 and 7.
Autoradiographs of nitro-cellulose strips containing subunits from affinity purified 
RNAPs I, II and III are shown in Fig. 4.5a. Figure 4.56 shows the same strips after 
blotting with representative anti-RNAP sera. No serum recognized any of the RNAP I 
or III subunits, even those sera with anti-RNAP III or anti-RNAP I/III specificities 
(Table 4.2; Fig. 4.56, lanes 1 and 2). However, all sera with anti-RNAP II antibodies 
recognized the largest RNAP II subunit in its phosphorylated (IIo) form (Tables 4.2 and 
4.3; Fig. 4.5, lanes 3 and 5-8), including sera which had also precipitated topo I. In 
addition, the unphosphorylated subunit Ila was recognized by all sera which had 
precipitated RNAP IIA (Tables 4.2 and 4.3; Fig. 4.5, lanes 3, 5 and 6).
Where the nitro-cellulose strips contained affinity purified topo I and RNAP IIO 
(Fig. A.6a, c), all sera with the anti-topo I specificity recognized the 100-kDa topo I 
band (Table 4.3; Fig. 4.66, lanes 5, 6, 9 and 10). Again, all sera which precipitated one 
or both forms of RNAP II recognized the IIo subunit (Tables 4.2 and 4.3; Fig. 4.66, 
lanes 3-5, 9 and 10; Fig. A.6d, lanes 3, 5, 6 and 8).
An autoradiograph of one of the nitro-cellulose strips containing subunits from 
affinity purified RNAP III is shown in Fig. 4.1a. However, no RNAP III subunits were 
recognized by any of the sera containing anti-RNAP III antibodies included in 
subsequent blotting studies (Table 4.2; Fig. 4.76, lanes 2-4 and 9).
Immunofluorescence
The two sera containing only anti-RNAP III antibodies produced a characteristic fuzzy 
nuclear pattern (see previous Fig. 3.3a). Sera with either anti-RNAP I/III or anti-RNAP 
I/II/III antibody specificities produced a rather different pattern, with variable speckling 
of both nucleus and nucleolus (Fig. 4.8a-c, see also previous Figs 3.4a6 and 3.5a). 
Meanwhile, anti-topo I sera produced broadly similar IF patterns, regardless of whether 
or not they also precipitated RNAPs: a grainy nuclear speckle with prominent nucleolar 
staining was produced by such sera (Fig. 4.8d-g). However, several of the anti-topo 
I/Ro ± La sera produced distinctive nucleolar staining patterns (see previous Fig. 3.56).
Clinical associations of anti-RNA polymerase autoantibodies in systemic sclerosis 
Tables 4.6-4.8 show the clinical details of patients whose sera precipitated (i) RNAP 
III, (ii) topo I, Ro and/or La antigens, and (iii) Ku, U1 RNP and/or Jo-1 antigens, 
respectively, and these data are summarized in Table 4.9. The remaining individuals 
were made up of (iv) ACA-positive patients, (v) patients whose sera contained other 
defined specificities (mainly ANoA-positive patients), and (vi) patients in whose serum 
no defined autoantibody specificities have been detected to date (Tables 4.1 and 4.9).
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Clinical data from patients whose sera contained a particular individual antibody 
were compared with clinical data from patients in the corresponding remaining group 
(i.e. patients whose sera did not contain that particular antibody) (Table 4.9). 
Comparisons were also made between groups of sera with different antibody profiles 
(Table 4.9). Where appropriate, the solitary anti-RNAP I/II/III/topo I serum was 
excluded from these calculations, as it often fulfilled inclusion criteria for both 
comparison groups.
Disease subtype and cutaneous involvement
The occurrence of lc- versus dc-SSc in the different antibody groups can be compared 
on Table 4.9. The individual antibody which showed the most significant association 
with dc-SSc was anti-RNAP III (69.2%; c.f remaining group, 15.2%: PcO.OOl; relative 
risk (RR), 4.6), and anti-RNAPs I, IIO and IIA were also each associated with the 
development of diffuse disease (RNAP I, 70.8%, c.f. remainder, 15.7%: PcO.OOl, RR, 
4.5; RNAP IIO, 56.7%, c.f. remainder, 16.3%: P<0.001, RR, 3.5; RNAP IIA, 70.0%; 
c.f. remainder, 17.2%: PcO.OOl, RR, 4.1). Furthermore, patients with anti-RNAP I/II/III 
antibodies had the highest calculated incidence of diffuse skin involvement (84.6%; c.f. 
remaining group 18.3%, PcO.OOl; RR, 4.6). Although the anti-RNAP I/III group also 
showed an increased incidence of dc-SSc (50.0%), this was not significantly different 
from the remaining group (21.6%: 0.05<P<0.1).
The presence of ACAs was associated with lc-SSc (93.9%; c.f. remaining group, 
70.3%: P<0.005). A majority of anti-topo I sera (68.3%) also came from patients with 
lc-SSc, but this was not significantly different from the remaining patients (79.4%), 
regardless of the absence (70.8%) or presence (66.7%) of anti-RNAP II antibodies or 
anti-RNAP IIO antibodies (70.0%). However, when anti-topo I sera (30.0% dc-SSc 
excluding patient PB) were compared with the anti-RNAP I/II/III group, a highly 
significant difference was found (PcO.001). Furthermore, comparison of the anti-topo I 
group with the anti-ACA group also revealed a significant difference (P<0.005). 
Although the anti-topo I group was not significantly different from the anti-RNAP I/III 
group, upon combining all sera with anti-RNAP III antibodies (32.0% lc-SSc, 
excluding patient PB) and comparing with the anti-topo I-positive group, a significant 
difference was apparent (P<0.02). Together, these results indicate that the three 
antibody groups (i.e. sera containing anti-centromere, anti-topo I, and anti-RNAP III 
antibodies respectively) are significantly different from one another with regard to 
cutaneous manifestations.
All the remaining ANAs (anti-Ro, anti-La, anti-Jo-1 and anti-Ul RNP) had a higher 
than average occurrence of lc-SSc, though none was significant when compared with 
the respective remaining group.
When considering the associations of individual anti-RNAP antibodies with disease 
subtype, it was difficult to separate the influence of anti-RNAPs I and III since most 
anti-RNAP III sera also precipitated RNAP I. However, by comparing the anti-RNAP
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I/II/III group with the anti-RNAP I/III group, the effect of the additional presence of 
anti-RNAP II could be assessed. Also, the separate population of anti-RNAP II/topo I 
sera could be compared with those sera which precipitated topo I in the absence of any 
RNAPs. Thus, any clinical effects associated with the additional presence of anti- 
RNAP II antibodies could be calculated in two different contexts. Despite the higher 
prevalence of dc-SSc in anti-RNAP I/II/III sera compared with the anti-RNAP I/III 
group (84.6% vs. 50.0% respectively), however, the difference was not significant, and 
anti-topo I-positive patients had a similarly low incidence of dc-SSc, regardless of the 
additional presence of anti-RNAP II antibodies (29.2% vs. 33.3% respectively; N.S.).
Renal involvement
The incidence of renal involvement in each of the different antibody groups is shown 
on Table 4.9. The individual anti-RNAP antibody groups each had a higher than 
average incidence of kidney involvement, but none of these results was found to be 
significant. Furthermore, the anti-RNAP I/II/III group (28.6% with renal involvement) 
also failed to show a significantly increased frequency when compared with the 
remaining group (10.1%). The anti-RNAP I/III group actually had a lower than average 
incidence of renal involvement (10.0%). When anti-RNAP-III-positive sera were 
considered, there was no significant difference when compared with the remaining 
group. Furthermore, when all anti-RNAP sera of any type were considered, and 
compared with the remaining group, the difference did not reach significance (20.9% vs 
8.6%, respectively: 0.05<P<0.1). However, small numbers were involved.
The highest rate of kidney involvement occurred in sera with anti-La antibodies, and 
this was found to be a significant association (42.9%; c.f. remaining group, 10.3%: 
P<0.05; RR, 4.2). Furthermore, anti-Ro antibodies were also significantly associated 
with renal involvement (31.2%; c.f. remaining group, 9.6%: P<0.05; RR, 3.2)
A higher than average occurrence of kidney involvement was noted for anti-topo I, 
anti-Jo-1- and anti-Ul RNP-positive patients, though neither was significant when 
compared with the respective remaining group. The relatively low incidence of kidney 
involvement in the ACA group (1.8%) was, however, significantly different from the 
remaining group (15.7%: P<0.02), and this was similar to previous reports (261).
The anti-RNAP I/III-positive patients and the anti-RNAP I/II/III-positive patients 
were not significantly different when compared with each other, and the anti-RNAP 
II/topo I group was not significantly different when compared with sera containing anti- 
topo I antibodies in the absence of anti-RNAPs. However, the anti-topo I group and the 
ACA group were significantly different with respect to renal involvement (19.5% vs 
1.8%, respectively: PcO.Ol).
Antibody profiles with a lower than average incidence of kidney involvement 
included anti-Jo-1 antibodies occurring alone, anti-Ul RNP antibodies alone, anti- 
RNAP IIO/topo I sera, and sera which contained no identified autoantibodies: of
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patients in these four groups, none had kidney involvement. However, these results 
were not significant when compared with the respective remaining groups.
Pulmonary involvement
The incidence of pulmonary involvement in each of the different antibody groups is 
also shown on Table 4.9. Pulmonary involvement was associated with anti-topo I 
antibodies (70.7%; c.f. remaining group, 44.7%: P<0.005; RR, 1.6), and with anti-Ro 
antibodies (81.2%; c.f. remaining group: 47.6% P<0.025; RR, 1.7). Furthermore, a 
higher incidence of pulmonary involvement occurred in those anti-topo I-positive 
patients whose sera also precipitated the Ro antigen (80.0%) than in anti-topo I-positive 
patients who did not also have anti-Ro antibodies (67.7%), although the difference 
between the two groups was not significant. When patients with either anti-topo I 
and/or anti-Ro antibodies were compared with patients whose sera contained neither 
antibody, an even more significant association with pulmonary involvement was found 
(72.3% vs. 43.0%; PcO.OOl; RR, 1.7). The ACA group had a significantly reduced 
incidence of pulmonary involvement (36.4%; c.f. remaining group, 56.7%: P<0.02), 
confirming previous findings (261).
The incidence of pulmonary involvement was similar in anti-topo I patients 
regardless of the additional presence of anti-RNAP II antibodies (75.0% vs. 66.7%: 
N.S.). Although the incidence of lung involvement was higher in anti-RNAP I/II/III- 
positive patients than in anti-RNAP I/III-positive individuals (64.3% vs. 50.0%, 
respectively), the difference was not significant.
The ACA group and the anti-topo I group were shown to have a significantly 
different incidence of lung involvement (36.4% vs. 70.7%, respectively: P<0.001).
None of the other comparisons which were made yielded a significant result.
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TABLE 4.1 Relative frequencies of autoantibody specificities identified in the 
sera of SSc patients by radioimmunoprecipitation assays
No. of patients 
Antibody specificity* (n=210)
RNAP I 26 (12.4)
RNAP IIO 34 (16.2)
RNAP IIA 24 (11.4)
RNAP m 28 (13.3)




U1 RNP±Sm 13 (6.2)
Ku 1 (0.5)
CENPst 55 (26.2)
Other defined8 20 (9.5)
None detected! 37 (17.6)
Figures in parentheses are percentages 
*Some sera had multiple antibody specificities
tDetermined by immunoblotting and/or immunofluorescence (some anti­
centromere (ACA) data was provided by other members of this laboratory)
8 Sera precipitating Th RNP, U3 RNP, Pm-Scl and/or PL-7 
TThis group is likely to be enriched with sera containing undetected ACAs 
and anti-nucleolar antibodies (see text)
RNAP, RNA polymerase; topo I, topoisomerase I; CENPs, centromere proteins
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TABLE 4.2 Profile of autoantibody reactivities in SSc sera found to contain anti-
RNA polymerase III antibodies





O ther defined Autoreactive 
AAbs* subunits by IB1
DG F dc-SSc III Negative
YB F lc-SSc m - - Negative
GM F lc-SSc i, m - - Negative
LC F lc-SSc i ,m - - Negative
MY F dc-SSc i, h i - - Negative
JHa F lc-SSc, Pm i ,m - - ND
JBe F lc-SSc i, h i - - ND
EF M lc-SSc i, h i - - ND
MB F dc-SSc i, h i - - ND
JV F dc-SSc i, h i - - ND
EB F dc-SSc i ,m - - ND
IL M dc-SSc i ,m - - ND
NW F dc-SSc, MCTD i, n o , i ia , m - - Bo (wk)
PBi F lc-SSc I, IIO, IIA, III - - Bo, Iia
ML F dc-SSc I, IIO, IIA, III - - Bo, Iia
JN F dc-SSc I, IIO, HA, m - - Bo, Ba
VP F dc-SSc, OA i, n o ,  i ia , m - - ND
LD F SSc I, IIO, BA, III - - ND
WO M dc-SSc, OA I, IIO, IIA, III - - ND
MRJ F dc-SSc i, 110, i ia ,  m - - ND
EMc F lc-SSc i, 110, i ia ,  m - - ND
WB F dc-SSc I, IIO, IIA, III - - ND
JMn F dc-SSc i, 110, i ia ,  m - - ND
JR F SSc-ss, SS, vase I, IIO, HA, m - - ND
WW F dc-SSc i, 110, i ia ,  m - - ND
MAn F dc-SSc i, n o ,  i ia , m - - ND
MCu F dc-SSc I, IIO, HA, III - - ND
PBu M dc-SSc I, IIO, BA, IB topo lt§ - Bo, 11a (wk), topo I
♦Detected by radioimmunoprecipitation 
t  also identified by immunodiffusion
§ independently tested and confirmed positive for topoisomerase I (topo I) in functional inhibition assay 
by Dr J. Whyte (see text)
^sera were tested against immunoblotting (IB) strips containing affinity purified, SDS-PAGE-separated 
RNAPs I, II and III, and against strips containing RNAP IIO and topo I
RNAP, RNA polymerase; AAbs, autoantibodies; dc-SSc, diffuse cutaneous SSc; lc-SSc, limited 
cutaneous SSc; Pm, polymyositis; MCTD, mixed connective tissue disease; OA, osteoarthritis; SSc-ss, 
SSc sine scleroderma; SS, Sjogren's syndrome; vase., vasculitis; ND, not done; wk, weak reactivity
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TABLE 4.3 Profile of autoantibody reactivities in SSc sera found to contain anti-
topoisomerase I antibodies





O ther defined Autoreactive 
AAbs* subunits by IB*
PBu M dc-SSc I, IIO, IIA, III topo t§ IIo, na(wk), topo I
ZK F lc-SSc IIO, IIA topo t§ R ot, La IIo, Iia, topo I
For M Si-lc-SSc IIO, IIA topo t§ Rot Ho, Ha, topo I
MW F SSc n o , IIA topo Ro IIo, Iia, topo I
LE F dc-SSc n o , IIA topo t§ - no, Iia, topo I
DS M lc-SSc IIO, IIA topo t§ - Ho (wk), topo I
RO F SSc 110, nA topo - ND
DJe M dc-SSc, MCTD n o , iia topo - ND
VS F lc-SSc IIO, IIA topo - ND
IC F lc-SSc IIO topo Ro IIo, topo I
AWS F dc-SSc, OP n o topo Ro Ho, topo I
JBa F lc-SSc, myositis IIO topo t§ Jo -It IIo, topo I
AC M lc-SSc IIO topo t§ - IIo, topo I
JP F lc-SSc IIO topo t§ - IIo, topo I
JWi F lc-SSc IIO topo t - IIo, topo I
JHw F dc-SSc IIO topo t§ - ND
MP F lc-SSc, MCTD n o topo - ND
CH M dc-SSc, myositis n o topo - ND
ES F lc-SSc n o topo - ND
TB M dc-SSc topo t§ R ot, L at ND
CFo F lc-SSc - topo Ro, La ND
EMi F lc-SSc - topo t Ro, Jo -it ND
Ble M Si-dc-SSc - topo t§ R ot ND
AG M lc-SSc, MCTD - topo t Ro ND
PS F lc-SSc - topo t§ Ro ND
ET F dc-SSc, MCTD - topo t U1 RNP±Sm ND
HC F lc-SSc, RA, MCTD - topo t - topo I
JWa F dc-SSc - topo t§ - ND
Her M Si-lc-SSc - topo t§ - ND
SW F lc-SSc - topo t§ - ND
Koe M Si-lc-SSc - topo t§ - ND
Mat M Si-lc-SSc - topo t§ - ND
Kuc M Si-lc-SSc - topo t§ - ND
Sch M Si-dc-SSc - topo t§ - ND
Spi M Si-dc-SSc - topo t§ - ND
Zor M Si-lc-SSc - topo t§ - ND
MO F lc-SSc - topo t - ND
OR F lc-SSc, SS, Pm/Dm - topo t - ND
MS M lc-SSc - topo t - ND
MCg F lc-SSc - topo t - ND
JeC F dc-SSc - topo t - ND
CFr F lc-SSc - topo t - ND
RH M lc-SSc, RA - topo - ND
MRm F SSc - topo - ND
♦Detected by radioimmunoprecipitation; t  also identified by immunodiffusion
§ independently tested and confirmed positive for topoisomerase I (topo I) in functional inhibition assay 
by Dr J. Whyte (see text)
*sera were tested against immunoblotting (IB) strips containing affinity purified, SDS-PAGE-separated 
RNAPs I, II and III, and against strips containing RNAP IIO and topo I
RNAP, RNA polymerase; AAbs, autoantibodies; dc-SSc, diffuse cutaneous SSc; lc-SSc, limited 
cutaneous SSc; Si-SSc, silica-associated SSc; MCTD, mixed connective tissue disease; OP, osteoporosis; 
RA, rheumatoid arthritis; SS, Sjogren's syndrome; Pm, polymyositis; Dm, dermatomyositis; wk, weak 
reactivity; ND, not done
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TABLE 4.4 Profile of autoantibody reactivities in SSc sera found to contain anti-
Ro and/or anti-La antibodies









ZK F lc-SSc IIO, IIA topo It§ Rot, La IIo, Iia, topo I
For M Si-lc-SSc IIO, IIA topo It§ Rot IIo, Iia, topo I
MW F SSc IIO, IIA topo I Ro IIo, Iia, topo I
IC F lc-SSc IIO topo I Ro IIo, topo I
AWS F dc-SSc, OP IIO topo I Ro IIo, topo I
TB M dc-SSc - topo Its R ot, Lat ND
CFo F lc-SSc - topo I Ro, La ND
EMi F lc-SSc - topo I t Ro, Jo -it ND
Ble M Si-dc-SSc - topo Its Rot ND
AG M lc-SSc, MCTD - topo I t Ro ND
PS F lc-SSc - topo Its Ro ND
AF F lc-SSc, SS, RA - - R ot, L at, Pm-Sclt ND
FS M lc-SSc - - R ot, L at, U3RNP ND
DA F lc-SSc, SS, Pm, RA - - Ro, La, Jo-1, U1 RNP±Sm ND
MN F SSc - - Ro, La ND
DJo M SSc - - Ro, La ND
HW F lc-SSc, MCTD, vase. - - R ot, U1 RNPt ND
RS M lc-SSc - - Rot ND
JL F SSc - - Ro ND
JHd F lc-SSc - - Ro ND
LN F SSc, SS - - Ro ND
DP F SSc - - Ro ND
PH F lc-SSc, RA, OP, vase. - - L at, Pm-Sclt ND
♦Detected by radioimmunoprecipitation 
t  also identified by immunodiffusion
§ independently tested and confirmed positive for topoisomerase I (topo I) in functional inhibition assay 
by Dr J. Whyte (see text)
Isera were tested against immunoblotting (IB) strips containing affinity purified, SDS-PAGE-separated 
RNAPs I, II and III, and against strips containing RNAP IIO and topo I
RNAP, RNA polymerase; AAbs, autoantibodies; lc-SSc, limited cutaneous SSc; dc-SSc, diffuse 
cutaneous SSc; Si-SSc, silica-associated SSc; OP, osteoporosis; MCTD, mixed connective tissue disease; 
SS, Sjogren's syndrome; RA, rheumatoid arthritis; Pm, polymyositis; vase., vasculitis; ND, not done
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TABLE 4.5 Profile of autoantibody reactivities in SSc sera found to contain anti-










PHod F lc-SSc, MCTD, RA - Jo -lt ND
HeDa F dc-SSc - Jo-It ND
ViRi F lc-SSc, RA - Jo -lt ND
VPr F lc-SSc - Jo -lt ND
DaGa F lc-SSc, RA - Jo -lt (wk) ND
FILe F lc-SSc, Pm - Jo-1 ND
ElWh F SSc - Jo-1 ND
JBa F lc-SSc, myositis IIO topo It§ Jo -lt IIo, topo I
EMi F lc-SSc topo I t Ro, Jo -lt ND
JoGo F lc-SSc, SLE, Pm - Jo -lt , U1 RNpt, Sm t 68K, A, B/B'#
DA F lc-SSc, SS, Pm, RA - - Ro, La, Jo-1, U1 RNP±Sm ND
HW F lc-SSc, MCTD, vase. - - Rot, U1 RNPt ND
JBr F lc-SSc - U1 RNPt ND
HeDe F lc-SSc, morphea - U1 RNPt ND
BaHe F lc-SSc - U1 RNPt 68K, A#
JHal F lc-SSc - U1 RNPt ND
EvTu F dc-SSc, MCTD topo I t U1 RNP ± Sm ND
HiHa F SSc - U1 RNP± Sm ND
MaBr F lc-SSc, MCTD - U1 RNP ± Sm ND
RiCh M SSc - U1 RNP ± Sm ND
ADe F dc-SSc - U1 RNP ± Sm ND
KrWo F lc-SSc - U1 RNP ± Sm ND
CMod F lc-SSc - Ku ND
♦Detected by radioimmunoprecipitation; talso identified by immunodiffusion
§ independently tested and confirmed positive for topoisomerase I (topo I) in functional inhibition assay 
by Dr J. Whyte (see text)
isera were tested against immunoblotting (IB) strips containing affinity purified, SDS-PAGE-separated 
RNAPs I, II and III, and against strips containing RNAP IIO and topo I, or against strips containing U1 
RNP subunits, as applicable 
#subunits of the U1 RNP particle
RNAP, RNA polymerase; AAbs, autoantibodies; lc-SSc, limited cutaneous SSc; dc-SSc, diffuse 
cutaneous SSc; SLE, systemic lupus erythematosus; Pm, polymyositis; SS, Sjogren's syndrome; RA, 
rheumatoid arthritis; MCTD, mixed connective tissue disease; vase., vasculitis; wk, weak reactivity; ND, 
not done
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TABLE 4.6 Clinical details of SSc patients whose sera were found to
contain anti-RNA polymerase III antibodies
Organ
Autoantibodies detected involvem en tt
P a t . RNAPs Topo I Others
D isease
sub type^ Kidney Lung
DG m D(3) No No
YB m - - L ( l) Yes No
GM i, in - - L (1) No No
LC i, h i - - L (1) No No
MY i, in - - D (3) No Yes (1)
JHa i, in - - L (2) No No
JBe i, h i - - L No No
EF i, in - L(2) No . Yes (2)
MB i ,m - - D(3) No Yes (1)
JV i ,m - - D(3) No Yes (2)
EB i, in - - D(3) No Yes (1)
IL i, in - - D(3) Yes (4) No
NW i, n o ,  i ia , m - - D(3) Yes No
PBi i, n o ,  i ia , m - - L (1) No No
ML i, n o ,  i ia , h i - - D(3) No Yes (2)
JN i, n o ,  i ia , m - - D (3) No Yes (2)
VP I, n o ,  IIA, III - - D (3) Yes (1) Yes (1)
WO I, IIO, IIA, III - - D(3) No Yes (2)
MRJ i, n o ,  i ia , m - - D(3) No Yes (2)
EMc i, n o ,  i ia , h i - - L (2) Yes No
WB i, n o ,  i ia , m - - D (3) No No
JMn I, n o ,  IIA, III - - D (3) No Yes (1)
JR i, n o ,  i ia , h i - - S(0) No No
WW i, n o ,  i ia , m - - D(3) Yes Yes (1)
MAn i, n o ,  i ia , m - - D(3) No Yes (1)
MCu I, n o ,  IIA, III - - D (3) No Yes (2)
PBu i, no, iia , m topo I - D (3) No Yes (2)
♦for details, see text
tfor details of organ involvement definitions, see text; for details of organ 
involvement severity scoring systems, see Appendix I 
Pat., Patient; RNAPs, RNA polymerases; topo I, topoisomerase I; D, 
diffuse cutaneous SSc; L, limited cutaneous SSc; S, SSc sine scleroderma
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TABLE 4.7 Clinical details of SSc patients whose sera were found to
contain anti-topoisomerase I, anti-Ro and/or anti-La antibodies
O rgan
A utoantibodies detected in vo lvem en t?
P a t . RNAPs Topo I Others
D isease
sub type* Kidney Lung
PBu I, IIO, IIA, m topo I D (3) No Yes (2)
ZK n o , DA topo I Ro, La L No Yes (1)
For n o , iia topo I Ro L No Yes
LE n o , HA topo I - D O ) No No
DS n o , iia topo I - L (2) No No
DJe n o ,n A topo I - D O ) No Yes (1)
VS n o , HA topo I - L (2) Yes Yes
IC n o topo I Ro L (2) No No
AWS n o topo I Ro D O ) Yes Yes (1)
JBa n o topo I Jo-1 L (1) No Yes (1)
AC n o topo I - L No Yes (1)
JP n o topo I - L (2) No Yes
JWi n o topo I - L (1) No No
JHw n o topo I - D (3) No No
MP n o topo I - L (1) No Yes (2)
CH n o topo I - D (3) Yes Yes (2)
ES n o topo I - L (1) No No
TB - topo I Ro, La D (3) No Yes (2)
CFo - topo I Ro, La L ( l) No No
EMi topo I Ro, Jo-1 L ( l) Yes (1) Yes (1)
Ble - topo I Ro D (3) Yes Yes
AG - topo I Ro L (1) No Yes (1)
PS - topo I Ro L No Yes (2)
ET - topo I U1 RNP±Sm D (3) No Yes (1)
HC - topo I - L (2) Yes (1) Yes (2)
JWa - topo I - D(3) No Yes (2)
Her - topo I - L No Yes
SW - topo I - L No No
Koe - topo I - L No Yes
Mat - topo I - L No Yes
Kuc - topo I - L No Yes
Sch - topo I - D(3) No Yes
Spi - topo I - D (3) No Yes
Zor - topo I - L No Yes
MO - topo I - L (2) Yes (2) No
OR - topo I - L (2) Yes (1) Yes (3)
MS - topo I - L No No
MCg - topo I - L No Yes (2)
JeC - topo I - D(3) No Yes (3)
CFr - topo I - L (1) No No
RH - topo I - L (1) No No
AF - - Ro, La, Pm-Scl L (1) Yes (1) Yes (2)
FS - - Ro, La, U3 RNP L (2) No Yes (1)
DA - - Ro,La,Jo-l,
U1 RNP±Sm
L (2) Yes (1) Yes (2)
HW - - Ro, U1 RNP L (2) No Yes (2)
RS - - Ro L (1) No No
JHd - - Ro, La L No Yes (2)
PH - - La, Pm-Scl L (2) Yes (1) Yes (2)
*for details, see text
tfor details of organ involvement definitions, see text; for details of organ involvement 
severity scoring systems, see Appendix I
Pat., Patient; RNAPs, RNA polymerases; topo I, topoisomerase I; D, diffuse 
cutaneous SSc; L, limited cutaneous SSc
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TABLE 4.8 Clinical details of SSc patients whose sera were found to
contain anti-Ku, anti-Ul RNP and/or anti-Jo-1 antibodies
Organ
Autoantibodies detected in v o lv em en tt
P a t .  RNAPs Topo I Others
D isease
subtype* Kidney Lung
PHod - Jo -It L (2) No No
HeDa - - Jo -It D (3) No Yes (++)
ViRi - - Jo -lt L (1) No Yes (2)
VPr - - Jo -It L No Yes (++)
DaGa - - Jo -lt L (1) No No
FILe - - Jo-1 L ( l) No Yes
JBa HO topo It§ Jo -lt L (1) No Yes (1)
EMi - topo I t Ro, J o -lt L (1) Yes (1) Yes (1)
JoGo - - U1 RNPt, 
Sm t J o - l t
L (1) No No
DA - - Ro, La, Jo-1 
U1 RNP±Sm
L (2) Yes (1) Yes (2)
HW - - R ot.U l RNPt L (2) No Yes (2)
JBr - - U1 RNPt L No No
HeDe - - U1 RNPt L (2) No No
BaHe - - U1 RNPt L No Yes.(++)
JHal - - U1 RNPt L No No
EvTu - topo It U1 RNP±Sm D(3) No Yes (1)
MaBr - - U1 RNP± Sm L ( l) No No
ADe - - U1 RNP±Sm D (3) No Yes (++)
KrWo - - U1 RNP±Sm L (2) No No
CMod - - Ku L No Yes (++)
♦for details, see text
tfor details of organ involvement definitions, see text; for details of organ involvement 
severity scoring systems, see Appendix I
Pat., Patient; RNAPs, RNA polymerases; topo I, topoisomerase I; D, diffuse cutaneous SSc; 
L, limited cutaneous SSc; NR, not recorded
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t a b l e  4.9 Clinical associations of defined autoantibodies detected in the sera of
SSc patients
Disease s u b t y p e t  Organ involvement^
n rfl Limited Diffuse nl Kidney nl Lung
Individual
antibodies**
RNAP I 26 24 7 (29.2) 17 (70.8)*5 25 5 (20.0) 25 15 (60.0)
RNAP n o 34 30 13 (43.3) 17 (56.7)*5 31 7 (22.6) 31 20 (64.5)
RNAP IIA 24 20 6 (30.0) 14 (70.0)*5 21 5 (23.8) 21 14 (66.7)
RNAP IIIA 28 26 8 (30.8) 18 (69.2)*5/*8 27 6 (22.2) 27 15 (55.6)
Topo IA 44 41 28 (68.3)*10/*n 13 ( 3 1  7 )* 8/*9 41 8 (19.5)*7 41 29 (70.7)*4/*12
Ro 22 16 13 (81.2) 3 (18.8) 16 5 (31.2)*1 16 13 (81.2)*2
La 9 7 6 (85.7) 1 (14.3) 7 3 (42.9)*1 7 6 (85.7)
Jo-1 11 10 9 (90.0) 1 (10.0) 10 2 (20.0) 10 7 (70.0)
U1 RNP (± Sm) 13 11 9 (81.8) 2 (18.2) 11 1 (9.1) 11 5 (45.5)
CENPs 55 49 46 (93 9)*4/*10 3 (6.1) 55 1 (1.8)*3/*7 55 20 (36.4)*3/*12
Other defined# 21 19 15 (78.9) 4 (21.1) 19 4 (21.1) 19 13 (68.4)
Antibody profiles
None identified 37 23 21 (91.3) 2 (8.7) 23 1 (4.3) 23 7 (30.1)
RNAP I+III 10 10 5 (50.0) 5 (50.0) 10 1 (10.0) 10 5 (50.0)
RNAP I+n+IIIA 15 13 2 (15.4)*n/*13 11 (84.6)*5/*6 14 4 (28.6) 14 9 (64.3)
RNAP I ± II + IIIA 25 23 7 (30.4) 16 (69.6 )*5/*9 24 5 (20.8) 24 14 (58.3)
topo I - RNAPs 25 24 17 (70.8)*13 7 (29.2) 24 5 (20.8) 24 18 (75.0)*3
topo I+RNAPIIO- IIAA 10 10 7 (70.0) 3 (30.0) 10 2 (20.0) 10 6 (60.0)
topo I+RNAPIIA 8 6 4 (66.7) 2 (33.3) 6 1 (16.7) 6 4 (66.7)
topo I+RNAPIIO±IIAA 18 16 11 (68.8) 5 (31.2)*6 16 3 (18.8) 16 10 (62.5)
topo I - Ro 33 31 21 (67.7) 10 (30.0) 31 5 (16.1) 31 21 (67.7)*1
topo I + Ro 11 10 7 (70.0) 3 (30.0) 10 3 (30.0) 10 8 (80.0)
Ro - topo I 11 6 6 (100.0) 0 (0.0) 6 2 (33.3) 6 5 (83.3)
topo I and/or Ro 55 47 34 (72.3) 13 (27.7) 47 10 (21.3) 47 34 (72.3)*5
Jo-1 alone 7 6 5 (83.3) 1 (16.7) 6 0 (0.0) 6 4 (66.7)
U1 RNP (± Sm) alone 9 7 6 (85.7) 1 (14.3) 7 0 (0.0) 7 2 (28.6)
Total 210 177 136 (76.8) 41 (23.2) 182 21 (11.5) 182 92 (50.5)
Figures in parentheses are percentages
*lP<0.05; *2P<0.025; *3P<0.02; *4P<0.005; *5P<0.001 when compared with the respective remaining group 
*6P<0.02 when compared with each other;*7P<0.01 when compared with each other;*8P<0.01 when compared with 
each other; 9P<0.01 when compared with each other; *10i><0.005 when compared with each other;*1 *P<0.001 when 
compared with each other;* 12P<0.001 when compared with each other;* 13P<0.001 when compared with each other (all 
comparisons by X2-test with Yates' correction where appropriate)
**Some sera had multiple antibody specificities 
tfor details, see text
5 for organ involvement definitions, see text
* total numbers of patients on whom this category of clinical information was available
# Ku, Th RNP, U3 RNP, Pm-Scl and/or PL-7
A Where appropriate, data relating to patient PB (anti-RNAP I/n/m/topo I) were excluded from comparisons 
A Excluding patient PB (anti-RNAP I/H/III/topo I)
RNAP, RNA polymerase; Topo I, topoisomerase I; CENPs, centromere proteins
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(a)
FIGURE 4.1 Radioimmunoprecipitation: identification of anti-RNA polymerase 
(RNAP) antibodies and anti-topoisomerase I (topo I) antibodies in sera from SSc 
patients, (a) Three main groups of sera were detected: sera precipitating RNAPs I and 
III (lane 3), sera precipitating RNAPs I, II and III (lane 4), and sera precipitating both 
topo I and the phosphorylated (IIO) form of RNAP II (lanes 5 and 6). Some sera in the 
third group also precipitated the unphosphorylated (IIA) form of RNAP II (lane 5). The 
characteristic large subunits of RNAP II are indicated: subunit lie occurs in both forms 
of RNAP II, while the phosphorylated subunit Ho is unique to RNAP IIO, and the 
unphosphorylated subunit Iia is only found in RNAP IIA. A normal human serum (NS) 
and an anti-topo I serum are shown for comparison in lanes 1 and 7 respectively. A 
serum which precipitated only RNAP III is shown in lane 2 (the additional band seen at 
210 kDa was later shown to be distinct from subunit Iia (see b)). (Continued overleaf...)
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(b)
FIGURE 4.1 (cont.) Radioimmunoprecipitation: identification of anti-RNAP 
antibodies and anti-topo I antibodies in sera from SSc patients. (b) Samples found 
to have unusual RNAP specificities were then run on an 8% SDS-polyacrylamide gel to 
verify molecular weights. The large subunits of all three RNAPs are indicated. Two 
sera precipitated only RNAP III (lane 2) and one serum precipitated RNAPs I, II 
(weakly, but verified upon longer autoradiograph exposures), III and topo I (lane 8). 
The serum in lane 5 is representative of the eight sera found to precipitate RNAP II and 
topo I, while lane 6 represents one of the ten sera precipitating RNAP IIO and topo I. 
Antibodies to Ro were also detected in some of these sera (a, lane 5; b, lane 5). 
Comparisons were made with sera of the following specificities: normal human serum 
(NS, lanes 1 and 10), anti-RNAP I/III (lane 3), anti-RNAP I/II/III (lanes 4 and 9), and 
anti-topo I (lane 7).
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FIGURE 4.2 Radioimmunoprecipitation: Co-precipitation of RNA polymerases 
(RNAPs) and antinuclear antigens by sera from SSc patients. Sera precipitating 
RNAP III, sera precipitating RNAPs I and III, and sera precipitating RNAPs I, II and III 
(lane 5) did not co-precipitate other antinuclear antigens. Meanwhile, sera which 
precipitated RNAP IIO (± IIA) in the absence of RNAPs I and III were often found to 
precipitate topo I (lanes 3 and 4). Anti-topo I sera frequently also precipitated the Ro 
autoantigen, regardless of the additional presence or absence of anti-RNAP IIO (± IIA) 
antibodies (lanes 4 and 1 respectively). Lane 2, normal serum (NS).
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(a)
FIGURE 4.3 Radioimmunoprecipitation of RNA polymerases (RNAPs) by sera 
from SSc patients using a K562-cell extract precleared of topoisomerase I (topo I).
A batch of radiolabelled K562-cell extract was specially prepared, and divided into two 
lots, (a) Several sera previously found to precipitate topo I and/or RNAPs were then 
included in immunoprecipitation (IP) assays using the first lot of whole extract. 
(Continued overleaf...)
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Control extract Topo I - depleted extract
(b)
FIGURE 4 .3  (icont.) Radioimmunoprecipitation of RNAPs by sera from SSc 
patients using a K562-cell extract precleared of topo I. (b) The second lot of whole­
cell extract was depleted of topo I twice: the topo I band is present in the whole extract 
(lane 14), reduced in the semi-depleted extract (*), and absent from the topo I-depleted 
extract (lanes 6-12). A control sample of whole extract was "depleted" in the same way 
using NS (lanes 1-5), and was shown to contain both topo I (lane 4) and all three 
RNAPs (lane 5). Representative sera which precipitated topo I and/or RNAP from the 
whole extract (a) were then included in IP assays using the topo I-depleted fraction of 
extract (lanes 6-12). Topoisomerase I was no longer precipitated by sera with anti-topo 
I reactivity (lanes 7-9, 11 and 12). However, all RNAP subunits seen with the whole 
extract were still present (lanes 8-11). The same normal human serum (NS) and the 
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FIGURE 4.4 Immunoblotting: affinity purified radiolabelled U1 RNP subunits 
recognized by prototype sera containing anti-Ul RNP ±-Sm antibodies. (a) U1 RNP
was affinity purified by radioimmunoprecipitation using a prototype anti-Ul RNP 
serum, (b) Following separation of constituent subunits by SDS-PAGE and their 
transfer to nitrocellulose, immunoblotting was carried out using prototype anti-Ul 
RNP±Sm sera of known specificities. Subsequent autoradiography revealed all U1 RNP 
subunits (A, B/B', C, D, E, F, G and the 68-kDa subunit) to be present (a, lanes 1-11). 
The subunit specificities of all prototype anti-Ul RNP±Sm sera (b, lanes 2, 5-7 and 8- 
10) were consistent with results previously obtained by immunoblotting studies using 
whole-cell K562 extracts. These included sera from two patients in the present study 
(patients JoGo and BaHe: lanes 6 and 7, respectively). The 68-kDa subunit was 
recognized by samples on lanes 4-10; subunit A was recognized by samples on lanes 2- 
10; subunits B and B' were recognized by samples in lanes 3, 6, 9 and 10; subunit C 
was recognized by samples in lanes 4, 5, 8 and 10, while subunit D was recognized by 
the sample shown in lane 3. Only background staining was observed on strips incubated 
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FIGURE 4.5 Immunoblotting: affinity purified, radiolabelled RNA polymerase 
(RNAP) subunits recognized by sera from SSc patients containing anti-RNAP 
antibodies, (a) The three classes of RNAP were affinity purified by 
radioimmunoprecipitation using a prototype anti-RNAP I/II/III serum. Subsequent 
autoradiography revealed all subunits of RNAPs I, II and III to be present. (b) 
Following separation of constituent subunits by SDS-PAGE and their transfer to 
nitrocellulose, immunoblotting was carried out using the test sera. Subsequent 
autoradiography of blots revealed all RNAP subunits to be present (a, lanes 1-9). All 
sera with anti-RNAP II (O and A) or anti-RNAP IIO specificities recognized the IIo 
subunit (b, lanes 3 and 5-8), while subunit Iia was recognized only by sera which had 
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FIGURE 4.6 Immunoblotting: affinity purified radiolabelled topoisomerase I 
(topo I) and RNA polymerase (RNAP) IIO subunits recognized by sera from SSc 
patients containing anti-topo I and/or anti-RNAP IIO antibodies, (a) and (c) The
topo I and RNAP IIO were affinity purified by radioimmunoprecipitation using a 
prototype anti-RNAP IIO/topo I serum. (b) and (d) Following separation of constituent 
polypeptides by SDS-PAGE and their transfer to nitrocellulose, immunoblotting was 
carried out using the test sera. The two largest subunits of RNAP-IIO and the 100-kDa 
topo I polypeptides are verified to be present on nitrocellulose by autoradiography (a, 
lanes 1-11; c , lanes 1-8). (b) and (d) All anti-topo I sera, including those with anti- 
RNAP specificities, recognized the 100-kDa topo I band (b , lanes 5, 6, 9 and 10; d, 
lanes 3, 5, 6 and 8)). Sera with anti-RNAP II or anti-RNAP IIO antibodies recognized 
the IIo subunit of RNAP IIO, regardless of whether they also had anti-topo I antibodies 















FIGURE 4.6 (cont.) Immunoblotting: affinity purified radiolabelled topo I and 
RNAP IIO subunits recognized by sera from SSc patients containing anti-topo I 

























5 anti-RNAP II/topo I
6 anti-RNAP II/topo I
7 anti-RNAP IIO/topo I
8 anti-RNAP IIO/topo I
9 anti-RNAP I/II/III/topo I
10 anti-topo I
11 anti-U3 RNP
FIGURE 4 .7  Immunoblotting: affinity purified radiolabelled RNA polymerase 
(RNAP) III subunits recognized by sera from SSc patients containing anti-RNAP 
III antibodies, (a) RNAP III was affinity purified by radioimmunoprecipitation using 
an anti-RNAP III serum. (b) Following separation of constituent subunits by SDS- 
PAGE and their transfer to nitrocellulose, immunoblotting was carried out using the test 
sera. Subsequent autoradiography of blots revealed all RNAP III subunits to be present 
(a, lanes 1-11). However, no serum with anti-RNAP III antibodies recognized any of 
the RNAP III subunits (b, lanes 2-4 and 9). Sera containing antibodies to RNAP IIO, 
RNAP IIA and/or topo I also gave a negative result (lanes 5-8). A normal serum and an 
anti-U3 RNP serum are included for comparison in lanes 1 and 11 respectively.
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FIGURE 4.8 Indirect immunofluorescence patterns produced by sera from SSc 
patients which immunoprecipitated topoisomerase I and/or one or more RNA 
polymerase enzyme, (a) Serum EB, which precipitated RNA polymerases (RNAPs) I 
and III, produced a strong homogeneous nuclear pattern by indirect 
immunofluorescence (IF). However, IF patterns produced by anti-RNAP I/III sera were 
found to vary significantly from serum to serum (c/ Fig.3.4a). (b) Serum ML, which 
precipitated RNAPs I, II and III, produced a discrete speckled nuclear pattern by IF. (c) 
Meanwhile, a different anti-RNAP I/II/III serum (JMn) produced a homogeneous/fine 
speckled nuclear pattern, though nucleoli were distinguishable in some cells. 
(c.f also Figs 3.4b and 3.5a). (d) The typical diffuse grainy speckled nuclear pattern 
with prominent nucleolar staining produced by anti-topoisomerase I (topo I) serum JeC: 
no RNA polymerases were immunoprecipitated by this serum. Patterns produced by 
sera from (e) anti-RNAP IIO/topo I, (/) anti-RNAPII/topo I and (g) anti-RNAP 
I/II/III/topo I sera (JP, Fo and PBu, respectively) were similar to that of the prototype 
anti-topo I serum. Patterns produced by sera with anti-RNAP III and anti-topo I/Ro/La 
specificities have been shown previously (see Figs 3.3a and 3.5b, respectively).
4.4 DISCUSSION
Prevalences of anti-RNAP antibodies, anti-topo I antibodies, and other anti­
nuclear antibodies in SSc patients
In the present study, a total of 26 sera from 210 SSc patients (12%) were found to 
precipitate both RNAPs I and III. Thus, these results are in general agreement with 
previous findings in this area (36,144,183,185,255). The detection of anti-topo I 
antibodies in 44 (21%) SSc patients also compared well with previous data 
(36,52,53,327,357), and, furthermore, the incidences of anti-centromere, anti-Jo-1, and 
anti-Ul RNP antibodies reported here were also compatible with previous reports 
(20,36,52,53,143,177,202,261,343). Meanwhile, the frequency of anti-Ro antibodies 
(22; 10%) was higher than recently found in SSc patients by Bunn et a l (5%) (36). 
However, in addition to the method of immunodiffusion, we have included anti-Ro 
antibodies detected by the more sensitive technique of IP. Fujimoto et a l  (104) have 
detected anti-Ro antibodies in 11% of SSc patients by immunodiffusion. Furthermore, 
using a sensitive ELISA technique, anti-Ro antibodies have been reported to occur in 
37% of SSc patients by Bell et a l (17).
Subgroups of anti-RNAP antibodies were similar to those which have been reported 
before (36,144,183,255), i.e. a very small group with anti-RNAP III antibodies alone 
(in the present study, 2 (1%)), a larger group with anti-RNAP I/III antibodies (10; 5%), 
and a group capable of precipitating all three RNAPs (6 ; 8 %). The additional detection 
of sera with antibodies which precipitated both RNAP IIO and topo I in the absence of 
RNAPs I and III (as found by Satoh et a l (299)) is discussed below.
Co-precipitation of autoantigens by SSc sera
Co-precipitation o f RNA polymerases and topoisomerase I
Results presented here confirm the association of anti-RNAP IIO and anti-topo I 
antibodies in SSc, and extend the findings of Satoh et a l  (299) to include Caucasian 
patients. The prevalence of sera with the anti-RNAP IIO/topo I antibody specificity 
found in Japanese SSc patients was 20%, while only 19 (9%) of the Caucasian SSc sera 
reported here were shown to co-precipitate RNAP IIO and topo I. However, when the 
data presented by Satoh et a l (299) are re-examined, and adjusted to include all SSc 
sera tested, regardless of race, then the figure of 1 2 % is comparable with the present 
study. Why the incidence of anti-RNAP IIO/topo I antibodies should be skewed 
towards Japanese individuals in this way may have been a consequence of the small 
numbers involved in the study of Satoh et a l (299). Alternatively, genuine differences 
may exist between the two racial groups concerning anti-RNAP antibody expression. 
Racial differences in the incidence of particular autoantibodies have been reported 
before (6,189,228,280). A subsequent publication by the same group (297), however,
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confirmed our original finding of sera with anti-RNAP IIO/topo I specificities in 
Caucasian SSc patients (126).
A further group of nine sera (4%) with autoantibodies to both forms of RNAP II, as 
well as to anti-topo I antibodies, has been identified in the present Caucasian group. As 
with the anti-RNAP IIO/topo I specificity, the majority of anti-RNAP II/topo I sera did 
not co-precipitate RNAPs I or III. The discrepancy between our study (126) and that of 
Satoh et al. (298,299) regarding the co-precipitation of RNAP IIA along with topo I and 
RNAP IIO in a minority (44%) of our anti-topo I/RNAP IIO sera was also resolved by 
their subsequent publication (297), which confirmed the existence of SSc sera with 
anti-RNAP II/topo I antibody specificities.
Importantly, Bunn et al. did not detect anti-RNAP IIO or anti-RNAP IIA antibodies 
in any of their anti-topo I sera (36). However, two points are in support of the existence 
of such an antibody profile in SSc sera. First, these sera were originally observed quite 
separately and independently in two different laboratories (136,298). Secondly, the 
present study demonstrated that these antibodies could be detected by IB techniques. In 
addition, difficulties in the visualization of RNAP IIo and Iia subunits were apparent in 
the study of Bunn et a l  (36). Thus, it is possible that some of their anti-topo I sera did 
contain unidentified anti-RNAP II antibodies. This would not have affected the 
detection of anti-RNAP I or III antibodies, which they found with a very similar 
frequency (12%) as in the present study (13%). The three studies (36,128,299) are, 
however, in agreement concerning the mutual exclusivity of anti-RNAP III and anti- 
topo I antibodies (apart from one exceptional serum reported here).
Co-precipitation o f RNAPs and other anti-nuclear antibodies by SSc sera 
Another apparent difference between this study and that of Satoh et al. (299) is the 
relative frequencies with which certain other ANAs occurred in the anti-RNAP sera. A 
high incidence of Japanese anti-RNAP IIO sera also contained anti-Ro, anti-Ul RNP, 
anti-Ku or anti-Su autoantibodies (33, 6 , 6  and 53% respectively). Of the eighteen anti- 
RNAP IIO/topo I and anti-RNAP II/topo I sera studied here, five (28%) contained anti- 
Ro, one (6 %) contained anti-La, one (6 %) contained anti-Jo-1, but none precipitated U1 
RNP or the Ku antigen. We were not in possession of an anti-Su standard serum, and, 
consequently, were unable to detect and analyze the frequency of anti-Su antibodies in 
the present population (the Su autoantigen is precipitated as a triplet of 100-, 102-, and 
200-kDa bands (300)). The figures for anti-Ro antibodies in the presence of anti-RNAP 
IIO antibodies compares well between the two studies, especially considering the small 
numbers involved. Furthermore, when the percentages calculated by Satoh et al. (299) 
are translated according to the total number of Japanese anti-RNAP IIO sera detected in 
their study (fifteen sera), the percentage of anti-RNAP IIO sera which co-precipitated 
either U1 RNP or the Ku antigen (6 % and 6 %, respectively) correspond to only one 
serum of each type. Therefore, the two studies are in accordance with one another on 
this point also, and, when considered together, imply that a minority (perhaps 1-5%) of
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anti-RNAP IIO (±IIA) sera also co-precipitate U1 RNP, Ku, Jo-1 or La antigens, while 
a much higher proportion (~30%) of anti-RNAP IIO (±IIA) sera also precipitate the Ro 
antigen.
However, no ANAs were found in conjunction with anti-RNAP I or anti-RNAP III 
antibodies, a finding also supported by Bunn et al. (36). Therefore, in SSc, it appears 
that only those anti-RNAP-II-positive sera which also precipitate topo I contain anti-Ro 
antibodies, and, further, that anti-RNAP III antibodies and anti-Ro antibodies are 
mutually exclusive.
Other multiple autoantibody specificities
The presence of other multiple autoantibody specificities in some SSc sera was also of 
interest. Six sera (3%) were found to precipitate both topo I and the Ro antigen in the 
absence of anti-RNAP antibodies. In four of these cases, two separate lines of identity 
had been observed by immunodiffusion techniques (Table 4.4), supporting the 
existence of distinct antibodies. Meanwhile, only one serum (0.5%) was found to 
contain both anti-topo I and anti-Ul RNP antibodies (Table 4.5). An earlier report by 
Sato et al. detected five sera (3%) with both these specificities in their cohort of 176 
SSc and 30 MCTD patients (189). However, the overall prevalence of anti-Ul RNP 
antibodies was in any case rather high in their study (25%), as has previously been 
demonstrated in Japanese SSc patients. None of the other SSc-specific antibodies, i.e. 
AC As, anti-Th RNP, -Pm-Scl or -U3 RNP antibodies were found to be co-precipitated 
with any of the RNAPs detected here. Also, of the 41 ACA-positive sera tested here, 
none was found to contain anti-topo I or anti-RNAP antibodies. Thus, these results are 
in accordance with previous reports (255).
Together, these results support the existence of three main groups of SSc sera, each 
characterized by the presence of a particular, mutually exclusive, SSc-specific 
autoantibody (ACAs, anti-topo I antibodies or anti-RNAP III antibodies), as suggested 
by Bunn et al. (36). Anti-topo I antibodies are frequently accompanied by antibodies to 
Ro (± La) and/or RNAP IIO (± IIA). Anti-RNAP III antibodies are usually accompan­
ied by antibodies recognizing RNAP I, and sometimes also by anti-RNAP II antibodies. 
Meanwhile, ACAs tend to occur alone.
Clinical associations of autoantibodies in SSc
Disease subtype associations
Results presented here confirm the very close association between the presence of 
ACAs and limited disease, and the association between the presence of each individual 
anti-RNAP antibody and diffuse disease is also in support of previous data. In the 
present study, however, the anti-RNAP I/II/III group had a highly significant 
association with dc-SSc, while the anti-RNAP I/III group did not.
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Meanwhile, the association of anti-topo I antibodies with diffuse disease has not 
been confirmed. Several factors could have led to a majority of our anti-topo I-positive 
patients having lc-SSc, including slightly different clinical interpretations of diffuse and 
limited SSc. As mentioned, clinical associations of the three main SSc antibody groups, 
i.e. ACAs, anti-topo I antibodies and anti-RNAP antibodies, have been studied 
simultaneously on relatively few occasions, while anti-topo I and ACAs have often 
been compared in the same patient population. The present results confirm that the anti- 
topo I group is associated with a significantly higher risk of dc-SSc compared to the 
ACA group, while the anti-RNAP Ill-positive group is shown to have an even greater 
incidence of diffuse disease, significantly higher than either the anti-centromere- or the 
anti-topo I-positive groups. When Giordano et al. (114) divided their 90 SSc patients 
into six groups based on the extent of cutaneous involvement, they found that, while 
ACAs were associated with the limited cutaneous groups (Groups 1 and 2), anti-topo I 
antibodies were associated with both the diffuse and the intermediate subsets (Groups 4 
and 5), while the diffuse subsets (Groups 5 and 6 ) were mainly composed of sera which 
displayed ANoA patterns by IF (these were not identified, but may have included anti- 
RNAP I-positive sera). Furthermore, Steen et al. (255) showed that, amongst dc-SSc 
patients, only 27% had anti-topo I antibodies, while 45% had anti-RNAP III antibodies.
The results of the present study would suggest that the three main SSc-specific 
antibodies are each distinguished by different degrees of cutaneous involvement, with 
members of the ACA group generally having the mildest degree of cutaneous spread, 
patients in the anti-RNAP III group frequently having the most diffuse form of the 
disease, and members of the anti-topo I group tending to have an intermediate pattern 
(and/or risk) of cutaneous manifestations.
Renal involvement
The association of renal involvement with anti-RNAP antibodies was not confirmed in 
the present study. There is evidence that the selection of patients for the SSc family 
study was biased against the inclusion of patients with renal involvement (Dr 
N.J.McHugh, pers.comm.). Furthermore, we have reported separately on our own anti- 
RNAP-positive patients (which are included here alongside patients from the SSc 
family study), and have shown a significant association of anti-RNAP antibodies with 
the presence of renal involvement (129).
Meanwhile, a significant association between renal involvement and the presence of 
anti-La and/or anti-Ro antibodies has been demonstrated here. However, some of these 
particular sera contained other ANA specificities, and the numbers involved were 
relatively small. Therefore, the existence of a link between anti-Ro (± La) antibodies 
and renal involvement would require further confirmation: this is one aim of our future 
research.
In the present study, the anti-topo I group had a significantly increased rate of renal 
involvement compared with the ACA group. Our finding of 29% renal involvement in
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anti-RNAP I/II/III patients was comparable with that reported by Kuwana et al. (185) 
and by Bunn et al. (36) (43% and 33%, respectively). However, our anti-topo I-positive 
patients had a somewhat higher rate of renal disease (2 0 %) than their anti-topo I- 
positive groups (6 % and 3%, respectively), while the incidence of renal disease in our 
ACA-positive patients (2%) was similar to that found by Kuwana et al. (185) (0%). A 
comparable study by Steen et al. (255) reported renal involvement in 33% of their anti- 
RNAP Ill-positive patients and 10% of their anti-topo I-positive patients.
While our criteria for renal involvement may have been less stringent than in other 
studies, these data provide further evidence of distinctive clinical patterns being 
associated with each of the three autoantibody groups discussed above.
Pulmonary involvement
In the present study it was shown that, whether occurring separately or together, anti- 
topo I antibodies and anti-Ro antibodies were each significantly associated with 
pulmonary involvement. Although most studies have concentrated on the prognostic 
significance of SSc-specific antibodies in SSc, an association between pulmonary 
involvement and anti-Ro antibodies in SSc has been reported previously (261). Again, 
an apparent link between the anti-topo I antibody response and the anti-Ro antibody 
response is implied by these results. In view of the significant association of anti-Ro 
antibodies with both renal involvement and lung involvement, it appears possible that 
anti-Ro antibodies are of relevance to SSc pathogenesis, particularly in the context of 
anti-RNAP II and/or anti-topo I antibodies.
Autoreactive subunits of RNA polymerases
The present findings indicate that autoreactive epitopes are located on RNAP 
complexes which are distinct and separate from those on topo I. First, all anti-RNAP 
sera still precipitated the same RNAPs in the absence of topo I. Secondly, IB studies 
indicated that anti-topo I sera recognized the 100-kDa topo I band, whether or not the 
sera also had anti-RNAP II or RNAP IIO autoantibodies. Thirdly, anti-RNAP IIO 
autoantibodies were detected by recognition of the largest, phosphorylated subunit 
(RNAP IIo; 240 kDa). In further support of this conclusion, it should be mentioned that 
the specificities of anti-topo I antibodies detected by IP and immunodiffusion were 
independently confirmed by Dr J. Whyte using a topo I functional inhibition assay, as 
described previously (227). Dr Whyte reported that all sera with anti-topo I antibodies 
by IP and immunodiffusion were able to inhibit topo I, including sera with anti-RNAP 
II/topo I, anti-RNAP IIO/topo I, and anti-RNAP I/II/III/topo I specificities, some of 
which had also precipitated the Jo-1, Ro, and/or La antigens (Table 4.3; (127)). 
Furthermore, as indicated on Table 4.3, two anti-RNAP II/topo I/Ro sera recognized 
subunits IIo and Iia on immunoblots, and also produced a positive result by 
immunodiffusion, producing lines of identity with both prototype anti-topo I sera and 
with anti-Ro prototype sera. Anti-RNAP antibodies are not detected by
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immunodiffusion. These results suggest that antibodies in these sera recognized 
separate epitopes on all three antigens.
Since the unphosphorylated Iia subunit of RNAP II (220 kDa) was also recognized 
by the majority of sera which had precipitated RNAP IIA, but never by sera which 
precipitated only RNAP IIO, it was further concluded that at least two different sites on 
the largest subunit of RNAP II are recognized by SSc sera, and that one of these sites is 
unique to the phosphorylated (IIO) form.
In the current report, the autoreactive subunits of RNAPs I and III were not 
identified by IB, although autoradiographs showed the presence of constituent subunits 
on affinity purified preparations transferred onto nitrocellulose. Previous studies have 
shown specific recognition of particular RNAP I and III subunits by anti-RNAP sera 
using slightly different methods. Using a HeLa-cell RNAP-enriched fraction, Kuwana, 
Kaburaki & Mimori (183) showed that one or other of the two subunits common to all 
three RNAPs (25 and 42 kDa) are recognized by most anti-RNAP I/III and anti-RNAP 
I/II/III sera (183). Although the extract used contained all three classes of RNAP, no 
serum reacted with any RNAP II-specific subunits. Okano et al. used a biochemical 
method to purify HeLa-cell RNAP III. The 138-kDa subunit, unique to RNAP III was 
recognized not only by anti-RNAP III sera, but also by anti-RNAP I/III and anti-RNAP 
I/II/III sera (255). All three groups also recognized the ~25-kDa subunit mentioned 
above.
In the present study, despite repeated attempts, antigenic determinants specific to 
RNAP I or RNAP III were not detected, possibly due to less sensitive methods of 
detection than those used by others (183,255). The cell type used is an unlikely 
explanation since RNAPs are ubiquitous and their structures well conserved. One 
further possibility is that autoreactive epitopes on one or more RNAPs are present only 
in the native conformation, especially considering that anti-RNAP III autoantibodies are 
able to inhibit transcription by native RNAP III (183).
Meanwhile, in the study of Hirakata et al. (144), the 220- and 145-kDa subunits of 
RNAP II were isolated from calf thymus and used as substrates in IB studies with anti- 
RNAP I/II/III sera. The 220-kDa subunit was recognized by 9/13 of these sera and the 
145-kDa subunit was recognized by 11/13. However, also mentioned in this paper was 
the observation that 12/13 of the same sera could immunoprecipitate the 23-kDa 
subunit, common to all three RNAPs, thus confirming the findings of Okano et al. 
(255), and Kuwana et al. (183) mentioned above.
Therefore, the present data, together with the results of others, suggest that, while anti- 
RNAP II/topo I sera and anti-RNAP IIO/topo I sera only recognize RNAP subunits 
which are specific to one or both forms of RNAP II, anti-RNAP I/II/III sera also 




There are two different pathways for the production of anti-RNA polymerase II 
antibodies in SSc
It is of great significance that no sera have been reported that precipitate only RNAPs I, 
IIO and III, while anti-RNAP IIO/topo I sera are relatively frequent. Furthermore, sera 
which precipitate only RNAP I, RNAP II, RNAP IIO, RNAPs I and II, or RNAPs II 
and III appear to be exceptionally uncommon in SSc. These data may indicate that, in 
most anti-RNAP-positive SSc sera, the anti-RNAP response begins with a breakdown 
of tolerance to one of a very small number of key autoantigens, and, furthermore, that 
the identity of the ’inciting' autoantigen, in turn, determines a particular, characteristic 
pathway of epitope spread. The apparent mutual exclusivity of anti-RNAP III and anti- 
Ro antibodies in SSc may provide further clues concerning the patterns of epitope 
spread occurring in particular SSc patients.
Specifically, when considered together, the various aspects of the anti-RNAP II 
antibody response strongly suggest that two different immune response pathways can 
lead to the production of anti-RNAP II antibodies in SSc. Indeed, in the case of the anti- 
RNAP I/II/III group, the model suggested by Hirakata et al. (142,144) favours the 
initial production of anti-RNAP I or anti-RNAP III antibodies, then, due to recognition 
of the shared 25-kDa subunit, the spreading of the immune response to include the 
RNAP II enzyme (144). This could be followed by eventual intramolecular epitope 
spreading within RNAP II which would often include antibodies specifically 
recognizing the IIo subunit and/or the Iia subunit. The present data are wholly 
compatible with this account. Significantly, one of our anti-RNAP I/II/III sera 
recognized only subunit IIo on IBs, although the same serum was capable of 
precipitating both RNAP IIO and RNAP IIA equally, presumably on account of 
common epitopes, possibly located on the 25-kDa subunit.
Meanwhile, the present data suggest that anti-RNAP IIO/topo I sera and anti-RNAP 
II/topo I sera do not recognize subunits common to all three RNAPs. Furthermore, anti- 
RNAP IIO/topo I sera do not recognize epitopes present on both RNAP IIO and RNAP 
IIA, since only RNAP IIO is precipitated by this particular group of sera, and only 
subunit IIo was ever recognized by these sera on IBs. Therefore, in the anti-RNAP IIO 
(± IIA)/topo I group, the immune response appears to begin with either topo I or RNAP 
IIO, with subsequent spread to include RNAP IIA in some cases. It therefore follows 
that, in the anti-RNAP I/II/III group, the original inciting antigen is highly unlikely to 
have been RNAP II: the recognition of RNAP II in this group appears to have resulted 
from epitope spread via a subunit shared with RNAPs I and III. Meanwhile the anti- 
RNAP II response in the anti-RNAP IIO (± IIA)/topo I group seems most likely to have 
resulted from the presentation of cryptic epitopes of either topo I or RNAP IIO or both. 
These conclusions suggest the presence of alternative pathological conditions in the two
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groups of patients which characteristically lead to the production of anti-RNAP III 
antibodies on the one hand and anti-topo I antibodies on the other.
Furthermore, based on the present data, it would appear that, although the anti- 
RNAP I/III antibody response may spread to include a common subunit found in RNAP 
II it does not subsequently spread to include topo I, while the anti-RNAP II/topo I 
antibody response does not appear to spread to include RNAPs I and III. Such 
discretionary epitope spreading, occurring in one direction but not in the other, may be 
explained by the nature of antigen processing by B cells, which is known to be affected 
by the specificity of the particular B cell concerned: since the antigenic site bound by 
the Ig molecule is protected from proteolysis, different peptides can be generated from 
the same antigen by B cells, depending on their particular epitope specificity (212).
A consequence of the production of anti-RNAP II antibodies by two distinct 
pathways regards HLA associations with disease, i.e. the context of antibody 
production may be important to its HLA associations. If, for example, a particular 
autoantibody is produced via processing of a particular cryptic epitope, then its HLA 
associations may be different to those of an antibody with the same specificity which 
has been produced as a result of processing of non-cryptic antigens during epitope 
spread, as is suggested by the recent report of Frank et al. (97).
There are three main clinical and serological groups of SSc patients
Based on a detailed analysis of HLA associations of SSc-specific autoantibodies (8 6 ), 
together with their previous results (36), it has been suggested by Fanning et al. (8 6 ) 
that the three main serologically defined subgroups of SSc patients actually represent 
patients with three different diseases.
The present study would support this hypothesis, but with the added point that the 
anti-topo I group is also associated with the occurrence of anti-Ro and/or anti-RNAP II 
antibodies. It seems possible that, in the context of this particular subset of SSc patients, 
the three antigens, RNAP II, topo I and Ro are embroiled in a sequence of events which 
results in a breakdown of tolerance to one, two or all three molecules. Significantly, 
both RNAP II and topo I (but not RNAP I, RNAP III or centromere proteins) were 
among the SSc antigens found to be uniquely susceptible to metal ion-catalyzed 
fragmentation under conditions of oxidative stress by Casciola-Rosen et al. (46). Since 
metal ions colocalize with these SSc antigens, such fragmentations may occur in vivo 
during ischaemic reperfusion. As they have pointed out, the array of autoantibodies 
found in a particular autoimmune syndrome represents the 'immunological memory' of 
pathological events (288). Thus, the subset of patients with anti-RNAP II and/or topo I 
antibodies described here may well correspond to the particular subgroup of SSc 
patients proposed by Casciola-Rosen et al. (46) to have unique access to RNAP II and 
topo I antigens in a particular, novel fragmented form. In their paper, it was 
hypothesized that these modified proteins permitted the presentation of cryptic epitopes 
to T cells, resulting in a breakdown of tolerance to these antigens. Thus, the findings of
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Casciola-Rosen et al. could explain the mutual exclusivity of the anti-topo I-positive 
group from the ACA group and the anti-RNAP Ill-positive group. The present results 
are in keeping with the existence of other, distinct pathological mechanisms which may 
underlie the breakdown of tolerance to RNAP III, and still others to the breakdown of 
tolerance to CENPs, as suggested by Rosen et al. (143). Were this shown to be the case, 
the separate disease model of Fanning et al. (8 6 ) would be inherently supported.
However, the Ro autoantigen was not found to be fragmented under conditions of 
oxidative stress by Casciola-Rosen et al. (46), and, consequently, the pathological 
processes underlying the co-existence of anti-Ro, anti-topo I and anti-RNAP II 
antibodies in some SSc patients are less clear. On this point, it is of interest that anti- 
RNAP II and anti-Ro antibodies are common in SLE sera (297), while reports of anti- 
topo I and other anti-RNAP antibodies in SLE are very rare (141). A pathogenic link 
between SLE and the subgroup of SSc characterized by the production of anti-Ro 
and/or anti-RNAP II antibodies is worth considering. However, an alternative 
possibility is suggested by the recent discovery that anti-EC antibodies are capable of 
inducing EC apoptosis (29). The anti-Ro subgroup may represent those SSc patients in 
whom excessive EC apoptosis takes place: such events may involve the production of 
blebs by the apoptotic ECs analogous to the blebs which occur during apoptosis of 
keratinocytes, and which were proposed by Rosen et al. to be involved in the 
production of anti-Ro antibodies in SLE patients (see Section 1.7; (47)). High levels of 
EC apoptosis occurring in the context of the inflammatory perivascular micro­
environment of SSc may thus lead to the production of anti-Ro antibodies, especially 
considering the occurrence of complement deficiencies in a proportion of SSc patients.
Further groups of SSc sera include those characterized by the presence of antibodies 
recognizing U3 RNP, Th RNP, Pm-Scl, Jo-1 and U1 RNP antigens. Based on previous 
results (127,251,252,294), together with the present data, it would appear that patients 
with each of these specificities also form distinct groups, which, in the majority of 
cases, are mutually exclusive. However, the proportions of SSc sera which contain each 
of these antibodies is relatively small. Here again though, distinct molecular processes 
may be at work, such as have been suggested by the induction of anti-fibrillarin 
antibodies in mice following treatment with mercury (151,152). It has been proposed 
that mercury modifies the structure of fibrillarin, forming a neoepitope that is 
immunogenic (120,270).
Distinct pathological processes in the three groups of SSc patients are responsible 
for the characteristic symptoms, for the modification of particular autoantigens, 
and, consequently, for the production of different autoantibodies
An important factor which contributed to the highly significant association of the anti- 
RNAP I/II/III group with diffuse disease appears to have been the presence of anti- 
RNAP II antibodies, since the anti-RNAP I/III group had a lower incidence of diffuse 
disease, which was not significantly different from the remaining group. Meanwhile,
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the incidence of dc-SSc found in both the anti-RNAP II/topo I group, and in the group 
of patients who had anti-topo I antibodies in the absence of anti-RNAP antibodies was 
identical, and rather low. Thus, our data suggest that the presence of anti-RNAP II 
antibodies contributes to the high incidence of dc-SSc in the anti-RNAP I/II/III group, 
but that a similar effect does not occur in the anti-RNAP II/topo I group. Although the 
numbers involved are too small to allow definitive conclusions, it appears that the 
presence of anti-RNAP II antibodies per se does not lead to an increased incidence of 
dc-SSc. Rather, the anti-RNAP I/III antibodies and the anti-RNAP II antibodies seem, 
in effect, to be acting synergistically to produce dc-SSc. An alternative, and more 
plausible, possibility is that the context in which anti-RNAP II antibodies are produced 
is a key aspect of their clinical significance. This would be an important observation, 
since it links disease expression with events leading to the production of particular 
cryptic epitopes of an autoantigen, rather than with the presence of a particular 
autoantibody as such. With regard to patients with anti-RNAP III antibodies, one 
distinct possibility is that the anti-RNAP I/III group and the anti-RNAP I/II/III group 
are actually a single subgroup of patients at a different stage of their disease, and that 
those anti-RNAP I/III patients who currently have 'limited' disease are likely, 
subsequently, to develop diffuse skin involvement, and, in the presence of appropriate 
HLA alleles, anti-RNAP II antibodies. The validity of this model could be tested by 
long-term serial measurement of anti-RNAP antibodies in SSc sera by IP assays.
Thus, although definitive proof was not obtained, several points suggest that funda­
mental differences exist in anti-RNAP II antibody production by different groups of 
SSc patients, and that these are dependent on the context of the anti-SSc-specific 
antibody which they accompany. This could result from distinct sets of cryptically 
presented antigens, produced in the context of different pathological processes.
It should be mentioned that the IF results also supported this model, since all topo I- 
positive sera showed a similar pattern of fluorescence, regardless of the presence or 
absence of RNAP II, while anti-RNAP I/II/III and anti-RNAP-I/III sera showed a rather 
different pattern, which was somewhat variable, presumably depending on the relative 
titres of the various antibodies recognizing the different component subunits of the 
three different RNAPs.
Concerning the three main groups of SSc patients: based on the available data, the 
most likely model is for the existence of three distinct disease processes each having 
certain key pathological features. In turn, each pathological state leads to the production 
of a distinctive set of modified autoantigens and, consequently, to the production of 
particular SSc-specific antibodies. Thus, identification of the original inciting antigen 
recognized by SSc sera may be the key to the subgrouping of SSc patients, as implied 
by the work of Casciola-Rosen et al. (47-49), Utz et al. (347), and Casiano et al. (50) in 
SLE, and, most particularly, the reports of Rosen et al. concerning the unique, oxidative 




Characterization of novel autoantigen systems in the 
relatives of systemic sclerosis patients
5.1 INTRODUCTION
The identification of SSc-associated antibodies, together with the detection of 
undefined autoantibody specificities, in sera from 62 SSc patients and their 239 family 
members was described previously ((127); Chapter 3). Following IP of 35S-methionine- 
labelled proteins from K562-cell extracts, and separation by SDS-PAGE, twenty-nine 
samples (from eight SSc patients (12.9%), 20 SSc-free relatives (9.3%) and one spouse 
(4.2%)) produced bands of unknown specificity, including sera from four probands who 
also had defined SSc-specific autoantibodies. Many of the unidentified IP bands were 
weak, but strong unidentified bands were seen with samples from six SSc patients 
(9.7%), twelve SSc-free relatives (5.6%) and one spouse (4.2%). A strong band at ~115 
kDa was produced by three SSc patients and seven SSc-free family members. This 
included the spouse (BD2) and three sisters (BD3, BD5 and BD7) of a proband (BD1) 
with anti-Ul RNP antibodies. Although a proportion of 120 normal sera also showed 
the presence of unidentified bands by IP (seven; 5.8%), only three were strong (2.5%), 
and none was found to precipitate a band of ~115 kDa.
Just as in SSc, many of the unidentified autoantigens recognized by sera from the 
first-degree relatives of SSc patients appeared to be located in the nucleolus, as 
indicated by the significantly increased incidence of IF-ANoAs in blood-relatives 
compared with controls. It was suggested that these undefined ANoAs may have 
resulted from some form of genetic or environmentally induced abnormality, present in 
both SSc patients and in some of their relatives, which worked to make the nucleolus a 
target for the immune response. It was further proposed that, along with this 
abnormality, additional pro-pathological factors (genetic or environmental) occurred in 
SSc patients and that these were responsible for the development of the complete 
disease syndrome, and, also, for the generation of particular sets of modified 
autoantigens. In turn, these caused the subsequent generation of SSc-specific 
autoantibodies in the proband. An alternative possibility was also mentioned: that the 
unidentified autoantigens represent proteins which are early participants in the 
aetiopathogenesis of SSc. Again, additional genetic or environmental factors, present 
only in those destined to develop SSc, may accompany the propagation of these early 
events to the development of the complete disease syndrome, together with the 
particular autoantibodies characteristic of SSc.
In the present study, eight of these "anti-115-kDa" sera were further investigated, to
determine whether the same protein was being precipitated in all cases, and to isolate,
characterize and identify the 115-kDa autoantigen/s. The immunoprecipitated proteins
were first compared by SDS-PAGE analysis on 10%- and 7.5%-polyacrylamide gels.
Relationships between the antigens precipitated by the study sera were then pursued by
a combination of antigen depletion studies, and IB experiments using affinity purified
autoantigens. Indirect immunofluorescence studies were also carried out in order to
describe clearly the subcellular distribution of the 115-kDa autoantigens. Finally,
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immunoaffinity column chromatographic techniques were performed, with the aim of 
purifying some of the 115-kDa autoantigens for subsequent amino-acid sequencing and 
identification.
During the early stages of this work, it was suggested (Dr N.J. McHugh, pers. 
comm.) that one or all of these precipitated proteins could be PADPRP, which has a 
molecular weight of 116 kDa. This enzyme catalyzes the repetitive transfer of ADP- 
ribose monomers from NAD+ to a particular range of nuclear proteins, most of which 
are directly involved in either nucleic acid metabolism or maintenance of chromatin 
structure, including histone proteins HI and H2B, topo I, RNAP II and PADPRP itself 
(240,272). In some circumstances the enzyme is thought to be responsible for triggering 
stress-induced apoptosis (246), following excessive DNA fragmentation, and the 
consequent stimulatory signal of intracellular NAD+ depletion (19). However, under 
conditions where there is less severe DNA damage, PADPRP activity may also 
function to promote DNA strand rejoining, and subsequent cell recovery (219,302).
The synthesis of poly(ADP-ribose) has been found to be decreased in family 
members of SLE patients, as well as in SLE patients themselves ((131); for review 
(309)). Further, sera from SLE patients (and a lower frequency of SSc patients) have 
been found to contain anti-poly(ADP-ribose) antibodies (72,81,148). Antibodies 
recognizing the PADPRP enzyme itself have also been reported in a variety of patients 
with CTDs (including SSc), particularly those with SLE and/or SS (240,369). In 
addition, aged mice with an inactivated PADPRP gene have been found to be prone to 
the spontaneous development of epidermal hyperplasia (355). To test the hypothesis 
that some or all of the eight study sera were precipitating PADPRP, an anti-PADPRP 
monoclonal antibody (MAb) was included in some of the antigen depletion experiments 
(kind gift of Dr Sylviae Muller, Institut de Biologie Moleculaire et Cellulaire, 
Strasbourg, France).
5.2 MATERIALS AND METHODS 
Clinical details and serology
Details regarding the eleven individuals whose sera were found to immunoprecipitate 
antigens of ~115 kDa from K562-cell extracts in the SSc family study are summarized 
on Table 5.1. All four patients were female, and all had the limited form of SSc. 
Additional unidentified bands were precipitated by two of the SSc sera, and three of the 
SSc patients had defined autoantibody specificities (Table 5.1a). None of the seven 
family members had a defined CTD, but three displayed symptoms of RP (43%: c.f 
26% total of SSc-free family members in the SSc family study had RP) (Table 5.1 b,c).
All seven anti-115-kDa sera from family members were selected for inclusion in the 
present study, together with one serum from an SSc patient (Table 5.2). The original 
serum samples were used (see Chapter 3), which had been kept stored at -20°C. Apart
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from the BD family (Table 5.2: Family 1 (FI)), where sera from the husband and three 
sisters of the SSc patient each precipitated a 115-kDa band, two of the sera were from 
mothers of SSc patients (F2 and F3), and one was from the son of an SSc patient (F5) 
(Table 5.2).
Immunodiffusion
All eight study samples had been screened by Ouchterlony double immunodiffusion as 
part of the SSc family study (Chapter 3; Table 5.1), and these tests were not repeated.
Immunofluorescence
Each of the eight study samples had been included in IF tests as part of the SSc family 
study, using HEp-2-cell slides from Biodiagnostics Ltd (Chapter 3; Table 5.1). 
However, our diagnostics laboratory had recently started using a superior brand of 
commercially prepared HEp-2 slides from Light Diagnostics Ltd (Mrs J.Dunphy, pers. 
comm.), and it was decided to repeat IF testing using the new slides. The opportunity 
was also taken to titre the sera. The usual method was used (Method 2.3.2), with each 
of the eight study sera being tested at the following dilutions: 1/40, 1/160, 1/640 and 
1/2560. In addition to antinuclear and antinucleolar IF, anti-cytoplasmic staining 
patterns were recorded. Antinuclear, antinucleolar and anticytoplasmic IF intensities 
were each scored as negative (-), very weak (+/-), weak (+), moderate (++), strong 
(+++) or very strong (++++). A number of sera with known autoantibody specificities 
were also tested, to serve as controls, and these included other members of the BD 
family (FI).
Comparison of immunoprecipitated proteins
Each of the eight study sera had been included in protein IP studies as part of the SSc 
family study (see previous Fig. 3.20). During the present study, each of these sera was 
again subject to protein IP techniques, using a single batch of 35S-methionine-labelled 
K562-cell extract (Method 2.3.3a). Again, other members of the BD family (FI) were 
included, along with prototype sera of known autoantibody specificity. Resulting 
immunoprecipitated proteins were separated on a 1 0%-polyacrylamide gel, dried, and 
autoradiographed as usual at two different time points. This allowed a subjective 
comparison of the relative band intensities produced by the eight sera to be made, 
which is influenced by (i) the titre of the serum, (ii) the avidity of the antibody, (iii) the 
relative abundance of the precipitated antigen in the cell extract, (iv) the molecular 
weight of the antigen, (v) the percentage methionine content of the antigen, and (vi) the 
turnover rate of the antigen in vivo.
Duplicate IP samples were then separated on a 7.5%-polyacrylamide gel, to compare 
the molecular weights of the different proteins. When proteins of this molecular weight 
are being studied, small differences in electrophoretic mobility are more readily 
apparent in lower percentage gels.
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Antigen depletion of K562-cell extracts
Similar IP experiments were then performed using aliquots of radiolabelled K562-cell 
extract which had been precleared of antigenic particles recognized by (i) serum BD5 
(FI: Sister 2), (ii) serum BD2 (FI: Husband), and (iii) normal control serum (Method 
2.3.3c). Four cycles of depletion were carried out to ensure removal of all traces of 
antigen. Along with the eight study sera, the anti-PADPRP MAb, an anti-Ul RNP 
prototype serum, and sera from the remaining members of the BD family (FI) were 
included amongst the test sera in these experiments.
Immunoprecipitation of ribonucleoproteins
Since serum from BD1 (FI: Patient) was known to contain anti-Ul RNP antibodies, it 
was considered possible that sera from other members of this family may contain 
antibodies which precipitated one or more UsnRNPs. Unlabelled cell extracts were 
prepared, and the eight study sera were subjected to RNA-IP techniques along with 
appropriate standards (Method 2.3.3b). The PCA-extracted samples were run on urea- 
polyacrylamide gels, which were silver stained and dried, in order to detect any RNAs 
associated with the unidentified autoantigens.
Immunoblotting of affinity purified autoantigens
Each of the eight study sera was used to affinity purify autoantigens from cell extracts 
by scaled-up IP techniques using 35S-methionine-labelled K562-cell extracts (Method 
2.3.3d). Following separation by SDS-PAGE, purified polypeptides were transferred 
onto nitrocellulose sheets. Immunoblotting studies were then performed using each 
purified protein extract as an antigen source. Each of the eight study sera was then 
tested against each of the eight purified antigen preparations as usual, with prototype 
sera of known autoantibody specificity being included for comparison. Again, other 
members of the BD family (FI) were also included. Immunoblots containing 
radiolabelled proteins were then subjected to autoradiography to reveal the positions of 
transferred polypeptides.
Similar experiments were then carried out using affinity purified antigens prepared 
using unlabelled K562-cell extract, in which case the quantities of Protein-A Sepharose, 
IPP buffer, serum, and cell extract used were further increased (3 x those stated in 
Method 2.3.3d): this allowed a greater concentration of purified antigen to be contained 
on each of the final blotting strips. In these experiments only two sera, BD2 (FI: 
Husband) and BD5 (FI: Sister 2), were used to purify antigens, while all eight study 
sera, together with controls, were included as test sera.
Purification of autoantigens by immunoaffinity column chromatography
Three sera from the present study (BD2 (FI: Husband), BD5 (FI: Sister 2) and MD9 
(F5: Son)) were selected for immunoaffinity column chromatography trials. These 
preliminary tests were carried out by preparing three mini-columns, each containing a
182
2-ml bed volume of Protein-A Sepharose CL-4B beads covalently linked to antibodies 
from the relevant serum. A 2-ml normal-serum pre-column was also constructed. The 
protocol described in Method 2.3.4 was followed, with all volumes being scaled down 
by a factor of 2.5. Following application of the low-pH glycine buffer, fractions of 
eluate were collected and tested for the presence of 115-kDa bands by silver-staining 
techniques. Any successfully eluted antigens were further purified by de-salting. 
Purified proteins were then subjected to SDS-PAGE using a 10%-polyacrylamide gel, 
and transferred to PVDF membranes. Coomassie blue staining of blots revealed the 
position of isolated proteins, which were sent for amino-acid sequencing.
Based on these preliminary results, a full-sized column was later constructed, 
containing a 5-ml bed volume of Protein-A Sepharose CL-4B beads covalently coupled 
to serum antibodies from a fourth study serum, BD3 (FI: Sister 1) (Method 2.3.4).
5.3 RESULTS 
Immunofluorescence
Results obtained using the two different brands of HEp-2-cell slides can be compared 
on Tables 5.1 and 5.2. In most cases, slightly different IF patterns and/or intensities 
were recorded when the same serum sample was tested on the two different types of 
slides. While the majority of differences were of a single gradation of intensity (e.g. the 
speckled nucleolar staining produced by serum from family member BE6  was strong 
with slides from Biodiagnostics Ltd (Table 5.1), but only moderate with slides from 
Light Diagnostics Ltd (Table 5.2)), occasionally differences were more substantial (e.g. 
with Biodiagnostics Ltd slides, serum from SSc patient LK1 showed a strong discrete 
course speckled nuclear pattern, nucleolar sparing; with slides from Light Diagnostics 
Ltd, however, a moderate grainy speckled staining pattern of both nucleus and 
nucleolus was observed).
Little uniformity was apparent between the eight study sera regardless of which 
slides were used (Tables 5.1 and 5.2). However, close examination reveals that two sera 
from FI (BD3 (Sister 1) and BD5 (Sister 2); Tables 5.1 and 5.2) produced a very 
similar pattern of nuclear IF, while the other two FI sera shared a different, 
predominantly cytoplasmic pattern (BD2 (Husband) and BD7 (Sister 3); Table 5.2). All 
four sera from FI had a high antibody titre (Table 5.2). The patterns produced by sera 
from FI in the SSc family study (using slides from Biodiagnostics Ltd) are shown in 
Fig. 5.1. For comparison, results obtained with some of the study sera when using slides 
from Light Diagnostics Ltd are shown in Fig. 5.2b,c,d. Prototype sera which had 
previously been tested on Biodiagnostics Ltd slides were also tested using the new 
slides (Fig. 5.2a,e,fg): again, slightly different patterns were sometimes produced by 
the two types of slides when the same serum was tested. On the whole, patterns
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produced by slides from Light Diagnostics Ltd were more distinctive, and were easier 
to read.
Comparison of immunoprecipitated proteins
When the eight study sera were immunoprecipitated and run on 10% SDS 
polyacrylamide gels (Fig. 5.3a), no obvious differences in electrophoretic mobilities 
were apparent. However, subjective differences between the band intensities of proteins 
precipitated by the study sera were clear. These were carefully judged using two 
different autoradiographs, one of which was exposed for twice as long as usual (Fig. 
5.3b). The large amounts of antigen apparently precipitated by sera from BD3 (FI: 
Sister 1, lane 8) and BD5 (FI: Sister 2, lane 5) were striking, and, in both cases, the 
bands were rather fuzzy. This phenomenon is known to occur with phosphorylated 
proteins, due to a number of variably dephosphorylated breakdown products. The U1 
RNP-positive proband of FI (BD1) was also included on this gel (lane 9). By 
comparing with previous Fig. 3.6, it seems likely that most of the study sera recognize 
antigens which are present in a fairly high copy number per cell (i.e. the strength of the 
bands resembles bands produced by U1 RNP and other ANAs rather than the ANoAs, 
which are about 10 x less plentiful per cell).
When the same experiment was conducted using an 8% SDS-polyacrylamide gel, 
relative band mobilities remained indistinguishable between the eight study sera (Fig. 
5.4).
Immunoprecipitation of ribonucleoproteins
The appearance of the silver-stained urea-PAGE-separated samples is shown in Fig. 
5.5. Although the standard sera precipitated the RNA species associated with the 
particular antigen concerned, no members of FI were found to precipitate any RNA 
species. However, serum from BD1 (FI: Patient) was confirmed positive for anti-Ul 
RNP antibodies, and U2 RNP was also found to be precipitated by this serum, as 
indicated by the presence of U2 RNA on the silver-stained gel (Fig. 5.5, lane 3).
These findings indicate that none of the anti-115-kDa sera tested recognized any 
RNPs.
Antigen depletion of K562-cell extracts
A radiolabelled extract was shown to contain antigens precipitated by all the test sera 
(Fig. 5.6a, lanes 2-9). Then, the extract was specifically depleted of antigens recognized 
by antibodies contained in serum from BD5 (FI: Sister 2) by successive incubations 
with BD5-antibody-coated Protein-A Sepharose beads (Fig. 5.6b, lanes 1-5). 
Meanwhile, a normal serum did not adsorb out any 115-kDa antigens (Fig. 5.6b, lanes 
12-16), including the 115-kDa antigen precipitated by serum BD5 (FI: Sister 2) (Fig. 
5.6b, lane 10). In contrast, sera that contained anti-Ul RNP antibodies, such as BD1 
(FI: Patient) (Fig. 5.6b, lanes 6 and 11), or anti-PADPRP antibodies (Fig. 5.6b, lanes 8
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and 9) were able to precipitate these antigens to the same degree regardless of which 
depleted extract was used.
When the study sera were subjected to IP studies using the BD5-antigen-depleted 
extract, most of the study sera were still able to precipitate 115-kDa antigens (Fig. 5.6c, 
lanes 2-6 and 9). However, as well as serum from BD5 (FI: Sister 2), serum from BD3 
(FI: Sister 1) was also unable to precipitate a 115-kDa antigen from the BD5-antigen- 
depleted extract (Fig. 5.6c, lanes 8 and 7 respectively).
Similarly, serum from BD2 (FI: Husband) was used to specifically deplete a third 
batch of the same original extract (Fig. 5.6d, lanes 10 and 9). A control extract, depleted 
using a normal serum (Fig. 5.6d, lanes 2 and 1) was shown still to contain the 115-kDa 
antigen recognized by serum BD2 (FI: Husband) (Fig. 5.6J, lane 4). Again, sera that 
contained anti-Ul RNP or anti-PADPRP antibodies were able to precipitate these 
antigens from both depleted extracts (Fig. 5.6c?, lanes 8 and 3, and 6 and 5, 
respectively). When the study sera were subjected to IP using the BD2-antigen-depleted 
extract, most of the study sera could still precipitate 115-kDa antigens (Fig. 5.6c, lanes
3-6, 8 and 9). However, as well as serum from BD2 (FI: Husband), serum from BD7 
(FI: Sister 3) was also unable to precipitate a 115-kDa antigen from the BD2-antigen- 
depleted extract (Fig. 5.6c, lanes 7 and 10, respectively).
These findings indicate that serum from BD5 (FI: Sister 2) precipitated all antigens 
precipitated by serum BD3 (FI: Sister 1), and, also, that serum BD2 (FI: Husband) 
precipitated all antigens precipitated by serum BD7 (FI: Sister 3).
Immunoblotting of affinity purified autoantigens
Autoradiographs of nitrocellulose strips containing the 115-kDa antigen precipitated by 
serum from BD3 (FI: Sister 1) are shown in Fig. 5.1a. Figure 5.1b shows the same 
strips after blotting with the study sera. No serum recognized the 115-kDa band, even 
serum from BD3 itself (Fig. 5.1b, lane 4). When the nitrocellulose strips contained 
affinity purified 115-kDa antigen purified using serum from BD7 (Fig. 5.7c,), a similar 
result was obtained, with none of the study sera recognizing the 115-kDa band, even 
serum from BD7 itself (Fig. 5.7d, lane 6).
The 115-kDa antigens recognized by sera from patient LK1 (F4), and by sera from 
family members BD2 (FI: Husband), BD5 (FI: Sister 2), LJ7 (F3: Mother) and MD9 
(F5: Son), were also successfully purified by the same method, as indicated by the 
presence of 115-kDa bands on autoradiographs (data not shown). In all these cases, 
when each set of IB strips was blotted using each of the test sera, no serum gave a 
positive result, even when the particular serum which had been used to purify the 
autoantigen concerned was used (data not shown).
It was thought possible that these negative results may have been due to low 
concentrations of antigens on the blotting strips. Therefore, similar purification 
procedures were carried out using two of the study sera (BD2 (FI: Husband) and BD5 
(FI: Sister 2)), and increased quantities of extract and other reagents. The extract used
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was not radiolabelled due to constraints on radioactive usage. However, as an 
alternative, it was intended to stain representative strips using the amido black 
technique in order to confirm successful purification of 115-kDa antigens, and their 
effective transfer to nitrocellulose sheets. Unfortunately, no success was experienced 
with this technique (data not shown): in retrospect, it may have been wiser to have 
transferred the purified proteins onto a more sturdy membrane such as PVDF, which 
can withstand Coomassie blue staining procedures. Nonetheless, the nitrocellulose 
blotting experiments were carried through with some success: although the 115-kDa 
antigen purified by serum from BD2 (FI: Husband) was not recognized by any of the 
study sera (Fig. 5.8a), including serum BD2 itself (Fig. 5.8a, lane 4), an antigen of 
~115-kDa purified by serum from BD5 (FI: Sister 2) did now appear to be recognized 
by serum from BD5 as well as by serum from BD3 (FI: Sister 1) (Fig. 5.8b, lanes 2 and 
5, respectively).
These results imply that the antigen recognized by serum from BD5 (FI: Sister 2) is 
recognized by antibodies contained in serum from BD3 (FI: Sister 1) and, further, that 
the autoantigenic epitopes recognized are likely to be linear (proteins are denatured 
during SDS-PAGE, however refolding of proteins on blots after electrophoretic transfer 
is possible).
Purification of autoantigens by immunoaffinity column chromatography
Study sera taken from BD2 (FI: Husband) and BD5 (FI: Sister 2) were used to 
successfully purify 115-kDa antigens, as shown by the presence of bands of the 
appropriate molecular weight in the silver-stained, eluted fractions of the mini-columns 
(Fig. 5.9b and c, respectively). The control mini-column, which contained Protein-A 
Sepharose beads covalently linked with antibodies from a normal serum, did not 
produce a band of 115-kDa when subjected to the same elution conditions (Fig. 5.9a).
The relevant fractions were further purified by de-salting, as described in Method 
2.3.4£, and, following SDS-PAGE and transfer to PVDF membranes, Coomassie blue 
staining revealed the presence of a 115-kDa band in both cases (data not shown). 
However, when sent for sequencing, these samples were not of sufficient quantity to 
enable sequencing.
A more efficient antigen purification was achieved using the full-sized column, 
which contained Protein-A Sepharose bound to antibodies from serum BD3 (FI: Sister 
1), as shown by the appearance of the silver-stained, eluted fractions in Fig. 5.9d. Once 
again, silver-stained elution fractions from the full-sized control column did not 
produce a band of 115-kDa (data not shown). The relevant fractions were further 
purified, as before, and, following SDS-PAGE and transfer to PVDF membranes, 
Coomassie-blue staining revealed the presence of a strong 115-kDa band (Fig. 5.10). 
This band was excised and sent for sequencing. However, although plenty of protein 
was found to be present, the protein was reported to be blocked at the NH2-terminal, 
and was unsuitable for direct sequencing.
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As described in Method 23  Ad, CNBr may be used to cleave such proteins, allowing 
separation and sequencing of polypeptide fragments. Therefore, a further batch of the 
protein was prepared. This was subjected to a more thorough purification procedure 
(see Method 2 3 A d )  in order to remove low molecular weight polypeptide 
contaminants. Following CNBr-induced fragmentation, the resulting polypeptides were 
SDS-PAGE separated and transferred to PVDF as before. However, to date, sufficient 
quantities of polypeptides to allow sequencing have not been isolated.
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TABLE 5.1 Sera from  SSc patients and SSc-free fam ily m em bers which 
precipitated unidentified autoantigens of 115-kDa in the SSc family study, (a) SSc
patients; (b) family members of SSc patients; (c) family members of SSc patient BD1 
(all members of this family are shown)
(a)











B1 F lc-SSc 49,57,115,190 U3RNP ++++cl./sp.
K1 F lc-SSc 115 (wk) - ++cs.sp. -
LK1+ F lc-SSc 115 Ro +++dis.cs.sp. -

















BE6+ F RP Mother 115§ +/-gr.sp +++sp.
LJ7* F - Mother 115§ - +f.sp. -

















BD1 F dc-SSc Proband U1 RNP ++++cs.dis.sp.
BD2* M - Husband 115 - +f.sp. +sp.
BD3+ F RP Sister 115 - +++f.sp. +/-
BD5+ F RP Sister 115 - +++gr.sp. +sp.
BD7+ F - Sister 115 - - -
BD4* F - Mother - - - -
BD6 M - Son - - - +sp./h.
♦Sera selected for further study
tAlso identified by immunodiffusion
§ Unidentified precipitin also detected by immunodiffusion
iThis serum was not included in the SSc family study, but an 8-year-old sample was tested subsequently 
IP, immunoprecipitation; IF, indirect immunofluorescence; lc-SSc, limited cutaneous SSc; dc-SSc, diffuse 
cutaneous SSc; RP, Raynaud's phenomenon; wk, weak; cs. course; cl. clumpy; sp. speckled; h. 
homogeneous; f. fine; dis. discrete; dif. diffuse; gr. grainy
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TABLE 5.2 Details of sera precipitating unidentified 115-kDa autoantigens which were selected for further study. Revised 
indirect immunofluorescence (IF) results, carried out using a different brand of HEp-2 slides, are included (see text): c.f Table 5.1
Cytoplasmic Nuclear Nucleolar











of IP  band Pattern Titre Pattern Titre Pattern Titre
FI: Husband BD2 M 77 ++ +/-cs.sp. 1/640
Sister 1 BD3 F 66 RP ++++ - - +++f.sp. 1/2560 - -
Sister 2 BD5 F 71 RP ++++ - - ++++f.sp. 1/2560 - -
Sister 3 BD7 F 69 - +++ +cs.sp. 1/640 - - - -
F2: Mother BE6* F 75 RP + ++gr.fil.sp. 1/640 - - ++sp. 1/640
F3: Mother U 7* F 75 - ++ ++f.sp. 1/640 ++f.sp. 1/640 + 1/40
F4: Proband LK1 F 46 lc-SSc ++ +/-f.sp. 1/40 ++gr.sp. 1/640 -H-gr.sp. 1/640
F5: Son MD9 M 14 - ++ +/-f.sp. 1/40 +f.gr.sp. 1/40 ++sp. 1/640
♦Unidentified precipitin also detected by immunodiffusion
RP, Raynaud's phenomenon; lc-SSc, limited cutaneous SSc; IP, immunoprecipitation; wk. weak; cs. course, sp. speckled; f. fine; gr. grainy; dis. discrete; 
dif. diffuse; h. homogeneous; cl. clumpy; fil. filamentous
F I G U R E  5.1 Indirect immunofluorescence patterns produced by sera from 
an SSc patient and from five of her connective tissue disease-free family 
members in the SSc family study. The original brand of HEp-2-cell slides was 
used (see text), (a) Serum from SSc proband BD1 contained anti-Ul RNP antibodies, 
and produced a very strong course speckled nuclear stain, nucleolar sparing; cytoplasmic 
staining was not present. (b) Serum from BD3, a Raynaud's phenomenon (RP)-affected 
sister of BD1, produced a strong diffuse fine speckled nuclear pattern, with very weak 
speckled nucleolar staining: cytoplasmic staining was not present. Serological tests had 
failed to identify antibodies of defined specificity: however, a very strong, unidentified 
115-kDa band was apparent by immunoprecipitation (IP), (c) Serum from another RP- 
affected sister, BD5, produced a diffuse fine/grainy speckled nuclear pattern, with a 
weak speckled nucleolar pattern; cytoplasmic staining was not present. Although no 
antibodies of defined specificity had been detected by serological tests, a very strong, 
unidentified 115-kDa band was apparent by IP. (d) Serum from BD7, the healthy sister 
of BD1, produced a weak grainy/filamentous cytoplasmic pattern, while nuclear and 
nucleolar immunofluorescence (IF) were scored as negative. Serological tests had failed 
to identify antibodies of defined specificity: however, a strong, unidentified 115-kDa 
band was apparent by IP. (e) Serum from BD6, the healthy son of BD1 was scored as 
'+' for nucleolar IF only. Serological tests failed to detect defined autoantibody 
specificities, and no unidentified bands were apparent by IP. if) A weak diffuse fine 
speckled nuclear pattern, with weak staining of the nucleolus, and a very weak grainy 
cytoplasmic pattern, was produced by serum from BD2, the healthy husband of BD1. 
Although no antibodies of defined specificity had been detected by serological tests, a 
strong, unidentified 115-kDa band was apparent by IP.
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F I G U R E  5.2 Indirect immunofluorescence patterns produced in the present 
study by sera precipitating a 115-kDa band by radioimmunoprecipitation.
A different brand of HEp-2-cell slides was used (see text). The staining patterns 
produced by the study sera were found to be more distinctive than they had been with the 
original slides (see Table 5.2, c.f. Table 5.1 and Fig. 5.1). A variety of other sera are 
included for comparison, each of which had also been tested using the original study 
slides, and some of these, too, produced slightly different staining patterns, {a) serum 
from BD1, the U1 RNP-positive proband from Family 1, produced a staining pattern 
similar to that observed previously {c.f. Fig. 5.1 a), (b) serum from BD2, the husband of 
BD1, produced a weak, but more definite, cytoplasmic staining pattern, with no nuclear 
or nucleolar staining {c.f. Fig. 5.If), (c) serum from BE6 , the Raynaud's phenomenon- 
affected mother of proband BE1, produced a much clearer cytoplasmic staining pattern, 
while nucleolar staining was slightly weaker than before {c.f. previous Fig. 3.8/). {d) 
serum from proband LK1 also produced weaker staining than before. (<e) The pattern 
produced by this normal control serum was shown previously in Fig. 3.1a, where it was 
scored as negative; similarly, (/) anti-PL-7 prototype {c.f. previous Fig 3.2c) and (g) 
anti-Ro/La serum {c.f. previous Fig. 3.3c) produced slightly stronger patterns than they 
had previously, {h) serum from BA2, the healthy sister of proband BA1 produced more 
prominent nucleolar staining than before {c.f. previous Fig. 3.8h), with no cytoplasmic 
staining. (Continued overleaf...)
F I G U R E  5.2 (c o n t.) Ind irect im m unofluorescence p a tte rn s  produced in 
the p re sen t study  by sera  p re c ip ita tin g  a 115-kD a band  by 
radioim m unoprecipitation
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F IG U R E  5.3 R ad io im m unoprecip ita tion : re la tive  band in tensities  of
unidentified  115-kDa autoantigens p rec ip ita ted  by the study sera.
Autoradiographs of SDS-PAGE-separated 35S-methionine-labelled proteins immuno­
precipitated from K562-cell extracts by serum antibodies attached to Protein-A Sepharose 
beads, (a) Lane 7, normal serum; lane 9, proteins of the U1 RNP complex precipitated 
by SSc patient BD1 from Family 1 (FI: Patient). Serum from SSc patient LK1 (F4: 
Patient) precipitated an unidentified 115-kDa protein as well as the Ro autoantigen (lane 
1); serum from SSc-free family members MD9 (F5: Son), LJ7 (F3: Mother), BE6 (F2: 
Mother), BD5 (FI: Sister 2), BD2 (FI: Husband), BD3 (FI: Sister 1) and BD7 (FI: 
Sister 3) precipitated 115-kDa proteins (lanes 2-6, 8 and 10 respectively). (b) A longer 
exposure of the same gel was compared with (a): subjective relative band intensities were 
as follows: BD5 and BD3, very strong; BD7, strong; LK1, MD9, LJ7, and BD2, 
moderate; BE6, weak (see Table 5.2).
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1 2 3 4 5 6 7 8 9
K ev:
1. BE6 (F2: Mother) 6. BD2 (FI: Husband)
2. Normal serum 7. LJ7 (F3: Mother)
3. BD5 (FI: Sister 2) 8. MD9 (F5: Son)
4. BD3 (FI: Sister 1) 9. LK1 (F4: Proband)
5. BD7 (FI: Sister 3)
F I G U R E  5.4 Radioim m unoprecipitation: relative electrophoretic mobilities 
of unidentified -115-kDa autoantigens p recip ita ted  by the study sera.
Autoradiographs of SDS-PAGE-separated 35S-methionine-labelled proteins immuno­
precipitated from K562-cell extracts by serum antibodies attached to Protein-A Sepharose 
beads. Samples were run on a 7.5%-polyacrylamide gel: antigens precipitated by all 
study sera (BE6, BD5, BD3, BD7, BD2, LJ7, MD9, and LK1) appeared to have very 
similar electrophoretic mobilities, and, therefore, molecular weights (lanes 1 and 3-9 







1 2 3 4 5  6 7  8 9  10 11
F I G U R E  5.5 RNP-im m unoprecipitation: RNA analysis of unidentified 115- 
kDa proteins precipitated by sfudy sera from a single family. Silver-salt 
staining of SDS-PAGE-separated unlabelled proteins immunoprecipitated from K562-cell 
extracts by serum antibodies attached to Protein-A Sepharose beads. As indicated by 
arrows, the prototype anti-Ul RNP serum in lane 2 precipitated both U1 and U2 RNAs; 
prototype Ro/La serum in lane 9 precipitated the hYl-5 RNAs, while the anti-Th RNP 
serum in lane 10 precipitated the 7-2 and 8-2 RNAs, as expected. Serum from SSc 
patient BD1 (Family 1 (FI): Patient; lane 3) also precipitated U1 and U2 RNAs. 
However, no RNAs were precipitated by sera from the SSc-free relatives (BD2 (FI: 
Husband), BD3 (FI: Sister 1), BD5 (FI: Sister 2), BD6 (FI: Son), BD7 (FI: Sister 3)) 
or BD1 (FI: Patient) (lanes 4-8 respectively)): c.f. lanes 1 and 11, normal sera.
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FIGURE 5.6 Radioimmunoprecipitation of unidentified 115-kDa autoantigens by 
sera from connective tissue disease (CTD)-free family members using a K562-cell 
extract precleared of certain 115-kDa autoantigens. A batch of radiolabelled K562- 
cell extract was specially prepared, and divided into three lots. (a) Test sera previously 
found to precipitate an unidentified 115-kDa band were then included in IP assays 
using the first lot of whole extract (lanes 2-9). Other members of the BD family 
(Family 1 (FI)) are included for comparison: patient BD1 (FI: Patient, lane 10) had 
only anti-Ul RNP antibodies, as shown by comparison with an anti-Ul RNP prototype 
serum (lane 12), while serum from the patient's mother BD4 (FI: Mother, lane 13), and 
the patient's son BD6 (FI: Son, lane 14) contained no detectable autoantibodies. Lanes 
1 and 11, normal sera. (Continued overleaf...)
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FIGURE 5.6 Radioimmunoprecipitation of unidentified 115-kDa autoantigens by 
sera from CTD-free family members using a K562-cell extract precleared of 
certain 115-kDa autoantigens, (cont.) (b ) A second lot of whole extract was 
depleted of an unidentified 115-kDa autoantigen four times using Protein A-Sepharose 
beads preincubated with serum from BD5 (FI: Sister 2). The 115-kDa band is present 
in the whole extract (lane 1), and reduced by successive depletions (lanes 2-5), being 
absent from the 4x-depleted extract (lane 5). However, other antigens, such as U1 RNP 
and poly(ADP-ribose) polymerase (PADPRP) could still precipitated by appropriate 
sera (lanes 6 and 8 respectively). A normal serum is shown for comparison in lane 7. A 
control sample of whole extract was "depleted" in the same way using NS (lanes 12- 
lb). This extract was shown to contain U1 RNP (lane 11), PADPRP (lane 9) as well as 
the unidentified 115-kDa antigen recognized by serum BD5 (FI: Sister 2; lane 10). (c) 
Sample sera which precipitated a 115-kDa band from the whole extract (a) were then 
included in IP assays using the fraction of extract depleted by serum BD5 (FI: Sister 2) 
(lanes 2-9). A 115-kDa band was no longer precipitated by serum BD3 (FI: Sister 1; 
lane 7). However, all other anti-115-kDa sera still precipitated a 115-kDa band (lanes 
2-6 and 9). The patient BD1 (FI: Patient) still precipitated the U1 RNP complex 
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FIGURE 5.6 Radioimmunoprecipitation of unidentified 115-kDa autoantigens by 
sera from a CTD-free family member using a K562-cell extract precleared of 
certain 115-kDa autoantigens, (cont.) (d ) A third lot of whole extract was 
depleted of an unidentified 115-kDa autoantigen four times using Protein A-Sepharose 
beads preincubated with serum BD2 (FI: Husband). The 115-kDa band is present in the 
whole extract (lane 10), and reduced by successive depletions, being absent from the 
4x-depleted extract (lane 9). However, U1 RNP and PADPRP could still be 
precipitated by appropriate sera (lanes 8 and 6 respectively). A normal serum is shown 
for comparison in lane 7. A control sample of whole extract was "depleted" in the same 
way using NS (lanes 1 and 2), and was shown to contain U1 RNP (lane 3), PADPRP 
(lane 5), as well as the unidentified 115-kDa antigen recognized by serum BD2 (FI: 
Husband; lane 4). (e) Sample sera which precipitated a 115-kDa band from the whole 
extract (a) were then included in IP assays using the fraction of extract depleted by 
serum BD2 (FI: Husband) (lanes 3-10). A 115-kDa band was no longer precipitated by 
sera from BD2 (FI: Husband) or BD7 (FI: Sister 3) (lanes 7 and 10 respectively). 
However, all other anti-115-kDa sera still precipitated a 115-kDa band (lanes 3-6, 8 and 












2 BD1 (FI: Patient)
3 BD2 (FI: Husband)
4 BD3 (FI: Sister 1)
6 BD7 (FI: Sister 3)
7 BD6 (FI: Son)
8 LJ7 (F3: Mother)
9 MD9 (F5: Son)
5 BD5 (FI: Sister 2) 10 LK1 (F4: Patient)
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FIGURE 5.7 Detection of affinity purified, radiolabelled 115-kDa autoantigens by 
immunoblotting. (a) Antigens were affinity purified by radioimmunoprecipitation 
using serum BD3 (Family 1 (FI): Sister 1) which had previously been found to 
precipitate an unidentified protein with a molecular weight of 115-kDa (b) Following 
SDS-PAGE of the autoantigen, and its transfer to nitrocellulose, immunoblotting was 
carried out using the test sera. Subsequent autoradiography of blots revealed the 
presence of the 115-kDa protein (a) (arrowed). However, none of the study sera (BD2, 
BD3, BD5, BD7, LJ7, MD9 and LK1) contained antibodies which recognized the band, 
including serum BD3 itself (b, lanes 3-6 and 8-10 respectively). Lane 1, normal serum 
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10LK1 (F4: Patient)
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FIGURE 5.7 Detection of affinity purified, radiolabelled 115-kDa autoantigens by 
immunoblotting. (cont.) (c) Antigens were affinity purified by radioimmuno- 
precipitation using serum BD7 (FI: Sister 3), which had previously been found to 
precipitate an unidentified protein with a molecular weight of 115-kDa (d) Following 
SDS-PAGE of the autoantigen, and its transfer to nitrocellulose, immunoblotting was 
carried out using the test sera. Subsequent autoradiography of blots revealed the 
presence of the 115-kDa protein (c) (arrowed). However, none of the study sera (BD2, 
BD3, BD5, BD7, LJ7, MD9 and LK1) contained antibodies which recognized the band, 
including serum BD7 itself (d, lanes 3-6 and 8-10 respectively). Lane 1, normal serum 










K e v :
1 Normal serum
2 BD3 (FI: Sister 1)
3 BD1 (FI: Patient)
4 BD2 (FI: Husband)
5 BD5 (FI: Sister 2)
6 BD4 (FI: Mother)
7 BD7 (FI: Sister 3)
8 BD6 (FI: Son)
9 anti-PADPRP mAb
FIGURE 5.8 Detection o f unlabelled a ffin ity  p u rified  115 -kD a  autoantigens by 
im m unoblotting of antigen-rich strips. Four SSc-free members of a single SSc family 
(BD2, BD3, BD5 and BD7) had been found to precipitate a 115-kDa band from K562- 
cell extracts. Unidentified 115-kDa autoantigens were affinity purified by 
immunoprecipitation using serum from BD2 and serum BD5 (a and b, respectively) 
Following SDS-PAGE of the autoantigens, and transfer to nitrocellulose, 
immunoblotting was carried out using sera from other members of this family (Family 
1 (FI)). (a) Sera from BD3 (FI: Sister 1), BD5 (FI: Sister 2) and BD7 (FI: Sister 3) all 
failed to recognize the 115-kDa autoantigen precipitated by serum BD2 (FI: Husband) 
(lanes 2, 5 and 7 respectively). The band was not recognized by sera from other 
members of the BD family either, including serum BD2 itself (lanes 2, 3 and 6-8), or by 
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FIGURE 5.8 Detection o f unlabelled a ffin ity  p u rified  115 -kD a  autoantigens by 
im m unoblotting o f antigen-rich strips, (cont.) (b) Serum from BD3 (FI: Sister 1) 
and serum from BD5 (FI: Sister 2) both recognized the 115-kDa antigen precipitated 
by serum BD3 (FI: Sister 1) (a, lanes 2 and 5 respectively). However, serum from BD2 
(FI: Husband) and serum from BD7 (FI: Sister 3), did not recognize the antigen (a, 
lanes 4 and 7 respectively). Further, the band was not recognized by sera from the 
patient BD1 (FI: Patient; lane 3), the patient's mother BD4 (FI: Mother; lane 6) or the 
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FIGURE 5.9 Protein silver staining: detection of purified 115-kDa autoantigens 
recognized by study sera, and eluted from an immunoaffinity column by a low pH, 
glycine buffer. During preliminary experiments, columns containing serum antibodies 
covalently attached to a 2-ml bed volume of Protein-A Sepharose were exposed to 
K562-cell extracts, washed, and eluted. Twenty 600-pl fractions of eluate were 
collected into 60 pi of Tris.Cl buffer (IM, pH9.0). A 20-pl sample of each fraction was 
then analyzed by SDS-PAGE on a 10%-polyacrylamide gel, followed by silver 
staining. (a) A precolumn containing normal serum-coated Protein-A Sepharose was 
used to preclear all extracts of non-specifically adsorbed proteins. This column was 
eluted before each re-use, and no bands of 115-kDa were detected in the eluted 
fractions (fractions shown in order of elution, lanes 1-7), although non-specifically 
binding proteins of lower molecular weight were detected (lane 5). (b) When this 
precleared extract was applied to a column containing Protein-A Sepharose beads 
linked to antibodies from serum BD2 (Family 1 (FI): Husband), however, a prominent 
band of 115-kDa was detected in eluted fractions 4-7 (lanes 4-7). Similarly, when 
precleared extracts were applied to a column containing Protein-A Sepharose linked to 
antibodies from BD5 (FI: Sister 2), a 115-kDa band was detected in eluted fractions (c, 
lanes 3-8). When fully scaled-up columns (5-ml bed volume) were later prepared using 
NS, and serum from BD3 (FI: Sister 1), a much cleaner preparation of antigen was 
eluted (1.2 ml fractions of eluate; 300 pi collection buffer) (d , lanes 2-6): fractions from 









FIGURE 5.10 Coomassie blue staining: detection of a purified 115-kDa 
autoantigen recognized by one of the study sera and eluted from an 
immunoaffinity column by a low pH, glycine buffer. Antibodies contained in serum 
from family member BD3 (FI: Sister 1) were covalently bound to Protein-A Sepharose 
beads in an immunoaffinity column. After application of an extract of K562 cells, 
followed by elution with a low-pH glycine buffer, antigen-rich fractions (see Fig. 5.9) 
were further purified by desalting, and separated on a 10% SDS-polyacrylamide gel. 
After electrophoretic transfer to a PVDF membrane, the purified protein was visualized 




Indirect immunofluorescent localization studies
The images produced by the second brand of HEp-2-cell slides were more distinctive 
than those produced by the original slides, and it is possible that these clearer images 
were due to more effective fixing techniques. However, it should not be assumed that 
the antigen distribution patterns of the cells on these particular slides were necessarily 
more representative of the in-vivo reality of subcellular antigen localization.
Regardless of which brand of slides produced the most accurate representation, the 
differences observed in staining patterns and intensities when the same serum was 
tested on the two types of slide indicate that results obtained from IF studies are 
extremely variable, and that a major source of variability lies in the choice of HEp-2 
slide used. Different fixing conditions may cause subtle changes to antigens or 
differential permeabilities of subcellular membranes to antigens and/or antibodies. 
Alternatively, the physiological state of the majority of cells prior to the fixing 
procedure may be a factor. Thus, the antigen profile of the cell substrate as well as the 
autoantibody profile of the test serum is a factor for consideration in IF studies. For 
effective comparisons, therefore, all samples should be prepared using slides from the 
same manufacturing batch, and all incubations should ideally be performed on the same 
day.
In the SSc family study, not only was the same brand of HEp-2 slides used within 
each separate experiment, but, in addition, slides from the same manufacturing batch 
were used. Thus, it is believed that the results presented in Chapter 3 are an accurate 
reflection of relative IF intensities within that particular system.
Possible identity of the autoantigens recognized by the study sera
To test the hypothesis that sera from this family were precipitating the 116-kDa enzyme 
PADPRP, an anti-PADPRP MAb was included as a test serum in the antigen depletion 
experiments. Despite specifically depleting extracts of the two different 115-kDa 
antigens recognized by sera from BD2 (FI: Husband) and BD5 (FI: Sister 2), it 
appeared that PADPRP could still be precipitated from both depleted extracts by the 
anti-PADPRP MAb, implying that none of the sera from this particular family 
contained antibodies which recognized PADPRP. Furthermore, the IF patterns of the 
BD family did not resemble those previously reported for PADPRP: using a HEp-2-cell 
substrate, Yamanaka et al. reported that autoimmune sera containing anti-PADPRP 
antibodies produce a distinctive diffuse nuclear fluorescence pattern, with intense 
nucleolar staining (369).
Information provided by the RNA-IP experiments showed that, apart from the 
proband BD1 (FI: Patient), no members of the BD Family precipitated an RNP.
Importantly, autoantibodies contained in serum BD1 did not precipitate a 115-kDa 
antigen, and the preclearing experiments did not affect the precipitation of any of the
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subunits of the U1 RNP particle by BD1. Thus, different proteins were precipitated by 
BD1, and by the other members of her family. All other results reported here are in 
accordance with these findings, i.e. that the U1 RNP particle and each of the 
unidentified 115-kDa antigens were recognized by separate autoantibody systems.
Relationships between the different 115-kDa antigens
Although the various study sera were shown to precipitate at least three different 115- 
kDa proteins, the very close mobilities of all the 115-kDa antigens means that a 
fundamental relationship between the antigens is not ruled out, particularly in the case 
of the two different antigens which were each recognized by two members of the same 
family.
One possibility is that the antigen recognized by serum from BD3 (FI: Sister 1) and 
BD5 (FI: Sister 2) is a phosphorylated variant of that recognized by sera from BD2 
(FI: Husband) and BD7 (FI: Sister 3). In support of this conjecture is the diffuse band 
produced on IP gels by the first two sera: such bands have been associated with 
phosphorylated proteins, such as the phosphorylated IIo subunit of RNAPII. As clearly 
illustrated in Chapter 4, two alternatively phosphorylated forms of a protein can be 
recognized by discrete sets of sera. Furthermore, cells have been shown to use 
phosphorylation as a localization signal to direct the segregation of a particular enzyme 
between different subcellular compartments, this being a form of controlling activity. In 
this regard, it may be significant that the two antigens mentioned above were located in 
separate cellular compartments, as indicated by the present IF results.
5.5 CONCLUSIONS
The involvement of an environmental trigger is suggested
As Kahaleh has pointed out (167), a single case report may contribute to the elucidation 
of pathogenetic mechanisms more than in-depth, wide-ranging laboratory studies. 
Similarly, the results concerning the autoantibody profile of members of the BD family 
provoke thoughts on aetiology and pathogenesis in SSc, despite the fact that only a 
single kindred has been described.
The spouse of an SSc-affected individual has been shown to have developed an 
autoimmune response, but not the disease itself. The apparent occurrence of the same 
autoantibody system in one of the patient's sisters implies an environmental factor is 
involved in the production of this particular autoantibody, and it is tempting to 
speculate that the same environmental factor may be responsible for triggering the 
disease in the proband, even though the patient recognized a different autoantigen. 
Furthermore, an autoantigen of the same molecular weight was recognized by the other 
two sisters in this family. In short, the evidence presented here is strongly in favour of 
an environmental factor triggering disease in the proband, while, in the remaining
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family members, the same proposed environmental agent provoked one of a number of 
alternative responses.
A connection between the pathogenesis of RP and SSc is supported
This variable response of the different members of a single family to the same 
environmental stimulus could have depended on individual genetic susceptibility 
factors. As mentioned in a recent review by Rosen et al., susceptibility factors 
contributing to the development of SSc are believed to include a pre-existing vascular 
defect (288,164,167). In this respect, it was of particular interest that BD3 and BD5, 
whose sera appeared to recognize the same protein, both had RP, but did not have SSc. 
Furthermore, it has been shown that there is a tendency for RP to cluster in certain 
families (100). Thus, along with the proband, BD3 and BD5 may have inherited a 
genetic susceptibility to the development of RP. Alternatively, their RP may have been 
triggered by the purported environmental factor which triggered SSc in the proband. In 
either case, whatever caused the development of RP in the sisters of the proband is 
implicated in the development of SSc in the patient herself.
An additional susceptibility factor may be required for the induction of SSc
Assuming that all the family members were indeed exposed to the same environmental 
trigger, the additional presence of a vascular defect in both BD3 and BD5 does not 
appear to have been sufficient to provoke the development of SSc. Therefore, the 
evidence suggests that an additional susceptibility factor was necessary, both for the 
induction of SSc, and for production of SSc-associated autoantibodies in the proband.
This would be consistent with the model of SSc proposed by Rosen et a l (288), in 
which RP was described as being a very important predisposing factor to the 
development of SSc (119,288). In Rosen's model, RP was proposed to interact with at 
least one other predisposing factor, namely abnormal metal ion status, to initiate the 
pathogenesis of SSc along with the production of particular SSc-associated 
autoantibodies. As reviewed in Section 1.7, this hypothesis was based on the previous 
study by this group in which it was demonstrated that some of the particular 
autoantigens recognized by dc-SSc sera could be specifically fragmented under 
conditions of oxidative stress by metal-ion catalysed processes (119,173). Metal ions 
have been shown to accumulate in the nucleolus, and severe RP is characterized by 
episodes of ischaemic reperfusion and the associated production of ROS. Significantly, 
the 70-kDa subunit of the U1 RNP particle was one of these antigens, along with topo I, 
the largest subunit of RNAP II, and NOR-90. (It should, however, be noted that, while 
the U1 RNP subunit was cleaved by Cu (II) ions, both topo I and the RNAP II subunit 
were most efficiently cleaved by Fe (II) ions (173), implying that the production of 
RNAP II/topo I fragments and the production of U1 RNP fragments are independent 
events, possibly occurring in separate groups of SSc patients. Those SSc sera with anti- 
RNAP II±topo I antibodies, and SSc sera with anti-Ul RNP antibodies do indeed seem
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to represent different subgroups of patients (see Chapter 4)). Thus, given the production 
of anti-Ul RNP antibodies by patient BD1, there is reason to believe that Cu (II) ion- 
catalysed fragmentation reactions may have occurred as part of the aetiopathogenesis of 
SSc in patient BD1. This suggests that a metal ion abnormality occurring only in the 
proband may have been the additional factor required to instigate the complete disease 
process in this particular family member.
The probable role of an environmental factor in SSc has been suggested by a number of 
studies (97,109,137,173,293,295,683), including the present one, and Rosen et al. did, 
in fact, state that their model was likely to be incomplete (288). Noticeably, while their 
model included the occurrence of RP in SSc, together with a plausible mechanism 
leading to the production of SSc-associated autoantibodies, the possible involvement of 
an environmental factor was not addressed (although it could be that the proposed 
environmental factor is an abnormal exposure to metal ions (91,120)). Two other key 
features of SSc also require inclusion in any reasonable model of aetiopathogenesis, 
namely the proposed cycle of vascular damage (40,197,263), and the characteristic 
cutaneous fibrosis (199). In the case of the model described by Rosen et al., it was 
suggested that the cycle of vascular damage arises via the generation of ROS. The metal 
abnormality was proposed to lower the threshold for vasospasm, substantially 
increasing ROS production. The ROS-induced damage was said to increase the 
frequency of ischaemic-reperfusion, with the consequence of a further increase in the 
generation of ROS. Hypoxia and ROS were proposed to promote the SSc-specific 
fibrotic phenotype, together with specific immune responses resulting from the ROS- 
induced autoantigen fragmentation events. These immune responses could, in turn, be 
responsible for inducing fibrogenic cytokine production (288).
However, other reasonable models of SSc have been suggested (40,105,164,199), 
and may also provide clues concerning the present results. For example, the vascular 
endothelial damage characteristic of SSc may be initiated by an environmental factor, 
rather than by ROS (293,195). Furthermore, as discussed in Section 1.3, there is strong 
evidence that, once endothelial damage has occurred, the cycle of damage in SSc is 
perpetuated by an immune-mediated mechanism (132,150,146,45). Also, the 
enrichment of certain HLA Class II and/or C4A null alleles in the SSc population 
should not be overlooked (25,33).
In the context of pathogenetic anti-EC autoantibodies, HLA alleles may also have 
been involved in the susceptibility of the proband to SSc
Thus, regarding the particular susceptibility of the proband to SSc, another possible 
predisposing factor necessary for disease induction in the proband could have been the 
presence of particular HLA alleles. As discussed in Chapter 3, given the same 
provoking factors, the mere presence of particular HLA alleles seems unlikely to 
explain the development of SSc in one member of a family but not in others, since
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autoantibodies which recognize intracellular antigens are not thought to be involved in 
the pathogenesis of SSc. However, one particular type of autoantibody has recently 
been linked with a directly pathological response in SSc: namely anti-EC antibodies 
(45,29,266), which have been shown to be capable of inducing EC apoptosis (29). 
Assuming that anti-EC antibodies are involved in the pathogenesis of SSc, a feasible 
mechanism is suggested, by which alternative HLA alleles can actually affect disease 
induction. For the expression of anti-EC antibodies to occur, the production of unusual 
EC-derived fragments is likely to be necessary, in order to overcome tolerance. In this 
regard, there is evidence that granzyme-1 is involved in the production of EC-derived 
fragments in SSc, and that these are subsequently processed into cryptic epitopes (5). 
Raised levels of granzyme-1 are often found in SSc. Environmental agents may also be 
capable of inciting the production of neoantigens during endothelial damage. Other 
possibilities include the proposed metal ion abnormality, acting on certain EC antigens 
in association with ROS. In any case, some HLA alleles would be capable of efficiently 
presenting a given cryptic peptide, while others would not. Consequently, the 
production of anti-EC antibodies would occur only in the presence of appropriate HLA 
alleles. Subsequently, anti-EC antibodies may set up the cycle of immune-mediated 
vascular damage believed to be central to the pathogenesis of SSc (197,45). Meanwhile, 
individuals without appropriate genetic factors would, presumably, still have evidence 
of damage to the vascular endothelium. In support of this is the reported detection of 
Factor VUI-related antigen (a marker of EC damage) in 20% of the first-degree 
relatives of SSc patients (c.fi 62% of SSc patients) (159), which implies that vascular 
endothelial damage occurs in some family members of SSc patients, but that it is not 
propagated into an immune-mediated cycle of destruction with the consequent 
production of fibrogenic cytokines at the inflammatory perivascular site. Further 
evidence is provided by the study of Si-SSc by Rustin et al., in which endothelial 
damage was observed not only in silica-exposed miners who developed Si-SSc, but also 
in a proportion of those who did not (293). This would also explain the observation 
that, in many multicase SSc families, the affected individuals tend to have similar HLA 
profiles (61,138,223,235,241,310). Indeed, in the previously reported case of conjugal 
SSc, the husband and wife both happened to share several HLA alleles, and the same 
inciting stimulus was implicated (56), which could indicate that the same cryptic 
endothelial antigens were produced in response to the same environmental stimulus.
To summarize, in the context of currently accepted models of the aetiopathogenesis of 
SSc, the present results strongly suggest that the same environmental insult has had an 
alternative denouement in the different family members, with only the proband 
responding in a pathological fashion, while some of her relatives appeared to possess a 
phenotypic and immunogenetic repertoire able to deal with and resolve the challenge 






The central conundrum of the immunopathogenesis of SSc is implicit in the close 
association between disease expression and autoantibody specificity in individual 
patients. Thus, while some SSc-specific autoantibodies are demonstrably capable of 
inhibiting the cellular functions of the autoantigens which they recognize during in vitro 
studies, they are unlikely to have access to the intracellular locations of these antigens 
in vivo. Indeed there is no evidence that functional inhibition of the intracellular 
autoantigens recognized by SSc sera is a direct or indirect cause of the pathological 
changes characteristic of the disease.
A major area of progress was the identification of the key steps required for the 
production of activated autoreactive T and B cells. Such work has demonstrated a 
general requirement for the presentation of cryptic epitopes of an autoantigen by APCs, 
in order for tolerance to be broken at the level of T cells recognizing minor antigenic 
determinants. It has been shown that, once this has occurred, the subsequent activation 
of autoreactive B cells, which includes their function as APCs, can lead to the spreading 
of T cell responses to different epitopes of the antigen, and the eventual perpetuation of 
the immune response by the self antigen itself, as minor antigenic determinants become 
major determinants in the established immune response.
While a number of events may lead to an APC presenting sufficient quantities of a
cryptic epitope to induce activation of naive autoreactive T cells, an inherent
requirement is the provision of an altered form of the self-antigen (or of an antigen with
which it is physically associated), or, alternatively, of a molecular mimic. Thus, it
appears that the autoantigens recognized by SSc sera are seen by the immune system in
an altered context, and, further, that the expression of SSc autoantibodies is disease-
specific. It therefore follows that a more accurate description of the situation would be
that the provision of certain self-antigens in an altered context is the truly disease-
specific aspect of SSc immunopathogenesis. This alternative concept has been
emerging in recent years, largely due to ground-breaking work of Rosen et al. (47-
49,288) and, also, Utz et al. (347), and Casiano et al. (50). Working mainly in the area
of SLE, such studies have provided a plethora of results, which demonstrate that
separate groups of autoantigens commonly recognized by SLE sera are the subject of
certain types of modification during apoptosis. Since deficiencies in apoptosis appear to
be central to the development of at least some forms of SLE, it was suggested that these
particular autoantibodies could be seen as the 'immunological footprints' of the
aetiopathogenesis of SLE (47). More recently, the exciting observation by Casciola-
Rosen et al. that metal-ion catalyzed oxidation reactions may result in the unusual
fragmentation of SSc autoantigens in the nucleolus (46) has begun to extend the
concepts described above for SLE, to include SSc. Thus, it was recently proposed by
Rosen et al. (288) that the particular autoantibodies produced in autoimmune diseases
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represent the '...immunological memory of the altered circumstances that initially
revealed cryptic structure...', and, furthermore, that these autoantibodies may be
indicative of aberrant disease-specific pathological processes. The present study 
contributes to this developing view.
6.2 Main conclusions
The present study began by examining the frequency and specificity of ANAs and 
ANoAs in sera from SSc patients and from their family members. The correlation 
between the production of SSc-associated autoantibodies and the presence of SSc was 
striking, despite the fact that some relatives produced strong IF-ANoAs together with 
strong bands on IP gels. Therefore, the views of Rosen et al. (288), as described above, 
were strongly supported.
However, an increased frequency of IF-ANoAs in the first-degree relatives of SSc 
patients compared with normal controls indicated that a genetic factor may cause the 
nucleolus to become a focus of the autoimmune response in both SSc patients and their 
blood-relatives. This finding suggested that some, but not all, of the factors required for 
the induction of SSc may be present in the patients' family members. Based on the 
central tenet of Rosen's suggestion, as quoted above, it therefore follows that the 
autoantibodies recognized by the SSc-free relatives of SSc patients are, in effect, 
reporting on the scenario which lead to the presentation of cryptic epitopes of the 
autoantigens which they recognize. The importance of this conjecture is that by 
identifying these autoantigens significant aspects of the early pathogenesis of SSc may 
be elucidated. Furthermore, differences between the affected and unaffected members 
of a family may be uncovered as a result of such knowledge, leading, in turn, to 
identification of vital predisposing factors involved in the development of SSc in the 
proband. Important protective factors may also be revealed. As well as aiding the 
development of a full aetiopathogenic model of the disease, such insights may have 
consequences for effective treatment of this condition.
Next, the clinical associations of autoantibodies were studied in a larger cohort of 
SSc patients. Three major subgroups of SSc patients, each characterized by the 
presence of a particular, mutually exclusive, SSc-specific autoantibody (viz. anti-RNAP 
III, anti-topo I and ACA groups) were detected, thus confirming the results of Bunn et 
al. (36). Our results demonstrated that anti-RNAP II antibodies frequently accompany 
anti-topo I antibodies, as well as being produced by patients in the anti-RNAP Ill- 
defined group.
The recognition of RNAP subunits by different groups of anti-RNAP sera were then 
explored. When considered alongside the results of others, these studies suggested that 
anti-RNAP II antibodies can be produced in the context of two distinct immune 
response pathways, each with a characteristic pattern of epitope spread, and, possibly 
involving different initiating stimuli. This possibility would have important 
implications for the study of HLA associations with autoantibody subgroups, in that the
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HLA alleles responsible for the production of a particular autoantibody would depend 
on the particular immune response pathway involved. This would not contradict the 
ideas of Rosen et a l , since each pathway leading to the production of a particular 
autoantibody would be representative of distinct pathological processes occurring in the 
relevant patient group.
It was further suggested that the subset of patients defined by the production of anti- 
RNAP II and/or topo I antibodies described here may correspond to the particular group 
of SSc patients alluded to by Casciola-Rosen et al., who appear to have unique access 
to RNAP II and topo I antigens in an unusually fragmented form (46). If this particular 
connection was confirmed, it would suggest that distinct pathological processes are 
occurring in the three subgroups of SSc patients defined by the presence of a particular 
SSc-associated autoantibody, and would be in direct support of the separate disease 
model of Fanning et a l (8 6 ).
In further support of the model of Fanning et a l was the other main aspect of this 
part of the project. Several of the previously reported clinical associations of SSc- 
associated antibodies were confirmed, and it was convincingly demonstrated that the 
three main groups of autoantibodies found in SSc (i.e. anti-RNAP III, anti-topo I and 
ACAs) are each associated with varying degrees of cutaneous involvement, further 
supporting the distinction between these three groups of SSc patients. An important 
additional finding was the demonstration that anti-Ro and anti-La antibodies may be of 
significance to the pathogenesis of SSc, and thus may be prognostically useful in 
individual cases.
The final part of this project concerned the production of autoantibodies by several 
different members of a single family including the spouse of a U1 RNP-positive 
proband. This provided convincing circumstantial evidence that a combination of 
several genetic and environmental factors is involved in the aetiopathogenesis of SSc, 
as suggested by a number of authors (288,331). Bearing in mind the model of LeRoy 
(195) and the model of Rosen et a l  (288) it appears possible that a total of six or more 
different factors may be required to be present for the development of SSc: vascular 
defects (as reflected by an inherited predisposition towards RP, with its episodes of 
ischaemic reperfusion and the generation of ROS), an environmental stimulus (which 
may initiate endothelial damage), the presence of abnormal metal ion status (which, as 
Rosen et a l propose, may lower the threshold for the induction of vascular spasms, and 
is responsible for the unique cleavage of SSc-associated autoantigens in association 
with ROS), complement deficiency (which may affect the efficient clearance of EC 
debris), the presence of particular HLA alleles (which allows propagation of 
environmentally induced endothelial damage into a cycle of immune-mediated 
endothelial damage, with the consequent production of a pro-inflammatory, pro-fibrotic 
perivascular environment), and, possibly, an unknown genetic factor which may make 
the nucleolus a focus for the immune response in SSc.
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If it is accepted that the aetiopathogenesis of SSc does involve the converging 
influences of several different genetic and environmental factors, and, further, that 
distinct pathological processes are occurring in the three main serologically defined 
subgroups of SSc patients, it follows that particular combinations of some of these 
susceptibility factors may be responsible for the development of particular subgroups of 
disease. This stresses the importance of carefully defining patient subgroups when 
studying the aetiopathogenesis of SSc.
To summarize, the results presented here are consistent with the current model of 
aetiopathogenesis in which SSc-specific autoantibodies, while not being directly 




Appendix I: Organ involvement severity scoring systems for SSc
Renal involvement
(0) No abnormalities: normal
(1) Mild: CC <60 mg/ml; SC 1.3-1.6 mg/dl; DBP 105-114 mmHg; UP 2+
(2) Moderate: SC 1.7-2.9 mg/dl; DBP >120 mmHg; UP 3-4+
(3) Severe: SC>3.0 mg/dl
(4) Endpoint: dialysis
Pulmonary involvement
(0) No abnormalities: normal
(1) Mild: DLCO 70-80%; FVC 70-80%; bibasilar dry rales/interstitial fibrosis
(2) Moderate: DLCO 50-69%; FVC 50-69%
(3) Severe: DLCO<50%; FVC <50%
(4) Endpoint: Oxygen required
CC, creatinine clearance; SC, serum creatinine; DBP, diastolic blood pressure; UP, 
urinary protein; DLCO, carbon monoxide diffusion capacity; FVC, forced vital capacity
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Appendix II: Centrifuge protocols







1 Hereaus, Labofuge 6000 10 3000 2 0
2 Beckman GPR/GH3.7 5 1500 1
3 Beckman GS-15R/F2402 2 0 1 2 0 0 0 1
4 Beckman GPR/GH3.7 3 4000 1
5 MSE, Microcentaur 10 sec 13000 2 0
6 MSE, Microcentaur 2 13000 2 0
7 Hereaus, Biofuge Fresco 10 9000 1
8 Jouan, BR4i/S40 5-20* 4100 1
9 Jouan, BR4i/S40 4 3400 1
*as applicable, see text
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Appendix III: Precautions taken for RNA work
1. Dimethyl pyrocarbonate-treated water was used to prepare all solutions (1 ml was 
added to each litre of Milli-Q water prior to autoclaving
2. All pipette tips and Eppendorf tubes were double-bagged and autoclaved prior to use
3. Clean, molecular biology-grade chemicals were always used, and were weighed by 
pouring directly into weighing boats lined with autoclaved aluminium foil
4. Tissue culture-grade plasticware was used for making up and storing solutions
5. Clean latex gloves were always worn
6 . All electrophoresis equipment and staining trays were kept clean. Equipment was 
soaked in Decon-90 (or similar laboratory cleanser) and rinsed well in autoclaved Milli- 
Q water prior to use. Glass plates were also rinsed in 50% methanol: 50% nitric acid, 
and rinsed in autoclaved Milli-Q water prior to use.
7. The sonicator probe was well cleaned before use: the sonicator was switched on 
whilst the probe was fully immersed in 50 ml of each of the following solutions in turn:
(i) Autoclaved Milli-Q water
(ii) Decon-90
(iii) Autoclaved Milli-Q water
(iv) Autoclaved Milli-Q water
(v) 50% methanol: 50% nitric acid
(vi) Autoclaved Milli-Q water
(vii) Autoclaved Milli-Q water
(viii) Ethanol
(ix) Autoclaved Milli-Q water
(x) Autoclaved Milli-Q water
(xi) Autoclaved Milli-Q water
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A ppendix IV: List o f fam ilies and fam ily m em bers studied
Sa  m p l e  Di  ap  n o s i s R e l a t i o n s h i p S e x S a m p l e  D i a g n o s i s Lp Sjlx
Al Ic-SSc Proband F 17 Brother M
A2 Father M Kl Ic-SSc Proband F
A3 Mother F K3 Juvenile arth. Son M
A4 Brother M K4 Spouse M
A5 Sister F K5 Daughter F
A6 P.O.father M LI Ic-SSc Proband F
A8 M.G.mother F L3 Son M
B 1 Ic-SSc Proband F LAI Ic-SSc. d LE Proband M
B 4 - Son M LA2 Spouse F
B 3 Daughter F LA3 RP Son M
B 6 - Son M LA4 RP Son M
B 7 Spouse M LA6 Father M
B 8 - Sister F LA7 RP Brother M
B 9 - Nephew M LA8 SLE Brother M
BIO Brother M LA9 RP Sister F
B 1 1 Brother M LCI dc-SSc Proband F
BA 1 Ic-SSc Proband F LC2 Mother F
BA2 - Sister F LC3 ?Arthritis Father M
BA3 T. sister F LC4 - Sister F
BBI dc-SSc Proband F LDI dc-SSc, mor. Proband F
BB2 Sister F LD2 Mother F
BB3 Sister F LD4 - Son M
BB4 Sister F LEI Ic-SSc Proband F
BB5 Spouse M LE2 RP Mother F
BB6 Mother F LE3 RP Father M
BB7 RA Father M LE4 - Sister F
BCI Ic-SSc Proband F LE5 - Brother M
BC2 - Spouse M LG1 Ic-SSc Proband F
BC3 Daughter F LG2 RP Son M
BC4 SLE/Pm M other F LG3 - Sister F
BC5 RP Father M LG4 - Sister F
BC6 RA Sister F LG5 RP Sister F
BOI dc-SSc Proband F U  1 dc-SSc Proband F
BD2 - Spouse M U 2 Spouse M
BD3 RP Sister F U 3 Son M
BD5 RP Sister F LJ 4 Daughter F
BD6 - Son M U S Son M
BD7 - Sister F U 6 Son M
BE 1 dc-SSc Proband F U  7 Mother F
BE 2 RP Spouse M U 8 PA Father M
BE 3 RP Daughter F U  9 Sister F
BE 4 Son M U IO RP Brother M
BES Brother M LKI Ic-SSc Proband F
BE 6 RP Mother F LK2 Brother M
BE 7 RP Sister F LK3 Son M
BE 8 RP Sister F LK4 Spouse M
BE 9 Brother M LK5 Sister F
BEIO RP Niece F LK6 Sister F
BE1I 1st degree NR LLI Ic-SSc. RA Proband F
BEI2 RP Niece F LL3 Daughter F
BE13 RP Niece F LL4 RA Sister F
BEI4 RP Niece F LL7 Daughter F
BEI5 - Nephew M MA 1 Ic-SSc Proband F
BEI6 - Nephew M MA 2 M other F
BGI Ic-SSc Proband F MA 3 Brother M
BG2 1st degree NR MA 4 RP Sister F
BG3 - Spouse M MA 6 Sister F
BG4 Mother F MA 7 Brother M
El dc-SSc Proband F MA 8 Brother M
E2 RP Mother F MAIO RP in past Sister F
E4 - Brother M MAI 1 Daughter F
E6 Sister F M AI2 Son M
E8 RP Brother M M AI3 Spouse M
E9 Sister F MAI 5 PA P.G.mother F
FI Ic-SSc Proband F MBI dc-SSc Proband F
F2 RP M other F MB3 - Son M
F3 Spouse M MB4 Son M
F4 - Daughter F MCI dc-SSc Proband F
Gl Ic-SSc Proband F MC2 - Daughter F
G2 Daughter F MC3 - Son M
HI dc-SSc Proband F MD 1 Ic-SSc Proband F
H2 M other F MD 2 Sister F
H3 Father M MD 3 - Sister F
H4 Daughter F M D4 RP Brother M
H5 - Son M MD 5 RP Brother M
II dc-SSc Proband M MD 6 - Mother F
12 Spouse F MD 7 RP Father M
13 dc-SSc Daughter F MD 8 - Spouse M
14 G. daughter F M D9 Son M
IS Spouse of 13 M MDIO Son M
16 Grandson M M il Ic-SSc Proband F
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MI9 RP Son M
MJ1 Ic-SSc Proband F
MJ2 - Son M
MJ3 PA Sister F
MJ4 RP Brother M
MKI dc-SSc Proband M
MK2 Daughter F
MK3 RP Daughter F
MM 1 Ic-SSc Proband F
MN1 Ic-SSc Proband F
MN2 - Son M
MN3 Son M
MN4 Arthritis Sister F
MOl Ic-SSc Proband F
M 02 - Son M
M 04 RP Brother M
MOS RP Sister F
MPI Ic-SSc Proband F
MP2 - Father M
MP4 RP in past Mother F
MP5 - Brother M
N 1 dc-SSc Proband F
N 2 Son M
N 3 Id.T. daughter F
N 4 Father M
N 5 Sister F
N 7 Hyperthyroid Sister F
N 8 - Brother M
N 9 Brother M
NIO Id.T. Daughter F
N i l Spouse M
NAI Ic-SSc Proband F
NA2 1st degree M
NA3 Mor., hyperthy. 1st degree F
NAA1 Ic-SSc Proband F
NAA2 Ic-SSc Sister F
NAA3 - Brother M
NAA4 - Father M
NAA5 Son M
NAA6 Ank. spond. Son M
NAA7 Daughter of NAA2 F
NAA9 - Nephew F
NABI dc-SSc Proband F
NAB2 1st degree F
NAB3 1st degree F
NACI dc-SSc Proband F
NAC2 1st degree F
NAC3 SLE 1st degree F
NAC4 1st degree F
NR1 SSc Proband F
NR2 Sister F
NR3 1st degree NR
NR4 1st degree NR
NRMI Ic-SSc Proband F
NRM2 Ic-SSc Daughter F
NRM3 Grandson M
NRM4 Grandson M
NRM5 RP Daughter F
NRM6 Daughter F
NRM7 RP Son M
NRTI Ic-SSc Proband F
NRT2 Ic-SSc Id.T.sister F
NRT3 Daughter F
NRT4 RP Son of NRT2 M
O l Ic-SSc Proband F
0 2 - T. sister F
0 3 Sister F
0 5 - Father M
PI Ic-SSc Proband F
P2 Spouse M
SAI dc-SSc Proband F
SA2 Mother F
SA4 Brother M
SA5 RP Brother M
SB 1 Ic-SSc Proband F
S a m p le  D ia g n o s i s R£iALiQDShiil S i *
SCI Ic-SSc Proband F
SC2 RP Father M
SC3 Sister F
SC4 - M other F
SC5 - M .G.mother F
SC6 M.G.father M
SC I RP P.G.mother F





SEI dc-SSc Proband F
SE2 RP Son M
SE3 - Spouse M
SE4 RP Sister F
SE5 RP Sister F
SE6 RP Daughter c
SF1 dc-SSc Proband F
SGI dc-SSc Proband F
SG2 RP M other F
SG6 - Sister F
SG7 Niece F
SG8 RP Niece F
SHI Ic-SSc Proband F
SH2 Son M
SH3 RP Daughter F
SH4 Spouse M






T1 dc-SSc Proband F
T2 M other F
T3 Spouse M




V 1 dc-SSc. PA Proband F
V 2 RP Sister F
V 3 RP Son M
V 4 Daughter F
VS RP Brother M
V 6 Spouse M
V 7 Son M
V 8 Hyperthyroid Sister F
V 9 Brother M
V10 Brother M
Wl dc-SSc Proband F
W2 Brother M
W3 M other F
W4 Father M
XI Ic-SSc Proband F
X2 1st degree F
X4 1st degree M
Kev:
Ic-SSc, limited cutaneous SSc 
dc-SSc, diffuse cutaneous SSc 
RA, rheumatoid arthritis 
SLE, systemic lupus erythematosus 
Pm, polymyositis 
RP, Raynaud's phenomenon 
NR, not recorded 
Arth., arthritis
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